<HTML><HEAD><TITLE>Gene Ontology Results</TITLE></HEAD><BODY>
<H1>Gene Ontology Enrichment Results</H1>
<A HREF="homerResults.html">Homer <i>de novo</i> Motif Enrichment Results</A><BR/>
<A HREF="knownResults.html">Known Motif Enrichment Results</A><BR/>
<H4>Text file version of complete results (i.e. open with Excel)
<UL>
<LI><A HREF="biological_process.txt">biological process</A>: Functional groupings of proteins (<A HREF="http://www.geneontology.org">Gene Ontology</A>)</LI>
<LI><A HREF="molecular_function.txt">molecular function</A>: Mechanistic actions of proteins (<A HREF="http://www.geneontology.org">Gene Ontology</A>)</LI>
<LI><A HREF="cellular_component.txt">cellular component</A>: Protein localization (<A HREF="http://www.geneontology.org">Gene Ontology</A>)</LI>
<LI><A HREF="chromosome.txt">chromosome location</A>: Genes with similar chromosome localization (<A HREF="http://www.ncbi.nlm.nih.gov/gene">NCBI Gene</A>)</LI>
<LI><A HREF="kegg.txt">KEGG pathways</A>: Groups of proteins in the same pathways (<A HREF="http://www.genome.jp/kegg/pathway.html">KEGG</A>)</LI>
<LI><A HREF="interactions.txt">protein interactions</A>: "Proteins interacting with a common protein (BIND, EcoCyc, HPRD)" (<A HREF="http://www.ncbi.nlm.nih.gov/gene">NCBI Gene</A>)</LI>
<LI><A HREF="interpro.txt">interpro domains</A>: Proteins with similar domains and features (<A HREF="http://www.ebi.ac.uk/interpro/">Interpro</A>)</LI>
<LI><A HREF="pfam.txt">pfam domains</A>: Proteins with similar domains and features (<A HREF="http://www.sanger.ac.uk/Software/Pfam/">Pfam</A>)</LI>
<LI><A HREF="smart.txt">smart domains</A>: Proteins with similar domains and features (<A HREF="http://smart.embl-heidelberg.de/">SMART</A>)</LI>
<LI><A HREF="gene3d.txt">gene3d domains</A>: Proteins with similar domains and features (<A HREF="http://cathwww.biochem.ucl.ac.uk:8080/Gene3D">Gene3D</A>)</LI>
<LI><A HREF="prosite.txt">prosite domains</A>: Proteins with similar domains and features (<A HREF="http://ca.expasy.org/prosite/">Prosite</A>)</LI>
<LI><A HREF="prints.txt">prints domains</A>: Proteins with similar domains and features (<A HREF="http://www.bioinf.manchester.ac.uk/dbbrowser/PRINTS/">PRINTS</A>)</LI>
<LI><A HREF="msigdb.txt">MSigDB lists</A>: "Genes sets for pathways, factor/miRNA target predictions, expression patterns, etc." (<A HREF="http://www.broadinstitute.org/gsea/msigdb/index.jsp">MSigDB</A>)</LI>
<LI><A HREF="biocyc.txt">BIOCYC pathways</A>: Groups of proteins in the same pathways (<A HREF="http://biocyc.org/">BIOCYC</A>)</LI>
<LI><A HREF="cosmic.txt">COSMIC cancer mutations</A>: Genes mutated in similar cancers (<A HREF="http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/">COSMIC</A>)</LI>
<LI><A HREF="gwas.txt">GWAS genes</A>: Genes mutated in similar diseases (<A HREF="http://www.genome.gov/26525384">GWAS Catalog</A>)</LI>
<LI><A HREF="lipidmaps.txt">Lipid Maps pathways</A>: Groups of proteins in the same lipid pathways (<A HREF="http://www.ncbi.nlm.nih.gov/biosystems/">Lipid Maps/Biosystems</A>)</LI>
<LI><A HREF="pathwayInteractionDB.txt">Pathway Interaction DB</A>: Groups of proteins in the same pathways (<A HREF="http://pid.nci.nih.gov/">Pathway Interaction Database</A>)</LI>
<LI><A HREF="reactome.txt">REACTOME pathways</A>: Groups of proteins in the same pathways (<A HREF="http://www.reactome.org/PathwayBrowser/">REACTOME</A>)</LI>
<LI><A HREF="smpdb.txt">SMPDB pathways</A>: Groups of proteins in the same pathways (<A HREF="http://www.smpdb.ca/">SMPDB</A>)</LI>
<LI><A HREF="wikipathways.txt">WikiPathways</A>: Groups of proteins in the same pathways (<A HREF="http://www.wikipathways.org/index.php/Special:BrowsePathwaysPage">Wikipathways</A>)</LI>
</UL>
<H2>Enriched Categories</H2>
<TABLE border="1" cellpading="0" cellspacing="0">
<TR><TH>P-value</TH><TD>ln(P)</TD><TD>Term</TD><TD>GO Tree</TD><TD>GO ID</TD><TD># of Genes in Term</TD><TD># of Target Genes in Term</TD><TD># of Total Genes</TD><TD># of Target Genes</TD><TD>Common Genes</TD></TR>
<TR><TD>1.827e-08</TD><TD>-17.82</TD><TD>AACTTT_UNKNOWN</TD><TD>MSigDB lists</TD><TD>AACTTT_UNKNOWN</TD><TD>1782</TD><TD>19</TD><TD>17758</TD><TD>45</TD>
<TD>LAMA4,EFNB2,FGF9,SLK,STXBP6,GRHL3,CLSTN2,PBX1,VIM,NR2F1,MSX2,CAMK2D,NEBL,CSMD3,NR2F2,ITGB4,ETV1,MMP16,PRPS1</TD></TR>
<TR><TD>3.100e-07</TD><TD>-14.99</TD><TD>tissue development</TD><TD>biological process</TD><TD>GO:0009888</TD><TD>1601</TD><TD>17</TD><TD>16441</TD><TD>44</TD>
<TD>EFNB2,SLC40A1,FGF9,MSX1,PPARG,GRHL3,PBX1,VIM,ZIC2,CAMK2D,MSX2,NEBL,WNT16,NR2F2,CD44,ITGB4,PDLIM5</TD></TR>
<TR><TD>4.031e-07</TD><TD>-14.72</TD><TD>organ development</TD><TD>biological process</TD><TD>GO:0048513</TD><TD>2766</TD><TD>22</TD><TD>16441</TD><TD>44</TD>
<TD>EFNB2,FGF9,SLC40A1,MSX1,PPARG,GRHL3,PBX1,VIM,ZIC2,NR2F1,MSX2,CAMK2D,NEBL,WNT16,ITGB4,NR2F2,CD44,PDLIM5,ETV1,PRPS1,MMP16,NT5E</TD></TR>
<TR><TD>6.532e-07</TD><TD>-14.24</TD><TD>CHICAS_RB1_TARGETS_CONFLUENT</TD><TD>MSigDB lists</TD><TD>CHICAS_RB1_TARGETS_CONFLUENT</TD><TD>531</TD><TD>10</TD><TD>17758</TD><TD>45</TD>
<TD>LAMA4,CAMK2D,S100A10,PPARG,STXBP6,VIM,NR2F2,CD44,PRPS1,PKIB</TD></TR>
<TR><TD>7.927e-07</TD><TD>-14.05</TD><TD>BENPORATH_EED_TARGETS</TD><TD>MSigDB lists</TD><TD>BENPORATH_EED_TARGETS</TD><TD>1009</TD><TD>13</TD><TD>17758</TD><TD>45</TD>
<TD>FGF9,MSX2,MSX1,PDE10A,STXBP6,CLSTN2,SLCO5A1,CSMD3,ZIC2,WNT16,CD44,SORCS2,NR2F2</TD></TR>
<TR><TD>9.922e-07</TD><TD>-13.82</TD><TD>nail development</TD><TD>biological process</TD><TD>GO:0035878</TD><TD>8</TD><TD>3</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2,MSX1,ITGB4</TD></TR>
<TR><TD>9.976e-07</TD><TD>-13.82</TD><TD>V$SRF_Q4</TD><TD>MSigDB lists</TD><TD>V$SRF_Q4</TD><TD>213</TD><TD>7</TD><TD>17758</TD><TD>45</TD>
<TD>MSX1,NR2F2,PPARG,PDLIM5,TANK,NR2F1,GRHL3</TD></TR>
<TR><TD>1.034e-06</TD><TD>-13.78</TD><TD>MEISSNER_BRAIN_HCP_WITH_H3K4ME3_AND_H3K27ME3</TD><TD>MSigDB lists</TD><TD>MEISSNER_BRAIN_HCP_WITH_H3K4ME3_AND_H3K27ME3</TD><TD>1033</TD><TD>13</TD><TD>17758</TD><TD>45</TD>
<TD>FGF9,MSX2,MSX1,PDE10A,STXBP6,GRHL3,SLCO5A1,ZIC2,VIM,SORCS2,PDLIM5,PDE3A,PKIB</TD></TR>
<TR><TD>1.513e-06</TD><TD>-13.40</TD><TD>PHONG_TNF_RESPONSE_NOT_VIA_P38</TD><TD>MSigDB lists</TD><TD>PHONG_TNF_RESPONSE_NOT_VIA_P38</TD><TD>329</TD><TD>8</TD><TD>17758</TD><TD>45</TD>
<TD>TNIK,PPARG,PDE10A,TANK,NR2F2,PDLIM5,ETV1,NR2F1</TD></TR>
<TR><TD>3.158e-06</TD><TD>-12.67</TD><TD>regulation of developmental process</TD><TD>biological process</TD><TD>GO:0050793</TD><TD>2113</TD><TD>18</TD><TD>16441</TD><TD>44</TD>
<TD>EFNB2,LAMA4,TNIK,FGF9,MSX1,PPARG,GRHL3,CLSTN2,PBX1,VIM,ZIC2,ANGPTL4,PDE3A,RHOU,MSX2,S100A10,UNC13A,PDLIM5</TD></TR>
<TR><TD>4.204e-06</TD><TD>-12.38</TD><TD>system development</TD><TD>biological process</TD><TD>GO:0048731</TD><TD>4011</TD><TD>25</TD><TD>16441</TD><TD>44</TD>
<TD>EFNB2,TNIK,FGF9,SLC40A1,MSX1,PPARG,GRHL3,PBX1,VIM,ZIC2,ANGPTL4,NR2F1,MSX2,CAMK2D,NEBL,UNC13A,WNT16,ITGB4,NR2F2,CD44,PDLIM5,ETV1,MMP16,PRPS1,NT5E</TD></TR>
<TR><TD>4.320e-06</TD><TD>-12.35</TD><TD>circulatory system development</TD><TD>biological process</TD><TD>GO:0072359</TD><TD>774</TD><TD>11</TD><TD>16441</TD><TD>44</TD>
<TD>EFNB2,MSX2,FGF9,CAMK2D,MSX1,NEBL,PPARG,WNT16,NR2F2,PDLIM5,ANGPTL4</TD></TR>
<TR><TD>4.320e-06</TD><TD>-12.35</TD><TD>cardiovascular system development</TD><TD>biological process</TD><TD>GO:0072358</TD><TD>774</TD><TD>11</TD><TD>16441</TD><TD>44</TD>
<TD>EFNB2,MSX2,FGF9,CAMK2D,MSX1,NEBL,PPARG,WNT16,NR2F2,PDLIM5,ANGPTL4</TD></TR>
<TR><TD>4.877e-06</TD><TD>-12.23</TD><TD>positive regulation of biological process</TD><TD>biological process</TD><TD>GO:0048518</TD><TD>5310</TD><TD>29</TD><TD>16441</TD><TD>44</TD>
<TD>EFNB2,SLC40A1,TNIK,FGF9,MSX1,PPARG,SLK,GRHL3,VSNL1,CLSTN2,PBX1,VIM,ZIC2,ANGPTL4,PDE3A,NR2F1,RHOU,MSX2,CAMK2D,S100A10,UNC13A,TANK,WNT16,CD44,NR2F2,ETV1,MMP16,PKIB,NT5E</TD></TR>
<TR><TD>5.669e-06</TD><TD>-12.08</TD><TD>WU_CELL_MIGRATION</TD><TD>MSigDB lists</TD><TD>WU_CELL_MIGRATION</TD><TD>179</TD><TD>6</TD><TD>17758</TD><TD>45</TD>
<TD>EFNB2,VIM,ITGB4,KRT7,NR2F2,AHNAK2</TD></TR>
<TR><TD>5.899e-06</TD><TD>-12.04</TD><TD>limb development</TD><TD>biological process</TD><TD>GO:0060173</TD><TD>171</TD><TD>6</TD><TD>16441</TD><TD>44</TD>
<TD>PBX1,MSX2,FGF9,MSX1,ITGB4,NR2F2</TD></TR>
<TR><TD>5.899e-06</TD><TD>-12.04</TD><TD>appendage development</TD><TD>biological process</TD><TD>GO:0048736</TD><TD>171</TD><TD>6</TD><TD>16441</TD><TD>44</TD>
<TD>PBX1,MSX2,FGF9,MSX1,ITGB4,NR2F2</TD></TR>
<TR><TD>6.494e-06</TD><TD>-11.94</TD><TD>regulation of multicellular organismal development</TD><TD>biological process</TD><TD>GO:2000026</TD><TD>1553</TD><TD>15</TD><TD>16441</TD><TD>44</TD>
<TD>EFNB2,LAMA4,MSX2,TNIK,FGF9,MSX1,PPARG,UNC13A,GRHL3,CLSTN2,PBX1,VIM,ZIC2,PDLIM5,ANGPTL4</TD></TR>
<TR><TD>6.641e-06</TD><TD>-11.92</TD><TD>epithelium development</TD><TD>biological process</TD><TD>GO:0060429</TD><TD>979</TD><TD>12</TD><TD>16441</TD><TD>44</TD>
<TD>EFNB2,MSX2,SLC40A1,MSX1,PPARG,GRHL3,PBX1,VIM,ZIC2,WNT16,NR2F2,CD44</TD></TR>
<TR><TD>6.641e-06</TD><TD>-11.92</TD><TD>P53_DN.V1_UP</TD><TD>MSigDB lists</TD><TD>P53_DN.V1_UP</TD><TD>184</TD><TD>6</TD><TD>17758</TD><TD>45</TD>
<TD>EFNB2,ITGB4,NEBL,NR2F2,PPARG,NR2F1</TD></TR>
<TR><TD>8.321e-06</TD><TD>-11.70</TD><TD>LEE_LIVER_CANCER_HEPATOBLAST</TD><TD>MSigDB lists</TD><TD>LEE_LIVER_CANCER_HEPATOBLAST</TD><TD>16</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>VIM,CD44,KRT7</TD></TR>
<TR><TD>8.728e-06</TD><TD>-11.65</TD><TD>BENPORATH_ES_WITH_H3K27ME3</TD><TD>MSigDB lists</TD><TD>BENPORATH_ES_WITH_H3K27ME3</TD><TD>1059</TD><TD>12</TD><TD>17758</TD><TD>45</TD>
<TD>MSX2,FGF9,SLC40A1,MSX1,STXBP6,PDE10A,GRHL3,CLSTN2,SLCO5A1,CSMD3,WNT16,NR2F2</TD></TR>
<TR><TD>1.013e-05</TD><TD>-11.50</TD><TD>nervous system development</TD><TD>biological process</TD><TD>GO:0007399</TD><TD>2292</TD><TD>18</TD><TD>16441</TD><TD>44</TD>
<TD>EFNB2,TNIK,FGF9,MSX1,PPARG,GRHL3,PBX1,VIM,ZIC2,NR2F1,CAMK2D,UNC13A,WNT16,NR2F2,ETV1,PDLIM5,PRPS1,NT5E</TD></TR>
<TR><TD>1.335e-05</TD><TD>-11.22</TD><TD>embryonic morphogenesis</TD><TD>biological process</TD><TD>GO:0048598</TD><TD>556</TD><TD>9</TD><TD>16441</TD><TD>44</TD>
<TD>FGF9,MSX2,MSX1,GRHL3,PBX1,ZIC2,WNT16,ITGB4,MMP16</TD></TR>
<TR><TD>1.400e-05</TD><TD>-11.18</TD><TD>organ morphogenesis</TD><TD>biological process</TD><TD>GO:0009887</TD><TD>876</TD><TD>11</TD><TD>16441</TD><TD>44</TD>
<TD>EFNB2,FGF9,SLC40A1,MSX2,MSX1,GRHL3,PBX1,WNT16,CD44,ITGB4,MMP16</TD></TR>
<TR><TD>1.494e-05</TD><TD>-11.11</TD><TD>anatomical structure morphogenesis</TD><TD>biological process</TD><TD>GO:0009653</TD><TD>2356</TD><TD>18</TD><TD>16441</TD><TD>44</TD>
<TD>EFNB2,TNIK,FGF9,SLC40A1,MSX1,GRHL3,PBX1,ZIC2,ANGPTL4,CAMK2D,MSX2,NEBL,WNT16,ITGB4,NR2F2,CD44,ETV1,MMP16</TD></TR>
<TR><TD>1.496e-05</TD><TD>-11.11</TD><TD>tissue morphogenesis</TD><TD>biological process</TD><TD>GO:0048729</TD><TD>564</TD><TD>9</TD><TD>16441</TD><TD>44</TD>
<TD>EFNB2,MSX2,MSX1,GRHL3,PBX1,ZIC2,WNT16,CD44,ITGB4</TD></TR>
<TR><TD>1.582e-05</TD><TD>-11.05</TD><TD>BEGUM_TARGETS_OF_PAX3_FOXO1_FUSION_UP</TD><TD>MSigDB lists</TD><TD>BEGUM_TARGETS_OF_PAX3_FOXO1_FUSION_UP</TD><TD>60</TD><TD>4</TD><TD>17758</TD><TD>45</TD>
<TD>CLSTN2,PBX1,NR2F1,NT5E</TD></TR>
<TR><TD>1.744e-05</TD><TD>-10.96</TD><TD>SABATES_COLORECTAL_ADENOMA_UP</TD><TD>MSigDB lists</TD><TD>SABATES_COLORECTAL_ADENOMA_UP</TD><TD>128</TD><TD>5</TD><TD>17758</TD><TD>45</TD>
<TD>MSX2,MSX1,CD44,GRHL3,VSNL1</TD></TR>
<TR><TD>1.803e-05</TD><TD>-10.92</TD><TD>PETROVA_PROX1_TARGETS_DN</TD><TD>MSigDB lists</TD><TD>PETROVA_PROX1_TARGETS_DN</TD><TD>62</TD><TD>4</TD><TD>17758</TD><TD>45</TD>
<TD>CD44,KRT7,TANK,AHNAK2</TD></TR>
<TR><TD>1.880e-05</TD><TD>-10.88</TD><TD>HOELZEL_NF1_TARGETS_UP</TD><TD>MSigDB lists</TD><TD>HOELZEL_NF1_TARGETS_UP</TD><TD>130</TD><TD>5</TD><TD>17758</TD><TD>45</TD>
<TD>CLSTN2,TNIK,S100A10,PDLIM5,AHNAK2</TD></TR>
<TR><TD>1.957e-05</TD><TD>-10.84</TD><TD>anatomical structure development</TD><TD>biological process</TD><TD>GO:0048856</TD><TD>4662</TD><TD>26</TD><TD>16441</TD><TD>44</TD>
<TD>EFNB2,TNIK,SLC40A1,FGF9,MSX1,PPARG,GRHL3,PBX1,VIM,ZIC2,ANGPTL4,NR2F1,PDE3A,MSX2,CAMK2D,NEBL,UNC13A,WNT16,ITGB4,CD44,NR2F2,ETV1,PDLIM5,MMP16,PRPS1,NT5E</TD></TR>
<TR><TD>2.096e-05</TD><TD>-10.77</TD><TD>embryonic nail plate morphogenesis</TD><TD>biological process</TD><TD>GO:0035880</TD><TD>3</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2,MSX1</TD></TR>
<TR><TD>2.096e-05</TD><TD>-10.77</TD><TD>positive regulation of mesenchymal cell apoptotic process</TD><TD>biological process</TD><TD>GO:2001055</TD><TD>3</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2,MSX1</TD></TR>
<TR><TD>2.315e-05</TD><TD>-10.67</TD><TD>regulation of multicellular organismal process</TD><TD>biological process</TD><TD>GO:0051239</TD><TD>2431</TD><TD>18</TD><TD>16441</TD><TD>44</TD>
<TD>EFNB2,LAMA4,TNIK,FGF9,MSX1,PPARG,GRHL3,CLSTN2,PBX1,VIM,ZIC2,ANGPTL4,PDE3A,MSX2,CAMK2D,UNC13A,NR2F2,PDLIM5</TD></TR>
<TR><TD>2.420e-05</TD><TD>-10.63</TD><TD>V$SRF_Q6</TD><TD>MSigDB lists</TD><TD>V$SRF_Q6</TD><TD>231</TD><TD>6</TD><TD>17758</TD><TD>45</TD>
<TD>CSMD3,MSX1,NR2F2,PPARG,PDLIM5,NR2F1</TD></TR>
<TR><TD>2.667e-05</TD><TD>-10.53</TD><TD>DUTERTRE_ESTRADIOL_RESPONSE_24HR_DN</TD><TD>MSigDB lists</TD><TD>DUTERTRE_ESTRADIOL_RESPONSE_24HR_DN</TD><TD>487</TD><TD>8</TD><TD>17758</TD><TD>45</TD>
<TD>EFNB2,MSX2,S100A10,PPARG,GRHL3,AHNAK2,PDLIM5,MMP16</TD></TR>
<TR><TD>3.051e-05</TD><TD>-10.40</TD><TD>cardiac epithelial to mesenchymal transition</TD><TD>biological process</TD><TD>GO:0060317</TD><TD>23</TD><TD>3</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2,MSX1,WNT16</TD></TR>
<TR><TD>3.367e-05</TD><TD>-10.30</TD><TD>DAVICIONI_TARGETS_OF_PAX_FOXO1_FUSIONS_UP</TD><TD>MSigDB lists</TD><TD>DAVICIONI_TARGETS_OF_PAX_FOXO1_FUSIONS_UP</TD><TD>245</TD><TD>6</TD><TD>17758</TD><TD>45</TD>
<TD>MSX2,CD44,NEBL,S100A10,NR2F2,MMP16</TD></TR>
<TR><TD>3.431e-05</TD><TD>-10.28</TD><TD>MSX2 (msh homeobox 2)</TD><TD>protein interactions</TD><TD>4488</TD><TD>25</TD><TD>3</TD><TD>16036</TD><TD>41</TD>
<TD>MSX2,MSX1,PPARG</TD></TR>
<TR><TD>3.749e-05</TD><TD>-10.19</TD><TD>anatomical structure formation involved in morphogenesis</TD><TD>biological process</TD><TD>GO:0048646</TD><TD>974</TD><TD>11</TD><TD>16441</TD><TD>44</TD>
<TD>EFNB2,FGF9,SLC40A1,MSX2,MSX1,NEBL,GRHL3,ZIC2,WNT16,ITGB4,ANGPTL4</TD></TR>
<TR><TD>4.113e-05</TD><TD>-10.10</TD><TD>follicular_lymphoma</TD><TD>COSMIC cancer mutations</TD><TD>follicular_lymphoma</TD><TD>1269</TD><TD>12</TD><TD>17775</TD><TD>44</TD>
<TD>TNIK,PDE10A,C1orf226,CSMD3,RNF43,CD44,SORCS2,ITGB4,PDLIM5,ETV1,MMP16,PDE3A</TD></TR>
<TR><TD>4.186e-05</TD><TD>-10.08</TD><TD>activation of meiosis</TD><TD>biological process</TD><TD>GO:0090427</TD><TD>4</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2,MSX1</TD></TR>
<TR><TD>4.514e-05</TD><TD>-10.01</TD><TD>PETROVA_ENDOTHELIUM_LYMPHATIC_VS_BLOOD_DN</TD><TD>MSigDB lists</TD><TD>PETROVA_ENDOTHELIUM_LYMPHATIC_VS_BLOOD_DN</TD><TD>156</TD><TD>5</TD><TD>17758</TD><TD>45</TD>
<TD>CD44,KRT7,NR2F2,TANK,AHNAK2</TD></TR>
<TR><TD>5.001e-05</TD><TD>-9.90</TD><TD>purine ribonucleotide catabolic process</TD><TD>biological process</TD><TD>GO:0009154</TD><TD>27</TD><TD>3</TD><TD>16441</TD><TD>44</TD>
<TD>PDE10A,PDE3A,NT5E</TD></TR>
<TR><TD>5.376e-05</TD><TD>-9.83</TD><TD>multicellular organismal development</TD><TD>biological process</TD><TD>GO:0007275</TD><TD>4594</TD><TD>25</TD><TD>16441</TD><TD>44</TD>
<TD>EFNB2,TNIK,SLC40A1,FGF9,MSX1,PPARG,GRHL3,PBX1,VIM,ZIC2,ANGPTL4,NR2F1,MSX2,CAMK2D,NEBL,UNC13A,WNT16,ITGB4,CD44,NR2F2,ETV1,PDLIM5,MMP16,PRPS1,NT5E</TD></TR>
<TR><TD>5.412e-05</TD><TD>-9.82</TD><TD>NSD1 (nuclear receptor binding SET domain protein 1)</TD><TD>protein interactions</TD><TD>64324</TD><TD>29</TD><TD>3</TD><TD>16036</TD><TD>41</TD>
<TD>NR2F2,PPARG,NR2F1</TD></TR>
<TR><TD>5.591e-05</TD><TD>-9.79</TD><TD>ribonucleotide catabolic process</TD><TD>biological process</TD><TD>GO:0009261</TD><TD>28</TD><TD>3</TD><TD>16441</TD><TD>44</TD>
<TD>PDE10A,PDE3A,NT5E</TD></TR>
<TR><TD>5.958e-05</TD><TD>-9.73</TD><TD>TGGNNNNNNKCCAR_UNKNOWN</TD><TD>MSigDB lists</TD><TD>TGGNNNNNNKCCAR_UNKNOWN</TD><TD>399</TD><TD>7</TD><TD>17758</TD><TD>45</TD>
<TD>RNF43,VIM,STXBP6,TANK,HFM1,NR2F1,GRHL3</TD></TR>
<TR><TD>6.156e-05</TD><TD>-9.70</TD><TD>COUP_TF</TD><TD>interpro domains</TD><TD>IPR003068</TD><TD>5</TD><TD>2</TD><TD>18293</TD><TD>46</TD>
<TD>NR2F2,NR2F1</TD></TR>
<TR><TD>6.271e-05</TD><TD>-9.68</TD><TD>BHAT_ESR1_TARGETS_NOT_VIA_AKT1_DN</TD><TD>MSigDB lists</TD><TD>BHAT_ESR1_TARGETS_NOT_VIA_AKT1_DN</TD><TD>85</TD><TD>4</TD><TD>17758</TD><TD>45</TD>
<TD>PBX1,EFNB2,RNF43,PPARG</TD></TR>
<TR><TD>6.803e-05</TD><TD>-9.60</TD><TD>BENPORATH_OCT4_TARGETS</TD><TD>MSigDB lists</TD><TD>BENPORATH_OCT4_TARGETS</TD><TD>278</TD><TD>6</TD><TD>17758</TD><TD>45</TD>
<TD>LAMA4,ZIC2,NEBL,NR2F2,CNTNAP3,PRPS1</TD></TR>
<TR><TD>6.903e-05</TD><TD>-9.58</TD><TD>regulation of meiotic nuclear division</TD><TD>biological process</TD><TD>GO:0040020</TD><TD>30</TD><TD>3</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2,MSX1,PDE3A</TD></TR>
<TR><TD>6.964e-05</TD><TD>-9.57</TD><TD>BMP signaling pathway involved in heart development</TD><TD>biological process</TD><TD>GO:0061312</TD><TD>5</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2,MSX1</TD></TR>
<TR><TD>9.403e-05</TD><TD>-9.27</TD><TD>LOPEZ_TRANSLATION_VIA_FN1_SIGNALING</TD><TD>MSigDB lists</TD><TD>LOPEZ_TRANSLATION_VIA_FN1_SIGNALING</TD><TD>35</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>EFNB2,MMP16,PDE3A</TD></TR>
<TR><TD>9.875e-05</TD><TD>-9.22</TD><TD>ERB2_UP.V1_UP</TD><TD>MSigDB lists</TD><TD>ERB2_UP.V1_UP</TD><TD>184</TD><TD>5</TD><TD>17758</TD><TD>45</TD>
<TD>MSX2,ITGB4,KRT7,PRPS1,ANGPTL4</TD></TR>
<TR><TD>1.093e-04</TD><TD>-9.12</TD><TD>RAF_UP.V1_UP</TD><TD>MSigDB lists</TD><TD>RAF_UP.V1_UP</TD><TD>188</TD><TD>5</TD><TD>17758</TD><TD>45</TD>
<TD>MSX2,CD44,PPARG,PRPS1,ANGPTL4</TD></TR>
<TR><TD>1.195e-04</TD><TD>-9.03</TD><TD>embryonic organ development</TD><TD>biological process</TD><TD>GO:0048568</TD><TD>423</TD><TD>7</TD><TD>16441</TD><TD>44</TD>
<TD>PBX1,FGF9,MSX1,WNT16,NR2F2,MMP16,GRHL3</TD></TR>
<TR><TD>1.212e-04</TD><TD>-9.02</TD><TD>tube development</TD><TD>biological process</TD><TD>GO:0035295</TD><TD>573</TD><TD>8</TD><TD>16441</TD><TD>44</TD>
<TD>EFNB2,MSX2,FGF9,GRHL3,PBX1,ZIC2,CD44,ITGB4</TD></TR>
<TR><TD>1.216e-04</TD><TD>-9.01</TD><TD>KINSEY_TARGETS_OF_EWSR1_FLII_FUSION_DN</TD><TD>MSigDB lists</TD><TD>KINSEY_TARGETS_OF_EWSR1_FLII_FUSION_DN</TD><TD>309</TD><TD>6</TD><TD>17758</TD><TD>45</TD>
<TD>LAMA4,SLC40A1,CAMK2D,VIM,S100A10,NT5E</TD></TR>
<TR><TD>1.231e-04</TD><TD>-9.00</TD><TD>morphogenesis of an epithelium</TD><TD>biological process</TD><TD>GO:0002009</TD><TD>425</TD><TD>7</TD><TD>16441</TD><TD>44</TD>
<TD>EFNB2,PBX1,MSX2,ZIC2,WNT16,CD44,GRHL3</TD></TR>
<TR><TD>1.335e-04</TD><TD>-8.92</TD><TD>CTTTGT_V$LEF1_Q2</TD><TD>MSigDB lists</TD><TD>CTTTGT_V$LEF1_Q2</TD><TD>1862</TD><TD>14</TD><TD>17758</TD><TD>45</TD>
<TD>LAMA4,EFNB2,FGF9,MSX1,STXBP6,PDE10A,HFM1,SLCO5A1,CSMD3,VIM,RNF43,NR2F2,ETV1,MMP16</TD></TR>
<TR><TD>1.342e-04</TD><TD>-8.92</TD><TD>COUPTNFACTOR</TD><TD>prints domains</TD><TD>PR01282</TD><TD>5</TD><TD>2</TD><TD>4759</TD><TD>18</TD>
<TD>NR2F2,NR2F1</TD></TR>
<TR><TD>1.362e-04</TD><TD>-8.90</TD><TD>BENPORATH_SUZ12_TARGETS</TD><TD>MSigDB lists</TD><TD>BENPORATH_SUZ12_TARGETS</TD><TD>980</TD><TD>10</TD><TD>17758</TD><TD>45</TD>
<TD>FGF9,SLC40A1,MSX1,STXBP6,CLSTN2,CSMD3,SLCO5A1,WNT16,NR2F2,CD44</TD></TR>
<TR><TD>1.388e-04</TD><TD>-8.88</TD><TD>BENPORATH_PRC2_TARGETS</TD><TD>MSigDB lists</TD><TD>BENPORATH_PRC2_TARGETS</TD><TD>616</TD><TD>8</TD><TD>17758</TD><TD>45</TD>
<TD>FGF9,MSX1,STXBP6,CSMD3,SLCO5A1,CLSTN2,WNT16,NR2F2</TD></TR>
<TR><TD>1.396e-04</TD><TD>-8.88</TD><TD>positive regulation of transmembrane receptor protein serine/threonine kinase signaling pathway</TD><TD>biological process</TD><TD>GO:0090100</TD><TD>99</TD><TD>4</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2,ZIC2,FGF9,MSX1</TD></TR>
<TR><TD>1.421e-04</TD><TD>-8.86</TD><TD>NUYTTEN_EZH2_TARGETS_UP</TD><TD>MSigDB lists</TD><TD>NUYTTEN_EZH2_TARGETS_UP</TD><TD>985</TD><TD>10</TD><TD>17758</TD><TD>45</TD>
<TD>RHOU,TNIK,TANK,AHNAK2,SORCS2,NR2F2,CD44,ANGPTL4,PKIB,NT5E</TD></TR>
<TR><TD>1.458e-04</TD><TD>-8.83</TD><TD>physiological muscle hypertrophy</TD><TD>biological process</TD><TD>GO:0003298</TD><TD>7</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>CAMK2D,PDLIM5</TD></TR>
<TR><TD>1.458e-04</TD><TD>-8.83</TD><TD>physiological cardiac muscle hypertrophy</TD><TD>biological process</TD><TD>GO:0003301</TD><TD>7</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>CAMK2D,PDLIM5</TD></TR>
<TR><TD>1.458e-04</TD><TD>-8.83</TD><TD>cell growth involved in cardiac muscle cell development</TD><TD>biological process</TD><TD>GO:0061049</TD><TD>7</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>CAMK2D,PDLIM5</TD></TR>
<TR><TD>1.460e-04</TD><TD>-8.83</TD><TD>epithelial tube morphogenesis</TD><TD>biological process</TD><TD>GO:0060562</TD><TD>303</TD><TD>6</TD><TD>16441</TD><TD>44</TD>
<TD>EFNB2,PBX1,MSX2,ZIC2,CD44,GRHL3</TD></TR>
<TR><TD>1.475e-04</TD><TD>-8.82</TD><TD>RNA polymerase II transcription factor activity, sequence-specific DNA binding</TD><TD>molecular function</TD><TD>GO:0000981</TD><TD>606</TD><TD>8</TD><TD>16491</TD><TD>43</TD>
<TD>MSX2,MSX1,PPARG,GRHL3,PBX1,NR2F2,ETV1,NR2F1</TD></TR>
<TR><TD>1.515e-04</TD><TD>-8.79</TD><TD>MODULE_455</TD><TD>MSigDB lists</TD><TD>MODULE_455</TD><TD>41</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>RHOU,PKIB,UNC13A</TD></TR>
<TR><TD>1.525e-04</TD><TD>-8.79</TD><TD>heart development</TD><TD>biological process</TD><TD>GO:0007507</TD><TD>440</TD><TD>7</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2,CAMK2D,MSX1,WNT16,NEBL,PPARG,PDLIM5</TD></TR>
<TR><TD>1.528e-04</TD><TD>-8.79</TD><TD>embryo development</TD><TD>biological process</TD><TD>GO:0009790</TD><TD>943</TD><TD>10</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2,FGF9,MSX1,GRHL3,PBX1,ZIC2,WNT16,ITGB4,NR2F2,MMP16</TD></TR>
<TR><TD>1.563e-04</TD><TD>-8.76</TD><TD>cell differentiation</TD><TD>biological process</TD><TD>GO:0030154</TD><TD>3353</TD><TD>20</TD><TD>16441</TD><TD>44</TD>
<TD>EFNB2,TNIK,FGF9,MSX1,PPARG,PBX1,VIM,ZIC2,ANGPTL4,PDE3A,NR2F1,CAMK2D,MSX2,NEBL,UNC13A,WNT16,ITGB4,NR2F2,PDLIM5,ETV1</TD></TR>
<TR><TD>1.622e-04</TD><TD>-8.73</TD><TD>haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-Burkitt_lymphoma</TD><TD>COSMIC cancer mutations</TD><TD>haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-Burkitt_lymphoma</TD><TD>2204</TD><TD>15</TD><TD>17775</TD><TD>44</TD>
<TD>EFNB2,LAMA4,SLC40A1,PPARG,PDE10A,STXBP6,TANK,CLSTN2,CSMD3,SORCS2,ITGB4,PDLIM5,MMP16,NR2F1,PDE3A</TD></TR>
<TR><TD>1.622e-04</TD><TD>-8.73</TD><TD>Burkitt_lymphoma</TD><TD>COSMIC cancer mutations</TD><TD>Burkitt_lymphoma</TD><TD>2204</TD><TD>15</TD><TD>17775</TD><TD>44</TD>
<TD>EFNB2,LAMA4,SLC40A1,PPARG,PDE10A,STXBP6,TANK,CLSTN2,CSMD3,SORCS2,ITGB4,PDLIM5,MMP16,NR2F1,PDE3A</TD></TR>
<TR><TD>1.639e-04</TD><TD>-8.72</TD><TD>haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-follicular_lymphoma</TD><TD>COSMIC cancer mutations</TD><TD>haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-follicular_lymphoma</TD><TD>1028</TD><TD>10</TD><TD>17775</TD><TD>44</TD>
<TD>PDE10A,C1orf226,CSMD3,RNF43,CD44,SORCS2,ITGB4,ETV1,MMP16,PDE3A</TD></TR>
<TR><TD>1.649e-04</TD><TD>-8.71</TD><TD>TSENG_IRS1_TARGETS_UP</TD><TD>MSigDB lists</TD><TD>TSENG_IRS1_TARGETS_UP</TD><TD>109</TD><TD>4</TD><TD>17758</TD><TD>45</TD>
<TD>LAMA4,RHOU,EFNB2,NR2F1</TD></TR>
<TR><TD>1.685e-04</TD><TD>-8.69</TD><TD>single-organism developmental process</TD><TD>biological process</TD><TD>GO:0044767</TD><TD>5226</TD><TD>26</TD><TD>16441</TD><TD>44</TD>
<TD>EFNB2,TNIK,SLC40A1,FGF9,MSX1,PPARG,GRHL3,PBX1,VIM,ZIC2,ANGPTL4,NR2F1,PDE3A,MSX2,CAMK2D,NEBL,UNC13A,WNT16,ITGB4,CD44,NR2F2,ETV1,PDLIM5,MMP16,PRPS1,NT5E</TD></TR>
<TR><TD>1.714e-04</TD><TD>-8.67</TD><TD>ATF2 (activating transcription factor 2)</TD><TD>protein interactions</TD><TD>1386</TD><TD>206</TD><TD>5</TD><TD>16036</TD><TD>41</TD>
<TD>VIM,ITGB4,CD44,KRT7,S100A10</TD></TR>
<TR><TD>1.715e-04</TD><TD>-8.67</TD><TD>V$SRF_Q5_01</TD><TD>MSigDB lists</TD><TD>V$SRF_Q5_01</TD><TD>207</TD><TD>5</TD><TD>17758</TD><TD>45</TD>
<TD>NR2F2,PPARG,PDLIM5,TANK,NR2F1</TD></TR>
<TR><TD>1.752e-04</TD><TD>-8.65</TD><TD>generation of neurons</TD><TD>biological process</TD><TD>GO:0048699</TD><TD>1584</TD><TD>13</TD><TD>16441</TD><TD>44</TD>
<TD>EFNB2,TNIK,FGF9,CAMK2D,PPARG,UNC13A,PBX1,VIM,WNT16,NR2F2,PDLIM5,ETV1,NR2F1</TD></TR>
<TR><TD>1.776e-04</TD><TD>-8.64</TD><TD>regulation of meiotic cell cycle</TD><TD>biological process</TD><TD>GO:0051445</TD><TD>41</TD><TD>3</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2,MSX1,PDE3A</TD></TR>
<TR><TD>1.828e-04</TD><TD>-8.61</TD><TD>positive regulation of cellular process</TD><TD>biological process</TD><TD>GO:0048522</TD><TD>4598</TD><TD>24</TD><TD>16441</TD><TD>44</TD>
<TD>EFNB2,SLC40A1,TNIK,FGF9,MSX1,PPARG,SLK,GRHL3,VSNL1,CLSTN2,PBX1,ZIC2,PDE3A,NR2F1,RHOU,MSX2,CAMK2D,S100A10,UNC13A,WNT16,CD44,NR2F2,ETV1,PKIB</TD></TR>
<TR><TD>1.871e-04</TD><TD>-8.58</TD><TD>NCOR2 (nuclear receptor corepressor 2)</TD><TD>protein interactions</TD><TD>9612</TD><TD>112</TD><TD>4</TD><TD>16036</TD><TD>41</TD>
<TD>TNIK,NR2F2,PPARG,NR2F1</TD></TR>
<TR><TD>1.959e-04</TD><TD>-8.54</TD><TD>V$CHX10_01</TD><TD>MSigDB lists</TD><TD>V$CHX10_01</TD><TD>213</TD><TD>5</TD><TD>17758</TD><TD>45</TD>
<TD>MSX1,NEBL,ETV1,NR2F1,VSNL1</TD></TR>
<TR><TD>2.046e-04</TD><TD>-8.49</TD><TD>RIGGINS_TAMOXIFEN_RESISTANCE_DN</TD><TD>MSigDB lists</TD><TD>RIGGINS_TAMOXIFEN_RESISTANCE_DN</TD><TD>215</TD><TD>5</TD><TD>17758</TD><TD>45</TD>
<TD>MSX1,NEBL,PDLIM5,MMP16,PDE10A</TD></TR>
<TR><TD>2.048e-04</TD><TD>-8.49</TD><TD>purine nucleotide catabolic process</TD><TD>biological process</TD><TD>GO:0006195</TD><TD>43</TD><TD>3</TD><TD>16441</TD><TD>44</TD>
<TD>PDE10A,PDE3A,NT5E</TD></TR>
<TR><TD>2.094e-04</TD><TD>-8.47</TD><TD>Znf_hrmn_rcpt</TD><TD>interpro domains</TD><TD>IPR001628</TD><TD>46</TD><TD>3</TD><TD>18293</TD><TD>46</TD>
<TD>NR2F2,PPARG,NR2F1</TD></TR>
<TR><TD>2.165e-04</TD><TD>-8.44</TD><TD>SANSOM_APC_TARGETS_UP</TD><TD>MSigDB lists</TD><TD>SANSOM_APC_TARGETS_UP</TD><TD>117</TD><TD>4</TD><TD>17758</TD><TD>45</TD>
<TD>RNF43,SLC40A1,MSX1,CD44</TD></TR>
<TR><TD>2.182e-04</TD><TD>-8.43</TD><TD>GRIP1 (glutamate receptor interacting protein 1)</TD><TD>protein interactions</TD><TD>23426</TD><TD>46</TD><TD>3</TD><TD>16036</TD><TD>41</TD>
<TD>EFNB2,PPARG,NR2F1</TD></TR>
<TR><TD>2.184e-04</TD><TD>-8.43</TD><TD>TTGTTT_V$FOXO4_01</TD><TD>MSigDB lists</TD><TD>TTGTTT_V$FOXO4_01</TD><TD>1950</TD><TD>14</TD><TD>17758</TD><TD>45</TD>
<TD>LAMA4,FGF9,SLC40A1,MSX2,MSX1,STXBP6,CLSTN2,PBX1,ZIC2,RNF43,ITGB4,NR2F2,ETV1,NR2F1</TD></TR>
<TR><TD>2.229e-04</TD><TD>-8.41</TD><TD>developmental process</TD><TD>biological process</TD><TD>GO:0032502</TD><TD>5307</TD><TD>26</TD><TD>16441</TD><TD>44</TD>
<TD>EFNB2,TNIK,SLC40A1,FGF9,MSX1,PPARG,GRHL3,PBX1,VIM,ZIC2,ANGPTL4,NR2F1,PDE3A,MSX2,CAMK2D,NEBL,UNC13A,WNT16,ITGB4,CD44,NR2F2,ETV1,PDLIM5,MMP16,PRPS1,NT5E</TD></TR>
<TR><TD>2.233e-04</TD><TD>-8.41</TD><TD>Nuclear_hrmn_rcpt</TD><TD>interpro domains</TD><TD>IPR001723</TD><TD>47</TD><TD>3</TD><TD>18293</TD><TD>46</TD>
<TD>NR2F2,PPARG,NR2F1</TD></TR>
<TR><TD>2.248e-04</TD><TD>-8.40</TD><TD>upper_aerodigestive_tract-larynx-carcinoma-squamous_cell_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>upper_aerodigestive_tract-larynx-carcinoma-squamous_cell_carcinoma</TD><TD>2007</TD><TD>14</TD><TD>17775</TD><TD>44</TD>
<TD>LAMA4,TNIK,SLC40A1,NEBL,CNTNAP3,HFM1,CLSTN2,SLCO5A1,CSMD3,ZIC2,SORCS2,PDLIM5,MMP16,PDE3A</TD></TR>
<TR><TD>2.272e-04</TD><TD>-8.39</TD><TD>larynx</TD><TD>COSMIC cancer mutations</TD><TD>larynx</TD><TD>2009</TD><TD>14</TD><TD>17775</TD><TD>44</TD>
<TD>LAMA4,TNIK,SLC40A1,NEBL,CNTNAP3,HFM1,CLSTN2,SLCO5A1,CSMD3,ZIC2,SORCS2,PDLIM5,MMP16,PDE3A</TD></TR>
<TR><TD>2.281e-04</TD><TD>-8.39</TD><TD>KRAS.50_UP.V1_UP</TD><TD>MSigDB lists</TD><TD>KRAS.50_UP.V1_UP</TD><TD>47</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>FGF9,ETV1,ANGPTL4</TD></TR>
<TR><TD>2.378e-04</TD><TD>-8.34</TD><TD>Nucl_hrmn_rcpt_lig-bd</TD><TD>interpro domains</TD><TD>IPR000536</TD><TD>48</TD><TD>3</TD><TD>18293</TD><TD>46</TD>
<TD>NR2F2,PPARG,NR2F1</TD></TR>
<TR><TD>2.422e-04</TD><TD>-8.33</TD><TD>regulation of cellular component organization</TD><TD>biological process</TD><TD>GO:0051128</TD><TD>2113</TD><TD>15</TD><TD>16441</TD><TD>44</TD>
<TD>RHOU,MSX2,TNIK,CAMK2D,MSX1,S100A10,PPARG,STXBP6,UNC13A,GRHL3,CLSTN2,VIM,PDLIM5,PKIB,PDE3A</TD></TR>
<TR><TD>2.423e-04</TD><TD>-8.33</TD><TD>zf-C4</TD><TD>pfam domains</TD><TD>PF00105</TD><TD>46</TD><TD>3</TD><TD>16629</TD><TD>44</TD>
<TD>NR2F2,PPARG,NR2F1</TD></TR>
<TR><TD>2.482e-04</TD><TD>-8.30</TD><TD>proteinaceous extracellular matrix</TD><TD>cellular component</TD><TD>GO:0005578</TD><TD>357</TD><TD>6</TD><TD>17570</TD><TD>44</TD>
<TD>LAMA4,FGF9,WNT16,ITGB4,MMP16,ANGPTL4</TD></TR>
<TR><TD>2.490e-04</TD><TD>-8.30</TD><TD>positive regulation of activin receptor signaling pathway</TD><TD>biological process</TD><TD>GO:0032927</TD><TD>9</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>ZIC2,FGF9</TD></TR>
<TR><TD>2.582e-04</TD><TD>-8.26</TD><TD>FRASOR_TAMOXIFEN_RESPONSE_UP</TD><TD>MSigDB lists</TD><TD>FRASOR_TAMOXIFEN_RESPONSE_UP</TD><TD>49</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>EFNB2,CD44,PRPS1</TD></TR>
<TR><TD>2.582e-04</TD><TD>-8.26</TD><TD>BECKER_TAMOXIFEN_RESISTANCE_DN</TD><TD>MSigDB lists</TD><TD>BECKER_TAMOXIFEN_RESISTANCE_DN</TD><TD>49</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>MSX2,MSX1,NR2F2</TD></TR>
<TR><TD>2.671e-04</TD><TD>-8.23</TD><TD>cardiac muscle cell development</TD><TD>biological process</TD><TD>GO:0055013</TD><TD>47</TD><TD>3</TD><TD>16441</TD><TD>44</TD>
<TD>CAMK2D,NEBL,PDLIM5</TD></TR>
<TR><TD>2.751e-04</TD><TD>-8.20</TD><TD>Hormone_recep</TD><TD>pfam domains</TD><TD>PF00104</TD><TD>48</TD><TD>3</TD><TD>16629</TD><TD>44</TD>
<TD>NR2F2,PPARG,NR2F1</TD></TR>
<TR><TD>2.798e-04</TD><TD>-8.18</TD><TD>transcription factor activity, direct ligand regulated sequence-specific DNA binding</TD><TD>molecular function</TD><TD>GO:0098531</TD><TD>49</TD><TD>3</TD><TD>16491</TD><TD>43</TD>
<TD>NR2F2,PPARG,NR2F1</TD></TR>
<TR><TD>2.798e-04</TD><TD>-8.18</TD><TD>RNA polymerase II transcription factor activity, ligand-activated sequence-specific DNA binding</TD><TD>molecular function</TD><TD>GO:0004879</TD><TD>49</TD><TD>3</TD><TD>16491</TD><TD>43</TD>
<TD>NR2F2,PPARG,NR2F1</TD></TR>
<TR><TD>2.820e-04</TD><TD>-8.17</TD><TD>positive regulation of metabolic process</TD><TD>biological process</TD><TD>GO:0009893</TD><TD>3495</TD><TD>20</TD><TD>16441</TD><TD>44</TD>
<TD>SLC40A1,TNIK,FGF9,MSX1,PPARG,SLK,GRHL3,PBX1,VIM,ZIC2,NR2F1,CAMK2D,S100A10,WNT16,CD44,NR2F2,ETV1,MMP16,PKIB,NT5E</TD></TR>
<TR><TD>2.833e-04</TD><TD>-8.17</TD><TD>DLX5 (distal-less homeobox 5)</TD><TD>protein interactions</TD><TD>1749</TD><TD>10</TD><TD>2</TD><TD>16036</TD><TD>41</TD>
<TD>MSX2,MSX1</TD></TR>
<TR><TD>2.854e-04</TD><TD>-8.16</TD><TD>tube morphogenesis</TD><TD>biological process</TD><TD>GO:0035239</TD><TD>343</TD><TD>6</TD><TD>16441</TD><TD>44</TD>
<TD>EFNB2,PBX1,MSX2,ZIC2,CD44,GRHL3</TD></TR>
<TR><TD>2.865e-04</TD><TD>-8.16</TD><TD>neurogenesis</TD><TD>biological process</TD><TD>GO:0022008</TD><TD>1664</TD><TD>13</TD><TD>16441</TD><TD>44</TD>
<TD>EFNB2,TNIK,FGF9,CAMK2D,PPARG,UNC13A,PBX1,VIM,WNT16,NR2F2,PDLIM5,ETV1,NR2F1</TD></TR>
<TR><TD>2.908e-04</TD><TD>-8.14</TD><TD>MODULE_325</TD><TD>MSigDB lists</TD><TD>MODULE_325</TD><TD>51</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>SLC40A1,MSX2,MMP16</TD></TR>
<TR><TD>3.023e-04</TD><TD>-8.10</TD><TD>purine-containing compound catabolic process</TD><TD>biological process</TD><TD>GO:0072523</TD><TD>49</TD><TD>3</TD><TD>16441</TD><TD>44</TD>
<TD>PDE10A,PDE3A,NT5E</TD></TR>
<TR><TD>3.023e-04</TD><TD>-8.10</TD><TD>cardiac cell development</TD><TD>biological process</TD><TD>GO:0055006</TD><TD>49</TD><TD>3</TD><TD>16441</TD><TD>44</TD>
<TD>CAMK2D,NEBL,PDLIM5</TD></TR>
<TR><TD>3.036e-04</TD><TD>-8.10</TD><TD>GOZGIT_ESR1_TARGETS_DN</TD><TD>MSigDB lists</TD><TD>GOZGIT_ESR1_TARGETS_DN</TD><TD>691</TD><TD>8</TD><TD>17758</TD><TD>45</TD>
<TD>EFNB2,NEBL,RNF43,NR2F2,CD44,PDLIM5,MMP16,PKIB</TD></TR>
<TR><TD>3.107e-04</TD><TD>-8.08</TD><TD>epithelial to mesenchymal transition involved in endocardial cushion formation</TD><TD>biological process</TD><TD>GO:0003198</TD><TD>10</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2,MSX1</TD></TR>
<TR><TD>3.174e-04</TD><TD>-8.06</TD><TD>regulation of cell differentiation</TD><TD>biological process</TD><TD>GO:0045595</TD><TD>1454</TD><TD>12</TD><TD>16441</TD><TD>44</TD>
<TD>EFNB2,MSX2,TNIK,FGF9,MSX1,S100A10,PPARG,UNC13A,PBX1,VIM,PDLIM5,PDE3A</TD></TR>
<TR><TD>3.193e-04</TD><TD>-8.05</TD><TD>cellular developmental process</TD><TD>biological process</TD><TD>GO:0048869</TD><TD>3526</TD><TD>20</TD><TD>16441</TD><TD>44</TD>
<TD>EFNB2,TNIK,FGF9,MSX1,PPARG,PBX1,VIM,ZIC2,ANGPTL4,PDE3A,NR2F1,CAMK2D,MSX2,NEBL,UNC13A,WNT16,ITGB4,NR2F2,PDLIM5,ETV1</TD></TR>
<TR><TD>3.250e-04</TD><TD>-8.03</TD><TD>PATIL_LIVER_CANCER</TD><TD>MSigDB lists</TD><TD>PATIL_LIVER_CANCER</TD><TD>698</TD><TD>8</TD><TD>17758</TD><TD>45</TD>
<TD>LAMA4,S100A10,PPARG,STXBP6,ZIC2,VIM,RNF43,ETV1</TD></TR>
<TR><TD>3.432e-04</TD><TD>-7.98</TD><TD>XU_GH1_AUTOCRINE_TARGETS_DN</TD><TD>MSigDB lists</TD><TD>XU_GH1_AUTOCRINE_TARGETS_DN</TD><TD>132</TD><TD>4</TD><TD>17758</TD><TD>45</TD>
<TD>EFNB2,CD44,NR2F2,SLK</TD></TR>
<TR><TD>3.629e-04</TD><TD>-7.92</TD><TD>embryonic limb morphogenesis</TD><TD>biological process</TD><TD>GO:0030326</TD><TD>127</TD><TD>4</TD><TD>16441</TD><TD>44</TD>
<TD>PBX1,FGF9,MSX2,MSX1</TD></TR>
<TR><TD>3.629e-04</TD><TD>-7.92</TD><TD>embryonic appendage morphogenesis</TD><TD>biological process</TD><TD>GO:0035113</TD><TD>127</TD><TD>4</TD><TD>16441</TD><TD>44</TD>
<TD>PBX1,FGF9,MSX2,MSX1</TD></TR>
<TR><TD>3.634e-04</TD><TD>-7.92</TD><TD>KRAS.300_UP.V1_UP</TD><TD>MSigDB lists</TD><TD>KRAS.300_UP.V1_UP</TD><TD>134</TD><TD>4</TD><TD>17758</TD><TD>45</TD>
<TD>SLCO5A1,FGF9,ETV1,ANGPTL4</TD></TR>
<TR><TD>3.901e-04</TD><TD>-7.85</TD><TD>cell development</TD><TD>biological process</TD><TD>GO:0048468</TD><TD>1717</TD><TD>13</TD><TD>16441</TD><TD>44</TD>
<TD>EFNB2,MSX2,TNIK,FGF9,CAMK2D,MSX1,NEBL,PPARG,VIM,WNT16,PDLIM5,ETV1,PDE3A</TD></TR>
<TR><TD>3.942e-04</TD><TD>-7.84</TD><TD>steroid hormone receptor activity</TD><TD>molecular function</TD><TD>GO:0003707</TD><TD>55</TD><TD>3</TD><TD>16491</TD><TD>43</TD>
<TD>NR2F2,PPARG,NR2F1</TD></TR>
<TR><TD>3.951e-04</TD><TD>-7.84</TD><TD>V$CREL_01</TD><TD>MSigDB lists</TD><TD>V$CREL_01</TD><TD>248</TD><TD>5</TD><TD>17758</TD><TD>45</TD>
<TD>RNF43,MSX1,S100A10,NR2F2,ETV1</TD></TR>
<TR><TD>3.959e-04</TD><TD>-7.83</TD><TD>Znf_NHR/GATA</TD><TD>interpro domains</TD><TD>IPR013088</TD><TD>57</TD><TD>3</TD><TD>18293</TD><TD>46</TD>
<TD>NR2F2,PPARG,NR2F1</TD></TR>
<TR><TD>4.025e-04</TD><TD>-7.82</TD><TD>V$OCT1_01</TD><TD>MSigDB lists</TD><TD>V$OCT1_01</TD><TD>249</TD><TD>5</TD><TD>17758</TD><TD>45</TD>
<TD>PBX1,CSMD3,NR2F2,ETV1,GRHL3</TD></TR>
<TR><TD>4.175e-04</TD><TD>-7.78</TD><TD>V$OCT1_Q6</TD><TD>MSigDB lists</TD><TD>V$OCT1_Q6</TD><TD>251</TD><TD>5</TD><TD>17758</TD><TD>45</TD>
<TD>CSMD3,ETV1,NR2F1,GRHL3,VSNL1</TD></TR>
<TR><TD>4.176e-04</TD><TD>-7.78</TD><TD>LEE_NEURAL_CREST_STEM_CELL_UP</TD><TD>MSigDB lists</TD><TD>LEE_NEURAL_CREST_STEM_CELL_UP</TD><TD>139</TD><TD>4</TD><TD>17758</TD><TD>45</TD>
<TD>MSX1,S100A10,NR2F2,NR2F1</TD></TR>
<TR><TD>4.256e-04</TD><TD>-7.76</TD><TD>VERRECCHIA_EARLY_RESPONSE_TO_TGFB1</TD><TD>MSigDB lists</TD><TD>VERRECCHIA_EARLY_RESPONSE_TO_TGFB1</TD><TD>58</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>LAMA4,CD44,MMP16</TD></TR>
<TR><TD>4.260e-04</TD><TD>-7.76</TD><TD>-</TD><TD>gene3d domains</TD><TD>1.10.565.10</TD><TD>48</TD><TD>3</TD><TD>9988</TD><TD>31</TD>
<TD>NR2F2,PPARG,NR2F1</TD></TR>
<TR><TD>4.329e-04</TD><TD>-7.75</TD><TD>V$AML_Q6</TD><TD>MSigDB lists</TD><TD>V$AML_Q6</TD><TD>253</TD><TD>5</TD><TD>17758</TD><TD>45</TD>
<TD>PBX1,CSMD3,VIM,RNF43,GRHL3</TD></TR>
<TR><TD>4.490e-04</TD><TD>-7.71</TD><TD>epithelial to mesenchymal transition</TD><TD>biological process</TD><TD>GO:0001837</TD><TD>56</TD><TD>3</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2,MSX1,WNT16</TD></TR>
<TR><TD>4.542e-04</TD><TD>-7.70</TD><TD>positive regulation of meiotic nuclear division</TD><TD>biological process</TD><TD>GO:0045836</TD><TD>12</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2,MSX1</TD></TR>
<TR><TD>4.680e-04</TD><TD>-7.67</TD><TD>Wnt signaling pathway</TD><TD>biological process</TD><TD>GO:0016055</TD><TD>244</TD><TD>5</TD><TD>16441</TD><TD>44</TD>
<TD>TNIK,RNF43,WNT16,CD44,GRHL3</TD></TR>
<TR><TD>4.731e-04</TD><TD>-7.66</TD><TD>steroid hormone mediated signaling pathway</TD><TD>biological process</TD><TD>GO:0043401</TD><TD>57</TD><TD>3</TD><TD>16441</TD><TD>44</TD>
<TD>NR2F2,PPARG,NR2F1</TD></TR>
<TR><TD>4.812e-04</TD><TD>-7.64</TD><TD>3_5_CYCLIC_NUCLEOTIDE_PHOSPHODIESTERASE_ACTIVITY</TD><TD>MSigDB lists</TD><TD>3_5_CYCLIC_NUCLEOTIDE_PHOSPHODIESTERASE_ACTIVITY</TD><TD>13</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>PDE10A,PDE3A</TD></TR>
<TR><TD>4.872e-04</TD><TD>-7.63</TD><TD>NUCLEAR_REC_DBD_2</TD><TD>prosite domains</TD><TD>PS51030</TD><TD>46</TD><TD>3</TD><TD>11866</TD><TD>40</TD>
<TD>NR2F2,PPARG,NR2F1</TD></TR>
<TR><TD>4.872e-04</TD><TD>-7.63</TD><TD>NUCLEAR_REC_DBD_1</TD><TD>prosite domains</TD><TD>PS00031</TD><TD>46</TD><TD>3</TD><TD>11866</TD><TD>40</TD>
<TD>NR2F2,PPARG,NR2F1</TD></TR>
<TR><TD>4.887e-04</TD><TD>-7.62</TD><TD>HOXC8 (homeobox C8)</TD><TD>protein interactions</TD><TD>3224</TD><TD>13</TD><TD>2</TD><TD>16036</TD><TD>41</TD>
<TD>PBX1,MSX1</TD></TR>
<TR><TD>4.887e-04</TD><TD>-7.62</TD><TD>BIK (BCL2-interacting killer (apoptosis-inducing))</TD><TD>protein interactions</TD><TD>638</TD><TD>13</TD><TD>2</TD><TD>16036</TD><TD>41</TD>
<TD>NR2F2,TANK</TD></TR>
<TR><TD>4.902e-04</TD><TD>-7.62</TD><TD>KRAS.600_UP.V1_UP</TD><TD>MSigDB lists</TD><TD>KRAS.600_UP.V1_UP</TD><TD>260</TD><TD>5</TD><TD>17758</TD><TD>45</TD>
<TD>CLSTN2,SLCO5A1,FGF9,ETV1,ANGPTL4</TD></TR>
<TR><TD>4.938e-04</TD><TD>-7.61</TD><TD>MARSON_FOXP3_TARGETS_UP</TD><TD>MSigDB lists</TD><TD>MARSON_FOXP3_TARGETS_UP</TD><TD>61</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>VIM,CD44,S100A10</TD></TR>
<TR><TD>4.938e-04</TD><TD>-7.61</TD><TD>MODULE_418</TD><TD>MSigDB lists</TD><TD>MODULE_418</TD><TD>61</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>RHOU,PKIB,UNC13A</TD></TR>
<TR><TD>4.989e-04</TD><TD>-7.60</TD><TD>V$IK1_01</TD><TD>MSigDB lists</TD><TD>V$IK1_01</TD><TD>261</TD><TD>5</TD><TD>17758</TD><TD>45</TD>
<TD>RNF43,MSX1,MMP16,PDE10A,VSNL1</TD></TR>
<TR><TD>5.136e-04</TD><TD>-7.57</TD><TD>regulation of nervous system development</TD><TD>biological process</TD><TD>GO:0051960</TD><TD>709</TD><TD>8</TD><TD>16441</TD><TD>44</TD>
<TD>TNIK,PPARG,UNC13A,GRHL3,PBX1,CLSTN2,VIM,PDLIM5</TD></TR>
<TR><TD>5.222e-04</TD><TD>-7.56</TD><TD>positive regulation of macromolecule metabolic process</TD><TD>biological process</TD><TD>GO:0010604</TD><TD>2797</TD><TD>17</TD><TD>16441</TD><TD>44</TD>
<TD>SLC40A1,TNIK,FGF9,MSX1,PPARG,SLK,GRHL3,PBX1,VIM,ZIC2,NR2F1,CAMK2D,WNT16,NR2F2,CD44,ETV1,PKIB</TD></TR>
<TR><TD>5.341e-04</TD><TD>-7.53</TD><TD>RIGGI_EWING_SARCOMA_PROGENITOR_UP</TD><TD>MSigDB lists</TD><TD>RIGGI_EWING_SARCOMA_PROGENITOR_UP</TD><TD>407</TD><TD>6</TD><TD>17758</TD><TD>45</TD>
<TD>CLSTN2,SLCO5A1,PBX1,MSX1,NR2F1,C1orf226</TD></TR>
<TR><TD>5.359e-04</TD><TD>-7.53</TD><TD>endocardial cushion formation</TD><TD>biological process</TD><TD>GO:0003272</TD><TD>13</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2,MSX1</TD></TR>
<TR><TD>5.359e-04</TD><TD>-7.53</TD><TD>regulation of transcription from RNA polymerase II promoter involved in heart development</TD><TD>biological process</TD><TD>GO:1901213</TD><TD>13</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2,MSX1</TD></TR>
<TR><TD>5.359e-04</TD><TD>-7.53</TD><TD>regulation of mesenchymal cell apoptotic process</TD><TD>biological process</TD><TD>GO:2001053</TD><TD>13</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2,MSX1</TD></TR>
<TR><TD>5.537e-04</TD><TD>-7.50</TD><TD>cellular response to steroid hormone stimulus</TD><TD>biological process</TD><TD>GO:0071383</TD><TD>142</TD><TD>4</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2,NR2F2,PPARG,NR2F1</TD></TR>
<TR><TD>5.582e-04</TD><TD>-7.49</TD><TD>TAATTA_V$CHX10_01</TD><TD>MSigDB lists</TD><TD>TAATTA_V$CHX10_01</TD><TD>757</TD><TD>8</TD><TD>17758</TD><TD>45</TD>
<TD>MSX2,MSX1,NEBL,GRHL3,SLCO5A1,CLSTN2,ETV1,NR2F1</TD></TR>
<TR><TD>5.590e-04</TD><TD>-7.49</TD><TD>positive regulation of developmental process</TD><TD>biological process</TD><TD>GO:0051094</TD><TD>1108</TD><TD>10</TD><TD>16441</TD><TD>44</TD>
<TD>EFNB2,MSX2,FGF9,S100A10,PPARG,UNC13A,CLSTN2,ZIC2,ANGPTL4,PDE3A</TD></TR>
<TR><TD>5.604e-04</TD><TD>-7.49</TD><TD>HOLLEMAN_VINCRISTINE_RESISTANCE_B_ALL_DN</TD><TD>MSigDB lists</TD><TD>HOLLEMAN_VINCRISTINE_RESISTANCE_B_ALL_DN</TD><TD>14</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>VIM,CD44</TD></TR>
<TR><TD>5.604e-04</TD><TD>-7.49</TD><TD>ZAIDI_OSTEOBLAST_TRANSCRIPTION_FACTORS</TD><TD>MSigDB lists</TD><TD>ZAIDI_OSTEOBLAST_TRANSCRIPTION_FACTORS</TD><TD>14</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>MSX2,MSX1</TD></TR>
<TR><TD>5.604e-04</TD><TD>-7.49</TD><TD>TSUNODA_CISPLATIN_RESISTANCE_UP</TD><TD>MSigDB lists</TD><TD>TSUNODA_CISPLATIN_RESISTANCE_UP</TD><TD>14</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>VIM,NT5E</TD></TR>
<TR><TD>5.604e-04</TD><TD>-7.49</TD><TD>CYCLIC_NUCLEOTIDE_PHOSPHODIESTERASE_ACTIVITY</TD><TD>MSigDB lists</TD><TD>CYCLIC_NUCLEOTIDE_PHOSPHODIESTERASE_ACTIVITY</TD><TD>14</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>PDE10A,PDE3A</TD></TR>
<TR><TD>5.775e-04</TD><TD>-7.46</TD><TD>nucleotide catabolic process</TD><TD>biological process</TD><TD>GO:0009166</TD><TD>61</TD><TD>3</TD><TD>16441</TD><TD>44</TD>
<TD>PDE10A,PDE3A,NT5E</TD></TR>
<TR><TD>6.038e-04</TD><TD>-7.41</TD><TD>extracellular matrix</TD><TD>cellular component</TD><TD>GO:0031012</TD><TD>422</TD><TD>6</TD><TD>17570</TD><TD>44</TD>
<TD>LAMA4,FGF9,WNT16,ITGB4,MMP16,ANGPTL4</TD></TR>
<TR><TD>6.232e-04</TD><TD>-7.38</TD><TD>STROIDFINGER</TD><TD>prints domains</TD><TD>PR00047</TD><TD>46</TD><TD>3</TD><TD>4759</TD><TD>18</TD>
<TD>NR2F2,PPARG,NR2F1</TD></TR>
<TR><TD>6.241e-04</TD><TD>-7.38</TD><TD>positive regulation of meiotic cell cycle</TD><TD>biological process</TD><TD>GO:0051446</TD><TD>14</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2,MSX1</TD></TR>
<TR><TD>6.241e-04</TD><TD>-7.38</TD><TD>cAMP catabolic process</TD><TD>biological process</TD><TD>GO:0006198</TD><TD>14</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>PDE10A,PDE3A</TD></TR>
<TR><TD>6.297e-04</TD><TD>-7.37</TD><TD>KEGG_PURINE_METABOLISM</TD><TD>MSigDB lists</TD><TD>KEGG_PURINE_METABOLISM</TD><TD>155</TD><TD>4</TD><TD>17758</TD><TD>45</TD>
<TD>PRPS1,PDE10A,PDE3A,NT5E</TD></TR>
<TR><TD>6.323e-04</TD><TD>-7.37</TD><TD>ACEVEDO_FGFR1_TARGETS_IN_PROSTATE_CANCER_MODEL_UP</TD><TD>MSigDB lists</TD><TD>ACEVEDO_FGFR1_TARGETS_IN_PROSTATE_CANCER_MODEL_UP</TD><TD>275</TD><TD>5</TD><TD>17758</TD><TD>45</TD>
<TD>TNIK,SLC40A1,CD44,KRT7,SLK</TD></TR>
<TR><TD>6.419e-04</TD><TD>-7.35</TD><TD>ZnF_C4</TD><TD>smart domains</TD><TD>SM00399</TD><TD>46</TD><TD>3</TD><TD>9131</TD><TD>34</TD>
<TD>NR2F2,PPARG,NR2F1</TD></TR>
<TR><TD>6.451e-04</TD><TD>-7.35</TD><TD>PHONG_TNF_RESPONSE_VIA_P38_PARTIAL</TD><TD>MSigDB lists</TD><TD>PHONG_TNF_RESPONSE_VIA_P38_PARTIAL</TD><TD>156</TD><TD>4</TD><TD>17758</TD><TD>45</TD>
<TD>EFNB2,CD44,NR2F2,TANK</TD></TR>
<TR><TD>6.557e-04</TD><TD>-7.33</TD><TD>DLX2 (distal-less homeobox 2)</TD><TD>protein interactions</TD><TD>1746</TD><TD>15</TD><TD>2</TD><TD>16036</TD><TD>41</TD>
<TD>MSX2,MSX1</TD></TR>
<TR><TD>6.636e-04</TD><TD>-7.32</TD><TD>appendage morphogenesis</TD><TD>biological process</TD><TD>GO:0035107</TD><TD>149</TD><TD>4</TD><TD>16441</TD><TD>44</TD>
<TD>PBX1,FGF9,MSX2,MSX1</TD></TR>
<TR><TD>6.636e-04</TD><TD>-7.32</TD><TD>limb morphogenesis</TD><TD>biological process</TD><TD>GO:0035108</TD><TD>149</TD><TD>4</TD><TD>16441</TD><TD>44</TD>
<TD>PBX1,FGF9,MSX2,MSX1</TD></TR>
<TR><TD>6.641e-04</TD><TD>-7.32</TD><TD>STRDHORMONER</TD><TD>prints domains</TD><TD>PR00398</TD><TD>47</TD><TD>3</TD><TD>4759</TD><TD>18</TD>
<TD>NR2F2,PPARG,NR2F1</TD></TR>
<TR><TD>6.792e-04</TD><TD>-7.29</TD><TD>ROSS_AML_OF_FAB_M7_TYPE</TD><TD>MSigDB lists</TD><TD>ROSS_AML_OF_FAB_M7_TYPE</TD><TD>68</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>TNIK,PDLIM5,STXBP6</TD></TR>
<TR><TD>7.072e-04</TD><TD>-7.25</TD><TD>-</TD><TD>gene3d domains</TD><TD>3.30.50.10</TD><TD>57</TD><TD>3</TD><TD>9988</TD><TD>31</TD>
<TD>NR2F2,PPARG,NR2F1</TD></TR>
<TR><TD>7.150e-04</TD><TD>-7.24</TD><TD>cartilage development</TD><TD>biological process</TD><TD>GO:0051216</TD><TD>152</TD><TD>4</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2,FGF9,MSX1,CD44</TD></TR>
<TR><TD>7.189e-04</TD><TD>-7.24</TD><TD>craniofacial suture morphogenesis</TD><TD>biological process</TD><TD>GO:0097094</TD><TD>15</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2,MMP16</TD></TR>
<TR><TD>7.189e-04</TD><TD>-7.24</TD><TD>AMP metabolic process</TD><TD>biological process</TD><TD>GO:0046033</TD><TD>15</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>PRPS1,NT5E</TD></TR>
<TR><TD>7.275e-04</TD><TD>-7.23</TD><TD>organ growth</TD><TD>biological process</TD><TD>GO:0035265</TD><TD>66</TD><TD>3</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2,CAMK2D,PDLIM5</TD></TR>
<TR><TD>7.277e-04</TD><TD>-7.23</TD><TD>HOLI</TD><TD>smart domains</TD><TD>SM00430</TD><TD>48</TD><TD>3</TD><TD>9131</TD><TD>34</TD>
<TD>NR2F2,PPARG,NR2F1</TD></TR>
<TR><TD>7.390e-04</TD><TD>-7.21</TD><TD>CUI_TCF21_TARGETS_2_DN</TD><TD>MSigDB lists</TD><TD>CUI_TCF21_TARGETS_2_DN</TD><TD>790</TD><TD>8</TD><TD>17758</TD><TD>45</TD>
<TD>EFNB2,CAMK2D,KRT7,NEBL,PDE10A,SLK,VIM,NT5E</TD></TR>
<TR><TD>7.392e-04</TD><TD>-7.21</TD><TD>REACTOME_TRANSCRIPTIONAL_REGULATION_OF_WHITE_ADIPOCYTE_DIFFERENTIATION</TD><TD>MSigDB lists</TD><TD>REACTOME_TRANSCRIPTIONAL_REGULATION_OF_WHITE_ADIPOCYTE_DIFFERENTIATION</TD><TD>70</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>NR2F2,PPARG,ANGPTL4</TD></TR>
<TR><TD>7.479e-04</TD><TD>-7.20</TD><TD>ACTB (actin, beta)</TD><TD>protein interactions</TD><TD>60</TD><TD>284</TD><TD>5</TD><TD>16036</TD><TD>41</TD>
<TD>NEBL,PDLIM5,ANGPTL4,NT5E,VSNL1</TD></TR>
<TR><TD>7.482e-04</TD><TD>-7.20</TD><TD>BCL11B (B-cell CLL/lymphoma 11B (zinc finger protein))</TD><TD>protein interactions</TD><TD>64919</TD><TD>16</TD><TD>2</TD><TD>16036</TD><TD>41</TD>
<TD>NR2F2,NR2F1</TD></TR>
<TR><TD>7.705e-04</TD><TD>-7.17</TD><TD>PEDERSEN_TARGETS_OF_611CTF_ISOFORM_OF_ERBB2</TD><TD>MSigDB lists</TD><TD>PEDERSEN_TARGETS_OF_611CTF_ISOFORM_OF_ERBB2</TD><TD>71</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>CD44,ANGPTL4,NT5E</TD></TR>
<TR><TD>7.886e-04</TD><TD>-7.15</TD><TD>Nuclear Receptors</TD><TD>WikiPathways</TD><TD>WP170</TD><TD>38</TD><TD>3</TD><TD>4455</TD><TD>22</TD>
<TD>NR2F2,PPARG,NR2F1</TD></TR>
<TR><TD>7.917e-04</TD><TD>-7.14</TD><TD>single-organism cellular process</TD><TD>biological process</TD><TD>GO:0044763</TD><TD>11471</TD><TD>40</TD><TD>16441</TD><TD>44</TD>
<TD>EFNB2,TNIK,CNTNAP3,STXBP6,SLK,HFM1,GPAT3,PBX1,RNF43,ZIC2,PDE3A,NEBL,S100A10,PDE10A,UNC13A,TANK,WNT16,CD44,ETV1,PRPS1,NT5E,LAMA4,FGF9,SLC40A1,MSX1,PPARG,GRHL3,VIM,ANGPTL4,NR2F1,RHOU,MSX2,CAMK2D,AHNAK2,SLCO5A1,ITGB4,SORCS2,NR2F2,PDLIM5,MMP16</TD></TR>
<TR><TD>8.026e-04</TD><TD>-7.13</TD><TD>SEITZ_NEOPLASTIC_TRANSFORMATION_BY_8P_DELETION_UP</TD><TD>MSigDB lists</TD><TD>SEITZ_NEOPLASTIC_TRANSFORMATION_BY_8P_DELETION_UP</TD><TD>72</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>EFNB2,PDLIM5,NR2F1</TD></TR>
<TR><TD>8.135e-04</TD><TD>-7.11</TD><TD>NR3C1 (nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor))</TD><TD>protein interactions</TD><TD>2908</TD><TD>165</TD><TD>4</TD><TD>16036</TD><TD>41</TD>
<TD>PBX1,MSX2,NR2F2,PPARG</TD></TR>
<TR><TD>8.283e-04</TD><TD>-7.10</TD><TD>nucleoside phosphate catabolic process</TD><TD>biological process</TD><TD>GO:1901292</TD><TD>69</TD><TD>3</TD><TD>16441</TD><TD>44</TD>
<TD>PDE10A,PDE3A,NT5E</TD></TR>
<TR><TD>8.323e-04</TD><TD>-7.09</TD><TD>CHARAFE_BREAST_CANCER_LUMINAL_VS_MESENCHYMAL_DN</TD><TD>MSigDB lists</TD><TD>CHARAFE_BREAST_CANCER_LUMINAL_VS_MESENCHYMAL_DN</TD><TD>443</TD><TD>6</TD><TD>17758</TD><TD>45</TD>
<TD>VIM,ZIC2,CD44,NR2F1,NT5E,AHNAK2</TD></TR>
<TR><TD>8.335e-04</TD><TD>-7.09</TD><TD>LE_SKI_TARGETS_UP</TD><TD>MSigDB lists</TD><TD>LE_SKI_TARGETS_UP</TD><TD>17</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>ITGB4,CD44</TD></TR>
<TR><TD>8.335e-04</TD><TD>-7.09</TD><TD>MATTHEWS_AP1_TARGETS</TD><TD>MSigDB lists</TD><TD>MATTHEWS_AP1_TARGETS</TD><TD>17</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>VIM,CD44</TD></TR>
<TR><TD>8.741e-04</TD><TD>-7.04</TD><TD>pattern specification process</TD><TD>biological process</TD><TD>GO:0007389</TD><TD>424</TD><TD>6</TD><TD>16441</TD><TD>44</TD>
<TD>PBX1,MSX2,MSX1,NR2F2,NR2F1,GRHL3</TD></TR>
<TR><TD>8.895e-04</TD><TD>-7.02</TD><TD>VERHAAK_GLIOBLASTOMA_PRONEURAL</TD><TD>MSigDB lists</TD><TD>VERHAAK_GLIOBLASTOMA_PRONEURAL</TD><TD>170</TD><TD>4</TD><TD>17758</TD><TD>45</TD>
<TD>SLCO5A1,FGF9,MMP16,PDE10A</TD></TR>
<TR><TD>9.002e-04</TD><TD>-7.01</TD><TD>embryonic organ morphogenesis</TD><TD>biological process</TD><TD>GO:0048562</TD><TD>282</TD><TD>5</TD><TD>16441</TD><TD>44</TD>
<TD>FGF9,MSX1,WNT16,MMP16,GRHL3</TD></TR>
<TR><TD>9.280e-04</TD><TD>-6.98</TD><TD>signal transduction involved in regulation of gene expression</TD><TD>biological process</TD><TD>GO:0023019</TD><TD>17</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2,MSX1</TD></TR>
<TR><TD>9.280e-04</TD><TD>-6.98</TD><TD>amelogenesis</TD><TD>biological process</TD><TD>GO:0097186</TD><TD>17</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2,ITGB4</TD></TR>
<TR><TD>9.280e-04</TD><TD>-6.98</TD><TD>cyclic nucleotide catabolic process</TD><TD>biological process</TD><TD>GO:0009214</TD><TD>17</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>PDE10A,PDE3A</TD></TR>
<TR><TD>9.280e-04</TD><TD>-6.98</TD><TD>negative regulation of transcription regulatory region DNA binding</TD><TD>biological process</TD><TD>GO:2000678</TD><TD>17</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2,MSX1</TD></TR>
<TR><TD>9.362e-04</TD><TD>-6.97</TD><TD>HOLLEMAN_VINCRISTINE_RESISTANCE_ALL_DN</TD><TD>MSigDB lists</TD><TD>HOLLEMAN_VINCRISTINE_RESISTANCE_ALL_DN</TD><TD>18</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>VIM,CD44</TD></TR>
<TR><TD>9.381e-04</TD><TD>-6.97</TD><TD>chordate embryonic development</TD><TD>biological process</TD><TD>GO:0043009</TD><TD>595</TD><TD>7</TD><TD>16441</TD><TD>44</TD>
<TD>PBX1,FGF9,ZIC2,MSX1,NR2F2,MMP16,GRHL3</TD></TR>
<TR><TD>9.699e-04</TD><TD>-6.94</TD><TD>RIGGI_EWING_SARCOMA_PROGENITOR_DN</TD><TD>MSigDB lists</TD><TD>RIGGI_EWING_SARCOMA_PROGENITOR_DN</TD><TD>174</TD><TD>4</TD><TD>17758</TD><TD>45</TD>
<TD>LAMA4,CD44,ETV1,MMP16</TD></TR>
<TR><TD>9.947e-04</TD><TD>-6.91</TD><TD>embryo development ending in birth or egg hatching</TD><TD>biological process</TD><TD>GO:0009792</TD><TD>601</TD><TD>7</TD><TD>16441</TD><TD>44</TD>
<TD>PBX1,FGF9,ZIC2,MSX1,NR2F2,MMP16,GRHL3</TD></TR>
<TR><TD>1.042e-03</TD><TD>-6.87</TD><TD>endocardial cushion morphogenesis</TD><TD>biological process</TD><TD>GO:0003203</TD><TD>18</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2,MSX1</TD></TR>
<TR><TD>1.045e-03</TD><TD>-6.86</TD><TD>REACTOME_CGMP_EFFECTS</TD><TD>MSigDB lists</TD><TD>REACTOME_CGMP_EFFECTS</TD><TD>19</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>PDE10A,PDE3A</TD></TR>
<TR><TD>1.045e-03</TD><TD>-6.86</TD><TD>HU_ANGIOGENESIS_UP</TD><TD>MSigDB lists</TD><TD>HU_ANGIOGENESIS_UP</TD><TD>19</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>CAMK2D,ITGB4</TD></TR>
<TR><TD>1.056e-03</TD><TD>-6.85</TD><TD>odontogenesis of dentin-containing tooth</TD><TD>biological process</TD><TD>GO:0042475</TD><TD>75</TD><TD>3</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2,MSX1,ITGB4</TD></TR>
<TR><TD>1.061e-03</TD><TD>-6.85</TD><TD>TLE2 (transducin-like enhancer of split 2)</TD><TD>protein interactions</TD><TD>7089</TD><TD>19</TD><TD>2</TD><TD>16036</TD><TD>41</TD>
<TD>MSX2,MSX1</TD></TR>
<TR><TD>1.069e-03</TD><TD>-6.84</TD><TD>regulation of cell development</TD><TD>biological process</TD><TD>GO:0060284</TD><TD>793</TD><TD>8</TD><TD>16441</TD><TD>44</TD>
<TD>TNIK,S100A10,PPARG,UNC13A,PBX1,VIM,PDLIM5,PDE3A</TD></TR>
<TR><TD>1.090e-03</TD><TD>-6.82</TD><TD>LEE_TARGETS_OF_PTCH1_AND_SUFU_DN</TD><TD>MSigDB lists</TD><TD>LEE_TARGETS_OF_PTCH1_AND_SUFU_DN</TD><TD>80</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>CLSTN2,CAMK2D,VSNL1</TD></TR>
<TR><TD>1.098e-03</TD><TD>-6.81</TD><TD>YOSHIMURA_MAPK8_TARGETS_UP</TD><TD>MSigDB lists</TD><TD>YOSHIMURA_MAPK8_TARGETS_UP</TD><TD>1274</TD><TD>10</TD><TD>17758</TD><TD>45</TD>
<TD>MSX2,SLK,UNC13A,VSNL1,VIM,ITGB4,CD44,PDE3A,NR2F1,PKIB</TD></TR>
<TR><TD>1.100e-03</TD><TD>-6.81</TD><TD>GCAAAAA,MIR-129</TD><TD>MSigDB lists</TD><TD>GCAAAAA,MIR-129</TD><TD>180</TD><TD>4</TD><TD>17758</TD><TD>45</TD>
<TD>EFNB2,NEBL,ETV1,PDLIM5</TD></TR>
<TR><TD>1.123e-03</TD><TD>-6.79</TD><TD>PRC2_EZH2_UP.V1_DN</TD><TD>MSigDB lists</TD><TD>PRC2_EZH2_UP.V1_DN</TD><TD>181</TD><TD>4</TD><TD>17758</TD><TD>45</TD>
<TD>ETV1,ANGPTL4,VSNL1,AHNAK2</TD></TR>
<TR><TD>1.139e-03</TD><TD>-6.78</TD><TD>cardiac muscle cell differentiation</TD><TD>biological process</TD><TD>GO:0055007</TD><TD>77</TD><TD>3</TD><TD>16441</TD><TD>44</TD>
<TD>CAMK2D,NEBL,PDLIM5</TD></TR>
<TR><TD>1.153e-03</TD><TD>-6.77</TD><TD>ZYX (zyxin)</TD><TD>protein interactions</TD><TD>7791</TD><TD>81</TD><TD>3</TD><TD>16036</TD><TD>41</TD>
<TD>VIM,NEBL,PDLIM5</TD></TR>
<TR><TD>1.159e-03</TD><TD>-6.76</TD><TD>WOTTON_RUNX_TARGETS_UP</TD><TD>MSigDB lists</TD><TD>WOTTON_RUNX_TARGETS_UP</TD><TD>20</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>SLC40A1,ANGPTL4</TD></TR>
<TR><TD>1.163e-03</TD><TD>-6.76</TD><TD>regulation of transcription involved in cell fate commitment</TD><TD>biological process</TD><TD>GO:0060850</TD><TD>19</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>NR2F2,PPARG</TD></TR>
<TR><TD>1.163e-03</TD><TD>-6.76</TD><TD>cell surface receptor signaling pathway involved in heart development</TD><TD>biological process</TD><TD>GO:0061311</TD><TD>19</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2,MSX1</TD></TR>
<TR><TD>1.183e-03</TD><TD>-6.74</TD><TD>carbohydrate derivative catabolic process</TD><TD>biological process</TD><TD>GO:1901136</TD><TD>174</TD><TD>4</TD><TD>16441</TD><TD>44</TD>
<TD>CD44,PDE10A,PDE3A,NT5E</TD></TR>
<TR><TD>1.193e-03</TD><TD>-6.73</TD><TD>GSE3982_EFF_MEMORY_CD4_TCELL_VS_TH1_UP</TD><TD>MSigDB lists</TD><TD>GSE3982_EFF_MEMORY_CD4_TCELL_VS_TH1_UP</TD><TD>184</TD><TD>4</TD><TD>17758</TD><TD>45</TD>
<TD>LAMA4,SLCO5A1,CD44,PDE10A</TD></TR>
<TR><TD>1.197e-03</TD><TD>-6.73</TD><TD>single-multicellular organism process</TD><TD>biological process</TD><TD>GO:0044707</TD><TD>6192</TD><TD>27</TD><TD>16441</TD><TD>44</TD>
<TD>EFNB2,TNIK,SLC40A1,FGF9,MSX1,PPARG,GRHL3,PBX1,VIM,ZIC2,ANGPTL4,NR2F1,PDE3A,MSX2,CAMK2D,NEBL,PDE10A,UNC13A,WNT16,ITGB4,CD44,NR2F2,ETV1,PDLIM5,MMP16,PRPS1,NT5E</TD></TR>
<TR><TD>1.233e-03</TD><TD>-6.70</TD><TD>positive regulation of gene expression</TD><TD>biological process</TD><TD>GO:0010628</TD><TD>1690</TD><TD>12</TD><TD>16441</TD><TD>44</TD>
<TD>SLC40A1,FGF9,MSX1,PPARG,GRHL3,PBX1,VIM,ZIC2,WNT16,CD44,NR2F2,ETV1</TD></TR>
<TR><TD>1.244e-03</TD><TD>-6.69</TD><TD>muscle structure development</TD><TD>biological process</TD><TD>GO:0061061</TD><TD>454</TD><TD>6</TD><TD>16441</TD><TD>44</TD>
<TD>CAMK2D,MSX1,NEBL,NR2F2,ETV1,PDLIM5</TD></TR>
<TR><TD>1.255e-03</TD><TD>-6.68</TD><TD>KEGG_ECM_RECEPTOR_INTERACTION</TD><TD>MSigDB lists</TD><TD>KEGG_ECM_RECEPTOR_INTERACTION</TD><TD>84</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>LAMA4,ITGB4,CD44</TD></TR>
<TR><TD>1.260e-03</TD><TD>-6.68</TD><TD>PDEase_catalytic_dom</TD><TD>interpro domains</TD><TD>IPR002073</TD><TD>21</TD><TD>2</TD><TD>18293</TD><TD>46</TD>
<TD>PDE10A,PDE3A</TD></TR>
<TR><TD>1.260e-03</TD><TD>-6.68</TD><TD>PDEase_CS</TD><TD>interpro domains</TD><TD>IPR023174</TD><TD>21</TD><TD>2</TD><TD>18293</TD><TD>46</TD>
<TD>PDE10A,PDE3A</TD></TR>
<TR><TD>1.275e-03</TD><TD>-6.66</TD><TD>vif (p23)</TD><TD>protein interactions</TD><TD>155459</TD><TD>320</TD><TD>5</TD><TD>16036</TD><TD>41</TD>
<TD>RHOU,VIM,CD44,PPARG,NT5E</TD></TR>
<TR><TD>1.292e-03</TD><TD>-6.65</TD><TD>GSE9037_WT_VS_IRAK4_KO_BMDM_UP</TD><TD>MSigDB lists</TD><TD>GSE9037_WT_VS_IRAK4_KO_BMDM_UP</TD><TD>188</TD><TD>4</TD><TD>17758</TD><TD>45</TD>
<TD>PBX1,VIM,NR2F2,TANK</TD></TR>
<TR><TD>1.316e-03</TD><TD>-6.63</TD><TD>regulation of organelle organization</TD><TD>biological process</TD><TD>GO:0033043</TD><TD>1022</TD><TD>9</TD><TD>16441</TD><TD>44</TD>
<TD>RHOU,MSX2,CAMK2D,MSX1,S100A10,STXBP6,GRHL3,PDE3A,PKIB</TD></TR>
<TR><TD>1.317e-03</TD><TD>-6.63</TD><TD>MEK_UP.V1_UP</TD><TD>MSigDB lists</TD><TD>MEK_UP.V1_UP</TD><TD>189</TD><TD>4</TD><TD>17758</TD><TD>45</TD>
<TD>ITGB4,KRT7,PPARG,ANGPTL4</TD></TR>
<TR><TD>1.325e-03</TD><TD>-6.63</TD><TD>cGMP effects</TD><TD>REACTOME pathways</TD><TD>R-HSA-418457</TD><TD>18</TD><TD>2</TD><TD>8202</TD><TD>25</TD>
<TD>PDE10A,PDE3A</TD></TR>
<TR><TD>1.340e-03</TD><TD>-6.61</TD><TD>central_nervous_system-thalamus-glioma-oligoastrocytoma_Grade_III</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-thalamus-glioma-oligoastrocytoma_Grade_III</TD><TD>22</TD><TD>2</TD><TD>17775</TD><TD>44</TD>
<TD>PDE10A,GRHL3</TD></TR>
<TR><TD>1.345e-03</TD><TD>-6.61</TD><TD>transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding</TD><TD>molecular function</TD><TD>GO:0001228</TD><TD>317</TD><TD>5</TD><TD>16491</TD><TD>43</TD>
<TD>PBX1,MSX1,PPARG,ETV1,GRHL3</TD></TR>
<TR><TD>1.359e-03</TD><TD>-6.60</TD><TD>membrane region</TD><TD>cellular component</TD><TD>GO:0098589</TD><TD>1097</TD><TD>9</TD><TD>17570</TD><TD>44</TD>
<TD>TNIK,SLC40A1,S100A10,UNC13A,CLSTN2,ITGB4,CD44,PDLIM5,NT5E</TD></TR>
<TR><TD>1.359e-03</TD><TD>-6.60</TD><TD>regulation of molecular function</TD><TD>biological process</TD><TD>GO:0065009</TD><TD>2753</TD><TD>16</TD><TD>16441</TD><TD>44</TD>
<TD>TNIK,FGF9,MSX1,PPARG,SLK,GRHL3,PBX1,ZIC2,ANGPTL4,CAMK2D,MSX2,S100A10,NR2F2,CD44,MMP16,PKIB</TD></TR>
<TR><TD>1.370e-03</TD><TD>-6.59</TD><TD>CREIGHTON_ENDOCRINE_THERAPY_RESISTANCE_1</TD><TD>MSigDB lists</TD><TD>CREIGHTON_ENDOCRINE_THERAPY_RESISTANCE_1</TD><TD>488</TD><TD>6</TD><TD>17758</TD><TD>45</TD>
<TD>PBX1,ZIC2,NR2F2,PKIB,AHNAK2,C1orf226</TD></TR>
<TR><TD>1.392e-03</TD><TD>-6.58</TD><TD>PDEase_I</TD><TD>pfam domains</TD><TD>PF00233</TD><TD>21</TD><TD>2</TD><TD>16629</TD><TD>44</TD>
<TD>PDE10A,PDE3A</TD></TR>
<TR><TD>1.399e-03</TD><TD>-6.57</TD><TD>WTTGKCTG_UNKNOWN</TD><TD>MSigDB lists</TD><TD>WTTGKCTG_UNKNOWN</TD><TD>490</TD><TD>6</TD><TD>17758</TD><TD>45</TD>
<TD>VIM,ZIC2,NR2F2,PPARG,PDE10A,TANK</TD></TR>
<TR><TD>1.423e-03</TD><TD>-6.55</TD><TD>lymph vessel development</TD><TD>biological process</TD><TD>GO:0001945</TD><TD>21</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>EFNB2,NR2F2</TD></TR>
<TR><TD>1.436e-03</TD><TD>-6.55</TD><TD>SANA_TNF_SIGNALING_DN</TD><TD>MSigDB lists</TD><TD>SANA_TNF_SIGNALING_DN</TD><TD>88</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>KRT7,AHNAK2,NT5E</TD></TR>
<TR><TD>1.436e-03</TD><TD>-6.55</TD><TD>NAKAYAMA_SOFT_TISSUE_TUMORS_PCA2_UP</TD><TD>MSigDB lists</TD><TD>NAKAYAMA_SOFT_TISSUE_TUMORS_PCA2_UP</TD><TD>88</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>MSX2,FGF9,AHNAK2</TD></TR>
<TR><TD>1.478e-03</TD><TD>-6.52</TD><TD>HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION</TD><TD>MSigDB lists</TD><TD>HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION</TD><TD>195</TD><TD>4</TD><TD>17758</TD><TD>45</TD>
<TD>VIM,MSX1,CD44,NT5E</TD></TR>
<TR><TD>1.478e-03</TD><TD>-6.52</TD><TD>HALLMARK_ADIPOGENESIS</TD><TD>MSigDB lists</TD><TD>HALLMARK_ADIPOGENESIS</TD><TD>195</TD><TD>4</TD><TD>17758</TD><TD>45</TD>
<TD>LAMA4,PPARG,ANGPTL4,TANK</TD></TR>
<TR><TD>1.501e-03</TD><TD>-6.50</TD><TD>skeletal system development</TD><TD>biological process</TD><TD>GO:0001501</TD><TD>471</TD><TD>6</TD><TD>16441</TD><TD>44</TD>
<TD>PBX1,MSX2,FGF9,MSX1,CD44,MMP16</TD></TR>
<TR><TD>1.531e-03</TD><TD>-6.48</TD><TD>DUTERTRE_ESTRADIOL_RESPONSE_6HR_DN</TD><TD>MSigDB lists</TD><TD>DUTERTRE_ESTRADIOL_RESPONSE_6HR_DN</TD><TD>90</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>MMP16,GRHL3,AHNAK2</TD></TR>
<TR><TD>1.534e-03</TD><TD>-6.48</TD><TD>HALLMARK_GLYCOLYSIS</TD><TD>MSigDB lists</TD><TD>HALLMARK_GLYCOLYSIS</TD><TD>197</TD><TD>4</TD><TD>17758</TD><TD>45</TD>
<TD>CD44,PRPS1,ANGPTL4,NT5E</TD></TR>
<TR><TD>1.536e-03</TD><TD>-6.48</TD><TD>V$MEF2_04</TD><TD>MSigDB lists</TD><TD>V$MEF2_04</TD><TD>23</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>SLCO5A1,NR2F1</TD></TR>
<TR><TD>1.536e-03</TD><TD>-6.48</TD><TD>VIETOR_IFRD1_TARGETS</TD><TD>MSigDB lists</TD><TD>VIETOR_IFRD1_TARGETS</TD><TD>23</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>MSX2,KRT7</TD></TR>
<TR><TD>1.563e-03</TD><TD>-6.46</TD><TD>regulation of receptor biosynthetic process</TD><TD>biological process</TD><TD>GO:0010869</TD><TD>22</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>PPARG,NR2F1</TD></TR>
<TR><TD>1.563e-03</TD><TD>-6.46</TD><TD>regulation of intrinsic apoptotic signaling pathway by p53 class mediator</TD><TD>biological process</TD><TD>GO:1902253</TD><TD>22</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>MSX1,CD44</TD></TR>
<TR><TD>1.568e-03</TD><TD>-6.46</TD><TD>bone morphogenesis</TD><TD>biological process</TD><TD>GO:0060349</TD><TD>86</TD><TD>3</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2,MSX1,MMP16</TD></TR>
<TR><TD>1.578e-03</TD><TD>-6.45</TD><TD>regulation of cell death</TD><TD>biological process</TD><TD>GO:0010941</TD><TD>1498</TD><TD>11</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2,SLC40A1,TNIK,CAMK2D,MSX1,PPARG,SLK,WNT16,CD44,ANGPTL4,PDE3A</TD></TR>
<TR><TD>1.581e-03</TD><TD>-6.45</TD><TD>GAUSSMANN_MLL_AF4_FUSION_TARGETS_E_UP</TD><TD>MSigDB lists</TD><TD>GAUSSMANN_MLL_AF4_FUSION_TARGETS_E_UP</TD><TD>91</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>S100A10,SORCS2,PDE10A</TD></TR>
<TR><TD>1.592e-03</TD><TD>-6.44</TD><TD>EBAUER_TARGETS_OF_PAX3_FOXO1_FUSION_UP</TD><TD>MSigDB lists</TD><TD>EBAUER_TARGETS_OF_PAX3_FOXO1_FUSION_UP</TD><TD>199</TD><TD>4</TD><TD>17758</TD><TD>45</TD>
<TD>CLSTN2,NEBL,PDLIM5,AHNAK2</TD></TR>
<TR><TD>1.592e-03</TD><TD>-6.44</TD><TD>PICCALUGA_ANGIOIMMUNOBLASTIC_LYMPHOMA_UP</TD><TD>MSigDB lists</TD><TD>PICCALUGA_ANGIOIMMUNOBLASTIC_LYMPHOMA_UP</TD><TD>199</TD><TD>4</TD><TD>17758</TD><TD>45</TD>
<TD>LAMA4,SLC40A1,NR2F2,PDLIM5</TD></TR>
<TR><TD>1.621e-03</TD><TD>-6.42</TD><TD>MODULE_342</TD><TD>MSigDB lists</TD><TD>MODULE_342</TD><TD>200</TD><TD>4</TD><TD>17758</TD><TD>45</TD>
<TD>RNF43,KRT7,NEBL,STXBP6</TD></TR>
<TR><TD>1.621e-03</TD><TD>-6.42</TD><TD>V$STAT5A_04</TD><TD>MSigDB lists</TD><TD>V$STAT5A_04</TD><TD>200</TD><TD>4</TD><TD>17758</TD><TD>45</TD>
<TD>PBX1,CSMD3,RNF43,MSX2</TD></TR>
<TR><TD>1.621e-03</TD><TD>-6.42</TD><TD>V$TFIII_Q6</TD><TD>MSigDB lists</TD><TD>V$TFIII_Q6</TD><TD>200</TD><TD>4</TD><TD>17758</TD><TD>45</TD>
<TD>PBX1,ZIC2,CD44,NR2F2</TD></TR>
<TR><TD>1.632e-03</TD><TD>-6.42</TD><TD>negative regulation of molecular function</TD><TD>biological process</TD><TD>GO:0044092</TD><TD>1054</TD><TD>9</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2,CAMK2D,MSX1,PPARG,PBX1,NR2F2,CD44,ANGPTL4,PKIB</TD></TR>
<TR><TD>1.635e-03</TD><TD>-6.42</TD><TD>mesenchyme development</TD><TD>biological process</TD><TD>GO:0060485</TD><TD>190</TD><TD>4</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2,FGF9,MSX1,WNT16</TD></TR>
<TR><TD>1.637e-03</TD><TD>-6.41</TD><TD>Transcriptional regulation of white adipocyte differentiation</TD><TD>REACTOME pathways</TD><TD>R-HSA-381340</TD><TD>78</TD><TD>3</TD><TD>8202</TD><TD>25</TD>
<TD>NR2F2,PPARG,ANGPTL4</TD></TR>
<TR><TD>1.641e-03</TD><TD>-6.41</TD><TD>plasma membrane region</TD><TD>cellular component</TD><TD>GO:0098590</TD><TD>906</TD><TD>8</TD><TD>17570</TD><TD>44</TD>
<TD>TNIK,SLC40A1,UNC13A,CLSTN2,CD44,ITGB4,PDLIM5,NT5E</TD></TR>
<TR><TD>1.648e-03</TD><TD>-6.41</TD><TD>HD/PDEase_dom</TD><TD>interpro domains</TD><TD>IPR003607</TD><TD>24</TD><TD>2</TD><TD>18293</TD><TD>46</TD>
<TD>PDE10A,PDE3A</TD></TR>
<TR><TD>1.676e-03</TD><TD>-6.39</TD><TD>basement membrane</TD><TD>cellular component</TD><TD>GO:0005604</TD><TD>94</TD><TD>3</TD><TD>17570</TD><TD>44</TD>
<TD>LAMA4,FGF9,ITGB4</TD></TR>
<TR><TD>1.681e-03</TD><TD>-6.39</TD><TD>MIYAGAWA_TARGETS_OF_EWSR1_ETS_FUSIONS_DN</TD><TD>MSigDB lists</TD><TD>MIYAGAWA_TARGETS_OF_EWSR1_ETS_FUSIONS_DN</TD><TD>202</TD><TD>4</TD><TD>17758</TD><TD>45</TD>
<TD>TNIK,CAMK2D,CD44,NR2F2</TD></TR>
<TR><TD>1.681e-03</TD><TD>-6.39</TD><TD>V$AHR_Q5</TD><TD>MSigDB lists</TD><TD>V$AHR_Q5</TD><TD>202</TD><TD>4</TD><TD>17758</TD><TD>45</TD>
<TD>FGF9,CAMK2D,ZIC2,NR2F2</TD></TR>
<TR><TD>1.689e-03</TD><TD>-6.38</TD><TD>regionalization</TD><TD>biological process</TD><TD>GO:0003002</TD><TD>325</TD><TD>5</TD><TD>16441</TD><TD>44</TD>
<TD>PBX1,MSX2,MSX1,NR2F2,NR2F1</TD></TR>
<TR><TD>1.709e-03</TD><TD>-6.37</TD><TD>cardiac muscle hypertrophy</TD><TD>biological process</TD><TD>GO:0003300</TD><TD>23</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>CAMK2D,PDLIM5</TD></TR>
<TR><TD>1.709e-03</TD><TD>-6.37</TD><TD>trabecula formation</TD><TD>biological process</TD><TD>GO:0060343</TD><TD>23</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>SLC40A1,MSX2</TD></TR>
<TR><TD>1.743e-03</TD><TD>-6.35</TD><TD>V$SRF_C</TD><TD>MSigDB lists</TD><TD>V$SRF_C</TD><TD>204</TD><TD>4</TD><TD>17758</TD><TD>45</TD>
<TD>NR2F2,PDLIM5,TANK,NR2F1</TD></TR>
<TR><TD>1.767e-03</TD><TD>-6.34</TD><TD>3',5'-cyclic-nucleotide phosphodiesterase activity</TD><TD>molecular function</TD><TD>GO:0004114</TD><TD>24</TD><TD>2</TD><TD>16491</TD><TD>43</TD>
<TD>PDE10A,PDE3A</TD></TR>
<TR><TD>1.767e-03</TD><TD>-6.34</TD><TD>cAMP binding</TD><TD>molecular function</TD><TD>GO:0030552</TD><TD>24</TD><TD>2</TD><TD>16491</TD><TD>43</TD>
<TD>PDE10A,PDE3A</TD></TR>
<TR><TD>1.775e-03</TD><TD>-6.33</TD><TD>RODWELL_AGING_KIDNEY_NO_BLOOD_UP</TD><TD>MSigDB lists</TD><TD>RODWELL_AGING_KIDNEY_NO_BLOOD_UP</TD><TD>205</TD><TD>4</TD><TD>17758</TD><TD>45</TD>
<TD>SLC40A1,PKIB,NR2F1,VSNL1</TD></TR>
<TR><TD>1.782e-03</TD><TD>-6.33</TD><TD>central nervous system development</TD><TD>biological process</TD><TD>GO:0007417</TD><TD>859</TD><TD>8</TD><TD>16441</TD><TD>44</TD>
<TD>FGF9,MSX1,GRHL3,ZIC2,VIM,NR2F2,NR2F1,NT5E</TD></TR>
<TR><TD>1.808e-03</TD><TD>-6.32</TD><TD>LEE_BMP2_TARGETS_UP</TD><TD>MSigDB lists</TD><TD>LEE_BMP2_TARGETS_UP</TD><TD>703</TD><TD>7</TD><TD>17758</TD><TD>45</TD>
<TD>SLC40A1,MSX1,ITGB4,KRT7,SORCS2,STXBP6,AHNAK2</TD></TR>
<TR><TD>1.815e-03</TD><TD>-6.31</TD><TD>REACTOME_NITRIC_OXIDE_STIMULATES_GUANYLATE_CYCLASE</TD><TD>MSigDB lists</TD><TD>REACTOME_NITRIC_OXIDE_STIMULATES_GUANYLATE_CYCLASE</TD><TD>25</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>PDE10A,PDE3A</TD></TR>
<TR><TD>1.843e-03</TD><TD>-6.30</TD><TD>MSX1 (msh homeobox 1)</TD><TD>protein interactions</TD><TD>4487</TD><TD>25</TD><TD>2</TD><TD>16036</TD><TD>41</TD>
<TD>MSX2,MSX1</TD></TR>
<TR><TD>1.843e-03</TD><TD>-6.30</TD><TD>PLA2G4A (phospholipase A2, group IVA (cytosolic, calcium-dependent))</TD><TD>protein interactions</TD><TD>5321</TD><TD>25</TD><TD>2</TD><TD>16036</TD><TD>41</TD>
<TD>VIM,S100A10</TD></TR>
<TR><TD>1.861e-03</TD><TD>-6.29</TD><TD>striated muscle hypertrophy</TD><TD>biological process</TD><TD>GO:0014897</TD><TD>24</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>CAMK2D,PDLIM5</TD></TR>
<TR><TD>1.861e-03</TD><TD>-6.29</TD><TD>cardiac muscle tissue growth</TD><TD>biological process</TD><TD>GO:0055017</TD><TD>24</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>CAMK2D,PDLIM5</TD></TR>
<TR><TD>1.887e-03</TD><TD>-6.27</TD><TD>-</TD><TD>gene3d domains</TD><TD>1.10.1300.10</TD><TD>21</TD><TD>2</TD><TD>9988</TD><TD>31</TD>
<TD>PDE10A,PDE3A</TD></TR>
<TR><TD>1.896e-03</TD><TD>-6.27</TD><TD>YNGTTNNNATT_UNKNOWN</TD><TD>MSigDB lists</TD><TD>YNGTTNNNATT_UNKNOWN</TD><TD>352</TD><TD>5</TD><TD>17758</TD><TD>45</TD>
<TD>PBX1,FGF9,ZIC2,CD44,ETV1</TD></TR>
<TR><TD>1.898e-03</TD><TD>-6.27</TD><TD>KOBAYASHI_EGFR_SIGNALING_24HR_UP</TD><TD>MSigDB lists</TD><TD>KOBAYASHI_EGFR_SIGNALING_24HR_UP</TD><TD>97</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>PBX1,NEBL,AHNAK2</TD></TR>
<TR><TD>1.901e-03</TD><TD>-6.27</TD><TD>connective tissue development</TD><TD>biological process</TD><TD>GO:0061448</TD><TD>198</TD><TD>4</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2,FGF9,MSX1,CD44</TD></TR>
<TR><TD>1.905e-03</TD><TD>-6.26</TD><TD>human chr6q14-q21</TD><TD>chromosome location</TD><TD>human chr6q14-q21</TD><TD>1</TD><TD>1</TD><TD>26250</TD><TD>50</TD>
<TD>NT5E</TD></TR>
<TR><TD>1.918e-03</TD><TD>-6.26</TD><TD>cyclic-nucleotide phosphodiesterase activity</TD><TD>molecular function</TD><TD>GO:0004112</TD><TD>25</TD><TD>2</TD><TD>16491</TD><TD>43</TD>
<TD>PDE10A,PDE3A</TD></TR>
<TR><TD>1.919e-03</TD><TD>-6.26</TD><TD>MODULE_12</TD><TD>MSigDB lists</TD><TD>MODULE_12</TD><TD>353</TD><TD>5</TD><TD>17758</TD><TD>45</TD>
<TD>ITGB4,NEBL,PDLIM5,NR2F1,VSNL1</TD></TR>
<TR><TD>1.938e-03</TD><TD>-6.25</TD><TD>CTTTAAR_UNKNOWN</TD><TD>MSigDB lists</TD><TD>CTTTAAR_UNKNOWN</TD><TD>918</TD><TD>8</TD><TD>17758</TD><TD>45</TD>
<TD>FGF9,MSX2,PDE10A,STXBP6,VSNL1,PBX1,ZIC2,NR2F2</TD></TR>
<TR><TD>1.959e-03</TD><TD>-6.24</TD><TD>CTGCAGY_UNKNOWN</TD><TD>MSigDB lists</TD><TD>CTGCAGY_UNKNOWN</TD><TD>713</TD><TD>7</TD><TD>17758</TD><TD>45</TD>
<TD>SLCO5A1,FGF9,CAMK2D,ETV1,HFM1,NR2F1,VSNL1</TD></TR>
<TR><TD>1.963e-03</TD><TD>-6.23</TD><TD>XU_HGF_SIGNALING_NOT_VIA_AKT1_6HR</TD><TD>MSigDB lists</TD><TD>XU_HGF_SIGNALING_NOT_VIA_AKT1_6HR</TD><TD>26</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>CD44,ANGPTL4</TD></TR>
<TR><TD>1.963e-03</TD><TD>-6.23</TD><TD>MODULE_68</TD><TD>MSigDB lists</TD><TD>MODULE_68</TD><TD>26</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>VIM,KRT7</TD></TR>
<TR><TD>1.994e-03</TD><TD>-6.22</TD><TD>ARHGEF1 (Rho guanine nucleotide exchange factor 1)</TD><TD>protein interactions</TD><TD>9138</TD><TD>26</TD><TD>2</TD><TD>16036</TD><TD>41</TD>
<TD>CD44,SLK</TD></TR>
<TR><TD>1.994e-03</TD><TD>-6.22</TD><TD>MPPED1 (metallophosphoesterase domain containing 1)</TD><TD>protein interactions</TD><TD>758</TD><TD>26</TD><TD>2</TD><TD>16036</TD><TD>41</TD>
<TD>NR2F2,NR2F1</TD></TR>
<TR><TD>2.008e-03</TD><TD>-6.21</TD><TD>anterior/posterior pattern specification</TD><TD>biological process</TD><TD>GO:0009952</TD><TD>201</TD><TD>4</TD><TD>16441</TD><TD>44</TD>
<TD>PBX1,MSX2,MSX1,NR2F2</TD></TR>
<TR><TD>2.013e-03</TD><TD>-6.21</TD><TD>KANG_IMMORTALIZED_BY_TERT_DN</TD><TD>MSigDB lists</TD><TD>KANG_IMMORTALIZED_BY_TERT_DN</TD><TD>99</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>MSX2,CD44,PDE10A</TD></TR>
<TR><TD>2.015e-03</TD><TD>-6.21</TD><TD>ovary-carcinoma-serous_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>ovary-carcinoma-serous_carcinoma</TD><TD>11219</TD><TD>37</TD><TD>17775</TD><TD>44</TD>
<TD>EFNB2,TNIK,CNTNAP3,HFM1,C1orf226,CLSTN2,RNF43,PDE3A,S100A10,NEBL,PDE10A,UNC13A,WNT16,ETV1,PRPS1,NT5E,LAMA4,SLC40A1,FGF9,MSX1,KRT7,PPARG,VSNL1,GRHL3,VIM,ANGPTL4,NR2F1,MSX2,CAMK2D,AHNAK2,CSMD3,SLCO5A1,NR2F2,SORCS2,ITGB4,PDLIM5,MMP16</TD></TR>
<TR><TD>2.019e-03</TD><TD>-6.20</TD><TD>positive regulation of cardiac muscle tissue development</TD><TD>biological process</TD><TD>GO:0055025</TD><TD>25</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>EFNB2,FGF9</TD></TR>
<TR><TD>2.019e-03</TD><TD>-6.20</TD><TD>heart growth</TD><TD>biological process</TD><TD>GO:0060419</TD><TD>25</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>CAMK2D,PDLIM5</TD></TR>
<TR><TD>2.019e-03</TD><TD>-6.20</TD><TD>regulation of activin receptor signaling pathway</TD><TD>biological process</TD><TD>GO:0032925</TD><TD>25</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>ZIC2,FGF9</TD></TR>
<TR><TD>2.023e-03</TD><TD>-6.20</TD><TD>hormone-mediated signaling pathway</TD><TD>biological process</TD><TD>GO:0009755</TD><TD>94</TD><TD>3</TD><TD>16441</TD><TD>44</TD>
<TD>NR2F2,PPARG,NR2F1</TD></TR>
<TR><TD>2.071e-03</TD><TD>-6.18</TD><TD>HOELZEL_NF1_TARGETS_DN</TD><TD>MSigDB lists</TD><TD>HOELZEL_NF1_TARGETS_DN</TD><TD>100</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>NR2F2,MMP16,NR2F1</TD></TR>
<TR><TD>2.085e-03</TD><TD>-6.17</TD><TD>positive regulation of cellular metabolic process</TD><TD>biological process</TD><TD>GO:0031325</TD><TD>2864</TD><TD>16</TD><TD>16441</TD><TD>44</TD>
<TD>SLC40A1,TNIK,FGF9,MSX1,PPARG,SLK,GRHL3,PBX1,ZIC2,NR2F1,CAMK2D,WNT16,NR2F2,CD44,ETV1,PKIB</TD></TR>
<TR><TD>2.104e-03</TD><TD>-6.16</TD><TD>RODRIGUES_THYROID_CARCINOMA_POORLY_DIFFERENTIATED_DN</TD><TD>MSigDB lists</TD><TD>RODRIGUES_THYROID_CARCINOMA_POORLY_DIFFERENTIATED_DN</TD><TD>722</TD><TD>7</TD><TD>17758</TD><TD>45</TD>
<TD>LAMA4,VIM,SLC40A1,CD44,KRT7,NR2F2,PDLIM5</TD></TR>
<TR><TD>2.104e-03</TD><TD>-6.16</TD><TD>ovary-other-neoplasm</TD><TD>COSMIC cancer mutations</TD><TD>ovary-other-neoplasm</TD><TD>13367</TD><TD>41</TD><TD>17775</TD><TD>44</TD>
<TD>EFNB2,TNIK,CNTNAP3,STXBP6,HFM1,C1orf226,CLSTN2,PBX1,RNF43,ZIC2,PDE3A,S100A10,NEBL,PDE10A,UNC13A,TANK,WNT16,CD44,ETV1,PRPS1,NT5E,LAMA4,SLC40A1,FGF9,MSX1,KRT7,PPARG,VSNL1,GRHL3,VIM,ANGPTL4,RHOU,MSX2,CAMK2D,CSMD3,SLCO5A1,NR2F2,ITGB4,PDLIM5,MMP16,PKIB</TD></TR>
<TR><TD>2.117e-03</TD><TD>-6.16</TD><TD>WATANABE_COLON_CANCER_MSI_VS_MSS_UP</TD><TD>MSigDB lists</TD><TD>WATANABE_COLON_CANCER_MSI_VS_MSS_UP</TD><TD>27</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>ZIC2,PDE10A</TD></TR>
<TR><TD>2.165e-03</TD><TD>-6.14</TD><TD>positive regulation of signaling</TD><TD>biological process</TD><TD>GO:0023056</TD><TD>1558</TD><TD>11</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2,TNIK,CAMK2D,FGF9,MSX1,UNC13A,VSNL1,CLSTN2,ZIC2,WNT16,CD44</TD></TR>
<TR><TD>2.165e-03</TD><TD>-6.14</TD><TD>bone-tibia-other-chondroblastoma</TD><TD>COSMIC cancer mutations</TD><TD>bone-tibia-other-chondroblastoma</TD><TD>104</TD><TD>3</TD><TD>17775</TD><TD>44</TD>
<TD>CLSTN2,RNF43,CNTNAP3</TD></TR>
<TR><TD>2.168e-03</TD><TD>-6.13</TD><TD>PEDERSEN_METASTASIS_BY_ERBB2_ISOFORM_7</TD><TD>MSigDB lists</TD><TD>PEDERSEN_METASTASIS_BY_ERBB2_ISOFORM_7</TD><TD>363</TD><TD>5</TD><TD>17758</TD><TD>45</TD>
<TD>PBX1,CD44,NR2F2,ANGPTL4,NT5E</TD></TR>
<TR><TD>2.170e-03</TD><TD>-6.13</TD><TD>Laminin interactions</TD><TD>REACTOME pathways</TD><TD>R-HSA-3000157</TD><TD>23</TD><TD>2</TD><TD>8202</TD><TD>25</TD>
<TD>LAMA4,ITGB4</TD></TR>
<TR><TD>2.184e-03</TD><TD>-6.13</TD><TD>muscle hypertrophy</TD><TD>biological process</TD><TD>GO:0014896</TD><TD>26</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>CAMK2D,PDLIM5</TD></TR>
<TR><TD>2.186e-03</TD><TD>-6.13</TD><TD>negative regulation of cellular process</TD><TD>biological process</TD><TD>GO:0048523</TD><TD>4068</TD><TD>20</TD><TD>16441</TD><TD>44</TD>
<TD>EFNB2,SLC40A1,FGF9,MSX1,PPARG,STXBP6,VSNL1,PBX1,VIM,ZIC2,RNF43,ANGPTL4,PDE3A,NR2F1,MSX2,CAMK2D,WNT16,CD44,NR2F2,PKIB</TD></TR>
<TR><TD>2.220e-03</TD><TD>-6.11</TD><TD>V$CDPCR3HD_01</TD><TD>MSigDB lists</TD><TD>V$CDPCR3HD_01</TD><TD>218</TD><TD>4</TD><TD>17758</TD><TD>45</TD>
<TD>CLSTN2,CSMD3,CAMK2D,ETV1</TD></TR>
<TR><TD>2.234e-03</TD><TD>-6.10</TD><TD>PDEASE_I</TD><TD>prosite domains</TD><TD>PS00126</TD><TD>21</TD><TD>2</TD><TD>11866</TD><TD>40</TD>
<TD>PDE10A,PDE3A</TD></TR>
<TR><TD>2.237e-03</TD><TD>-6.10</TD><TD>actinin binding</TD><TD>molecular function</TD><TD>GO:0042805</TD><TD>27</TD><TD>2</TD><TD>16491</TD><TD>43</TD>
<TD>PPARG,PDLIM5</TD></TR>
<TR><TD>2.253e-03</TD><TD>-6.10</TD><TD>LIN_SILENCED_BY_TUMOR_MICROENVIRONMENT</TD><TD>MSigDB lists</TD><TD>LIN_SILENCED_BY_TUMOR_MICROENVIRONMENT</TD><TD>103</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>KRT7,NEBL,GRHL3</TD></TR>
<TR><TD>2.262e-03</TD><TD>-6.09</TD><TD>regulation of signaling</TD><TD>biological process</TD><TD>GO:0023051</TD><TD>2886</TD><TD>16</TD><TD>16441</TD><TD>44</TD>
<TD>TNIK,FGF9,MSX1,PPARG,GPAT3,VSNL1,CLSTN2,RNF43,ZIC2,RHOU,CAMK2D,MSX2,PDE10A,UNC13A,WNT16,CD44</TD></TR>
<TR><TD>2.276e-03</TD><TD>-6.09</TD><TD>TSENG_ADIPOGENIC_POTENTIAL_UP</TD><TD>MSigDB lists</TD><TD>TSENG_ADIPOGENIC_POTENTIAL_UP</TD><TD>28</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>RHOU,EFNB2</TD></TR>
<TR><TD>2.278e-03</TD><TD>-6.08</TD><TD>cardiocyte differentiation</TD><TD>biological process</TD><TD>GO:0035051</TD><TD>98</TD><TD>3</TD><TD>16441</TD><TD>44</TD>
<TD>CAMK2D,NEBL,PDLIM5</TD></TR>
<TR><TD>2.279e-03</TD><TD>-6.08</TD><TD>BENPORATH_NANOG_TARGETS</TD><TD>MSigDB lists</TD><TD>BENPORATH_NANOG_TARGETS</TD><TD>942</TD><TD>8</TD><TD>17758</TD><TD>45</TD>
<TD>LAMA4,SLC40A1,NEBL,CNTNAP3,PBX1,ZIC2,VIM,PKIB</TD></TR>
<TR><TD>2.294e-03</TD><TD>-6.08</TD><TD>KONDO_EZH2_TARGETS</TD><TD>MSigDB lists</TD><TD>KONDO_EZH2_TARGETS</TD><TD>220</TD><TD>4</TD><TD>17758</TD><TD>45</TD>
<TD>MSX2,NEBL,CNTNAP3,NT5E</TD></TR>
<TR><TD>2.311e-03</TD><TD>-6.07</TD><TD>RNF13 (ring finger protein 13)</TD><TD>protein interactions</TD><TD>11342</TD><TD>28</TD><TD>2</TD><TD>16036</TD><TD>41</TD>
<TD>NR2F2,NR2F1</TD></TR>
<TR><TD>2.345e-03</TD><TD>-6.06</TD><TD>CAGGTA_V$AREB6_01</TD><TD>MSigDB lists</TD><TD>CAGGTA_V$AREB6_01</TD><TD>736</TD><TD>7</TD><TD>17758</TD><TD>45</TD>
<TD>PBX1,CSMD3,RNF43,FGF9,MSX1,HFM1,VSNL1</TD></TR>
<TR><TD>2.348e-03</TD><TD>-6.05</TD><TD>positive regulation of cell communication</TD><TD>biological process</TD><TD>GO:0010647</TD><TD>1574</TD><TD>11</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2,TNIK,CAMK2D,FGF9,MSX1,UNC13A,VSNL1,CLSTN2,ZIC2,WNT16,CD44</TD></TR>
<TR><TD>2.363e-03</TD><TD>-6.05</TD><TD>Nitric oxide stimulates guanylate cyclase</TD><TD>REACTOME pathways</TD><TD>R-HSA-392154</TD><TD>24</TD><TD>2</TD><TD>8202</TD><TD>25</TD>
<TD>PDE10A,PDE3A</TD></TR>
<TR><TD>2.405e-03</TD><TD>-6.03</TD><TD>multicellular organismal process</TD><TD>biological process</TD><TD>GO:0032501</TD><TD>6447</TD><TD>27</TD><TD>16441</TD><TD>44</TD>
<TD>EFNB2,SLC40A1,TNIK,FGF9,MSX1,PPARG,GRHL3,PBX1,VIM,ZIC2,ANGPTL4,PDE3A,NR2F1,MSX2,CAMK2D,NEBL,PDE10A,UNC13A,WNT16,ITGB4,CD44,NR2F2,PDLIM5,ETV1,MMP16,PRPS1,NT5E</TD></TR>
<TR><TD>2.449e-03</TD><TD>-6.01</TD><TD>V$NFKB_Q6_01</TD><TD>MSigDB lists</TD><TD>V$NFKB_Q6_01</TD><TD>224</TD><TD>4</TD><TD>17758</TD><TD>45</TD>
<TD>RNF43,MSX1,NR2F2,ETV1</TD></TR>
<TR><TD>2.456e-03</TD><TD>-6.01</TD><TD>haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-diffuse_large_B_cell_lymphoma</TD><TD>COSMIC cancer mutations</TD><TD>haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-diffuse_large_B_cell_lymphoma</TD><TD>3776</TD><TD>18</TD><TD>17775</TD><TD>44</TD>
<TD>EFNB2,LAMA4,TNIK,PPARG,STXBP6,VSNL1,CLSTN2,PDE3A,CAMK2D,NEBL,UNC13A,TANK,CSMD3,SLCO5A1,SORCS2,PDLIM5,MMP16,PKIB</TD></TR>
<TR><TD>2.491e-03</TD><TD>-6.00</TD><TD>Z disc</TD><TD>cellular component</TD><TD>GO:0030018</TD><TD>108</TD><TD>3</TD><TD>17570</TD><TD>44</TD>
<TD>NEBL,PDLIM5,AHNAK2</TD></TR>
<TR><TD>2.511e-03</TD><TD>-5.99</TD><TD>HOOI_ST7_TARGETS_DN</TD><TD>MSigDB lists</TD><TD>HOOI_ST7_TARGETS_DN</TD><TD>107</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>VIM,CNTNAP3,ANGPTL4</TD></TR>
<TR><TD>2.515e-03</TD><TD>-5.99</TD><TD>5'-Nucleotdase_C</TD><TD>interpro domains</TD><TD>IPR008334</TD><TD>1</TD><TD>1</TD><TD>18293</TD><TD>46</TD>
<TD>NT5E</TD></TR>
<TR><TD>2.515e-03</TD><TD>-5.99</TD><TD>DUF4628</TD><TD>interpro domains</TD><TD>IPR027851</TD><TD>1</TD><TD>1</TD><TD>18293</TD><TD>46</TD>
<TD>C1orf226</TD></TR>
<TR><TD>2.515e-03</TD><TD>-5.99</TD><TD>S100-A10</TD><TD>interpro domains</TD><TD>IPR028476</TD><TD>1</TD><TD>1</TD><TD>18293</TD><TD>46</TD>
<TD>S100A10</TD></TR>
<TR><TD>2.515e-03</TD><TD>-5.99</TD><TD>FGF9</TD><TD>interpro domains</TD><TD>IPR028251</TD><TD>1</TD><TD>1</TD><TD>18293</TD><TD>46</TD>
<TD>FGF9</TD></TR>
<TR><TD>2.515e-03</TD><TD>-5.99</TD><TD>UVR_dom</TD><TD>interpro domains</TD><TD>IPR001943</TD><TD>1</TD><TD>1</TD><TD>18293</TD><TD>46</TD>
<TD>SLK</TD></TR>
<TR><TD>2.515e-03</TD><TD>-5.99</TD><TD>Ferroportin-1</TD><TD>interpro domains</TD><TD>IPR009716</TD><TD>1</TD><TD>1</TD><TD>18293</TD><TD>46</TD>
<TD>SLC40A1</TD></TR>
<TR><TD>2.515e-03</TD><TD>-5.99</TD><TD>CD44_antigen</TD><TD>interpro domains</TD><TD>IPR001231</TD><TD>1</TD><TD>1</TD><TD>18293</TD><TD>46</TD>
<TD>CD44</TD></TR>
<TR><TD>2.515e-03</TD><TD>-5.99</TD><TD>5'-Nucleotdase_CS</TD><TD>interpro domains</TD><TD>IPR006146</TD><TD>1</TD><TD>1</TD><TD>18293</TD><TD>46</TD>
<TD>NT5E</TD></TR>
<TR><TD>2.515e-03</TD><TD>-5.99</TD><TD>PPARgamma_N</TD><TD>interpro domains</TD><TD>IPR022590</TD><TD>1</TD><TD>1</TD><TD>18293</TD><TD>46</TD>
<TD>PPARG</TD></TR>
<TR><TD>2.515e-03</TD><TD>-5.99</TD><TD>Wnt16</TD><TD>interpro domains</TD><TD>IPR013304</TD><TD>1</TD><TD>1</TD><TD>18293</TD><TD>46</TD>
<TD>WNT16</TD></TR>
<TR><TD>2.515e-03</TD><TD>-5.99</TD><TD>ANGPTL4</TD><TD>interpro domains</TD><TD>IPR028793</TD><TD>1</TD><TD>1</TD><TD>18293</TD><TD>46</TD>
<TD>ANGPTL4</TD></TR>
<TR><TD>2.515e-03</TD><TD>-5.99</TD><TD>Integrin_bsu-4</TD><TD>interpro domains</TD><TD>IPR012013</TD><TD>1</TD><TD>1</TD><TD>18293</TD><TD>46</TD>
<TD>ITGB4</TD></TR>
<TR><TD>2.515e-03</TD><TD>-5.99</TD><TD>5_nucleotidase/apyrase</TD><TD>interpro domains</TD><TD>IPR006179</TD><TD>1</TD><TD>1</TD><TD>18293</TD><TD>46</TD>
<TD>NT5E</TD></TR>
<TR><TD>2.515e-03</TD><TD>-5.99</TD><TD>MMP16</TD><TD>interpro domains</TD><TD>IPR028697</TD><TD>1</TD><TD>1</TD><TD>18293</TD><TD>46</TD>
<TD>MMP16</TD></TR>
<TR><TD>2.515e-03</TD><TD>-5.99</TD><TD>1Cnucl_rcpt_G</TD><TD>interpro domains</TD><TD>IPR003077</TD><TD>1</TD><TD>1</TD><TD>18293</TD><TD>46</TD>
<TD>PPARG</TD></TR>
<TR><TD>2.529e-03</TD><TD>-5.98</TD><TD>V$EVI1_04</TD><TD>MSigDB lists</TD><TD>V$EVI1_04</TD><TD>226</TD><TD>4</TD><TD>17758</TD><TD>45</TD>
<TD>CSMD3,SLC40A1,NR2F2,NR2F1</TD></TR>
<TR><TD>2.531e-03</TD><TD>-5.98</TD><TD>regulation of DNA damage response, signal transduction by p53 class mediator</TD><TD>biological process</TD><TD>GO:0043516</TD><TD>28</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>MSX1,CD44</TD></TR>
<TR><TD>2.534e-03</TD><TD>-5.98</TD><TD>transcription factor activity, sequence-specific DNA binding</TD><TD>molecular function</TD><TD>GO:0003700</TD><TD>1155</TD><TD>9</TD><TD>16491</TD><TD>43</TD>
<TD>MSX2,MSX1,PPARG,GRHL3,PBX1,ZIC2,NR2F2,ETV1,NR2F1</TD></TR>
<TR><TD>2.534e-03</TD><TD>-5.98</TD><TD>nucleic acid binding transcription factor activity</TD><TD>molecular function</TD><TD>GO:0001071</TD><TD>1155</TD><TD>9</TD><TD>16491</TD><TD>43</TD>
<TD>MSX2,MSX1,PPARG,GRHL3,PBX1,ZIC2,NR2F2,ETV1,NR2F1</TD></TR>
<TR><TD>2.557e-03</TD><TD>-5.97</TD><TD>G (attachment glycoprotein)</TD><TD>protein interactions</TD><TD>920955</TD><TD>1</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>EFNB2</TD></TR>
<TR><TD>2.557e-03</TD><TD>-5.97</TD><TD>ACTB (actin, beta)</TD><TD>protein interactions</TD><TD>396526</TD><TD>1</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>VSNL1</TD></TR>
<TR><TD>2.557e-03</TD><TD>-5.97</TD><TD>ANKRD35 (ankyrin repeat domain 35)</TD><TD>protein interactions</TD><TD>148741</TD><TD>1</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>VIM</TD></TR>
<TR><TD>2.557e-03</TD><TD>-5.97</TD><TD>daf-12 (Nuclear hormone receptor family member daf-12)</TD><TD>protein interactions</TD><TD>181263</TD><TD>1</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>PPARG</TD></TR>
<TR><TD>2.557e-03</TD><TD>-5.97</TD><TD>Ephb1 (Eph receptor B1)</TD><TD>protein interactions</TD><TD>24338</TD><TD>1</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>EFNB2</TD></TR>
<TR><TD>2.557e-03</TD><TD>-5.97</TD><TD>Rps6ka1 (ribosomal protein S6 kinase, polypeptide A1)</TD><TD>protein interactions</TD><TD>81771</TD><TD>1</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>ETV1</TD></TR>
<TR><TD>2.561e-03</TD><TD>-5.97</TD><TD>PIAS1 (protein inhibitor of activated STAT 1)</TD><TD>protein interactions</TD><TD>8554</TD><TD>107</TD><TD>3</TD><TD>16036</TD><TD>41</TD>
<TD>MSX1,NR2F2,PPARG</TD></TR>
<TR><TD>2.563e-03</TD><TD>-5.97</TD><TD>positive regulation of multicellular organismal process</TD><TD>biological process</TD><TD>GO:0051240</TD><TD>1353</TD><TD>10</TD><TD>16441</TD><TD>44</TD>
<TD>EFNB2,MSX2,CAMK2D,FGF9,PPARG,UNC13A,CLSTN2,ZIC2,ANGPTL4,PDE3A</TD></TR>
<TR><TD>2.573e-03</TD><TD>-5.96</TD><TD>Fibrinogen_a/b/g_C_1</TD><TD>interpro domains</TD><TD>IPR014716</TD><TD>30</TD><TD>2</TD><TD>18293</TD><TD>46</TD>
<TD>CNTNAP3,ANGPTL4</TD></TR>
<TR><TD>2.607e-03</TD><TD>-5.95</TD><TD>regulation of transmembrane receptor protein serine/threonine kinase signaling pathway</TD><TD>biological process</TD><TD>GO:0090092</TD><TD>216</TD><TD>4</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2,ZIC2,FGF9,MSX1</TD></TR>
<TR><TD>2.607e-03</TD><TD>-5.95</TD><TD>iron channel activity</TD><TD>molecular function</TD><TD>GO:0097689</TD><TD>1</TD><TD>1</TD><TD>16491</TD><TD>43</TD>
<TD>SLC40A1</TD></TR>
<TR><TD>2.611e-03</TD><TD>-5.95</TD><TD>regulation of anatomical structure morphogenesis</TD><TD>biological process</TD><TD>GO:0022603</TD><TD>913</TD><TD>8</TD><TD>16441</TD><TD>44</TD>
<TD>RHOU,TNIK,MSX1,S100A10,UNC13A,GRHL3,PDLIM5,ANGPTL4</TD></TR>
<TR><TD>2.611e-03</TD><TD>-5.95</TD><TD>RODRIGUES_NTN1_AND_DCC_TARGETS</TD><TD>MSigDB lists</TD><TD>RODRIGUES_NTN1_AND_DCC_TARGETS</TD><TD>30</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>MSX2,CAMK2D</TD></TR>
<TR><TD>2.611e-03</TD><TD>-5.95</TD><TD>TING_SILENCED_BY_DICER</TD><TD>MSigDB lists</TD><TD>TING_SILENCED_BY_DICER</TD><TD>30</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>SLC40A1,VIM</TD></TR>
<TR><TD>2.613e-03</TD><TD>-5.95</TD><TD>HAN_SATB1_TARGETS_UP</TD><TD>MSigDB lists</TD><TD>HAN_SATB1_TARGETS_UP</TD><TD>379</TD><TD>5</TD><TD>17758</TD><TD>45</TD>
<TD>ITGB4,PDE10A,STXBP6,NR2F1,VSNL1</TD></TR>
<TR><TD>2.625e-03</TD><TD>-5.94</TD><TD>odontogenesis</TD><TD>biological process</TD><TD>GO:0042476</TD><TD>103</TD><TD>3</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2,MSX1,ITGB4</TD></TR>
<TR><TD>2.646e-03</TD><TD>-5.93</TD><TD>DUF4628</TD><TD>pfam domains</TD><TD>PF15429</TD><TD>1</TD><TD>1</TD><TD>16629</TD><TD>44</TD>
<TD>C1orf226</TD></TR>
<TR><TD>2.646e-03</TD><TD>-5.93</TD><TD>5_nucleotid_C</TD><TD>pfam domains</TD><TD>PF02872</TD><TD>1</TD><TD>1</TD><TD>16629</TD><TD>44</TD>
<TD>NT5E</TD></TR>
<TR><TD>2.646e-03</TD><TD>-5.93</TD><TD>PPARgamma_N</TD><TD>pfam domains</TD><TD>PF12577</TD><TD>1</TD><TD>1</TD><TD>16629</TD><TD>44</TD>
<TD>PPARG</TD></TR>
<TR><TD>2.646e-03</TD><TD>-5.93</TD><TD>FPN1</TD><TD>pfam domains</TD><TD>PF06963</TD><TD>1</TD><TD>1</TD><TD>16629</TD><TD>44</TD>
<TD>SLC40A1</TD></TR>
<TR><TD>2.654e-03</TD><TD>-5.93</TD><TD>negative regulation of biological process</TD><TD>biological process</TD><TD>GO:0048519</TD><TD>4447</TD><TD>21</TD><TD>16441</TD><TD>44</TD>
<TD>EFNB2,SLC40A1,FGF9,MSX1,PPARG,STXBP6,VSNL1,PBX1,VIM,ZIC2,RNF43,ANGPTL4,PDE3A,NR2F1,MSX2,CAMK2D,WNT16,CD44,NR2F2,PKIB,NT5E</TD></TR>
<TR><TD>2.665e-03</TD><TD>-5.93</TD><TD>haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-mantle_cell_lymphoma</TD><TD>COSMIC cancer mutations</TD><TD>haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-mantle_cell_lymphoma</TD><TD>2863</TD><TD>15</TD><TD>17775</TD><TD>44</TD>
<TD>NEBL,STXBP6,HFM1,UNC13A,CLSTN2,SLCO5A1,CSMD3,ZIC2,CD44,SORCS2,PDLIM5,MMP16,PDE3A,NR2F1,NT5E</TD></TR>
<TR><TD>2.666e-03</TD><TD>-5.93</TD><TD>regulation of cell communication</TD><TD>biological process</TD><TD>GO:0010646</TD><TD>2931</TD><TD>16</TD><TD>16441</TD><TD>44</TD>
<TD>TNIK,FGF9,MSX1,PPARG,GPAT3,VSNL1,CLSTN2,RNF43,ZIC2,RHOU,CAMK2D,MSX2,PDE10A,UNC13A,WNT16,CD44</TD></TR>
<TR><TD>2.676e-03</TD><TD>-5.92</TD><TD>radial pattern formation</TD><TD>biological process</TD><TD>GO:0009956</TD><TD>1</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>NR2F2</TD></TR>
<TR><TD>2.676e-03</TD><TD>-5.92</TD><TD>iron cation export</TD><TD>biological process</TD><TD>GO:1903414</TD><TD>1</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>SLC40A1</TD></TR>
<TR><TD>2.676e-03</TD><TD>-5.92</TD><TD>spleen trabecula formation</TD><TD>biological process</TD><TD>GO:0060345</TD><TD>1</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>SLC40A1</TD></TR>
<TR><TD>2.676e-03</TD><TD>-5.92</TD><TD>adenosine biosynthetic process</TD><TD>biological process</TD><TD>GO:0046086</TD><TD>1</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>NT5E</TD></TR>
<TR><TD>2.676e-03</TD><TD>-5.92</TD><TD>cardiac muscle thin filament assembly</TD><TD>biological process</TD><TD>GO:0071691</TD><TD>1</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>NEBL</TD></TR>
<TR><TD>2.676e-03</TD><TD>-5.92</TD><TD>negative regulation of pancreatic stellate cell proliferation</TD><TD>biological process</TD><TD>GO:2000230</TD><TD>1</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>PPARG</TD></TR>
<TR><TD>2.676e-03</TD><TD>-5.92</TD><TD>ferrous iron export</TD><TD>biological process</TD><TD>GO:1903988</TD><TD>1</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>SLC40A1</TD></TR>
<TR><TD>2.676e-03</TD><TD>-5.92</TD><TD>low-density lipoprotein particle receptor biosynthetic process</TD><TD>biological process</TD><TD>GO:0045713</TD><TD>1</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>PPARG</TD></TR>
<TR><TD>2.676e-03</TD><TD>-5.92</TD><TD>response to metformin</TD><TD>biological process</TD><TD>GO:1901558</TD><TD>1</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>PPARG</TD></TR>
<TR><TD>2.681e-03</TD><TD>-5.92</TD><TD>cellular response to endogenous stimulus</TD><TD>biological process</TD><TD>GO:0071495</TD><TD>1133</TD><TD>9</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2,CAMK2D,FGF9,MSX1,PPARG,NR2F2,CD44,PDE3A,NR2F1</TD></TR>
<TR><TD>2.714e-03</TD><TD>-5.91</TD><TD>embryonic hindlimb morphogenesis</TD><TD>biological process</TD><TD>GO:0035116</TD><TD>29</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2,MSX1</TD></TR>
<TR><TD>2.714e-03</TD><TD>-5.91</TD><TD>endocardial cushion development</TD><TD>biological process</TD><TD>GO:0003197</TD><TD>29</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2,MSX1</TD></TR>
<TR><TD>2.762e-03</TD><TD>-5.89</TD><TD>ovary</TD><TD>COSMIC cancer mutations</TD><TD>ovary</TD><TD>15550</TD><TD>44</TD><TD>17775</TD><TD>44</TD>
<TD>EFNB2,TNIK,CNTNAP3,STXBP6,HFM1,C1orf226,CLSTN2,PBX1,RNF43,ZIC2,PDE3A,S100A10,NEBL,PDE10A,UNC13A,TANK,WNT16,CD44,ETV1,PRPS1,NT5E,LAMA4,SLC40A1,FGF9,MSX1,KRT7,PPARG,VSNL1,GRHL3,VIM,ANGPTL4,NR2F1,RHOU,MSX2,CAMK2D,AHNAK2,SLCO5A1,CSMD3,SORCS2,NR2F2,ITGB4,PDLIM5,MMP16,PKIB</TD></TR>
<TR><TD>2.766e-03</TD><TD>-5.89</TD><TD>cellular response to organic cyclic compound</TD><TD>biological process</TD><TD>GO:0071407</TD><TD>364</TD><TD>5</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2,NR2F2,PPARG,NR2F1,PDE3A</TD></TR>
<TR><TD>2.825e-03</TD><TD>-5.87</TD><TD>neoplasm</TD><TD>COSMIC cancer mutations</TD><TD>neoplasm</TD><TD>15558</TD><TD>44</TD><TD>17775</TD><TD>44</TD>
<TD>EFNB2,TNIK,CNTNAP3,STXBP6,HFM1,C1orf226,CLSTN2,PBX1,RNF43,ZIC2,PDE3A,S100A10,NEBL,PDE10A,UNC13A,TANK,WNT16,CD44,ETV1,PRPS1,NT5E,LAMA4,SLC40A1,FGF9,MSX1,KRT7,PPARG,VSNL1,GRHL3,VIM,ANGPTL4,NR2F1,RHOU,MSX2,CAMK2D,AHNAK2,SLCO5A1,CSMD3,SORCS2,NR2F2,ITGB4,PDLIM5,MMP16,PKIB</TD></TR>
<TR><TD>2.830e-03</TD><TD>-5.87</TD><TD>BCL11A (B-cell CLL/lymphoma 11A (zinc finger protein))</TD><TD>protein interactions</TD><TD>53335</TD><TD>31</TD><TD>2</TD><TD>16036</TD><TD>41</TD>
<TD>NR2F2,NR2F1</TD></TR>
<TR><TD>2.867e-03</TD><TD>-5.85</TD><TD>PLASARI_TGFB1_TARGETS_10HR_DN</TD><TD>MSigDB lists</TD><TD>PLASARI_TGFB1_TARGETS_10HR_DN</TD><TD>234</TD><TD>4</TD><TD>17758</TD><TD>45</TD>
<TD>LAMA4,PBX1,SLC40A1,MMP16</TD></TR>
<TR><TD>2.909e-03</TD><TD>-5.84</TD><TD>-</TD><TD>gene3d domains</TD><TD>2.60.120.200</TD><TD>93</TD><TD>3</TD><TD>9988</TD><TD>31</TD>
<TD>CLSTN2,LAMA4,CNTNAP3</TD></TR>
<TR><TD>2.924e-03</TD><TD>-5.83</TD><TD>THUM_SYSTOLIC_HEART_FAILURE_UP</TD><TD>MSigDB lists</TD><TD>THUM_SYSTOLIC_HEART_FAILURE_UP</TD><TD>389</TD><TD>5</TD><TD>17758</TD><TD>45</TD>
<TD>ETV1,PRPS1,TANK,VSNL1,NT5E</TD></TR>
<TR><TD>2.924e-03</TD><TD>-5.83</TD><TD>Fibrinogen_a/b/g_C_dom</TD><TD>interpro domains</TD><TD>IPR002181</TD><TD>32</TD><TD>2</TD><TD>18293</TD><TD>46</TD>
<TD>CNTNAP3,ANGPTL4</TD></TR>
<TR><TD>2.976e-03</TD><TD>-5.82</TD><TD>plasma membrane part</TD><TD>cellular component</TD><TD>GO:0044459</TD><TD>2566</TD><TD>14</TD><TD>17570</TD><TD>44</TD>
<TD>EFNB2,TNIK,SLC40A1,S100A10,UNC13A,AHNAK2,CLSTN2,SLCO5A1,RNF43,ITGB4,CD44,PDLIM5,MMP16,NT5E</TD></TR>
<TR><TD>3.001e-03</TD><TD>-5.81</TD><TD>RRAGTTGT_UNKNOWN</TD><TD>MSigDB lists</TD><TD>RRAGTTGT_UNKNOWN</TD><TD>237</TD><TD>4</TD><TD>17758</TD><TD>45</TD>
<TD>CSMD3,MSX2,ETV1,NR2F1</TD></TR>
<TR><TD>3.026e-03</TD><TD>-5.80</TD><TD>signal transduction</TD><TD>biological process</TD><TD>GO:0007165</TD><TD>4816</TD><TD>22</TD><TD>16441</TD><TD>44</TD>
<TD>EFNB2,TNIK,FGF9,MSX1,PPARG,SLK,GRHL3,VIM,RNF43,NR2F1,PDE3A,RHOU,MSX2,CAMK2D,PDE10A,TANK,UNC13A,WNT16,ITGB4,SORCS2,NR2F2,CD44</TD></TR>
<TR><TD>3.089e-03</TD><TD>-5.78</TD><TD>cell-substrate junction</TD><TD>cellular component</TD><TD>GO:0030055</TD><TD>399</TD><TD>5</TD><TD>17570</TD><TD>44</TD>
<TD>EFNB2,RHOU,VIM,ITGB4,CD44</TD></TR>
<TR><TD>3.093e-03</TD><TD>-5.78</TD><TD>V$CP2_02</TD><TD>MSigDB lists</TD><TD>V$CP2_02</TD><TD>239</TD><TD>4</TD><TD>17758</TD><TD>45</TD>
<TD>FGF9,ETV1,NR2F1,GRHL3</TD></TR>
<TR><TD>3.101e-03</TD><TD>-5.78</TD><TD>ANATOMICAL_STRUCTURE_DEVELOPMENT</TD><TD>MSigDB lists</TD><TD>ANATOMICAL_STRUCTURE_DEVELOPMENT</TD><TD>990</TD><TD>8</TD><TD>17758</TD><TD>45</TD>
<TD>EFNB2,SLC40A1,MSX2,MSX1,PBX1,ZIC2,ANGPTL4,PRPS1</TD></TR>
<TR><TD>3.104e-03</TD><TD>-5.78</TD><TD>-</TD><TD>gene3d domains</TD><TD>3.90.780.10</TD><TD>1</TD><TD>1</TD><TD>9988</TD><TD>31</TD>
<TD>NT5E</TD></TR>
<TR><TD>3.141e-03</TD><TD>-5.76</TD><TD>PHB2 (prohibitin 2)</TD><TD>protein interactions</TD><TD>11331</TD><TD>115</TD><TD>3</TD><TD>16036</TD><TD>41</TD>
<TD>NR2F2,PPARG,NR2F1</TD></TR>
<TR><TD>3.218e-03</TD><TD>-5.74</TD><TD>NCOA3 (nuclear receptor coactivator 3)</TD><TD>protein interactions</TD><TD>8202</TD><TD>116</TD><TD>3</TD><TD>16036</TD><TD>41</TD>
<TD>PPARG,ETV1,NR2F1</TD></TR>
<TR><TD>3.235e-03</TD><TD>-5.73</TD><TD>V$PBX1_01</TD><TD>MSigDB lists</TD><TD>V$PBX1_01</TD><TD>242</TD><TD>4</TD><TD>17758</TD><TD>45</TD>
<TD>RNF43,CAMK2D,ZIC2,SLK</TD></TR>
<TR><TD>3.252e-03</TD><TD>-5.73</TD><TD>Purine metabolism</TD><TD>KEGG pathways</TD><TD>hsa00230</TD><TD>174</TD><TD>4</TD><TD>6908</TD><TD>25</TD>
<TD>PDE10A,PRPS1,PDE3A,NT5E</TD></TR>
<TR><TD>3.252e-03</TD><TD>-5.73</TD><TD>Purine metabolism</TD><TD>KEGG pathways</TD><TD>ko00230</TD><TD>174</TD><TD>4</TD><TD>6908</TD><TD>25</TD>
<TD>PRPS1,PDE10A,PDE3A,NT5E</TD></TR>
<TR><TD>3.281e-03</TD><TD>-5.72</TD><TD>cerebellum</TD><TD>COSMIC cancer mutations</TD><TD>cerebellum</TD><TD>801</TD><TD>7</TD><TD>17775</TD><TD>44</TD>
<TD>CLSTN2,SLCO5A1,CSMD3,CAMK2D,NEBL,SORCS2,PDE10A</TD></TR>
<TR><TD>3.283e-03</TD><TD>-5.72</TD><TD>KAAB_HEART_ATRIUM_VS_VENTRICLE_UP</TD><TD>MSigDB lists</TD><TD>KAAB_HEART_ATRIUM_VS_VENTRICLE_UP</TD><TD>243</TD><TD>4</TD><TD>17758</TD><TD>45</TD>
<TD>VIM,NR2F2,NR2F1,VSNL1</TD></TR>
<TR><TD>3.299e-03</TD><TD>-5.71</TD><TD>regulation of transcription regulatory region DNA binding</TD><TD>biological process</TD><TD>GO:2000677</TD><TD>32</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2,MSX1</TD></TR>
<TR><TD>3.299e-03</TD><TD>-5.71</TD><TD>positive regulation of BMP signaling pathway</TD><TD>biological process</TD><TD>GO:0030513</TD><TD>32</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2,MSX1</TD></TR>
<TR><TD>3.331e-03</TD><TD>-5.70</TD><TD>RICKMAN_METASTASIS_DN</TD><TD>MSigDB lists</TD><TD>RICKMAN_METASTASIS_DN</TD><TD>244</TD><TD>4</TD><TD>17758</TD><TD>45</TD>
<TD>CAMK2D,ITGB4,CD44,AHNAK2</TD></TR>
<TR><TD>3.331e-03</TD><TD>-5.70</TD><TD>V$AREB6_03</TD><TD>MSigDB lists</TD><TD>V$AREB6_03</TD><TD>244</TD><TD>4</TD><TD>17758</TD><TD>45</TD>
<TD>FGF9,ITGB4,MMP16,GRHL3</TD></TR>
<TR><TD>3.331e-03</TD><TD>-5.70</TD><TD>V$MYOD_01</TD><TD>MSigDB lists</TD><TD>V$MYOD_01</TD><TD>244</TD><TD>4</TD><TD>17758</TD><TD>45</TD>
<TD>CSMD3,FGF9,SORCS2,ETV1</TD></TR>
<TR><TD>3.331e-03</TD><TD>-5.70</TD><TD>V$PAX2_02</TD><TD>MSigDB lists</TD><TD>V$PAX2_02</TD><TD>244</TD><TD>4</TD><TD>17758</TD><TD>45</TD>
<TD>CSMD3,FGF9,PPARG,NR2F1</TD></TR>
<TR><TD>3.357e-03</TD><TD>-5.70</TD><TD>other</TD><TD>COSMIC cancer mutations</TD><TD>other</TD><TD>15619</TD><TD>44</TD><TD>17775</TD><TD>44</TD>
<TD>EFNB2,TNIK,CNTNAP3,STXBP6,HFM1,C1orf226,CLSTN2,PBX1,RNF43,ZIC2,PDE3A,S100A10,NEBL,PDE10A,UNC13A,TANK,WNT16,CD44,ETV1,PRPS1,NT5E,LAMA4,SLC40A1,FGF9,MSX1,KRT7,PPARG,VSNL1,GRHL3,VIM,ANGPTL4,NR2F1,RHOU,MSX2,CAMK2D,AHNAK2,SLCO5A1,CSMD3,SORCS2,NR2F2,ITGB4,PDLIM5,MMP16,PKIB</TD></TR>
<TR><TD>3.359e-03</TD><TD>-5.70</TD><TD>regulation of apoptotic process</TD><TD>biological process</TD><TD>GO:0042981</TD><TD>1404</TD><TD>10</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2,SLC40A1,TNIK,CAMK2D,MSX1,PPARG,SLK,CD44,ANGPTL4,PDE3A</TD></TR>
<TR><TD>3.371e-03</TD><TD>-5.69</TD><TD>5_NUCLEOTIDASE_1</TD><TD>prosite domains</TD><TD>PS00785</TD><TD>1</TD><TD>1</TD><TD>11866</TD><TD>40</TD>
<TD>NT5E</TD></TR>
<TR><TD>3.371e-03</TD><TD>-5.69</TD><TD>5_NUCLEOTIDASE_2</TD><TD>prosite domains</TD><TD>PS00786</TD><TD>1</TD><TD>1</TD><TD>11866</TD><TD>40</TD>
<TD>NT5E</TD></TR>
<TR><TD>3.371e-03</TD><TD>-5.69</TD><TD>UVR</TD><TD>prosite domains</TD><TD>PS50151</TD><TD>1</TD><TD>1</TD><TD>11866</TD><TD>40</TD>
<TD>SLK</TD></TR>
<TR><TD>3.380e-03</TD><TD>-5.69</TD><TD>regulation of cell cycle</TD><TD>biological process</TD><TD>GO:0051726</TD><TD>952</TD><TD>8</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2,TNIK,CAMK2D,MSX1,SLK,PBX1,NR2F2,PDE3A</TD></TR>
<TR><TD>3.392e-03</TD><TD>-5.69</TD><TD>YEGNASUBRAMANIAN_PROSTATE_CANCER</TD><TD>MSigDB lists</TD><TD>YEGNASUBRAMANIAN_PROSTATE_CANCER</TD><TD>119</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>NEBL,ETV1,PDE10A</TD></TR>
<TR><TD>3.397e-03</TD><TD>-5.68</TD><TD>NR2F2 (nuclear receptor subfamily 2, group F, member 2)</TD><TD>protein interactions</TD><TD>7026</TD><TD>34</TD><TD>2</TD><TD>16036</TD><TD>41</TD>
<TD>NR2F2,NT5E</TD></TR>
<TR><TD>3.405e-03</TD><TD>-5.68</TD><TD>SP1 (Sp1 transcription factor)</TD><TD>protein interactions</TD><TD>6667</TD><TD>244</TD><TD>4</TD><TD>16036</TD><TD>41</TD>
<TD>VIM,MSX1,PPARG,NR2F1</TD></TR>
<TR><TD>3.430e-03</TD><TD>-5.68</TD><TD>V$OCT_C</TD><TD>MSigDB lists</TD><TD>V$OCT_C</TD><TD>246</TD><TD>4</TD><TD>17758</TD><TD>45</TD>
<TD>ETV1,STXBP6,GRHL3,VSNL1</TD></TR>
<TR><TD>3.430e-03</TD><TD>-5.68</TD><TD>response to wounding</TD><TD>biological process</TD><TD>GO:0009611</TD><TD>747</TD><TD>7</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2,ITGB4,CD44,PDE10A,PDE3A,GRHL3,AHNAK2</TD></TR>
<TR><TD>3.506e-03</TD><TD>-5.65</TD><TD>KOINUMA_TARGETS_OF_SMAD2_OR_SMAD3</TD><TD>MSigDB lists</TD><TD>KOINUMA_TARGETS_OF_SMAD2_OR_SMAD3</TD><TD>791</TD><TD>7</TD><TD>17758</TD><TD>45</TD>
<TD>VIM,CD44,KRT7,S100A10,CNTNAP3,NT5E,GRHL3</TD></TR>
<TR><TD>3.529e-03</TD><TD>-5.65</TD><TD>HDc</TD><TD>smart domains</TD><TD>SM00471</TD><TD>24</TD><TD>2</TD><TD>9131</TD><TD>34</TD>
<TD>PDE10A,PDE3A</TD></TR>
<TR><TD>3.536e-03</TD><TD>-5.64</TD><TD>regulation of programmed cell death</TD><TD>biological process</TD><TD>GO:0043067</TD><TD>1414</TD><TD>10</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2,SLC40A1,TNIK,CAMK2D,MSX1,PPARG,SLK,CD44,ANGPTL4,PDE3A</TD></TR>
<TR><TD>3.543e-03</TD><TD>-5.64</TD><TD>SPECIFIC_RNA_POLYMERASE_II_TRANSCRIPTION_FACTOR_ACTIVITY</TD><TD>MSigDB lists</TD><TD>SPECIFIC_RNA_POLYMERASE_II_TRANSCRIPTION_FACTOR_ACTIVITY</TD><TD>35</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>NR2F2,NR2F1</TD></TR>
<TR><TD>3.543e-03</TD><TD>-5.64</TD><TD>LIEN_BREAST_CARCINOMA_METAPLASTIC</TD><TD>MSigDB lists</TD><TD>LIEN_BREAST_CARCINOMA_METAPLASTIC</TD><TD>35</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>MSX1,MMP16</TD></TR>
<TR><TD>3.555e-03</TD><TD>-5.64</TD><TD>RODRIGUES_DCC_TARGETS_DN</TD><TD>MSigDB lists</TD><TD>RODRIGUES_DCC_TARGETS_DN</TD><TD>121</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>CD44,TANK,NR2F1</TD></TR>
<TR><TD>3.584e-03</TD><TD>-5.63</TD><TD>ear morphogenesis</TD><TD>biological process</TD><TD>GO:0042471</TD><TD>115</TD><TD>3</TD><TD>16441</TD><TD>44</TD>
<TD>FGF9,MSX1,GRHL3</TD></TR>
<TR><TD>3.597e-03</TD><TD>-5.63</TD><TD>I band</TD><TD>cellular component</TD><TD>GO:0031674</TD><TD>123</TD><TD>3</TD><TD>17570</TD><TD>44</TD>
<TD>NEBL,PDLIM5,AHNAK2</TD></TR>
<TR><TD>3.601e-03</TD><TD>-5.63</TD><TD>Transcriptional misregulation in cancer</TD><TD>KEGG pathways</TD><TD>hsa05202</TD><TD>179</TD><TD>4</TD><TD>6908</TD><TD>25</TD>
<TD>PBX1,WNT16,ETV1,PPARG</TD></TR>
<TR><TD>3.601e-03</TD><TD>-5.63</TD><TD>Transcriptional misregulation in cancer</TD><TD>KEGG pathways</TD><TD>ko05202</TD><TD>179</TD><TD>4</TD><TD>6908</TD><TD>25</TD>
<TD>PBX1,WNT16,ETV1,PPARG</TD></TR>
<TR><TD>3.623e-03</TD><TD>-5.62</TD><TD>BOQUEST_STEM_CELL_CULTURED_VS_FRESH_UP</TD><TD>MSigDB lists</TD><TD>BOQUEST_STEM_CELL_CULTURED_VS_FRESH_UP</TD><TD>409</TD><TD>5</TD><TD>17758</TD><TD>45</TD>
<TD>CD44,KRT7,PPARG,PDLIM5,ANGPTL4</TD></TR>
<TR><TD>3.627e-03</TD><TD>-5.62</TD><TD>synaptic membrane</TD><TD>cellular component</TD><TD>GO:0097060</TD><TD>253</TD><TD>4</TD><TD>17570</TD><TD>44</TD>
<TD>CLSTN2,PDLIM5,UNC13A,NT5E</TD></TR>
<TR><TD>3.632e-03</TD><TD>-5.62</TD><TD>ECM-receptor interaction</TD><TD>KEGG pathways</TD><TD>hsa04512</TD><TD>87</TD><TD>3</TD><TD>6908</TD><TD>25</TD>
<TD>LAMA4,ITGB4,CD44</TD></TR>
<TR><TD>3.632e-03</TD><TD>-5.62</TD><TD>ECM-receptor interaction</TD><TD>KEGG pathways</TD><TD>ko04512</TD><TD>87</TD><TD>3</TD><TD>6908</TD><TD>25</TD>
<TD>LAMA4,ITGB4,CD44</TD></TR>
<TR><TD>3.661e-03</TD><TD>-5.61</TD><TD>JOHNSTONE_PARVB_TARGETS_3_UP</TD><TD>MSigDB lists</TD><TD>JOHNSTONE_PARVB_TARGETS_3_UP</TD><TD>410</TD><TD>5</TD><TD>17758</TD><TD>45</TD>
<TD>VIM,TNIK,ITGB4,NR2F2,AHNAK2</TD></TR>
<TR><TD>3.672e-03</TD><TD>-5.61</TD><TD>organophosphate catabolic process</TD><TD>biological process</TD><TD>GO:0046434</TD><TD>116</TD><TD>3</TD><TD>16441</TD><TD>44</TD>
<TD>PDE10A,PDE3A,NT5E</TD></TR>
<TR><TD>3.685e-03</TD><TD>-5.60</TD><TD>V$OCT1_B</TD><TD>MSigDB lists</TD><TD>V$OCT1_B</TD><TD>251</TD><TD>4</TD><TD>17758</TD><TD>45</TD>
<TD>CSMD3,ETV1,GRHL3,VSNL1</TD></TR>
<TR><TD>3.685e-03</TD><TD>-5.60</TD><TD>V$AFP1_Q6</TD><TD>MSigDB lists</TD><TD>V$AFP1_Q6</TD><TD>251</TD><TD>4</TD><TD>17758</TD><TD>45</TD>
<TD>MSX2,TANK,NR2F1,GRHL3</TD></TR>
<TR><TD>3.685e-03</TD><TD>-5.60</TD><TD>V$STAT4_01</TD><TD>MSigDB lists</TD><TD>V$STAT4_01</TD><TD>251</TD><TD>4</TD><TD>17758</TD><TD>45</TD>
<TD>PBX1,RNF43,GRHL3,VSNL1</TD></TR>
<TR><TD>3.719e-03</TD><TD>-5.59</TD><TD>regulation of telomerase activity</TD><TD>biological process</TD><TD>GO:0051972</TD><TD>34</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>PPARG,PKIB</TD></TR>
<TR><TD>3.719e-03</TD><TD>-5.59</TD><TD>embryonic forelimb morphogenesis</TD><TD>biological process</TD><TD>GO:0035115</TD><TD>34</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2,MSX1</TD></TR>
<TR><TD>3.745e-03</TD><TD>-5.59</TD><TD>HUANG_FOXA2_TARGETS_DN</TD><TD>MSigDB lists</TD><TD>HUANG_FOXA2_TARGETS_DN</TD><TD>36</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>ITGB4,CD44</TD></TR>
<TR><TD>3.782e-03</TD><TD>-5.58</TD><TD>CD44</TD><TD>prints domains</TD><TD>PR00658</TD><TD>1</TD><TD>1</TD><TD>4759</TD><TD>18</TD>
<TD>CD44</TD></TR>
<TR><TD>3.782e-03</TD><TD>-5.58</TD><TD>PROXISOMPAGR</TD><TD>prints domains</TD><TD>PR01291</TD><TD>1</TD><TD>1</TD><TD>4759</TD><TD>18</TD>
<TD>PPARG</TD></TR>
<TR><TD>3.782e-03</TD><TD>-5.58</TD><TD>WNT16PROTEIN</TD><TD>prints domains</TD><TD>PR01895</TD><TD>1</TD><TD>1</TD><TD>4759</TD><TD>18</TD>
<TD>WNT16</TD></TR>
<TR><TD>3.782e-03</TD><TD>-5.58</TD><TD>APYRASEFAMLY</TD><TD>prints domains</TD><TD>PR01607</TD><TD>1</TD><TD>1</TD><TD>4759</TD><TD>18</TD>
<TD>NT5E</TD></TR>
<TR><TD>3.800e-03</TD><TD>-5.57</TD><TD>regulation of biological process</TD><TD>biological process</TD><TD>GO:0050789</TD><TD>10636</TD><TD>37</TD><TD>16441</TD><TD>44</TD>
<TD>EFNB2,TNIK,STXBP6,SLK,GPAT3,CLSTN2,PBX1,RNF43,ZIC2,PDE3A,S100A10,PDE10A,UNC13A,TANK,WNT16,CD44,ETV1,NT5E,LAMA4,FGF9,SLC40A1,MSX1,PPARG,GRHL3,VSNL1,VIM,ANGPTL4,NR2F1,RHOU,MSX2,CAMK2D,ITGB4,SORCS2,NR2F2,PDLIM5,MMP16,PKIB</TD></TR>
<TR><TD>3.806e-03</TD><TD>-5.57</TD><TD>human chr8q23.3</TD><TD>chromosome location</TD><TD>human chr8q23.3</TD><TD>2</TD><TD>1</TD><TD>26250</TD><TD>50</TD>
<TD>CSMD3</TD></TR>
<TR><TD>3.806e-03</TD><TD>-5.57</TD><TD>human chr1q42.11-q42.3</TD><TD>chromosome location</TD><TD>human chr1q42.11-q42.3</TD><TD>2</TD><TD>1</TD><TD>26250</TD><TD>50</TD>
<TD>RHOU</TD></TR>
<TR><TD>3.806e-03</TD><TD>-5.57</TD><TD>human chr5p14.1</TD><TD>chromosome location</TD><TD>human chr5p14.1</TD><TD>2</TD><TD>1</TD><TD>26250</TD><TD>50</TD>
<TD>LINC01021</TD></TR>
<TR><TD>3.816e-03</TD><TD>-5.57</TD><TD>CUI_TCF21_TARGETS_2_UP</TD><TD>MSigDB lists</TD><TD>CUI_TCF21_TARGETS_2_UP</TD><TD>414</TD><TD>5</TD><TD>17758</TD><TD>45</TD>
<TD>CLSTN2,RHOU,LAMA4,NR2F2,MMP16</TD></TR>
<TR><TD>3.842e-03</TD><TD>-5.56</TD><TD>-</TD><TD>gene3d domains</TD><TD>3.90.215.10</TD><TD>30</TD><TD>2</TD><TD>9988</TD><TD>31</TD>
<TD>CNTNAP3,ANGPTL4</TD></TR>
<TR><TD>3.852e-03</TD><TD>-5.56</TD><TD>Laminin_G_2</TD><TD>pfam domains</TD><TD>PF02210</TD><TD>35</TD><TD>2</TD><TD>16629</TD><TD>44</TD>
<TD>LAMA4,CNTNAP3</TD></TR>
<TR><TD>3.853e-03</TD><TD>-5.56</TD><TD>striated muscle cell development</TD><TD>biological process</TD><TD>GO:0055002</TD><TD>118</TD><TD>3</TD><TD>16441</TD><TD>44</TD>
<TD>CAMK2D,NEBL,PDLIM5</TD></TR>
<TR><TD>3.912e-03</TD><TD>-5.54</TD><TD>mantle_cell_lymphoma</TD><TD>COSMIC cancer mutations</TD><TD>mantle_cell_lymphoma</TD><TD>2976</TD><TD>15</TD><TD>17775</TD><TD>44</TD>
<TD>NEBL,STXBP6,HFM1,UNC13A,CLSTN2,SLCO5A1,CSMD3,ZIC2,CD44,SORCS2,PDLIM5,MMP16,PDE3A,NR2F1,NT5E</TD></TR>
<TR><TD>3.922e-03</TD><TD>-5.54</TD><TD>serous_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>serous_carcinoma</TD><TD>11513</TD><TD>37</TD><TD>17775</TD><TD>44</TD>
<TD>EFNB2,TNIK,CNTNAP3,HFM1,C1orf226,CLSTN2,RNF43,PDE3A,S100A10,NEBL,PDE10A,UNC13A,WNT16,ETV1,PRPS1,NT5E,LAMA4,SLC40A1,FGF9,MSX1,KRT7,PPARG,VSNL1,GRHL3,VIM,ANGPTL4,NR2F1,MSX2,CAMK2D,AHNAK2,CSMD3,SLCO5A1,NR2F2,SORCS2,ITGB4,PDLIM5,MMP16</TD></TR>
<TR><TD>3.935e-03</TD><TD>-5.54</TD><TD>extracellular matrix component</TD><TD>cellular component</TD><TD>GO:0044420</TD><TD>127</TD><TD>3</TD><TD>17570</TD><TD>44</TD>
<TD>LAMA4,FGF9,ITGB4</TD></TR>
<TR><TD>3.938e-03</TD><TD>-5.54</TD><TD>cAMP metabolic process</TD><TD>biological process</TD><TD>GO:0046058</TD><TD>35</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>PDE10A,PDE3A</TD></TR>
<TR><TD>3.938e-03</TD><TD>-5.54</TD><TD>mesenchyme morphogenesis</TD><TD>biological process</TD><TD>GO:0072132</TD><TD>35</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2,MSX1</TD></TR>
<TR><TD>3.955e-03</TD><TD>-5.53</TD><TD>frizzled binding</TD><TD>molecular function</TD><TD>GO:0005109</TD><TD>36</TD><TD>2</TD><TD>16491</TD><TD>43</TD>
<TD>RNF43,WNT16</TD></TR>
<TR><TD>3.958e-03</TD><TD>-5.53</TD><TD>sequence-specific DNA binding</TD><TD>molecular function</TD><TD>GO:0043565</TD><TD>1004</TD><TD>8</TD><TD>16491</TD><TD>43</TD>
<TD>MSX2,MSX1,PPARG,GRHL3,PBX1,NR2F2,ETV1,NR2F1</TD></TR>
<TR><TD>3.997e-03</TD><TD>-5.52</TD><TD>transcription from RNA polymerase II promoter</TD><TD>biological process</TD><TD>GO:0006366</TD><TD>768</TD><TD>7</TD><TD>16441</TD><TD>44</TD>
<TD>PBX1,MSX2,MSX1,PPARG,ETV1,NR2F1,GRHL3</TD></TR>
<TR><TD>4.056e-03</TD><TD>-5.51</TD><TD>BAELDE_DIABETIC_NEPHROPATHY_DN</TD><TD>MSigDB lists</TD><TD>BAELDE_DIABETIC_NEPHROPATHY_DN</TD><TD>420</TD><TD>5</TD><TD>17758</TD><TD>45</TD>
<TD>FGF9,VIM,NEBL,PDLIM5,SLK</TD></TR>
<TR><TD>4.064e-03</TD><TD>-5.51</TD><TD>V$IK2_01</TD><TD>MSigDB lists</TD><TD>V$IK2_01</TD><TD>258</TD><TD>4</TD><TD>17758</TD><TD>45</TD>
<TD>MSX1,ETV1,PDLIM5,VSNL1</TD></TR>
<TR><TD>4.072e-03</TD><TD>-5.50</TD><TD>GAL_LEUKEMIC_STEM_CELL_UP</TD><TD>MSigDB lists</TD><TD>GAL_LEUKEMIC_STEM_CELL_UP</TD><TD>127</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>TNIK,ITGB4,PDLIM5</TD></TR>
<TR><TD>4.119e-03</TD><TD>-5.49</TD><TD>skin-head_neck-carcinoma-squamous_cell_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>skin-head_neck-carcinoma-squamous_cell_carcinoma</TD><TD>14911</TD><TD>43</TD><TD>17775</TD><TD>44</TD>
<TD>EFNB2,TNIK,CNTNAP3,STXBP6,HFM1,C1orf226,CLSTN2,RNF43,ZIC2,PDE3A,S100A10,NEBL,PDE10A,UNC13A,TANK,WNT16,CD44,ETV1,PRPS1,NT5E,LAMA4,SLC40A1,FGF9,MSX1,KRT7,PPARG,VSNL1,GRHL3,VIM,ANGPTL4,NR2F1,RHOU,MSX2,CAMK2D,AHNAK2,SLCO5A1,CSMD3,NR2F2,SORCS2,ITGB4,PDLIM5,MMP16,PKIB</TD></TR>
<TR><TD>4.133e-03</TD><TD>-5.49</TD><TD>mesenchymal cell development</TD><TD>biological process</TD><TD>GO:0014031</TD><TD>121</TD><TD>3</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2,MSX1,WNT16</TD></TR>
<TR><TD>4.165e-03</TD><TD>-5.48</TD><TD>GU_PDEF_TARGETS_DN</TD><TD>MSigDB lists</TD><TD>GU_PDEF_TARGETS_DN</TD><TD>38</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>ITGB4,KRT7</TD></TR>
<TR><TD>4.174e-03</TD><TD>-5.48</TD><TD>cyclic nucleotide binding</TD><TD>molecular function</TD><TD>GO:0030551</TD><TD>37</TD><TD>2</TD><TD>16491</TD><TD>43</TD>
<TD>PDE10A,PDE3A</TD></TR>
<TR><TD>4.177e-03</TD><TD>-5.48</TD><TD>V$ER_Q6</TD><TD>MSigDB lists</TD><TD>V$ER_Q6</TD><TD>260</TD><TD>4</TD><TD>17758</TD><TD>45</TD>
<TD>FGF9,ZIC2,NR2F2,NR2F1</TD></TR>
<TR><TD>4.234e-03</TD><TD>-5.46</TD><TD>V$COREBINDINGFACTOR_Q6</TD><TD>MSigDB lists</TD><TD>V$COREBINDINGFACTOR_Q6</TD><TD>261</TD><TD>4</TD><TD>17758</TD><TD>45</TD>
<TD>CSMD3,VIM,RNF43,PPARG</TD></TR>
<TR><TD>4.250e-03</TD><TD>-5.46</TD><TD>Developmental Biology</TD><TD>REACTOME pathways</TD><TD>R-HSA-1266738</TD><TD>710</TD><TD>7</TD><TD>8202</TD><TD>25</TD>
<TD>PBX1,EFNB2,FGF9,CAMK2D,NR2F2,PPARG,ANGPTL4</TD></TR>
<TR><TD>4.254e-03</TD><TD>-5.46</TD><TD>GGGNNTTTCC_V$NFKB_Q6_01</TD><TD>MSigDB lists</TD><TD>GGGNNTTTCC_V$NFKB_Q6_01</TD><TD>129</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>MSX1,NR2F2,ETV1</TD></TR>
<TR><TD>4.335e-03</TD><TD>-5.44</TD><TD>sensory organ morphogenesis</TD><TD>biological process</TD><TD>GO:0090596</TD><TD>249</TD><TD>4</TD><TD>16441</TD><TD>44</TD>
<TD>FGF9,MSX1,WNT16,GRHL3</TD></TR>
<TR><TD>4.347e-03</TD><TD>-5.44</TD><TD>RODWELL_AGING_KIDNEY_DN</TD><TD>MSigDB lists</TD><TD>RODWELL_AGING_KIDNEY_DN</TD><TD>130</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>NEBL,SLK,C1orf226</TD></TR>
<TR><TD>4.384e-03</TD><TD>-5.43</TD><TD>GAZDA_DIAMOND_BLACKFAN_ANEMIA_PROGENITOR_UP</TD><TD>MSigDB lists</TD><TD>GAZDA_DIAMOND_BLACKFAN_ANEMIA_PROGENITOR_UP</TD><TD>39</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>FGF9,PDE10A</TD></TR>
<TR><TD>4.384e-03</TD><TD>-5.43</TD><TD>TOMLINS_PROSTATE_CANCER_DN</TD><TD>MSigDB lists</TD><TD>TOMLINS_PROSTATE_CANCER_DN</TD><TD>39</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>LAMA4,ITGB4</TD></TR>
<TR><TD>4.393e-03</TD><TD>-5.43</TD><TD>trabecula morphogenesis</TD><TD>biological process</TD><TD>GO:0061383</TD><TD>37</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>SLC40A1,MSX2</TD></TR>
<TR><TD>4.470e-03</TD><TD>-5.41</TD><TD>cellular component morphogenesis</TD><TD>biological process</TD><TD>GO:0032989</TD><TD>1223</TD><TD>9</TD><TD>16441</TD><TD>44</TD>
<TD>EFNB2,TNIK,FGF9,CAMK2D,MSX2,MSX1,NEBL,WNT16,ETV1</TD></TR>
<TR><TD>4.477e-03</TD><TD>-5.41</TD><TD>acute_lymphoblastic_B_cell_leukaemia</TD><TD>COSMIC cancer mutations</TD><TD>acute_lymphoblastic_B_cell_leukaemia</TD><TD>3979</TD><TD>18</TD><TD>17775</TD><TD>44</TD>
<TD>LAMA4,TNIK,SLC40A1,CNTNAP3,STXBP6,HFM1,CLSTN2,PDE3A,MSX2,NEBL,UNC13A,CSMD3,ITGB4,SORCS2,ETV1,PDLIM5,PRPS1,MMP16</TD></TR>
<TR><TD>4.477e-03</TD><TD>-5.41</TD><TD>haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-acute_lymphoblastic_B_cell_leukaemia</TD><TD>COSMIC cancer mutations</TD><TD>haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-acute_lymphoblastic_B_cell_leukaemia</TD><TD>3979</TD><TD>18</TD><TD>17775</TD><TD>44</TD>
<TD>LAMA4,TNIK,SLC40A1,CNTNAP3,STXBP6,HFM1,CLSTN2,PDE3A,MSX2,NEBL,UNC13A,CSMD3,ITGB4,SORCS2,ETV1,PDLIM5,PRPS1,MMP16</TD></TR>
<TR><TD>4.527e-03</TD><TD>-5.40</TD><TD>stem cell development</TD><TD>biological process</TD><TD>GO:0048864</TD><TD>125</TD><TD>3</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2,MSX1,WNT16</TD></TR>
<TR><TD>4.536e-03</TD><TD>-5.40</TD><TD>KRAS.LUNG.BREAST_UP.V1_UP</TD><TD>MSigDB lists</TD><TD>KRAS.LUNG.BREAST_UP.V1_UP</TD><TD>132</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>CLSTN2,SLCO5A1,ANGPTL4</TD></TR>
<TR><TD>4.567e-03</TD><TD>-5.39</TD><TD>acute_myeloid_leukaemia_therapy_related</TD><TD>COSMIC cancer mutations</TD><TD>acute_myeloid_leukaemia_therapy_related</TD><TD>1584</TD><TD>10</TD><TD>17775</TD><TD>44</TD>
<TD>LAMA4,CAMK2D,FGF9,NEBL,VSNL1,CLSTN2,CSMD3,SORCS2,PDLIM5,PDE3A</TD></TR>
<TR><TD>4.567e-03</TD><TD>-5.39</TD><TD>haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-acute_myeloid_leukaemia_therapy_related</TD><TD>COSMIC cancer mutations</TD><TD>haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-acute_myeloid_leukaemia_therapy_related</TD><TD>1584</TD><TD>10</TD><TD>17775</TD><TD>44</TD>
<TD>LAMA4,CAMK2D,FGF9,NEBL,VSNL1,CLSTN2,CSMD3,SORCS2,PDLIM5,PDE3A</TD></TR>
<TR><TD>4.589e-03</TD><TD>-5.38</TD><TD>SHEDDEN_LUNG_CANCER_GOOD_SURVIVAL_A12</TD><TD>MSigDB lists</TD><TD>SHEDDEN_LUNG_CANCER_GOOD_SURVIVAL_A12</TD><TD>267</TD><TD>4</TD><TD>17758</TD><TD>45</TD>
<TD>MSX2,ITGB4,NEBL,STXBP6</TD></TR>
<TR><TD>4.607e-03</TD><TD>-5.38</TD><TD>PHOSPHORIC_DIESTER_HYDROLASE_ACTIVITY</TD><TD>MSigDB lists</TD><TD>PHOSPHORIC_DIESTER_HYDROLASE_ACTIVITY</TD><TD>40</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>PDE10A,PDE3A</TD></TR>
<TR><TD>4.629e-03</TD><TD>-5.38</TD><TD>hindlimb morphogenesis</TD><TD>biological process</TD><TD>GO:0035137</TD><TD>38</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2,MSX1</TD></TR>
<TR><TD>4.629e-03</TD><TD>-5.38</TD><TD>cellular response to metal ion</TD><TD>biological process</TD><TD>GO:0071248</TD><TD>126</TD><TD>3</TD><TD>16441</TD><TD>44</TD>
<TD>SLC40A1,CAMK2D,PPARG</TD></TR>
<TR><TD>4.730e-03</TD><TD>-5.35</TD><TD>WWTAAGGC_UNKNOWN</TD><TD>MSigDB lists</TD><TD>WWTAAGGC_UNKNOWN</TD><TD>134</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>SLCO5A1,NR2F2,NR2F1</TD></TR>
<TR><TD>4.730e-03</TD><TD>-5.35</TD><TD>ALK_DN.V1_UP</TD><TD>MSigDB lists</TD><TD>ALK_DN.V1_UP</TD><TD>134</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>ETV1,ANGPTL4,UNC13A</TD></TR>
<TR><TD>4.774e-03</TD><TD>-5.34</TD><TD>V$GATA1_05</TD><TD>MSigDB lists</TD><TD>V$GATA1_05</TD><TD>270</TD><TD>4</TD><TD>17758</TD><TD>45</TD>
<TD>MSX1,NR2F2,ETV1,VSNL1</TD></TR>
<TR><TD>4.835e-03</TD><TD>-5.33</TD><TD>MIKKELSEN_ES_HCP_WITH_H3K27ME3</TD><TD>MSigDB lists</TD><TD>MIKKELSEN_ES_HCP_WITH_H3K27ME3</TD><TD>41</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>NR2F2,NR2F1</TD></TR>
<TR><TD>4.837e-03</TD><TD>-5.33</TD><TD>embryonic skeletal system development</TD><TD>biological process</TD><TD>GO:0048706</TD><TD>128</TD><TD>3</TD><TD>16441</TD><TD>44</TD>
<TD>PBX1,FGF9,MMP16</TD></TR>
<TR><TD>4.837e-03</TD><TD>-5.33</TD><TD>positive regulation of cell division</TD><TD>biological process</TD><TD>GO:0051781</TD><TD>128</TD><TD>3</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2,FGF9,MSX1</TD></TR>
<TR><TD>4.871e-03</TD><TD>-5.32</TD><TD>spleen development</TD><TD>biological process</TD><TD>GO:0048536</TD><TD>39</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>PBX1,SLC40A1</TD></TR>
<TR><TD>4.910e-03</TD><TD>-5.32</TD><TD>TNPO2 (transportin 2)</TD><TD>protein interactions</TD><TD>30000</TD><TD>41</TD><TD>2</TD><TD>16036</TD><TD>41</TD>
<TD>CAMK2D,NT5E</TD></TR>
<TR><TD>4.943e-03</TD><TD>-5.31</TD><TD>kidney epithelium development</TD><TD>biological process</TD><TD>GO:0072073</TD><TD>129</TD><TD>3</TD><TD>16441</TD><TD>44</TD>
<TD>PBX1,EFNB2,CD44</TD></TR>
<TR><TD>4.978e-03</TD><TD>-5.30</TD><TD>diffuse_large_B_cell_lymphoma</TD><TD>COSMIC cancer mutations</TD><TD>diffuse_large_B_cell_lymphoma</TD><TD>4353</TD><TD>19</TD><TD>17775</TD><TD>44</TD>
<TD>EFNB2,LAMA4,TNIK,PPARG,STXBP6,HFM1,VSNL1,CLSTN2,PDE3A,CAMK2D,NEBL,UNC13A,TANK,CSMD3,SLCO5A1,SORCS2,PDLIM5,MMP16,PKIB</TD></TR>
<TR><TD>5.002e-03</TD><TD>-5.30</TD><TD>macrophage migration inhibitory factor receptor complex</TD><TD>cellular component</TD><TD>GO:0035692</TD><TD>2</TD><TD>1</TD><TD>17570</TD><TD>44</TD>
<TD>CD44</TD></TR>
<TR><TD>5.023e-03</TD><TD>-5.29</TD><TD>PKK</TD><TD>interpro domains</TD><TD>IPR022165</TD><TD>2</TD><TD>1</TD><TD>18293</TD><TD>46</TD>
<TD>SLK</TD></TR>
<TR><TD>5.023e-03</TD><TD>-5.29</TD><TD>Sec3-PIP2_bind</TD><TD>interpro domains</TD><TD>IPR028258</TD><TD>2</TD><TD>1</TD><TD>18293</TD><TD>46</TD>
<TD>STXBP6</TD></TR>
<TR><TD>5.023e-03</TD><TD>-5.29</TD><TD>CASPR3</TD><TD>interpro domains</TD><TD>IPR028873</TD><TD>2</TD><TD>1</TD><TD>18293</TD><TD>46</TD>
<TD>CNTNAP3</TD></TR>
<TR><TD>5.026e-03</TD><TD>-5.29</TD><TD>LRIF1 (ligand dependent nuclear receptor interacting factor 1)</TD><TD>protein interactions</TD><TD>55791</TD><TD>136</TD><TD>3</TD><TD>16036</TD><TD>41</TD>
<TD>LAMA4,VIM,PPARG</TD></TR>
<TR><TD>5.031e-03</TD><TD>-5.29</TD><TD>BMI1_DN.V1_DN</TD><TD>MSigDB lists</TD><TD>BMI1_DN.V1_DN</TD><TD>137</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>MSX2,WNT16,ETV1</TD></TR>
<TR><TD>5.031e-03</TD><TD>-5.29</TD><TD>KRAS.KIDNEY_UP.V1_UP</TD><TD>MSigDB lists</TD><TD>KRAS.KIDNEY_UP.V1_UP</TD><TD>137</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>FGF9,NEBL,ETV1</TD></TR>
<TR><TD>5.078e-03</TD><TD>-5.28</TD><TD>developmental process involved in reproduction</TD><TD>biological process</TD><TD>GO:0003006</TD><TD>602</TD><TD>6</TD><TD>16441</TD><TD>44</TD>
<TD>PBX1,FGF9,CD44,NR2F2,PPARG,PDE3A</TD></TR>
<TR><TD>5.107e-03</TD><TD>-5.28</TD><TD>ZDHHC2 (zinc finger, DHHC-type containing 2)</TD><TD>protein interactions</TD><TD>51201</TD><TD>2</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>MSX2</TD></TR>
<TR><TD>5.107e-03</TD><TD>-5.28</TD><TD>Myh10 (myosin, heavy polypeptide 10, non-muscle)</TD><TD>protein interactions</TD><TD>77579</TD><TD>2</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>PBX1</TD></TR>
<TR><TD>5.107e-03</TD><TD>-5.28</TD><TD>RNF180 (ring finger protein 180)</TD><TD>protein interactions</TD><TD>285671</TD><TD>2</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>ZIC2</TD></TR>
<TR><TD>5.107e-03</TD><TD>-5.28</TD><TD>Foxo1 (forkhead box O1)</TD><TD>protein interactions</TD><TD>56458</TD><TD>2</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>PPARG</TD></TR>
<TR><TD>5.107e-03</TD><TD>-5.28</TD><TD>DMP1 (dentin matrix acidic phosphoprotein 1)</TD><TD>protein interactions</TD><TD>1758</TD><TD>2</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>CD44</TD></TR>
<TR><TD>5.107e-03</TD><TD>-5.28</TD><TD>Fbxo45 (F-box protein 45)</TD><TD>protein interactions</TD><TD>268882</TD><TD>2</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>UNC13A</TD></TR>
<TR><TD>5.107e-03</TD><TD>-5.28</TD><TD>FAM171B (family with sequence similarity 171, member B)</TD><TD>protein interactions</TD><TD>165215</TD><TD>2</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>CAMK2D</TD></TR>
<TR><TD>5.107e-03</TD><TD>-5.28</TD><TD>ARMCX2 (armadillo repeat containing, X-linked 2)</TD><TD>protein interactions</TD><TD>9823</TD><TD>2</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>VIM</TD></TR>
<TR><TD>5.107e-03</TD><TD>-5.28</TD><TD>Ncor1 (nuclear receptor co-repressor 1)</TD><TD>protein interactions</TD><TD>20185</TD><TD>2</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>PPARG</TD></TR>
<TR><TD>5.107e-03</TD><TD>-5.28</TD><TD>GRHL1 (grainyhead-like transcription factor 1)</TD><TD>protein interactions</TD><TD>29841</TD><TD>2</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>GRHL3</TD></TR>
<TR><TD>5.107e-03</TD><TD>-5.28</TD><TD>Tbk1 (TANK-binding kinase 1)</TD><TD>protein interactions</TD><TD>56480</TD><TD>2</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>TANK</TD></TR>
<TR><TD>5.107e-03</TD><TD>-5.28</TD><TD>DACT2 (dishevelled-binding antagonist of beta-catenin 2)</TD><TD>protein interactions</TD><TD>168002</TD><TD>2</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>CAMK2D</TD></TR>
<TR><TD>5.107e-03</TD><TD>-5.28</TD><TD>TNFAIP8L2 (tumor necrosis factor, alpha-induced protein 8-like 2)</TD><TD>protein interactions</TD><TD>79626</TD><TD>2</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>AHNAK2</TD></TR>
<TR><TD>5.121e-03</TD><TD>-5.27</TD><TD>regulation of transcription from RNA polymerase II promoter</TD><TD>biological process</TD><TD>GO:0006357</TD><TD>1740</TD><TD>11</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2,SLC40A1,CAMK2D,FGF9,MSX1,PPARG,GRHL3,PBX1,NR2F2,ETV1,NR2F1</TD></TR>
<TR><TD>5.131e-03</TD><TD>-5.27</TD><TD>FBG</TD><TD>smart domains</TD><TD>SM00186</TD><TD>29</TD><TD>2</TD><TD>9131</TD><TD>34</TD>
<TD>CNTNAP3,ANGPTL4</TD></TR>
<TR><TD>5.134e-03</TD><TD>-5.27</TD><TD>GOZGIT_ESR1_TARGETS_UP</TD><TD>MSigDB lists</TD><TD>GOZGIT_ESR1_TARGETS_UP</TD><TD>138</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>SORCS2,PPARG,NT5E</TD></TR>
<TR><TD>5.147e-03</TD><TD>-5.27</TD><TD>TRIP4 (thyroid hormone receptor interactor 4)</TD><TD>protein interactions</TD><TD>9325</TD><TD>42</TD><TD>2</TD><TD>16036</TD><TD>41</TD>
<TD>NR2F2,PPARG</TD></TR>
<TR><TD>5.147e-03</TD><TD>-5.27</TD><TD>DST (dystonin)</TD><TD>protein interactions</TD><TD>667</TD><TD>42</TD><TD>2</TD><TD>16036</TD><TD>41</TD>
<TD>TNIK,ITGB4</TD></TR>
<TR><TD>5.149e-03</TD><TD>-5.27</TD><TD>astrocytoma_Grade_III</TD><TD>COSMIC cancer mutations</TD><TD>astrocytoma_Grade_III</TD><TD>1611</TD><TD>10</TD><TD>17775</TD><TD>44</TD>
<TD>EFNB2,MSX2,CAMK2D,HFM1,UNC13A,CSMD3,SLCO5A1,CLSTN2,PDLIM5,NT5E</TD></TR>
<TR><TD>5.155e-03</TD><TD>-5.27</TD><TD>FIBRINOGEN_C_2</TD><TD>prosite domains</TD><TD>PS51406</TD><TD>32</TD><TD>2</TD><TD>11866</TD><TD>40</TD>
<TD>CNTNAP3,ANGPTL4</TD></TR>
<TR><TD>5.159e-03</TD><TD>-5.27</TD><TD>muscle cell development</TD><TD>biological process</TD><TD>GO:0055001</TD><TD>131</TD><TD>3</TD><TD>16441</TD><TD>44</TD>
<TD>CAMK2D,NEBL,PDLIM5</TD></TR>
<TR><TD>5.175e-03</TD><TD>-5.26</TD><TD>RODWELL_AGING_KIDNEY_UP</TD><TD>MSigDB lists</TD><TD>RODWELL_AGING_KIDNEY_UP</TD><TD>445</TD><TD>5</TD><TD>17758</TD><TD>45</TD>
<TD>SLC40A1,VIM,NR2F1,NT5E,VSNL1</TD></TR>
<TR><TD>5.208e-03</TD><TD>-5.26</TD><TD>cGMP-inhibited cyclic-nucleotide phosphodiesterase activity</TD><TD>molecular function</TD><TD>GO:0004119</TD><TD>2</TD><TD>1</TD><TD>16491</TD><TD>43</TD>
<TD>PDE3A</TD></TR>
<TR><TD>5.285e-03</TD><TD>-5.24</TD><TD>Sec3-PIP2_bind</TD><TD>pfam domains</TD><TD>PF15277</TD><TD>2</TD><TD>1</TD><TD>16629</TD><TD>44</TD>
<TD>STXBP6</TD></TR>
<TR><TD>5.285e-03</TD><TD>-5.24</TD><TD>PKK</TD><TD>pfam domains</TD><TD>PF12474</TD><TD>2</TD><TD>1</TD><TD>16629</TD><TD>44</TD>
<TD>SLK</TD></TR>
<TR><TD>5.308e-03</TD><TD>-5.24</TD><TD>STREICHER_LSM1_TARGETS_UP</TD><TD>MSigDB lists</TD><TD>STREICHER_LSM1_TARGETS_UP</TD><TD>43</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>PBX1,NR2F2</TD></TR>
<TR><TD>5.308e-03</TD><TD>-5.24</TD><TD>KRASNOSELSKAYA_ILF3_TARGETS_DN</TD><TD>MSigDB lists</TD><TD>KRASNOSELSKAYA_ILF3_TARGETS_DN</TD><TD>43</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>MSX2,NT5E</TD></TR>
<TR><TD>5.343e-03</TD><TD>-5.23</TD><TD>RODWELL_AGING_KIDNEY_NO_BLOOD_DN</TD><TD>MSigDB lists</TD><TD>RODWELL_AGING_KIDNEY_NO_BLOOD_DN</TD><TD>140</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>NEBL,SLK,C1orf226</TD></TR>
<TR><TD>5.345e-03</TD><TD>-5.23</TD><TD>urate biosynthetic process</TD><TD>biological process</TD><TD>GO:0034418</TD><TD>2</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>PRPS1</TD></TR>
<TR><TD>5.345e-03</TD><TD>-5.23</TD><TD>low-density lipoprotein receptor particle metabolic process</TD><TD>biological process</TD><TD>GO:0032799</TD><TD>2</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>PPARG</TD></TR>
<TR><TD>5.345e-03</TD><TD>-5.23</TD><TD>regulation of cholesterol transporter activity</TD><TD>biological process</TD><TD>GO:0060694</TD><TD>2</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>PPARG</TD></TR>
<TR><TD>5.345e-03</TD><TD>-5.23</TD><TD>divalent metal ion export</TD><TD>biological process</TD><TD>GO:0070839</TD><TD>2</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>SLC40A1</TD></TR>
<TR><TD>5.345e-03</TD><TD>-5.23</TD><TD>response to diuretic</TD><TD>biological process</TD><TD>GO:0036270</TD><TD>2</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>PPARG</TD></TR>
<TR><TD>5.345e-03</TD><TD>-5.23</TD><TD>regulation of pancreatic stellate cell proliferation</TD><TD>biological process</TD><TD>GO:2000229</TD><TD>2</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>PPARG</TD></TR>
<TR><TD>5.345e-03</TD><TD>-5.23</TD><TD>lymphatic endothelial cell fate commitment</TD><TD>biological process</TD><TD>GO:0060838</TD><TD>2</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>NR2F2</TD></TR>
<TR><TD>5.345e-03</TD><TD>-5.23</TD><TD>positive regulation of Rac protein signal transduction</TD><TD>biological process</TD><TD>GO:0035022</TD><TD>2</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>CAMK2D</TD></TR>
<TR><TD>5.345e-03</TD><TD>-5.23</TD><TD>AMP catabolic process</TD><TD>biological process</TD><TD>GO:0006196</TD><TD>2</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>NT5E</TD></TR>
<TR><TD>5.345e-03</TD><TD>-5.23</TD><TD>Wnt receptor catabolic process</TD><TD>biological process</TD><TD>GO:0038018</TD><TD>2</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>RNF43</TD></TR>
<TR><TD>5.345e-03</TD><TD>-5.23</TD><TD>cardiac muscle cell contraction</TD><TD>biological process</TD><TD>GO:0086003</TD><TD>2</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>CAMK2D</TD></TR>
<TR><TD>5.345e-03</TD><TD>-5.23</TD><TD>regulation of transcription involved in lymphatic endothelial cell fate commitment</TD><TD>biological process</TD><TD>GO:0060849</TD><TD>2</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>NR2F2</TD></TR>
<TR><TD>5.345e-03</TD><TD>-5.23</TD><TD>regulation of transcription from RNA polymerase II promoter in response to iron</TD><TD>biological process</TD><TD>GO:0034395</TD><TD>2</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>SLC40A1</TD></TR>
<TR><TD>5.358e-03</TD><TD>-5.23</TD><TD>GATAAGR_V$GATA_C</TD><TD>MSigDB lists</TD><TD>GATAAGR_V$GATA_C</TD><TD>279</TD><TD>4</TD><TD>17758</TD><TD>45</TD>
<TD>MSX2,NEBL,ETV1,NR2F1</TD></TR>
<TR><TD>5.372e-03</TD><TD>-5.23</TD><TD>purine nucleobase metabolic process</TD><TD>biological process</TD><TD>GO:0006144</TD><TD>41</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>PRPS1,NT5E</TD></TR>
<TR><TD>5.472e-03</TD><TD>-5.21</TD><TD>striated muscle tissue development</TD><TD>biological process</TD><TD>GO:0014706</TD><TD>266</TD><TD>4</TD><TD>16441</TD><TD>44</TD>
<TD>CAMK2D,NEBL,NR2F2,PDLIM5</TD></TR>
<TR><TD>5.494e-03</TD><TD>-5.20</TD><TD>mesenchymal cell differentiation</TD><TD>biological process</TD><TD>GO:0048762</TD><TD>134</TD><TD>3</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2,MSX1,WNT16</TD></TR>
<TR><TD>5.552e-03</TD><TD>-5.19</TD><TD>NAKAMURA_METASTASIS</TD><TD>MSigDB lists</TD><TD>NAKAMURA_METASTASIS</TD><TD>44</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>ETV1,PDE10A</TD></TR>
<TR><TD>5.552e-03</TD><TD>-5.19</TD><TD>BURTON_ADIPOGENESIS_4</TD><TD>MSigDB lists</TD><TD>BURTON_ADIPOGENESIS_4</TD><TD>44</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>RHOU,ANGPTL4</TD></TR>
<TR><TD>5.558e-03</TD><TD>-5.19</TD><TD>GCCNNNWTAAR_UNKNOWN</TD><TD>MSigDB lists</TD><TD>GCCNNNWTAAR_UNKNOWN</TD><TD>142</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>FGF9,CAMK2D,MSX1</TD></TR>
<TR><TD>5.558e-03</TD><TD>-5.19</TD><TD>HALLMARK_UV_RESPONSE_DN</TD><TD>MSigDB lists</TD><TD>HALLMARK_UV_RESPONSE_DN</TD><TD>142</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>PPARG,PDLIM5,MMP16</TD></TR>
<TR><TD>5.631e-03</TD><TD>-5.18</TD><TD>forelimb morphogenesis</TD><TD>biological process</TD><TD>GO:0035136</TD><TD>42</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2,MSX1</TD></TR>
<TR><TD>5.704e-03</TD><TD>-5.17</TD><TD>human chr13q11-q12</TD><TD>chromosome location</TD><TD>human chr13q11-q12</TD><TD>3</TD><TD>1</TD><TD>26250</TD><TD>50</TD>
<TD>FGF9</TD></TR>
<TR><TD>5.717e-03</TD><TD>-5.16</TD><TD>prostate-carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>prostate-carcinoma</TD><TD>9403</TD><TD>32</TD><TD>17775</TD><TD>44</TD>
<TD>TNIK,CNTNAP3,STXBP6,HFM1,CLSTN2,PBX1,RNF43,PDE3A,NEBL,PDE10A,UNC13A,TANK,WNT16,ETV1,NT5E,LAMA4,SLC40A1,FGF9,MSX1,KRT7,PPARG,VSNL1,GRHL3,ANGPTL4,RHOU,CAMK2D,MSX2,CSMD3,SLCO5A1,SORCS2,PDLIM5,MMP16</TD></TR>
<TR><TD>5.782e-03</TD><TD>-5.15</TD><TD>movement of cell or subcellular component</TD><TD>biological process</TD><TD>GO:0006928</TD><TD>1515</TD><TD>10</TD><TD>16441</TD><TD>44</TD>
<TD>EFNB2,MSX2,CAMK2D,FGF9,VIM,ITGB4,NR2F2,CD44,ETV1,NR2F1</TD></TR>
<TR><TD>5.805e-03</TD><TD>-5.15</TD><TD>SMID_BREAST_CANCER_BASAL_DN</TD><TD>MSigDB lists</TD><TD>SMID_BREAST_CANCER_BASAL_DN</TD><TD>653</TD><TD>6</TD><TD>17758</TD><TD>45</TD>
<TD>CLSTN2,PBX1,TNIK,MSX2,NEBL,NR2F1</TD></TR>
<TR><TD>5.841e-03</TD><TD>-5.14</TD><TD>renal system development</TD><TD>biological process</TD><TD>GO:0072001</TD><TD>271</TD><TD>4</TD><TD>16441</TD><TD>44</TD>
<TD>PBX1,EFNB2,ITGB4,CD44</TD></TR>
<TR><TD>5.851e-03</TD><TD>-5.14</TD><TD>regulation of neurogenesis</TD><TD>biological process</TD><TD>GO:0050767</TD><TD>620</TD><TD>6</TD><TD>16441</TD><TD>44</TD>
<TD>PBX1,VIM,TNIK,PPARG,PDLIM5,UNC13A</TD></TR>
<TR><TD>5.889e-03</TD><TD>-5.13</TD><TD>BROWNE_HCMV_INFECTION_24HR_DN</TD><TD>MSigDB lists</TD><TD>BROWNE_HCMV_INFECTION_24HR_DN</TD><TD>145</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>LAMA4,S100A10,CD44</TD></TR>
<TR><TD>5.889e-03</TD><TD>-5.13</TD><TD>YTAAYNGCT_UNKNOWN</TD><TD>MSigDB lists</TD><TD>YTAAYNGCT_UNKNOWN</TD><TD>145</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>PBX1,CSMD3,WNT16</TD></TR>
<TR><TD>5.890e-03</TD><TD>-5.13</TD><TD>SMARCD3 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily d, member 3)</TD><TD>protein interactions</TD><TD>6604</TD><TD>45</TD><TD>2</TD><TD>16036</TD><TD>41</TD>
<TD>PBX1,PPARG</TD></TR>
<TR><TD>5.890e-03</TD><TD>-5.13</TD><TD>ERBB2 (erb-b2 receptor tyrosine kinase 2)</TD><TD>protein interactions</TD><TD>2064</TD><TD>144</TD><TD>3</TD><TD>16036</TD><TD>41</TD>
<TD>ITGB4,CD44,MMP16</TD></TR>
<TR><TD>6.002e-03</TD><TD>-5.12</TD><TD>ACCTGTTG_UNKNOWN</TD><TD>MSigDB lists</TD><TD>ACCTGTTG_UNKNOWN</TD><TD>146</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>LAMA4,RNF43,MMP16</TD></TR>
<TR><TD>6.002e-03</TD><TD>-5.12</TD><TD>GSE13485_DAY3_VS_DAY21_YF17D_VACCINE_PBMC_DN</TD><TD>MSigDB lists</TD><TD>GSE13485_DAY3_VS_DAY21_YF17D_VACCINE_PBMC_DN</TD><TD>146</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>WNT16,PPARG,PRPS1</TD></TR>
<TR><TD>6.002e-03</TD><TD>-5.12</TD><TD>PHOSPHORIC_ESTER_HYDROLASE_ACTIVITY</TD><TD>MSigDB lists</TD><TD>PHOSPHORIC_ESTER_HYDROLASE_ACTIVITY</TD><TD>146</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>PDE10A,PDE3A,NT5E</TD></TR>
<TR><TD>6.052e-03</TD><TD>-5.11</TD><TD>LIM_MAMMARY_STEM_CELL_UP</TD><TD>MSigDB lists</TD><TD>LIM_MAMMARY_STEM_CELL_UP</TD><TD>462</TD><TD>5</TD><TD>17758</TD><TD>45</TD>
<TD>VIM,MSX1,ITGB4,NT5E,VSNL1</TD></TR>
<TR><TD>6.054e-03</TD><TD>-5.11</TD><TD>KHETCHOUMIAN_TRIM24_TARGETS_UP</TD><TD>MSigDB lists</TD><TD>KHETCHOUMIAN_TRIM24_TARGETS_UP</TD><TD>46</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>VIM,CD44</TD></TR>
<TR><TD>6.054e-03</TD><TD>-5.11</TD><TD>NUTT_GBM_VS_AO_GLIOMA_UP</TD><TD>MSigDB lists</TD><TD>NUTT_GBM_VS_AO_GLIOMA_UP</TD><TD>46</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>VIM,ITGB4</TD></TR>
<TR><TD>6.054e-03</TD><TD>-5.11</TD><TD>SESTO_RESPONSE_TO_UV_C5</TD><TD>MSigDB lists</TD><TD>SESTO_RESPONSE_TO_UV_C5</TD><TD>46</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>ITGB4,SLK</TD></TR>
<TR><TD>6.054e-03</TD><TD>-5.11</TD><TD>PID_A6B1_A6B4_INTEGRIN_PATHWAY</TD><TD>MSigDB lists</TD><TD>PID_A6B1_A6B4_INTEGRIN_PATHWAY</TD><TD>46</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>LAMA4,ITGB4</TD></TR>
<TR><TD>6.116e-03</TD><TD>-5.10</TD><TD>IGLESIAS_E2F_TARGETS_UP</TD><TD>MSigDB lists</TD><TD>IGLESIAS_E2F_TARGETS_UP</TD><TD>147</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>LAMA4,S100A10,TANK</TD></TR>
<TR><TD>6.117e-03</TD><TD>-5.10</TD><TD>actin filament-based process</TD><TD>biological process</TD><TD>GO:0030029</TD><TD>439</TD><TD>5</TD><TD>16441</TD><TD>44</TD>
<TD>RHOU,VIM,TNIK,CAMK2D,NEBL</TD></TR>
<TR><TD>6.145e-03</TD><TD>-5.09</TD><TD>LAM_G_DOMAIN</TD><TD>prosite domains</TD><TD>PS50025</TD><TD>35</TD><TD>2</TD><TD>11866</TD><TD>40</TD>
<TD>LAMA4,CNTNAP3</TD></TR>
<TR><TD>6.148e-03</TD><TD>-5.09</TD><TD>CAMK2D (calcium/calmodulin-dependent protein kinase II delta)</TD><TD>protein interactions</TD><TD>817</TD><TD>46</TD><TD>2</TD><TD>16036</TD><TD>41</TD>
<TD>VIM,CAMK2D</TD></TR>
<TR><TD>6.186e-03</TD><TD>-5.09</TD><TD>central_nervous_system-cerebellum-primitive_neuroectodermal_tumour-medulloblastoma-SHH_subtype</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-cerebellum-primitive_neuroectodermal_tumour-medulloblastoma-SHH_subtype</TD><TD>678</TD><TD>6</TD><TD>17775</TD><TD>44</TD>
<TD>CLSTN2,SLCO5A1,CSMD3,CAMK2D,NEBL,SORCS2</TD></TR>
<TR><TD>6.229e-03</TD><TD>-5.08</TD><TD>SHH_subtype</TD><TD>COSMIC cancer mutations</TD><TD>SHH_subtype</TD><TD>679</TD><TD>6</TD><TD>17775</TD><TD>44</TD>
<TD>CLSTN2,SLCO5A1,CSMD3,CAMK2D,NEBL,SORCS2</TD></TR>
<TR><TD>6.232e-03</TD><TD>-5.08</TD><TD>RTTTNNNYTGGM_UNKNOWN</TD><TD>MSigDB lists</TD><TD>RTTTNNNYTGGM_UNKNOWN</TD><TD>148</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>ZIC2,ETV1,TANK</TD></TR>
<TR><TD>6.312e-03</TD><TD>-5.07</TD><TD>positive regulation of cellular component organization</TD><TD>biological process</TD><TD>GO:0051130</TD><TD>1056</TD><TD>8</TD><TD>16441</TD><TD>44</TD>
<TD>RHOU,MSX2,MSX1,S100A10,PPARG,UNC13A,CLSTN2,PKIB</TD></TR>
<TR><TD>6.313e-03</TD><TD>-5.07</TD><TD>REACTOME_NUCLEAR_RECEPTOR_TRANSCRIPTION_PATHWAY</TD><TD>MSigDB lists</TD><TD>REACTOME_NUCLEAR_RECEPTOR_TRANSCRIPTION_PATHWAY</TD><TD>47</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>PPARG,NR2F1</TD></TR>
<TR><TD>6.313e-03</TD><TD>-5.07</TD><TD>KOHOUTEK_CCNT1_TARGETS</TD><TD>MSigDB lists</TD><TD>KOHOUTEK_CCNT1_TARGETS</TD><TD>47</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>ITGB4,AHNAK2</TD></TR>
<TR><TD>6.329e-03</TD><TD>-5.06</TD><TD>SENESE_HDAC3_TARGETS_UP</TD><TD>MSigDB lists</TD><TD>SENESE_HDAC3_TARGETS_UP</TD><TD>467</TD><TD>5</TD><TD>17758</TD><TD>45</TD>
<TD>TNIK,CAMK2D,CD44,CNTNAP3,MMP16</TD></TR>
<TR><TD>6.349e-03</TD><TD>-5.06</TD><TD>V$OCT1_07</TD><TD>MSigDB lists</TD><TD>V$OCT1_07</TD><TD>149</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>ETV1,NR2F1,GRHL3</TD></TR>
<TR><TD>6.442e-03</TD><TD>-5.04</TD><TD>regulation of cardiac muscle tissue development</TD><TD>biological process</TD><TD>GO:0055024</TD><TD>45</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>EFNB2,FGF9</TD></TR>
<TR><TD>6.503e-03</TD><TD>-5.04</TD><TD>positive regulation of biosynthetic process</TD><TD>biological process</TD><TD>GO:0009891</TD><TD>1796</TD><TD>11</TD><TD>16441</TD><TD>44</TD>
<TD>SLC40A1,MSX1,PPARG,GRHL3,PBX1,ZIC2,NR2F2,ETV1,NR2F1,PKIB,NT5E</TD></TR>
<TR><TD>6.547e-03</TD><TD>-5.03</TD><TD>muscle tissue development</TD><TD>biological process</TD><TD>GO:0060537</TD><TD>280</TD><TD>4</TD><TD>16441</TD><TD>44</TD>
<TD>CAMK2D,NEBL,NR2F2,PDLIM5</TD></TR>
<TR><TD>6.557e-03</TD><TD>-5.03</TD><TD>ZWANG_CLASS_1_TRANSIENTLY_INDUCED_BY_EGF</TD><TD>MSigDB lists</TD><TD>ZWANG_CLASS_1_TRANSIENTLY_INDUCED_BY_EGF</TD><TD>471</TD><TD>5</TD><TD>17758</TD><TD>45</TD>
<TD>EFNB2,CAMK2D,PDLIM5,SLK,ANGPTL4</TD></TR>
<TR><TD>6.576e-03</TD><TD>-5.02</TD><TD>branching morphogenesis of an epithelial tube</TD><TD>biological process</TD><TD>GO:0048754</TD><TD>143</TD><TD>3</TD><TD>16441</TD><TD>44</TD>
<TD>PBX1,MSX2,CD44</TD></TR>
<TR><TD>6.577e-03</TD><TD>-5.02</TD><TD>LEE_AGING_MUSCLE_DN</TD><TD>MSigDB lists</TD><TD>LEE_AGING_MUSCLE_DN</TD><TD>48</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>S100A10,NR2F1</TD></TR>
<TR><TD>6.587e-03</TD><TD>-5.02</TD><TD>ovary-carcinoma-clear_cell_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>ovary-carcinoma-clear_cell_carcinoma</TD><TD>687</TD><TD>6</TD><TD>17775</TD><TD>44</TD>
<TD>CSMD3,RNF43,TNIK,CAMK2D,NR2F2,TANK</TD></TR>
<TR><TD>6.614e-03</TD><TD>-5.02</TD><TD>SWEET_LUNG_CANCER_KRAS_UP</TD><TD>MSigDB lists</TD><TD>SWEET_LUNG_CANCER_KRAS_UP</TD><TD>472</TD><TD>5</TD><TD>17758</TD><TD>45</TD>
<TD>CD44,KRT7,PPARG,TANK,NR2F1</TD></TR>
<TR><TD>6.697e-03</TD><TD>-5.01</TD><TD>Cortical thickness(PMID:22792071)</TD><TD>GWAS genes</TD><TD>Cortical thickness(PMID:22792071)</TD><TD>1</TD><TD>1</TD><TD>2389</TD><TD>16</TD>
<TD>WNT16</TD></TR>
<TR><TD>6.697e-03</TD><TD>-5.01</TD><TD>Bone mineral density(PMID:22792071)</TD><TD>GWAS genes</TD><TD>Bone mineral density(PMID:22792071)</TD><TD>1</TD><TD>1</TD><TD>2389</TD><TD>16</TD>
<TD>WNT16</TD></TR>
<TR><TD>6.723e-03</TD><TD>-5.00</TD><TD>branching involved in ureteric bud morphogenesis</TD><TD>biological process</TD><TD>GO:0001658</TD><TD>46</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>PBX1,CD44</TD></TR>
<TR><TD>6.771e-03</TD><TD>-5.00</TD><TD>clear_cell_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>clear_cell_carcinoma</TD><TD>691</TD><TD>6</TD><TD>17775</TD><TD>44</TD>
<TD>CSMD3,RNF43,TNIK,CAMK2D,NR2F2,TANK</TD></TR>
<TR><TD>6.832e-03</TD><TD>-4.99</TD><TD>cellular response to inorganic substance</TD><TD>biological process</TD><TD>GO:0071241</TD><TD>145</TD><TD>3</TD><TD>16441</TD><TD>44</TD>
<TD>SLC40A1,CAMK2D,PPARG</TD></TR>
<TR><TD>6.846e-03</TD><TD>-4.98</TD><TD>WANG_BARRETTS_ESOPHAGUS_UP</TD><TD>MSigDB lists</TD><TD>WANG_BARRETTS_ESOPHAGUS_UP</TD><TD>49</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>ITGB4,NR2F2</TD></TR>
<TR><TD>6.846e-03</TD><TD>-4.98</TD><TD>EBAUER_MYOGENIC_TARGETS_OF_PAX3_FOXO1_FUSION</TD><TD>MSigDB lists</TD><TD>EBAUER_MYOGENIC_TARGETS_OF_PAX3_FOXO1_FUSION</TD><TD>49</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>NEBL,PDLIM5</TD></TR>
<TR><TD>6.846e-03</TD><TD>-4.98</TD><TD>MODULE_485</TD><TD>MSigDB lists</TD><TD>MODULE_485</TD><TD>49</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>SLC40A1,MSX2</TD></TR>
<TR><TD>6.846e-03</TD><TD>-4.98</TD><TD>TSUNODA_CISPLATIN_RESISTANCE_DN</TD><TD>MSigDB lists</TD><TD>TSUNODA_CISPLATIN_RESISTANCE_DN</TD><TD>49</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>KRT7,PDE3A</TD></TR>
<TR><TD>6.952e-03</TD><TD>-4.97</TD><TD>DPYSL2 (dihydropyrimidinase-like 2)</TD><TD>protein interactions</TD><TD>1808</TD><TD>49</TD><TD>2</TD><TD>16036</TD><TD>41</TD>
<TD>TNIK,PDE3A</TD></TR>
<TR><TD>7.010e-03</TD><TD>-4.96</TD><TD>negative regulation of DNA binding</TD><TD>biological process</TD><TD>GO:0043392</TD><TD>47</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2,MSX1</TD></TR>
<TR><TD>7.095e-03</TD><TD>-4.95</TD><TD>cardiac muscle tissue development</TD><TD>biological process</TD><TD>GO:0048738</TD><TD>147</TD><TD>3</TD><TD>16441</TD><TD>44</TD>
<TD>CAMK2D,NEBL,PDLIM5</TD></TR>
<TR><TD>7.095e-03</TD><TD>-4.95</TD><TD>morphogenesis of embryonic epithelium</TD><TD>biological process</TD><TD>GO:0016331</TD><TD>147</TD><TD>3</TD><TD>16441</TD><TD>44</TD>
<TD>ZIC2,WNT16,GRHL3</TD></TR>
<TR><TD>7.128e-03</TD><TD>-4.94</TD><TD>Non-integrin membrane-ECM interactions</TD><TD>REACTOME pathways</TD><TD>R-HSA-3000171</TD><TD>42</TD><TD>2</TD><TD>8202</TD><TD>25</TD>
<TD>LAMA4,ITGB4</TD></TR>
<TR><TD>7.230e-03</TD><TD>-4.93</TD><TD>cell morphogenesis involved in differentiation</TD><TD>biological process</TD><TD>GO:0000904</TD><TD>857</TD><TD>7</TD><TD>16441</TD><TD>44</TD>
<TD>EFNB2,CAMK2D,MSX2,FGF9,MSX1,WNT16,ETV1</TD></TR>
<TR><TD>7.303e-03</TD><TD>-4.92</TD><TD>positive regulation of muscle organ development</TD><TD>biological process</TD><TD>GO:0048636</TD><TD>48</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>EFNB2,FGF9</TD></TR>
<TR><TD>7.303e-03</TD><TD>-4.92</TD><TD>actin-mediated cell contraction</TD><TD>biological process</TD><TD>GO:0070252</TD><TD>48</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>VIM,CAMK2D</TD></TR>
<TR><TD>7.303e-03</TD><TD>-4.92</TD><TD>positive regulation of striated muscle tissue development</TD><TD>biological process</TD><TD>GO:0045844</TD><TD>48</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>EFNB2,FGF9</TD></TR>
<TR><TD>7.331e-03</TD><TD>-4.92</TD><TD>GSE29614_CTRL_VS_TIV_FLU_VACCINE_PBMC_2007_DN</TD><TD>MSigDB lists</TD><TD>GSE29614_CTRL_VS_TIV_FLU_VACCINE_PBMC_2007_DN</TD><TD>157</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>MSX1,CNTNAP3,GRHL3</TD></TR>
<TR><TD>7.393e-03</TD><TD>-4.91</TD><TD>MODULE_19</TD><TD>MSigDB lists</TD><TD>MODULE_19</TD><TD>306</TD><TD>4</TD><TD>17758</TD><TD>45</TD>
<TD>PBX1,ZIC2,NR2F1,VSNL1</TD></TR>
<TR><TD>7.399e-03</TD><TD>-4.91</TD><TD>PID_CASPASE_PATHWAY</TD><TD>MSigDB lists</TD><TD>PID_CASPASE_PATHWAY</TD><TD>51</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>VIM,SLK</TD></TR>
<TR><TD>7.399e-03</TD><TD>-4.91</TD><TD>chr6q21</TD><TD>MSigDB lists</TD><TD>chr6q21</TD><TD>51</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>LAMA4,PKIB</TD></TR>
<TR><TD>7.399e-03</TD><TD>-4.91</TD><TD>BRAIN_DEVELOPMENT</TD><TD>MSigDB lists</TD><TD>BRAIN_DEVELOPMENT</TD><TD>51</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>PBX1,ZIC2</TD></TR>
<TR><TD>7.408e-03</TD><TD>-4.91</TD><TD>NS-other-Krukenberg_tumour</TD><TD>COSMIC cancer mutations</TD><TD>NS-other-Krukenberg_tumour</TD><TD>3</TD><TD>1</TD><TD>17775</TD><TD>44</TD>
<TD>RNF43</TD></TR>
<TR><TD>7.489e-03</TD><TD>-4.89</TD><TD>brain development</TD><TD>biological process</TD><TD>GO:0007420</TD><TD>653</TD><TD>6</TD><TD>16441</TD><TD>44</TD>
<TD>FGF9,ZIC2,MSX1,NR2F2,NR2F1,NT5E</TD></TR>
<TR><TD>7.503e-03</TD><TD>-4.89</TD><TD>CTTTGA_V$LEF1_Q2</TD><TD>MSigDB lists</TD><TD>CTTTGA_V$LEF1_Q2</TD><TD>1147</TD><TD>8</TD><TD>17758</TD><TD>45</TD>
<TD>MSX1,PPARG,VSNL1,CLSTN2,RNF43,NR2F2,ETV1,NR2F1</TD></TR>
<TR><TD>7.525e-03</TD><TD>-4.89</TD><TD>1Cnucl_rcpt</TD><TD>interpro domains</TD><TD>IPR003074</TD><TD>3</TD><TD>1</TD><TD>18293</TD><TD>46</TD>
<TD>PPARG</TD></TR>
<TR><TD>7.525e-03</TD><TD>-4.89</TD><TD>ETS_PEA3_N</TD><TD>interpro domains</TD><TD>IPR006715</TD><TD>3</TD><TD>1</TD><TD>18293</TD><TD>46</TD>
<TD>ETV1</TD></TR>
<TR><TD>7.525e-03</TD><TD>-4.89</TD><TD>TBD</TD><TD>interpro domains</TD><TD>IPR024581</TD><TD>3</TD><TD>1</TD><TD>18293</TD><TD>46</TD>
<TD>TANK</TD></TR>
<TR><TD>7.525e-03</TD><TD>-4.89</TD><TD>cAMP_dep_PKI</TD><TD>interpro domains</TD><TD>IPR004171</TD><TD>3</TD><TD>1</TD><TD>18293</TD><TD>46</TD>
<TD>PKIB</TD></TR>
<TR><TD>7.525e-03</TD><TD>-4.89</TD><TD>PRib_PP_synth_CS</TD><TD>interpro domains</TD><TD>IPR000842</TD><TD>3</TD><TD>1</TD><TD>18293</TD><TD>46</TD>
<TD>PRPS1</TD></TR>
<TR><TD>7.525e-03</TD><TD>-4.89</TD><TD>Unc-13</TD><TD>interpro domains</TD><TD>IPR027080</TD><TD>3</TD><TD>1</TD><TD>18293</TD><TD>46</TD>
<TD>UNC13A</TD></TR>
<TR><TD>7.525e-03</TD><TD>-4.89</TD><TD>Calsyntenin</TD><TD>interpro domains</TD><TD>IPR026914</TD><TD>3</TD><TD>1</TD><TD>18293</TD><TD>46</TD>
<TD>CLSTN2</TD></TR>
<TR><TD>7.561e-03</TD><TD>-4.88</TD><TD>LEI_MYB_TARGETS</TD><TD>MSigDB lists</TD><TD>LEI_MYB_TARGETS</TD><TD>308</TD><TD>4</TD><TD>17758</TD><TD>45</TD>
<TD>VIM,KRT7,S100A10,AHNAK2</TD></TR>
<TR><TD>7.561e-03</TD><TD>-4.88</TD><TD>PASINI_SUZ12_TARGETS_DN</TD><TD>MSigDB lists</TD><TD>PASINI_SUZ12_TARGETS_DN</TD><TD>308</TD><TD>4</TD><TD>17758</TD><TD>45</TD>
<TD>VIM,S100A10,PDLIM5,NT5E</TD></TR>
<TR><TD>7.567e-03</TD><TD>-4.88</TD><TD>plasma membrane</TD><TD>cellular component</TD><TD>GO:0005886</TD><TD>4806</TD><TD>20</TD><TD>17570</TD><TD>44</TD>
<TD>EFNB2,TNIK,SLC40A1,CNTNAP3,STXBP6,CLSTN2,VIM,RNF43,RHOU,CAMK2D,S100A10,UNC13A,AHNAK2,SLCO5A1,CSMD3,ITGB4,CD44,PDLIM5,MMP16,NT5E</TD></TR>
<TR><TD>7.590e-03</TD><TD>-4.88</TD><TD>GSE15659_TREG_VS_TCONV_UP</TD><TD>MSigDB lists</TD><TD>GSE15659_TREG_VS_TCONV_UP</TD><TD>159</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>CAMK2D,NEBL,HFM1</TD></TR>
<TR><TD>7.600e-03</TD><TD>-4.88</TD><TD>regulation of signal transduction by p53 class mediator</TD><TD>biological process</TD><TD>GO:1901796</TD><TD>49</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>MSX1,CD44</TD></TR>
<TR><TD>7.600e-03</TD><TD>-4.88</TD><TD>positive regulation of muscle tissue development</TD><TD>biological process</TD><TD>GO:1901863</TD><TD>49</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>EFNB2,FGF9</TD></TR>
<TR><TD>7.651e-03</TD><TD>-4.87</TD><TD>CLCA2 (chloride channel accessory 2)</TD><TD>protein interactions</TD><TD>9635</TD><TD>3</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>ITGB4</TD></TR>
<TR><TD>7.651e-03</TD><TD>-4.87</TD><TD>RHBDL2 (rhomboid, veinlet-like 2 (Drosophila))</TD><TD>protein interactions</TD><TD>54933</TD><TD>3</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>EFNB2</TD></TR>
<TR><TD>7.651e-03</TD><TD>-4.87</TD><TD>ENPP2 (ectonucleotide pyrophosphatase/phosphodiesterase 2)</TD><TD>protein interactions</TD><TD>5168</TD><TD>3</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>ITGB4</TD></TR>
<TR><TD>7.651e-03</TD><TD>-4.87</TD><TD>GRHL2 (grainyhead-like transcription factor 2)</TD><TD>protein interactions</TD><TD>79977</TD><TD>3</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>GRHL3</TD></TR>
<TR><TD>7.651e-03</TD><TD>-4.87</TD><TD>PLA2G4C (phospholipase A2, group IVC (cytosolic, calcium-independent))</TD><TD>protein interactions</TD><TD>8605</TD><TD>3</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>S100A10</TD></TR>
<TR><TD>7.651e-03</TD><TD>-4.87</TD><TD>UPP2 (uridine phosphorylase 2)</TD><TD>protein interactions</TD><TD>151531</TD><TD>3</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>VIM</TD></TR>
<TR><TD>7.651e-03</TD><TD>-4.87</TD><TD>SLC6A8 (solute carrier family 6 (neurotransmitter transporter), member 8)</TD><TD>protein interactions</TD><TD>6535</TD><TD>3</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>NT5E</TD></TR>
<TR><TD>7.651e-03</TD><TD>-4.87</TD><TD>ALOX15B (arachidonate 15-lipoxygenase, type B)</TD><TD>protein interactions</TD><TD>247</TD><TD>3</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>PPARG</TD></TR>
<TR><TD>7.651e-03</TD><TD>-4.87</TD><TD>HAMP (hepcidin antimicrobial peptide)</TD><TD>protein interactions</TD><TD>57817</TD><TD>3</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>SLC40A1</TD></TR>
<TR><TD>7.651e-03</TD><TD>-4.87</TD><TD>CYP2S1 (cytochrome P450, family 2, subfamily S, polypeptide 1)</TD><TD>protein interactions</TD><TD>29785</TD><TD>3</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>NT5E</TD></TR>
<TR><TD>7.651e-03</TD><TD>-4.87</TD><TD>LY6D (lymphocyte antigen 6 complex, locus D)</TD><TD>protein interactions</TD><TD>8581</TD><TD>3</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>PKIB</TD></TR>
<TR><TD>7.651e-03</TD><TD>-4.87</TD><TD>MAP7D2 (MAP7 domain containing 2)</TD><TD>protein interactions</TD><TD>256714</TD><TD>3</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>EFNB2</TD></TR>
<TR><TD>7.651e-03</TD><TD>-4.87</TD><TD>URGCP (upregulator of cell proliferation)</TD><TD>protein interactions</TD><TD>55665</TD><TD>3</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>VIM</TD></TR>
<TR><TD>7.651e-03</TD><TD>-4.87</TD><TD>CLCA1 (chloride channel accessory 1)</TD><TD>protein interactions</TD><TD>1179</TD><TD>3</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>ITGB4</TD></TR>
<TR><TD>7.682e-03</TD><TD>-4.87</TD><TD>V$CDPCR3_01</TD><TD>MSigDB lists</TD><TD>V$CDPCR3_01</TD><TD>52</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>CSMD3,PPARG</TD></TR>
<TR><TD>7.721e-03</TD><TD>-4.86</TD><TD>V$NCX_01</TD><TD>MSigDB lists</TD><TD>V$NCX_01</TD><TD>160</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>RNF43,ETV1,NR2F1</TD></TR>
<TR><TD>7.754e-03</TD><TD>-4.86</TD><TD>regulation of cell division</TD><TD>biological process</TD><TD>GO:0051302</TD><TD>294</TD><TD>4</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2,FGF9,MSX1,PDE3A</TD></TR>
<TR><TD>7.803e-03</TD><TD>-4.85</TD><TD>ferrous iron transmembrane transporter activity</TD><TD>molecular function</TD><TD>GO:0015093</TD><TD>3</TD><TD>1</TD><TD>16491</TD><TD>43</TD>
<TD>SLC40A1</TD></TR>
<TR><TD>7.803e-03</TD><TD>-4.85</TD><TD>cGMP-stimulated cyclic-nucleotide phosphodiesterase activity</TD><TD>molecular function</TD><TD>GO:0004118</TD><TD>3</TD><TD>1</TD><TD>16491</TD><TD>43</TD>
<TD>PDE10A</TD></TR>
<TR><TD>7.917e-03</TD><TD>-4.84</TD><TD>TBD</TD><TD>pfam domains</TD><TD>PF12845</TD><TD>3</TD><TD>1</TD><TD>16629</TD><TD>44</TD>
<TD>TANK</TD></TR>
<TR><TD>7.917e-03</TD><TD>-4.84</TD><TD>ETS_PEA3_N</TD><TD>pfam domains</TD><TD>PF04621</TD><TD>3</TD><TD>1</TD><TD>16629</TD><TD>44</TD>
<TD>ETV1</TD></TR>
<TR><TD>7.917e-03</TD><TD>-4.84</TD><TD>PKI</TD><TD>pfam domains</TD><TD>PF02827</TD><TD>3</TD><TD>1</TD><TD>16629</TD><TD>44</TD>
<TD>PKIB</TD></TR>
<TR><TD>7.936e-03</TD><TD>-4.84</TD><TD>regulation of response to stimulus</TD><TD>biological process</TD><TD>GO:0048583</TD><TD>3566</TD><TD>17</TD><TD>16441</TD><TD>44</TD>
<TD>EFNB2,TNIK,FGF9,MSX1,PPARG,GPAT3,VSNL1,RNF43,ZIC2,RHOU,MSX2,CAMK2D,PDE10A,TANK,WNT16,CD44,NT5E</TD></TR>
<TR><TD>7.971e-03</TD><TD>-4.83</TD><TD>BROWNE_HCMV_INFECTION_10HR_DN</TD><TD>MSigDB lists</TD><TD>BROWNE_HCMV_INFECTION_10HR_DN</TD><TD>53</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>ETV1,NT5E</TD></TR>
<TR><TD>7.988e-03</TD><TD>-4.83</TD><TD>SERVITJA_ISLET_HNF1A_TARGETS_UP</TD><TD>MSigDB lists</TD><TD>SERVITJA_ISLET_HNF1A_TARGETS_UP</TD><TD>162</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>VIM,NEBL,NR2F1</TD></TR>
<TR><TD>7.988e-03</TD><TD>-4.83</TD><TD>GSE17974_IL4_AND_ANTI_IL12_VS_UNTREATED_2H_ACT_CD4_TCELL_UP</TD><TD>MSigDB lists</TD><TD>GSE17974_IL4_AND_ANTI_IL12_VS_UNTREATED_2H_ACT_CD4_TCELL_UP</TD><TD>162</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>SLC40A1,CAMK2D,MMP16</TD></TR>
<TR><TD>8.008e-03</TD><TD>-4.83</TD><TD>ferrous iron transmembrane transport</TD><TD>biological process</TD><TD>GO:1903874</TD><TD>3</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>SLC40A1</TD></TR>
<TR><TD>8.008e-03</TD><TD>-4.83</TD><TD>regulation of monocyte aggregation</TD><TD>biological process</TD><TD>GO:1900623</TD><TD>3</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>CD44</TD></TR>
<TR><TD>8.008e-03</TD><TD>-4.83</TD><TD>positive regulation of nodal signaling pathway involved in determination of lateral mesoderm left/right asymmetry</TD><TD>biological process</TD><TD>GO:1900224</TD><TD>3</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>ZIC2</TD></TR>
<TR><TD>8.008e-03</TD><TD>-4.83</TD><TD>cellular response to vitamin E</TD><TD>biological process</TD><TD>GO:0071306</TD><TD>3</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>PPARG</TD></TR>
<TR><TD>8.008e-03</TD><TD>-4.83</TD><TD>positive regulation of monocyte aggregation</TD><TD>biological process</TD><TD>GO:1900625</TD><TD>3</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>CD44</TD></TR>
<TR><TD>8.008e-03</TD><TD>-4.83</TD><TD>optic cup formation involved in camera-type eye development</TD><TD>biological process</TD><TD>GO:0003408</TD><TD>3</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>WNT16</TD></TR>
<TR><TD>8.008e-03</TD><TD>-4.83</TD><TD>positive regulation of intrinsic apoptotic signaling pathway by p53 class mediator</TD><TD>biological process</TD><TD>GO:1902255</TD><TD>3</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>MSX1</TD></TR>
<TR><TD>8.008e-03</TD><TD>-4.83</TD><TD>monocyte aggregation</TD><TD>biological process</TD><TD>GO:0070487</TD><TD>3</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>CD44</TD></TR>
<TR><TD>8.008e-03</TD><TD>-4.83</TD><TD>positive regulation of catagen</TD><TD>biological process</TD><TD>GO:0051795</TD><TD>3</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2</TD></TR>
<TR><TD>8.097e-03</TD><TD>-4.82</TD><TD>Extracellular matrix organization</TD><TD>REACTOME pathways</TD><TD>R-HSA-1474244</TD><TD>267</TD><TD>4</TD><TD>8202</TD><TD>25</TD>
<TD>LAMA4,ITGB4,CD44,MMP16</TD></TR>
<TR><TD>8.124e-03</TD><TD>-4.81</TD><TD>WNT_UP.V1_DN</TD><TD>MSigDB lists</TD><TD>WNT_UP.V1_DN</TD><TD>163</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>EFNB2,VIM,CD44</TD></TR>
<TR><TD>8.212e-03</TD><TD>-4.80</TD><TD>regulation of G2/M transition of mitotic cell cycle</TD><TD>biological process</TD><TD>GO:0010389</TD><TD>51</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>PBX1,CAMK2D</TD></TR>
<TR><TD>8.218e-03</TD><TD>-4.80</TD><TD>response to metal ion</TD><TD>biological process</TD><TD>GO:0010038</TD><TD>299</TD><TD>4</TD><TD>16441</TD><TD>44</TD>
<TD>SLC40A1,CAMK2D,PPARG,NT5E</TD></TR>
<TR><TD>8.261e-03</TD><TD>-4.80</TD><TD>ELVIDGE_HYPOXIA_UP</TD><TD>MSigDB lists</TD><TD>ELVIDGE_HYPOXIA_UP</TD><TD>164</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>KRT7,ANGPTL4,AHNAK2</TD></TR>
<TR><TD>8.276e-03</TD><TD>-4.79</TD><TD>wound healing</TD><TD>biological process</TD><TD>GO:0042060</TD><TD>667</TD><TD>6</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2,CD44,PDE10A,PDE3A,GRHL3,AHNAK2</TD></TR>
<TR><TD>8.303e-03</TD><TD>-4.79</TD><TD>single organism signaling</TD><TD>biological process</TD><TD>GO:0044700</TD><TD>5196</TD><TD>22</TD><TD>16441</TD><TD>44</TD>
<TD>EFNB2,TNIK,FGF9,MSX1,PPARG,SLK,GRHL3,VIM,RNF43,NR2F1,PDE3A,RHOU,MSX2,CAMK2D,PDE10A,TANK,UNC13A,WNT16,ITGB4,SORCS2,NR2F2,CD44</TD></TR>
<TR><TD>8.364e-03</TD><TD>-4.78</TD><TD>signaling</TD><TD>biological process</TD><TD>GO:0023052</TD><TD>5199</TD><TD>22</TD><TD>16441</TD><TD>44</TD>
<TD>EFNB2,TNIK,FGF9,MSX1,PPARG,SLK,GRHL3,VIM,RNF43,PDE3A,NR2F1,RHOU,MSX2,CAMK2D,PDE10A,TANK,UNC13A,WNT16,ITGB4,CD44,SORCS2,NR2F2</TD></TR>
<TR><TD>8.381e-03</TD><TD>-4.78</TD><TD>regulation of cellular process</TD><TD>biological process</TD><TD>GO:0050794</TD><TD>10106</TD><TD>35</TD><TD>16441</TD><TD>44</TD>
<TD>EFNB2,TNIK,STXBP6,SLK,GPAT3,CLSTN2,PBX1,RNF43,ZIC2,PDE3A,S100A10,PDE10A,UNC13A,TANK,WNT16,CD44,ETV1,LAMA4,FGF9,SLC40A1,MSX1,PPARG,GRHL3,VSNL1,VIM,ANGPTL4,NR2F1,RHOU,MSX2,CAMK2D,ITGB4,SORCS2,NR2F2,PDLIM5,PKIB</TD></TR>
<TR><TD>8.385e-03</TD><TD>-4.78</TD><TD>primary_central_nervous_system_lymphoma</TD><TD>COSMIC cancer mutations</TD><TD>primary_central_nervous_system_lymphoma</TD><TD>723</TD><TD>6</TD><TD>17775</TD><TD>44</TD>
<TD>CSMD3,LAMA4,NR2F2,SORCS2,CNTNAP3,MMP16</TD></TR>
<TR><TD>8.385e-03</TD><TD>-4.78</TD><TD>haematopoietic_and_lymphoid_tissue-central_nervous_system-lymphoid_neoplasm-primary_central_nervous_system_lymphoma</TD><TD>COSMIC cancer mutations</TD><TD>haematopoietic_and_lymphoid_tissue-central_nervous_system-lymphoid_neoplasm-primary_central_nervous_system_lymphoma</TD><TD>723</TD><TD>6</TD><TD>17775</TD><TD>44</TD>
<TD>CSMD3,LAMA4,NR2F2,SORCS2,CNTNAP3,MMP16</TD></TR>
<TR><TD>8.399e-03</TD><TD>-4.78</TD><TD>GSE6269_HEALTHY_VS_STREP_AUREUS_INF_PBMC_DN</TD><TD>MSigDB lists</TD><TD>GSE6269_HEALTHY_VS_STREP_AUREUS_INF_PBMC_DN</TD><TD>165</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>LAMA4,VIM,S100A10</TD></TR>
<TR><TD>8.496e-03</TD><TD>-4.77</TD><TD>regulation of nuclear division</TD><TD>biological process</TD><TD>GO:0051783</TD><TD>157</TD><TD>3</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2,MSX1,PDE3A</TD></TR>
<TR><TD>8.527e-03</TD><TD>-4.76</TD><TD>endochondral bone morphogenesis</TD><TD>biological process</TD><TD>GO:0060350</TD><TD>52</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2,MMP16</TD></TR>
<TR><TD>8.694e-03</TD><TD>-4.75</TD><TD>ANP32A (acidic nuclear phosphoprotein 32 family member A)</TD><TD>protein interactions</TD><TD>8125</TD><TD>55</TD><TD>2</TD><TD>16036</TD><TD>41</TD>
<TD>PPARG,PDLIM5</TD></TR>
<TR><TD>8.719e-03</TD><TD>-4.74</TD><TD>MULLIGHAN_NPM1_SIGNATURE_3_UP</TD><TD>MSigDB lists</TD><TD>MULLIGHAN_NPM1_SIGNATURE_3_UP</TD><TD>321</TD><TD>4</TD><TD>17758</TD><TD>45</TD>
<TD>PDLIM5,PRPS1,TANK,PDE3A</TD></TR>
<TR><TD>8.799e-03</TD><TD>-4.73</TD><TD>purine ribonucleotide metabolic process</TD><TD>biological process</TD><TD>GO:0009150</TD><TD>305</TD><TD>4</TD><TD>16441</TD><TD>44</TD>
<TD>PDE10A,PRPS1,PDE3A,NT5E</TD></TR>
<TR><TD>8.799e-03</TD><TD>-4.73</TD><TD>urogenital system development</TD><TD>biological process</TD><TD>GO:0001655</TD><TD>305</TD><TD>4</TD><TD>16441</TD><TD>44</TD>
<TD>PBX1,EFNB2,ITGB4,CD44</TD></TR>
<TR><TD>8.822e-03</TD><TD>-4.73</TD><TD>GSE26928_EFF_MEMORY_VS_CXCR5_POS_CD4_TCELL_UP</TD><TD>MSigDB lists</TD><TD>GSE26928_EFF_MEMORY_VS_CXCR5_POS_CD4_TCELL_UP</TD><TD>168</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>SLCO5A1,S100A10,NR2F2</TD></TR>
<TR><TD>8.865e-03</TD><TD>-4.73</TD><TD>AMIT_SERUM_RESPONSE_240_MCF10A</TD><TD>MSigDB lists</TD><TD>AMIT_SERUM_RESPONSE_240_MCF10A</TD><TD>56</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>PDLIM5,ANGPTL4</TD></TR>
<TR><TD>8.865e-03</TD><TD>-4.73</TD><TD>KEGG_HEDGEHOG_SIGNALING_PATHWAY</TD><TD>MSigDB lists</TD><TD>KEGG_HEDGEHOG_SIGNALING_PATHWAY</TD><TD>56</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>ZIC2,WNT16</TD></TR>
<TR><TD>9.001e-03</TD><TD>-4.71</TD><TD>KEGG_PATHWAYS_IN_CANCER</TD><TD>MSigDB lists</TD><TD>KEGG_PATHWAYS_IN_CANCER</TD><TD>324</TD><TD>4</TD><TD>17758</TD><TD>45</TD>
<TD>LAMA4,FGF9,WNT16,PPARG</TD></TR>
<TR><TD>9.036e-03</TD><TD>-4.71</TD><TD>negative regulation of cell death</TD><TD>biological process</TD><TD>GO:0060548</TD><TD>894</TD><TD>7</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2,SLC40A1,WNT16,MSX1,CD44,ANGPTL4,PDE3A</TD></TR>
<TR><TD>9.117e-03</TD><TD>-4.70</TD><TD>5-Phosphoribose 1-diphosphate biosynthesis</TD><TD>REACTOME pathways</TD><TD>R-HSA-73843</TD><TD>3</TD><TD>1</TD><TD>8202</TD><TD>25</TD>
<TD>PRPS1</TD></TR>
<TR><TD>9.161e-03</TD><TD>-4.69</TD><TD>TGCTGAY_UNKNOWN</TD><TD>MSigDB lists</TD><TD>TGCTGAY_UNKNOWN</TD><TD>511</TD><TD>5</TD><TD>17758</TD><TD>45</TD>
<TD>MSX2,RNF43,FGF9,ETV1,GRHL3</TD></TR>
<TR><TD>9.253e-03</TD><TD>-4.68</TD><TD>bone development</TD><TD>biological process</TD><TD>GO:0060348</TD><TD>162</TD><TD>3</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2,MSX1,MMP16</TD></TR>
<TR><TD>9.257e-03</TD><TD>-4.68</TD><TD>BENPORATH_NOS_TARGETS</TD><TD>MSigDB lists</TD><TD>BENPORATH_NOS_TARGETS</TD><TD>171</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>LAMA4,ZIC2,NEBL</TD></TR>
<TR><TD>9.330e-03</TD><TD>-4.67</TD><TD>central_nervous_system-brain-glioma-astrocytoma_Grade_III</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-brain-glioma-astrocytoma_Grade_III</TD><TD>1482</TD><TD>9</TD><TD>17775</TD><TD>44</TD>
<TD>EFNB2,MSX2,CAMK2D,HFM1,UNC13A,CSMD3,CLSTN2,PDLIM5,NT5E</TD></TR>
<TR><TD>9.351e-03</TD><TD>-4.67</TD><TD>Laminin_G</TD><TD>interpro domains</TD><TD>IPR001791</TD><TD>58</TD><TD>2</TD><TD>18293</TD><TD>46</TD>
<TD>LAMA4,CNTNAP3</TD></TR>
<TR><TD>9.405e-03</TD><TD>-4.67</TD><TD>PTEN_DN.V1_DN</TD><TD>MSigDB lists</TD><TD>PTEN_DN.V1_DN</TD><TD>172</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>MSX2,VIM,WNT16</TD></TR>
<TR><TD>9.485e-03</TD><TD>-4.66</TD><TD>REACTOME_INTERFERON_GAMMA_SIGNALING</TD><TD>MSigDB lists</TD><TD>REACTOME_INTERFERON_GAMMA_SIGNALING</TD><TD>58</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>CAMK2D,CD44</TD></TR>
<TR><TD>9.485e-03</TD><TD>-4.66</TD><TD>FONTAINE_PAPILLARY_THYROID_CARCINOMA_UP</TD><TD>MSigDB lists</TD><TD>FONTAINE_PAPILLARY_THYROID_CARCINOMA_UP</TD><TD>58</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>S100A10,ETV1</TD></TR>
<TR><TD>9.485e-03</TD><TD>-4.66</TD><TD>SANSOM_WNT_PATHWAY_REQUIRE_MYC</TD><TD>MSigDB lists</TD><TD>SANSOM_WNT_PATHWAY_REQUIRE_MYC</TD><TD>58</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>MSX1,CD44</TD></TR>
<TR><TD>9.488e-03</TD><TD>-4.66</TD><TD>human chr5q14</TD><TD>chromosome location</TD><TD>human chr5q14</TD><TD>5</TD><TD>1</TD><TD>26250</TD><TD>50</TD>
<TD>NR2F1</TD></TR>
<TR><TD>9.488e-03</TD><TD>-4.66</TD><TD>human chr13q33</TD><TD>chromosome location</TD><TD>human chr13q33</TD><TD>5</TD><TD>1</TD><TD>26250</TD><TD>50</TD>
<TD>EFNB2</TD></TR>
<TR><TD>9.501e-03</TD><TD>-4.66</TD><TD>ureteric bud morphogenesis</TD><TD>biological process</TD><TD>GO:0060675</TD><TD>55</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>PBX1,CD44</TD></TR>
<TR><TD>9.501e-03</TD><TD>-4.66</TD><TD>regulation of cell cycle G2/M phase transition</TD><TD>biological process</TD><TD>GO:1902749</TD><TD>55</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>PBX1,CAMK2D</TD></TR>
<TR><TD>9.502e-03</TD><TD>-4.66</TD><TD>cellular response to hormone stimulus</TD><TD>biological process</TD><TD>GO:0032870</TD><TD>687</TD><TD>6</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2,CAMK2D,FGF9,NR2F2,PPARG,NR2F1</TD></TR>
<TR><TD>9.631e-03</TD><TD>-4.64</TD><TD>ZHX1 (zinc fingers and homeoboxes 1)</TD><TD>protein interactions</TD><TD>11244</TD><TD>58</TD><TD>2</TD><TD>16036</TD><TD>41</TD>
<TD>LAMA4,VIM</TD></TR>
<TR><TD>9.664e-03</TD><TD>-4.64</TD><TD>cell periphery</TD><TD>cellular component</TD><TD>GO:0071944</TD><TD>4907</TD><TD>20</TD><TD>17570</TD><TD>44</TD>
<TD>EFNB2,SLC40A1,TNIK,CNTNAP3,STXBP6,CLSTN2,VIM,RNF43,RHOU,CAMK2D,S100A10,UNC13A,AHNAK2,CSMD3,SLCO5A1,ITGB4,CD44,PDLIM5,MMP16,NT5E</TD></TR>
<TR><TD>9.705e-03</TD><TD>-4.64</TD><TD>V$AP2REP_01</TD><TD>MSigDB lists</TD><TD>V$AP2REP_01</TD><TD>174</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>PBX1,VIM,PDE10A</TD></TR>
<TR><TD>9.743e-03</TD><TD>-4.63</TD><TD>positive regulation of macromolecule biosynthetic process</TD><TD>biological process</TD><TD>GO:0010557</TD><TD>1634</TD><TD>10</TD><TD>16441</TD><TD>44</TD>
<TD>SLC40A1,MSX1,PPARG,GRHL3,PBX1,ZIC2,NR2F2,ETV1,NR2F1,PKIB</TD></TR>
<TR><TD>9.802e-03</TD><TD>-4.63</TD><TD>DAVICIONI_RHABDOMYOSARCOMA_PAX_FOXO1_FUSION_UP</TD><TD>MSigDB lists</TD><TD>DAVICIONI_RHABDOMYOSARCOMA_PAX_FOXO1_FUSION_UP</TD><TD>59</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>NEBL,NR2F2</TD></TR>
<TR><TD>9.836e-03</TD><TD>-4.62</TD><TD>mesonephric tubule morphogenesis</TD><TD>biological process</TD><TD>GO:0072171</TD><TD>56</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>PBX1,CD44</TD></TR>
<TR><TD>9.881e-03</TD><TD>-4.62</TD><TD>transcription factor activity, RNA polymerase II core promoter proximal region sequence-specific binding</TD><TD>molecular function</TD><TD>GO:0000982</TD><TD>324</TD><TD>4</TD><TD>16491</TD><TD>43</TD>
<TD>PBX1,MSX2,MSX1,ETV1</TD></TR>
<TR><TD>9.894e-03</TD><TD>-4.62</TD><TD>head development</TD><TD>biological process</TD><TD>GO:0060322</TD><TD>693</TD><TD>6</TD><TD>16441</TD><TD>44</TD>
<TD>ZIC2,FGF9,MSX1,NR2F2,NR2F1,NT5E</TD></TR>
<TR><TD>9.980e-03</TD><TD>-4.61</TD><TD>ribose phosphate diphosphokinase complex</TD><TD>cellular component</TD><TD>GO:0002189</TD><TD>4</TD><TD>1</TD><TD>17570</TD><TD>44</TD>
<TD>PRPS1</TD></TR>
<TR><TD>1.001e-02</TD><TD>-4.60</TD><TD>cell morphogenesis</TD><TD>biological process</TD><TD>GO:0000902</TD><TD>1143</TD><TD>8</TD><TD>16441</TD><TD>44</TD>
<TD>EFNB2,TNIK,FGF9,CAMK2D,MSX2,MSX1,WNT16,ETV1</TD></TR>
<TR><TD>1.002e-02</TD><TD>-4.60</TD><TD>Ca/CaM-dep_prot_kinase-assoc</TD><TD>interpro domains</TD><TD>IPR013543</TD><TD>4</TD><TD>1</TD><TD>18293</TD><TD>46</TD>
<TD>CAMK2D</TD></TR>
<TR><TD>1.002e-02</TD><TD>-4.60</TD><TD>Pept_M10A_metallopeptidase_C</TD><TD>interpro domains</TD><TD>IPR021805</TD><TD>4</TD><TD>1</TD><TD>18293</TD><TD>46</TD>
<TD>MMP16</TD></TR>
<TR><TD>1.002e-02</TD><TD>-4.60</TD><TD>PBX</TD><TD>interpro domains</TD><TD>IPR005542</TD><TD>4</TD><TD>1</TD><TD>18293</TD><TD>46</TD>
<TD>PBX1</TD></TR>
<TR><TD>1.002e-02</TD><TD>-4.60</TD><TD>Nebulin_repeat</TD><TD>interpro domains</TD><TD>IPR000900</TD><TD>4</TD><TD>1</TD><TD>18293</TD><TD>46</TD>
<TD>NEBL</TD></TR>
<TR><TD>1.002e-02</TD><TD>-4.60</TD><TD>Sec63-dom</TD><TD>interpro domains</TD><TD>IPR004179</TD><TD>4</TD><TD>1</TD><TD>18293</TD><TD>46</TD>
<TD>HFM1</TD></TR>
<TR><TD>1.005e-02</TD><TD>-4.60</TD><TD>CASP3 (caspase 3)</TD><TD>protein interactions</TD><TD>836</TD><TD>175</TD><TD>3</TD><TD>16036</TD><TD>41</TD>
<TD>VIM,PDE10A,SLK</TD></TR>
<TR><TD>1.008e-02</TD><TD>-4.60</TD><TD>PRPP_SYNTHASE</TD><TD>prosite domains</TD><TD>PS00114</TD><TD>3</TD><TD>1</TD><TD>11866</TD><TD>40</TD>
<TD>PRPS1</TD></TR>
<TR><TD>1.010e-02</TD><TD>-4.60</TD><TD>chr9q12</TD><TD>MSigDB lists</TD><TD>chr9q12</TD><TD>4</TD><TD>1</TD><TD>17758</TD><TD>45</TD>
<TD>CNTNAP3</TD></TR>
<TR><TD>1.017e-02</TD><TD>-4.59</TD><TD>E2F3_UP.V1_UP</TD><TD>MSigDB lists</TD><TD>E2F3_UP.V1_UP</TD><TD>177</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>FGF9,ZIC2,NR2F1</TD></TR>
<TR><TD>1.018e-02</TD><TD>-4.59</TD><TD>positive regulation of nuclear division</TD><TD>biological process</TD><TD>GO:0051785</TD><TD>57</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2,MSX1</TD></TR>
<TR><TD>1.019e-02</TD><TD>-4.59</TD><TD>EPHA10 (EPH receptor A10)</TD><TD>protein interactions</TD><TD>284656</TD><TD>4</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>CAMK2D</TD></TR>
<TR><TD>1.019e-02</TD><TD>-4.59</TD><TD>JAZF1 (JAZF zinc finger 1)</TD><TD>protein interactions</TD><TD>221895</TD><TD>4</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>PPARG</TD></TR>
<TR><TD>1.019e-02</TD><TD>-4.59</TD><TD>HOXB8 (homeobox B8)</TD><TD>protein interactions</TD><TD>3218</TD><TD>4</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>PBX1</TD></TR>
<TR><TD>1.019e-02</TD><TD>-4.59</TD><TD>MADCAM1 (mucosal vascular addressin cell adhesion molecule 1)</TD><TD>protein interactions</TD><TD>8174</TD><TD>4</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>CD44</TD></TR>
<TR><TD>1.019e-02</TD><TD>-4.59</TD><TD>KRT27 (keratin 27, type I)</TD><TD>protein interactions</TD><TD>342574</TD><TD>4</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>KRT7</TD></TR>
<TR><TD>1.019e-02</TD><TD>-4.59</TD><TD>SLC41A1 (solute carrier family 41 (magnesium transporter), member 1)</TD><TD>protein interactions</TD><TD>254428</TD><TD>4</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>NT5E</TD></TR>
<TR><TD>1.019e-02</TD><TD>-4.59</TD><TD>NABA_SECRETED_FACTORS</TD><TD>MSigDB lists</TD><TD>NABA_SECRETED_FACTORS</TD><TD>336</TD><TD>4</TD><TD>17758</TD><TD>45</TD>
<TD>FGF9,WNT16,S100A10,ANGPTL4</TD></TR>
<TR><TD>1.030e-02</TD><TD>-4.58</TD><TD>SCHUETZ_BREAST_CANCER_DUCTAL_INVASIVE_UP</TD><TD>MSigDB lists</TD><TD>SCHUETZ_BREAST_CANCER_DUCTAL_INVASIVE_UP</TD><TD>337</TD><TD>4</TD><TD>17758</TD><TD>45</TD>
<TD>LAMA4,ETV1,PDE10A,AHNAK2</TD></TR>
<TR><TD>1.034e-02</TD><TD>-4.57</TD><TD>sensory organ development</TD><TD>biological process</TD><TD>GO:0007423</TD><TD>499</TD><TD>5</TD><TD>16441</TD><TD>44</TD>
<TD>VIM,FGF9,MSX1,WNT16,GRHL3</TD></TR>
<TR><TD>1.037e-02</TD><TD>-4.57</TD><TD>ribonucleotide metabolic process</TD><TD>biological process</TD><TD>GO:0009259</TD><TD>320</TD><TD>4</TD><TD>16441</TD><TD>44</TD>
<TD>PDE10A,PRPS1,PDE3A,NT5E</TD></TR>
<TR><TD>1.038e-02</TD><TD>-4.57</TD><TD>Nuclear Receptor transcription pathway</TD><TD>REACTOME pathways</TD><TD>R-HSA-383280</TD><TD>51</TD><TD>2</TD><TD>8202</TD><TD>25</TD>
<TD>PPARG,NR2F1</TD></TR>
<TR><TD>1.038e-02</TD><TD>-4.57</TD><TD>cell communication</TD><TD>biological process</TD><TD>GO:0007154</TD><TD>5288</TD><TD>22</TD><TD>16441</TD><TD>44</TD>
<TD>EFNB2,TNIK,FGF9,MSX1,PPARG,SLK,GRHL3,VIM,RNF43,NR2F1,PDE3A,RHOU,MSX2,CAMK2D,PDE10A,TANK,UNC13A,WNT16,ITGB4,SORCS2,NR2F2,CD44</TD></TR>
<TR><TD>1.038e-02</TD><TD>-4.57</TD><TD>pancreas-carcinoma-acinar_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>pancreas-carcinoma-acinar_carcinoma</TD><TD>2069</TD><TD>11</TD><TD>17775</TD><TD>44</TD>
<TD>HFM1,UNC13A,TANK,CSMD3,SLCO5A1,RNF43,WNT16,CD44,SORCS2,PDLIM5,NT5E</TD></TR>
<TR><TD>1.038e-02</TD><TD>-4.57</TD><TD>acinar_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>acinar_carcinoma</TD><TD>2069</TD><TD>11</TD><TD>17775</TD><TD>44</TD>
<TD>HFM1,UNC13A,TANK,CSMD3,SLCO5A1,RNF43,WNT16,CD44,SORCS2,PDLIM5,NT5E</TD></TR>
<TR><TD>1.039e-02</TD><TD>-4.57</TD><TD>glycerol-3-phosphate O-acyltransferase activity</TD><TD>molecular function</TD><TD>GO:0004366</TD><TD>4</TD><TD>1</TD><TD>16491</TD><TD>43</TD>
<TD>GPAT3</TD></TR>
<TR><TD>1.041e-02</TD><TD>-4.57</TD><TD>synapse part</TD><TD>cellular component</TD><TD>GO:0044456</TD><TD>534</TD><TD>5</TD><TD>17570</TD><TD>44</TD>
<TD>CLSTN2,SLC40A1,PDLIM5,UNC13A,NT5E</TD></TR>
<TR><TD>1.045e-02</TD><TD>-4.56</TD><TD>locomotion</TD><TD>biological process</TD><TD>GO:0040011</TD><TD>1396</TD><TD>9</TD><TD>16441</TD><TD>44</TD>
<TD>EFNB2,MSX2,CAMK2D,FGF9,ITGB4,NR2F2,CD44,ETV1,NR2F1</TD></TR>
<TR><TD>1.052e-02</TD><TD>-4.55</TD><TD>cyclic nucleotide metabolic process</TD><TD>biological process</TD><TD>GO:0009187</TD><TD>58</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>PDE10A,PDE3A</TD></TR>
<TR><TD>1.054e-02</TD><TD>-4.55</TD><TD>Nebulin</TD><TD>pfam domains</TD><TD>PF00880</TD><TD>4</TD><TD>1</TD><TD>16629</TD><TD>44</TD>
<TD>NEBL</TD></TR>
<TR><TD>1.054e-02</TD><TD>-4.55</TD><TD>Sec63</TD><TD>pfam domains</TD><TD>PF02889</TD><TD>4</TD><TD>1</TD><TD>16629</TD><TD>44</TD>
<TD>HFM1</TD></TR>
<TR><TD>1.054e-02</TD><TD>-4.55</TD><TD>CaMKII_AD</TD><TD>pfam domains</TD><TD>PF08332</TD><TD>4</TD><TD>1</TD><TD>16629</TD><TD>44</TD>
<TD>CAMK2D</TD></TR>
<TR><TD>1.054e-02</TD><TD>-4.55</TD><TD>PBC</TD><TD>pfam domains</TD><TD>PF03792</TD><TD>4</TD><TD>1</TD><TD>16629</TD><TD>44</TD>
<TD>PBX1</TD></TR>
<TR><TD>1.054e-02</TD><TD>-4.55</TD><TD>DUF3377</TD><TD>pfam domains</TD><TD>PF11857</TD><TD>4</TD><TD>1</TD><TD>16629</TD><TD>44</TD>
<TD>MMP16</TD></TR>
<TR><TD>1.061e-02</TD><TD>-4.55</TD><TD>sarcomere</TD><TD>cellular component</TD><TD>GO:0030017</TD><TD>182</TD><TD>3</TD><TD>17570</TD><TD>44</TD>
<TD>NEBL,PDLIM5,AHNAK2</TD></TR>
<TR><TD>1.066e-02</TD><TD>-4.54</TD><TD>5-phosphoribose 1-diphosphate biosynthetic process</TD><TD>biological process</TD><TD>GO:0006015</TD><TD>4</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>PRPS1</TD></TR>
<TR><TD>1.066e-02</TD><TD>-4.54</TD><TD>regulation of nodal signaling pathway involved in determination of left/right asymmetry</TD><TD>biological process</TD><TD>GO:1900145</TD><TD>4</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>ZIC2</TD></TR>
<TR><TD>1.066e-02</TD><TD>-4.54</TD><TD>positive regulation of hair follicle maturation</TD><TD>biological process</TD><TD>GO:0048818</TD><TD>4</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2</TD></TR>
<TR><TD>1.066e-02</TD><TD>-4.54</TD><TD>regulation of generation of L-type calcium current</TD><TD>biological process</TD><TD>GO:1902514</TD><TD>4</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>CAMK2D</TD></TR>
<TR><TD>1.066e-02</TD><TD>-4.54</TD><TD>oxidative stress-induced premature senescence</TD><TD>biological process</TD><TD>GO:0090403</TD><TD>4</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>WNT16</TD></TR>
<TR><TD>1.066e-02</TD><TD>-4.54</TD><TD>5-phosphoribose 1-diphosphate metabolic process</TD><TD>biological process</TD><TD>GO:0046391</TD><TD>4</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>PRPS1</TD></TR>
<TR><TD>1.066e-02</TD><TD>-4.54</TD><TD>frontal suture morphogenesis</TD><TD>biological process</TD><TD>GO:0060364</TD><TD>4</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2</TD></TR>
<TR><TD>1.066e-02</TD><TD>-4.54</TD><TD>regulation of catagen</TD><TD>biological process</TD><TD>GO:0051794</TD><TD>4</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2</TD></TR>
<TR><TD>1.066e-02</TD><TD>-4.54</TD><TD>positive regulation of oocyte development</TD><TD>biological process</TD><TD>GO:0060282</TD><TD>4</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>PDE3A</TD></TR>
<TR><TD>1.066e-02</TD><TD>-4.54</TD><TD>regulation of nodal signaling pathway involved in determination of lateral mesoderm left/right asymmetry</TD><TD>biological process</TD><TD>GO:1900175</TD><TD>4</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>ZIC2</TD></TR>
<TR><TD>1.080e-02</TD><TD>-4.53</TD><TD>GSE360_L_MAJOR_VS_B_MALAYI_LOW_DOSE_MAC_UP</TD><TD>MSigDB lists</TD><TD>GSE360_L_MAJOR_VS_B_MALAYI_LOW_DOSE_MAC_UP</TD><TD>181</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>EFNB2,CD44,TANK</TD></TR>
<TR><TD>1.080e-02</TD><TD>-4.53</TD><TD>TGFB_UP.V1_DN</TD><TD>MSigDB lists</TD><TD>TGFB_UP.V1_DN</TD><TD>181</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>RNF43,NR2F2,ANGPTL4</TD></TR>
<TR><TD>1.082e-02</TD><TD>-4.53</TD><TD>TATAAA_V$TATA_01</TD><TD>MSigDB lists</TD><TD>TATAAA_V$TATA_01</TD><TD>1222</TD><TD>8</TD><TD>17758</TD><TD>45</TD>
<TD>PPARG,TANK,HFM1,RNF43,NR2F2,ETV1,ANGPTL4,NR2F1</TD></TR>
<TR><TD>1.088e-02</TD><TD>-4.52</TD><TD>morphogenesis of a branching epithelium</TD><TD>biological process</TD><TD>GO:0061138</TD><TD>172</TD><TD>3</TD><TD>16441</TD><TD>44</TD>
<TD>PBX1,MSX2,CD44</TD></TR>
<TR><TD>1.091e-02</TD><TD>-4.52</TD><TD>Homeobox_CS</TD><TD>interpro domains</TD><TD>IPR017970</TD><TD>183</TD><TD>3</TD><TD>18293</TD><TD>46</TD>
<TD>PBX1,MSX2,MSX1</TD></TR>
<TR><TD>1.095e-02</TD><TD>-4.51</TD><TD>POU2F1 (POU class 2 homeobox 1)</TD><TD>protein interactions</TD><TD>5451</TD><TD>62</TD><TD>2</TD><TD>16036</TD><TD>41</TD>
<TD>PBX1,MSX1</TD></TR>
<TR><TD>1.096e-02</TD><TD>-4.51</TD><TD>E2F1_UP.V1_DN</TD><TD>MSigDB lists</TD><TD>E2F1_UP.V1_DN</TD><TD>182</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>LAMA4,ANGPTL4,TANK</TD></TR>
<TR><TD>1.096e-02</TD><TD>-4.51</TD><TD>GSE360_L_MAJOR_VS_B_MALAYI_HIGH_DOSE_MAC_UP</TD><TD>MSigDB lists</TD><TD>GSE360_L_MAJOR_VS_B_MALAYI_HIGH_DOSE_MAC_UP</TD><TD>182</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>CD44,S100A10,TANK</TD></TR>
<TR><TD>1.096e-02</TD><TD>-4.51</TD><TD>Intermediate_filament_CS</TD><TD>interpro domains</TD><TD>IPR018039</TD><TD>63</TD><TD>2</TD><TD>18293</TD><TD>46</TD>
<TD>VIM,KRT7</TD></TR>
<TR><TD>1.100e-02</TD><TD>-4.51</TD><TD>adenosine nucleotides degradation II</TD><TD>BIOCYC pathways</TD><TD>META_SALVADEHYPOX-PWY</TD><TD>5</TD><TD>1</TD><TD>907</TD><TD>2</TD>
<TD>NT5E</TD></TR>
<TR><TD>1.100e-02</TD><TD>-4.51</TD><TD>urate biosynthesis/inosine 5'-phosphate degradation</TD><TD>BIOCYC pathways</TD><TD>HUMAN_PWY-5695</TD><TD>5</TD><TD>1</TD><TD>907</TD><TD>2</TD>
<TD>NT5E</TD></TR>
<TR><TD>1.100e-02</TD><TD>-4.51</TD><TD>negative regulation of transcription, DNA-templated</TD><TD>biological process</TD><TD>GO:0045892</TD><TD>1162</TD><TD>8</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2,FGF9,MSX1,PPARG,PBX1,ZIC2,NR2F2,NR2F1</TD></TR>
<TR><TD>1.103e-02</TD><TD>-4.51</TD><TD>monocarboxylic acid binding</TD><TD>molecular function</TD><TD>GO:0033293</TD><TD>61</TD><TD>2</TD><TD>16491</TD><TD>43</TD>
<TD>NR2F2,PPARG</TD></TR>
<TR><TD>1.103e-02</TD><TD>-4.51</TD><TD>regulation of neuron differentiation</TD><TD>biological process</TD><TD>GO:0045664</TD><TD>507</TD><TD>5</TD><TD>16441</TD><TD>44</TD>
<TD>PBX1,VIM,TNIK,PDLIM5,UNC13A</TD></TR>
<TR><TD>1.104e-02</TD><TD>-4.51</TD><TD>eye development</TD><TD>biological process</TD><TD>GO:0001654</TD><TD>326</TD><TD>4</TD><TD>16441</TD><TD>44</TD>
<TD>VIM,FGF9,WNT16,GRHL3</TD></TR>
<TR><TD>1.112e-02</TD><TD>-4.50</TD><TD>BOYAULT_LIVER_CANCER_SUBCLASS_G6_UP</TD><TD>MSigDB lists</TD><TD>BOYAULT_LIVER_CANCER_SUBCLASS_G6_UP</TD><TD>63</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>RNF43,VSNL1</TD></TR>
<TR><TD>1.112e-02</TD><TD>-4.50</TD><TD>GSE13306_LAMINA_PROPRIA_VS_SPLEEN_TREG_DN</TD><TD>MSigDB lists</TD><TD>GSE13306_LAMINA_PROPRIA_VS_SPLEEN_TREG_DN</TD><TD>183</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>MSX1,ANGPTL4,NR2F1</TD></TR>
<TR><TD>1.112e-02</TD><TD>-4.50</TD><TD>LEF1_UP.V1_UP</TD><TD>MSigDB lists</TD><TD>LEF1_UP.V1_UP</TD><TD>183</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>FGF9,VIM,PRPS1</TD></TR>
<TR><TD>1.112e-02</TD><TD>-4.50</TD><TD>GSE3982_BCELL_VS_EFF_MEMORY_CD4_TCELL_DN</TD><TD>MSigDB lists</TD><TD>GSE3982_BCELL_VS_EFF_MEMORY_CD4_TCELL_DN</TD><TD>183</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>LAMA4,PDE10A,PDE3A</TD></TR>
<TR><TD>1.116e-02</TD><TD>-4.50</TD><TD>purine nucleotide metabolic process</TD><TD>biological process</TD><TD>GO:0006163</TD><TD>327</TD><TD>4</TD><TD>16441</TD><TD>44</TD>
<TD>PDE10A,PRPS1,PDE3A,NT5E</TD></TR>
<TR><TD>1.123e-02</TD><TD>-4.49</TD><TD>mammary gland epithelium development</TD><TD>biological process</TD><TD>GO:0061180</TD><TD>60</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2,MSX1</TD></TR>
<TR><TD>1.123e-02</TD><TD>-4.49</TD><TD>regulation of DNA biosynthetic process</TD><TD>biological process</TD><TD>GO:2000278</TD><TD>60</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>PPARG,PKIB</TD></TR>
<TR><TD>1.123e-02</TD><TD>-4.49</TD><TD>embryonic digit morphogenesis</TD><TD>biological process</TD><TD>GO:0042733</TD><TD>60</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2,MSX1</TD></TR>
<TR><TD>1.129e-02</TD><TD>-4.48</TD><TD>CCDC136 (coiled-coil domain containing 136)</TD><TD>protein interactions</TD><TD>64753</TD><TD>63</TD><TD>2</TD><TD>16036</TD><TD>41</TD>
<TD>NEBL,PDLIM5</TD></TR>
<TR><TD>1.129e-02</TD><TD>-4.48</TD><TD>PKN1 (protein kinase N1)</TD><TD>protein interactions</TD><TD>5585</TD><TD>63</TD><TD>2</TD><TD>16036</TD><TD>41</TD>
<TD>VIM,CD44</TD></TR>
<TR><TD>1.129e-02</TD><TD>-4.48</TD><TD>GSE37416_12H_VS_24H_F_TULARENSIS_LVS_NEUTROPHIL_UP</TD><TD>MSigDB lists</TD><TD>GSE37416_12H_VS_24H_F_TULARENSIS_LVS_NEUTROPHIL_UP</TD><TD>184</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>SLC40A1,ITGB4,CD44</TD></TR>
<TR><TD>1.129e-02</TD><TD>-4.48</TD><TD>ESC_V6.5_UP_LATE.V1_UP</TD><TD>MSigDB lists</TD><TD>ESC_V6.5_UP_LATE.V1_UP</TD><TD>184</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>RHOU,MSX2,KRT7</TD></TR>
<TR><TD>1.131e-02</TD><TD>-4.48</TD><TD>PROXISOMEPAR</TD><TD>prints domains</TD><TD>PR01288</TD><TD>3</TD><TD>1</TD><TD>4759</TD><TD>18</TD>
<TD>PPARG</TD></TR>
<TR><TD>1.138e-02</TD><TD>-4.48</TD><TD>human chr10p12</TD><TD>chromosome location</TD><TD>human chr10p12</TD><TD>6</TD><TD>1</TD><TD>26250</TD><TD>50</TD>
<TD>NEBL</TD></TR>
<TR><TD>1.145e-02</TD><TD>-4.47</TD><TD>ESC_J1_UP_LATE.V1_UP</TD><TD>MSigDB lists</TD><TD>ESC_J1_UP_LATE.V1_UP</TD><TD>185</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>RHOU,SLC40A1,KRT7</TD></TR>
<TR><TD>1.145e-02</TD><TD>-4.47</TD><TD>TGASTMAGC_V$NFE2_01</TD><TD>MSigDB lists</TD><TD>TGASTMAGC_V$NFE2_01</TD><TD>185</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>FGF9,CD44,ANGPTL4</TD></TR>
<TR><TD>1.146e-02</TD><TD>-4.47</TD><TD>HERNANDEZ_MITOTIC_ARREST_BY_DOCETAXEL_2_UP</TD><TD>MSigDB lists</TD><TD>HERNANDEZ_MITOTIC_ARREST_BY_DOCETAXEL_2_UP</TD><TD>64</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>LAMA4,NT5E</TD></TR>
<TR><TD>1.155e-02</TD><TD>-4.46</TD><TD>LamG</TD><TD>smart domains</TD><TD>SM00282</TD><TD>44</TD><TD>2</TD><TD>9131</TD><TD>34</TD>
<TD>LAMA4,CNTNAP3</TD></TR>
<TR><TD>1.159e-02</TD><TD>-4.46</TD><TD>chondrocyte differentiation</TD><TD>biological process</TD><TD>GO:0002062</TD><TD>61</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2,FGF9</TD></TR>
<TR><TD>1.159e-02</TD><TD>-4.46</TD><TD>negative regulation of cyclin-dependent protein kinase activity</TD><TD>biological process</TD><TD>GO:1904030</TD><TD>61</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>NR2F2,PKIB</TD></TR>
<TR><TD>1.159e-02</TD><TD>-4.46</TD><TD>stem cell proliferation</TD><TD>biological process</TD><TD>GO:0072089</TD><TD>61</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>RNF43,MSX1</TD></TR>
<TR><TD>1.162e-02</TD><TD>-4.45</TD><TD>GSE15324_NAIVE_VS_ACTIVATED_ELF4_KO_CD8_TCELL_UP</TD><TD>MSigDB lists</TD><TD>GSE15324_NAIVE_VS_ACTIVATED_ELF4_KO_CD8_TCELL_UP</TD><TD>186</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>TNIK,PDLIM5,NT5E</TD></TR>
<TR><TD>1.162e-02</TD><TD>-4.45</TD><TD>GSE3982_EFF_MEMORY_CD4_TCELL_VS_TH2_UP</TD><TD>MSigDB lists</TD><TD>GSE3982_EFF_MEMORY_CD4_TCELL_VS_TH2_UP</TD><TD>186</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>ITGB4,CD44,PDE10A</TD></TR>
<TR><TD>1.162e-02</TD><TD>-4.45</TD><TD>GSE3982_MAST_CELL_VS_EFF_MEMORY_CD4_TCELL_DN</TD><TD>MSigDB lists</TD><TD>GSE3982_MAST_CELL_VS_EFF_MEMORY_CD4_TCELL_DN</TD><TD>186</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>SLCO5A1,S100A10,PDE3A</TD></TR>
<TR><TD>1.171e-02</TD><TD>-4.45</TD><TD>GRUETZMANN_PANCREATIC_CANCER_UP</TD><TD>MSigDB lists</TD><TD>GRUETZMANN_PANCREATIC_CANCER_UP</TD><TD>350</TD><TD>4</TD><TD>17758</TD><TD>45</TD>
<TD>LAMA4,ITGB4,S100A10,TANK</TD></TR>
<TR><TD>1.175e-02</TD><TD>-4.44</TD><TD>ribose phosphate metabolic process</TD><TD>biological process</TD><TD>GO:0019693</TD><TD>332</TD><TD>4</TD><TD>16441</TD><TD>44</TD>
<TD>PRPS1,PDE10A,PDE3A,NT5E</TD></TR>
<TR><TD>1.179e-02</TD><TD>-4.44</TD><TD>GSE3982_MAC_VS_EFF_MEMORY_CD4_TCELL_DN</TD><TD>MSigDB lists</TD><TD>GSE3982_MAC_VS_EFF_MEMORY_CD4_TCELL_DN</TD><TD>187</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>NR2F2,PDE10A,STXBP6</TD></TR>
<TR><TD>1.179e-02</TD><TD>-4.44</TD><TD>WAMUNYOKOLI_OVARIAN_CANCER_LMP_DN</TD><TD>MSigDB lists</TD><TD>WAMUNYOKOLI_OVARIAN_CANCER_LMP_DN</TD><TD>187</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>LAMA4,PRPS1,NR2F1</TD></TR>
<TR><TD>1.180e-02</TD><TD>-4.44</TD><TD>CORRE_MULTIPLE_MYELOMA_UP</TD><TD>MSigDB lists</TD><TD>CORRE_MULTIPLE_MYELOMA_UP</TD><TD>65</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>PDE10A,ANGPTL4</TD></TR>
<TR><TD>1.180e-02</TD><TD>-4.44</TD><TD>RIGGINS_TAMOXIFEN_RESISTANCE_UP</TD><TD>MSigDB lists</TD><TD>RIGGINS_TAMOXIFEN_RESISTANCE_UP</TD><TD>65</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>LAMA4,TNIK</TD></TR>
<TR><TD>1.181e-02</TD><TD>-4.44</TD><TD>GGGTGGRR_V$PAX4_03</TD><TD>MSigDB lists</TD><TD>GGGTGGRR_V$PAX4_03</TD><TD>1241</TD><TD>8</TD><TD>17758</TD><TD>45</TD>
<TD>EFNB2,MSX2,S100A10,GRHL3,PBX1,ZIC2,VIM,NR2F1</TD></TR>
<TR><TD>1.196e-02</TD><TD>-4.43</TD><TD>GSE2826_WT_VS_BTK_KO_BCELL_DN</TD><TD>MSigDB lists</TD><TD>GSE2826_WT_VS_BTK_KO_BCELL_DN</TD><TD>188</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>SLCO5A1,MSX2,PPARG</TD></TR>
<TR><TD>1.196e-02</TD><TD>-4.43</TD><TD>GSE13306_RA_VS_UNTREATED_MEM_CD4_TCELL_DN</TD><TD>MSigDB lists</TD><TD>GSE13306_RA_VS_UNTREATED_MEM_CD4_TCELL_DN</TD><TD>188</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>VIM,PRPS1,PKIB</TD></TR>
<TR><TD>1.196e-02</TD><TD>-4.43</TD><TD>GSE9037_CTRL_VS_LPS_1H_STIM_IRAK4_KO_BMDM_UP</TD><TD>MSigDB lists</TD><TD>GSE9037_CTRL_VS_LPS_1H_STIM_IRAK4_KO_BMDM_UP</TD><TD>188</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>PDE3A,PKIB,AHNAK2</TD></TR>
<TR><TD>1.203e-02</TD><TD>-4.42</TD><TD>chondroblastoma</TD><TD>COSMIC cancer mutations</TD><TD>chondroblastoma</TD><TD>560</TD><TD>5</TD><TD>17775</TD><TD>44</TD>
<TD>CLSTN2,CSMD3,LAMA4,RNF43,CNTNAP3</TD></TR>
<TR><TD>1.212e-02</TD><TD>-4.41</TD><TD>striated muscle cell differentiation</TD><TD>biological process</TD><TD>GO:0051146</TD><TD>179</TD><TD>3</TD><TD>16441</TD><TD>44</TD>
<TD>CAMK2D,NEBL,PDLIM5</TD></TR>
<TR><TD>1.213e-02</TD><TD>-4.41</TD><TD>GSE17721_0.5H_VS_4H_GARDIQUIMOD_BMDM_DN</TD><TD>MSigDB lists</TD><TD>GSE17721_0.5H_VS_4H_GARDIQUIMOD_BMDM_DN</TD><TD>189</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>SLCO5A1,CAMK2D,SLK</TD></TR>
<TR><TD>1.215e-02</TD><TD>-4.41</TD><TD>DAVICIONI_TARGETS_OF_PAX_FOXO1_FUSIONS_DN</TD><TD>MSigDB lists</TD><TD>DAVICIONI_TARGETS_OF_PAX_FOXO1_FUSIONS_DN</TD><TD>66</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>TNIK,FGF9</TD></TR>
<TR><TD>1.221e-02</TD><TD>-4.41</TD><TD>parathyroid-adenoma</TD><TD>COSMIC cancer mutations</TD><TD>parathyroid-adenoma</TD><TD>194</TD><TD>3</TD><TD>17775</TD><TD>44</TD>
<TD>MMP16,PDE3A,NT5E</TD></TR>
<TR><TD>1.228e-02</TD><TD>-4.40</TD><TD>RICKMAN_TUMOR_DIFFERENTIATED_WELL_VS_POORLY_DN</TD><TD>MSigDB lists</TD><TD>RICKMAN_TUMOR_DIFFERENTIATED_WELL_VS_POORLY_DN</TD><TD>355</TD><TD>4</TD><TD>17758</TD><TD>45</TD>
<TD>CD44,GRHL3,AHNAK2,NT5E</TD></TR>
<TR><TD>1.230e-02</TD><TD>-4.40</TD><TD>positive regulation of organelle organization</TD><TD>biological process</TD><TD>GO:0010638</TD><TD>521</TD><TD>5</TD><TD>16441</TD><TD>44</TD>
<TD>RHOU,MSX2,MSX1,S100A10,PKIB</TD></TR>
<TR><TD>1.230e-02</TD><TD>-4.40</TD><TD>GSE30083_SP3_VS_SP4_THYMOCYTE_DN</TD><TD>MSigDB lists</TD><TD>GSE30083_SP3_VS_SP4_THYMOCYTE_DN</TD><TD>190</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>CAMK2D,CD44,NT5E</TD></TR>
<TR><TD>1.248e-02</TD><TD>-4.38</TD><TD>GSE27786_NKTCELL_VS_ERYTHROBLAST_DN</TD><TD>MSigDB lists</TD><TD>GSE27786_NKTCELL_VS_ERYTHROBLAST_DN</TD><TD>191</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>SLK,NR2F1,VSNL1</TD></TR>
<TR><TD>1.250e-02</TD><TD>-4.38</TD><TD>GGATTA_V$PITX2_Q2</TD><TD>MSigDB lists</TD><TD>GGATTA_V$PITX2_Q2</TD><TD>552</TD><TD>5</TD><TD>17758</TD><TD>45</TD>
<TD>PBX1,CSMD3,RNF43,MSX1,NEBL</TD></TR>
<TR><TD>1.251e-02</TD><TD>-4.38</TD><TD>Munc13_dom-2</TD><TD>interpro domains</TD><TD>IPR014772</TD><TD>5</TD><TD>1</TD><TD>18293</TD><TD>46</TD>
<TD>UNC13A</TD></TR>
<TR><TD>1.251e-02</TD><TD>-4.38</TD><TD>VPS10</TD><TD>interpro domains</TD><TD>IPR006581</TD><TD>5</TD><TD>1</TD><TD>18293</TD><TD>46</TD>
<TD>SORCS2</TD></TR>
<TR><TD>1.251e-02</TD><TD>-4.38</TD><TD>Rib-P_diPkinase</TD><TD>interpro domains</TD><TD>IPR005946</TD><TD>5</TD><TD>1</TD><TD>18293</TD><TD>46</TD>
<TD>PRPS1</TD></TR>
<TR><TD>1.251e-02</TD><TD>-4.38</TD><TD>Sortilin_C</TD><TD>interpro domains</TD><TD>IPR031777</TD><TD>5</TD><TD>1</TD><TD>18293</TD><TD>46</TD>
<TD>SORCS2</TD></TR>
<TR><TD>1.251e-02</TD><TD>-4.38</TD><TD>Sortilin_N</TD><TD>interpro domains</TD><TD>IPR031778</TD><TD>5</TD><TD>1</TD><TD>18293</TD><TD>46</TD>
<TD>SORCS2</TD></TR>
<TR><TD>1.251e-02</TD><TD>-4.38</TD><TD>Ca-dep_secretion_activator</TD><TD>interpro domains</TD><TD>IPR010439</TD><TD>5</TD><TD>1</TD><TD>18293</TD><TD>46</TD>
<TD>UNC13A</TD></TR>
<TR><TD>1.251e-02</TD><TD>-4.38</TD><TD>Munc13_subgr_dom-2</TD><TD>interpro domains</TD><TD>IPR019558</TD><TD>5</TD><TD>1</TD><TD>18293</TD><TD>46</TD>
<TD>UNC13A</TD></TR>
<TR><TD>1.251e-02</TD><TD>-4.38</TD><TD>Laminin_aI</TD><TD>interpro domains</TD><TD>IPR009254</TD><TD>5</TD><TD>1</TD><TD>18293</TD><TD>46</TD>
<TD>LAMA4</TD></TR>
<TR><TD>1.251e-02</TD><TD>-4.38</TD><TD>Pribosyltran_N</TD><TD>interpro domains</TD><TD>IPR029099</TD><TD>5</TD><TD>1</TD><TD>18293</TD><TD>46</TD>
<TD>PRPS1</TD></TR>
<TR><TD>1.251e-02</TD><TD>-4.38</TD><TD>Laminin_domII</TD><TD>interpro domains</TD><TD>IPR010307</TD><TD>5</TD><TD>1</TD><TD>18293</TD><TD>46</TD>
<TD>LAMA4</TD></TR>
<TR><TD>1.257e-02</TD><TD>-4.38</TD><TD>negative regulation of transcription from RNA polymerase II promoter</TD><TD>biological process</TD><TD>GO:0000122</TD><TD>730</TD><TD>6</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2,FGF9,MSX1,NR2F2,PPARG,NR2F1</TD></TR>
<TR><TD>1.261e-02</TD><TD>-4.37</TD><TD>SMIRNOV_CIRCULATING_ENDOTHELIOCYTES_IN_CANCER_DN</TD><TD>MSigDB lists</TD><TD>SMIRNOV_CIRCULATING_ENDOTHELIOCYTES_IN_CANCER_DN</TD><TD>5</TD><TD>1</TD><TD>17758</TD><TD>45</TD>
<TD>ANGPTL4</TD></TR>
<TR><TD>1.261e-02</TD><TD>-4.37</TD><TD>TESAR_ALK_AND_JAK_TARGETS_MOUSE_ES_D4_UP</TD><TD>MSigDB lists</TD><TD>TESAR_ALK_AND_JAK_TARGETS_MOUSE_ES_D4_UP</TD><TD>5</TD><TD>1</TD><TD>17758</TD><TD>45</TD>
<TD>MSX1</TD></TR>
<TR><TD>1.261e-02</TD><TD>-4.37</TD><TD>TESAR_ALK_TARGETS_HUMAN_ES_5D_UP</TD><TD>MSigDB lists</TD><TD>TESAR_ALK_TARGETS_HUMAN_ES_5D_UP</TD><TD>5</TD><TD>1</TD><TD>17758</TD><TD>45</TD>
<TD>MSX1</TD></TR>
<TR><TD>1.261e-02</TD><TD>-4.37</TD><TD>CALVET_IRINOTECAN_SENSITIVE_VS_REVERTED_UP</TD><TD>MSigDB lists</TD><TD>CALVET_IRINOTECAN_SENSITIVE_VS_REVERTED_UP</TD><TD>5</TD><TD>1</TD><TD>17758</TD><TD>45</TD>
<TD>VIM</TD></TR>
<TR><TD>1.264e-02</TD><TD>-4.37</TD><TD>biological regulation</TD><TD>biological process</TD><TD>GO:0065007</TD><TD>11168</TD><TD>37</TD><TD>16441</TD><TD>44</TD>
<TD>EFNB2,TNIK,STXBP6,SLK,GPAT3,CLSTN2,PBX1,RNF43,ZIC2,PDE3A,S100A10,PDE10A,UNC13A,TANK,WNT16,CD44,ETV1,NT5E,LAMA4,FGF9,SLC40A1,MSX1,PPARG,GRHL3,VSNL1,VIM,ANGPTL4,NR2F1,RHOU,MSX2,CAMK2D,ITGB4,SORCS2,NR2F2,PDLIM5,MMP16,PKIB</TD></TR>
<TR><TD>1.266e-02</TD><TD>-4.37</TD><TD>GSE17721_CTRL_VS_GARDIQUIMOD_12H_BMDM_UP</TD><TD>MSigDB lists</TD><TD>GSE17721_CTRL_VS_GARDIQUIMOD_12H_BMDM_UP</TD><TD>192</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>LAMA4,SLC40A1,ZIC2</TD></TR>
<TR><TD>1.266e-02</TD><TD>-4.37</TD><TD>GSE24142_DN2_VS_DN3_THYMOCYTE_FETAL_DN</TD><TD>MSigDB lists</TD><TD>GSE24142_DN2_VS_DN3_THYMOCYTE_FETAL_DN</TD><TD>192</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>SORCS2,PPARG,PDLIM5</TD></TR>
<TR><TD>1.266e-02</TD><TD>-4.37</TD><TD>GSE24142_ADULT_VS_FETAL_DN3_THYMOCYTE_DN</TD><TD>MSigDB lists</TD><TD>GSE24142_ADULT_VS_FETAL_DN3_THYMOCYTE_DN</TD><TD>192</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>SLCO5A1,PPARG,PDLIM5</TD></TR>
<TR><TD>1.267e-02</TD><TD>-4.37</TD><TD>morphogenesis of a branching structure</TD><TD>biological process</TD><TD>GO:0001763</TD><TD>182</TD><TD>3</TD><TD>16441</TD><TD>44</TD>
<TD>PBX1,MSX2,CD44</TD></TR>
<TR><TD>1.272e-02</TD><TD>-4.36</TD><TD>FGF9 (fibroblast growth factor 9)</TD><TD>protein interactions</TD><TD>2254</TD><TD>5</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>FGF9</TD></TR>
<TR><TD>1.272e-02</TD><TD>-4.36</TD><TD>XIRP2 (xin actin binding repeat containing 2)</TD><TD>protein interactions</TD><TD>129446</TD><TD>5</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>NEBL</TD></TR>
<TR><TD>1.272e-02</TD><TD>-4.36</TD><TD>DEFB1 (defensin, beta 1)</TD><TD>protein interactions</TD><TD>1672</TD><TD>5</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>VIM</TD></TR>
<TR><TD>1.272e-02</TD><TD>-4.36</TD><TD>PRPS1L1 (phosphoribosyl pyrophosphate synthetase 1-like 1)</TD><TD>protein interactions</TD><TD>221823</TD><TD>5</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>PRPS1</TD></TR>
<TR><TD>1.272e-02</TD><TD>-4.36</TD><TD>BSN (bassoon presynaptic cytomatrix protein)</TD><TD>protein interactions</TD><TD>8927</TD><TD>5</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>UNC13A</TD></TR>
<TR><TD>1.272e-02</TD><TD>-4.36</TD><TD>BOD1L1 (biorientation of chromosomes in cell division 1-like 1)</TD><TD>protein interactions</TD><TD>259282</TD><TD>5</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>PRPS1</TD></TR>
<TR><TD>1.272e-02</TD><TD>-4.36</TD><TD>FABP1 (fatty acid binding protein 1, liver)</TD><TD>protein interactions</TD><TD>2168</TD><TD>5</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>PPARG</TD></TR>
<TR><TD>1.272e-02</TD><TD>-4.36</TD><TD>ZBTB20 (zinc finger and BTB domain containing 20)</TD><TD>protein interactions</TD><TD>26137</TD><TD>5</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>PPARG</TD></TR>
<TR><TD>1.272e-02</TD><TD>-4.36</TD><TD>HNMT (histamine N-methyltransferase)</TD><TD>protein interactions</TD><TD>3176</TD><TD>5</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>CAMK2D</TD></TR>
<TR><TD>1.272e-02</TD><TD>-4.36</TD><TD>LHX2 (LIM homeobox 2)</TD><TD>protein interactions</TD><TD>9355</TD><TD>5</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>MSX1</TD></TR>
<TR><TD>1.275e-02</TD><TD>-4.36</TD><TD>BASAKI_YBX1_TARGETS_DN</TD><TD>MSigDB lists</TD><TD>BASAKI_YBX1_TARGETS_DN</TD><TD>359</TD><TD>4</TD><TD>17758</TD><TD>45</TD>
<TD>SLC40A1,NEBL,CNTNAP3,NT5E</TD></TR>
<TR><TD>1.275e-02</TD><TD>-4.36</TD><TD>MODULE_1</TD><TD>MSigDB lists</TD><TD>MODULE_1</TD><TD>359</TD><TD>4</TD><TD>17758</TD><TD>45</TD>
<TD>MSX1,CD44,PDLIM5,NR2F1</TD></TR>
<TR><TD>1.278e-02</TD><TD>-4.36</TD><TD>haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm</TD><TD>COSMIC cancer mutations</TD><TD>haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm</TD><TD>792</TD><TD>6</TD><TD>17775</TD><TD>44</TD>
<TD>CLSTN2,CSMD3,SORCS2,PDLIM5,ANGPTL4,PDE3A</TD></TR>
<TR><TD>1.283e-02</TD><TD>-4.36</TD><TD>GSE20366_TREG_VS_NAIVE_CD4_TCELL_DN</TD><TD>MSigDB lists</TD><TD>GSE20366_TREG_VS_NAIVE_CD4_TCELL_DN</TD><TD>193</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>MSX2,RNF43,ANGPTL4</TD></TR>
<TR><TD>1.283e-02</TD><TD>-4.36</TD><TD>GSE17721_CPG_VS_GARDIQUIMOD_0.5H_BMDM_UP</TD><TD>MSigDB lists</TD><TD>GSE17721_CPG_VS_GARDIQUIMOD_0.5H_BMDM_UP</TD><TD>193</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>LAMA4,PDE10A,NT5E</TD></TR>
<TR><TD>1.286e-02</TD><TD>-4.35</TD><TD>GTATGAT,MIR-154,MIR-487</TD><TD>MSigDB lists</TD><TD>GTATGAT,MIR-154,MIR-487</TD><TD>68</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>CSMD3,ETV1</TD></TR>
<TR><TD>1.297e-02</TD><TD>-4.35</TD><TD>sodium channel inhibitor activity</TD><TD>molecular function</TD><TD>GO:0019871</TD><TD>5</TD><TD>1</TD><TD>16491</TD><TD>43</TD>
<TD>CAMK2D</TD></TR>
<TR><TD>1.297e-02</TD><TD>-4.35</TD><TD>ribose phosphate diphosphokinase activity</TD><TD>molecular function</TD><TD>GO:0004749</TD><TD>5</TD><TD>1</TD><TD>16491</TD><TD>43</TD>
<TD>PRPS1</TD></TR>
<TR><TD>1.297e-02</TD><TD>-4.35</TD><TD>keratin filament binding</TD><TD>molecular function</TD><TD>GO:1990254</TD><TD>5</TD><TD>1</TD><TD>16491</TD><TD>43</TD>
<TD>VIM</TD></TR>
<TR><TD>1.297e-02</TD><TD>-4.35</TD><TD>arachidonic acid binding</TD><TD>molecular function</TD><TD>GO:0050544</TD><TD>5</TD><TD>1</TD><TD>16491</TD><TD>43</TD>
<TD>PPARG</TD></TR>
<TR><TD>1.301e-02</TD><TD>-4.34</TD><TD>GSE360_CTRL_VS_L_DONOVANI_DC_DN</TD><TD>MSigDB lists</TD><TD>GSE360_CTRL_VS_L_DONOVANI_DC_DN</TD><TD>194</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>TNIK,S100A10,NR2F1</TD></TR>
<TR><TD>1.301e-02</TD><TD>-4.34</TD><TD>GSE3337_CTRL_VS_4H_IFNG_IN_CD8POS_DC_DN</TD><TD>MSigDB lists</TD><TD>GSE3337_CTRL_VS_4H_IFNG_IN_CD8POS_DC_DN</TD><TD>194</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>CAMK2D,CD44,PKIB</TD></TR>
<TR><TD>1.301e-02</TD><TD>-4.34</TD><TD>GSE17721_POLYIC_VS_PAM3CSK4_8H_BMDM_UP</TD><TD>MSigDB lists</TD><TD>GSE17721_POLYIC_VS_PAM3CSK4_8H_BMDM_UP</TD><TD>194</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>PBX1,VIM,PKIB</TD></TR>
<TR><TD>1.301e-02</TD><TD>-4.34</TD><TD>KAECH_NAIVE_VS_DAY15_EFF_CD8_TCELL_DN</TD><TD>MSigDB lists</TD><TD>KAECH_NAIVE_VS_DAY15_EFF_CD8_TCELL_DN</TD><TD>194</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>CD44,S100A10,NT5E</TD></TR>
<TR><TD>1.301e-02</TD><TD>-4.34</TD><TD>GSE24026_PD1_LIGATION_VS_CTRL_IN_ACT_TCELL_LINE_UP</TD><TD>MSigDB lists</TD><TD>GSE24026_PD1_LIGATION_VS_CTRL_IN_ACT_TCELL_LINE_UP</TD><TD>194</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>VIM,S100A10,NT5E</TD></TR>
<TR><TD>1.303e-02</TD><TD>-4.34</TD><TD>SMAD3 (SMAD family member 3)</TD><TD>protein interactions</TD><TD>4088</TD><TD>359</TD><TD>4</TD><TD>16036</TD><TD>41</TD>
<TD>VIM,ITGB4,PPARG,TANK</TD></TR>
<TR><TD>1.311e-02</TD><TD>-4.33</TD><TD>BENPORATH_ES_1</TD><TD>MSigDB lists</TD><TD>BENPORATH_ES_1</TD><TD>362</TD><TD>4</TD><TD>17758</TD><TD>45</TD>
<TD>ZIC2,ETV1,PRPS1,VSNL1</TD></TR>
<TR><TD>1.316e-02</TD><TD>-4.33</TD><TD>DUF1041</TD><TD>pfam domains</TD><TD>PF06292</TD><TD>5</TD><TD>1</TD><TD>16629</TD><TD>44</TD>
<TD>UNC13A</TD></TR>
<TR><TD>1.316e-02</TD><TD>-4.33</TD><TD>Sortilin-Vps10</TD><TD>pfam domains</TD><TD>PF15902</TD><TD>5</TD><TD>1</TD><TD>16629</TD><TD>44</TD>
<TD>SORCS2</TD></TR>
<TR><TD>1.316e-02</TD><TD>-4.33</TD><TD>Pribosyltran_N</TD><TD>pfam domains</TD><TD>PF13793</TD><TD>5</TD><TD>1</TD><TD>16629</TD><TD>44</TD>
<TD>PRPS1</TD></TR>
<TR><TD>1.316e-02</TD><TD>-4.33</TD><TD>Laminin_II</TD><TD>pfam domains</TD><TD>PF06009</TD><TD>5</TD><TD>1</TD><TD>16629</TD><TD>44</TD>
<TD>LAMA4</TD></TR>
<TR><TD>1.316e-02</TD><TD>-4.33</TD><TD>Membr_traf_MHD</TD><TD>pfam domains</TD><TD>PF10540</TD><TD>5</TD><TD>1</TD><TD>16629</TD><TD>44</TD>
<TD>UNC13A</TD></TR>
<TR><TD>1.316e-02</TD><TD>-4.33</TD><TD>Sortilin_C</TD><TD>pfam domains</TD><TD>PF15901</TD><TD>5</TD><TD>1</TD><TD>16629</TD><TD>44</TD>
<TD>SORCS2</TD></TR>
<TR><TD>1.316e-02</TD><TD>-4.33</TD><TD>Laminin_I</TD><TD>pfam domains</TD><TD>PF06008</TD><TD>5</TD><TD>1</TD><TD>16629</TD><TD>44</TD>
<TD>LAMA4</TD></TR>
<TR><TD>1.316e-02</TD><TD>-4.33</TD><TD>Pribosyl_synth</TD><TD>pfam domains</TD><TD>PF14572</TD><TD>5</TD><TD>1</TD><TD>16629</TD><TD>44</TD>
<TD>PRPS1</TD></TR>
<TR><TD>1.316e-02</TD><TD>-4.33</TD><TD>BUYTAERT_PHOTODYNAMIC_THERAPY_STRESS_UP</TD><TD>MSigDB lists</TD><TD>BUYTAERT_PHOTODYNAMIC_THERAPY_STRESS_UP</TD><TD>778</TD><TD>6</TD><TD>17758</TD><TD>45</TD>
<TD>MSX1,PPARG,PDE10A,SLK,TANK,AHNAK2</TD></TR>
<TR><TD>1.317e-02</TD><TD>-4.33</TD><TD>regulation of cell morphogenesis</TD><TD>biological process</TD><TD>GO:0022604</TD><TD>530</TD><TD>5</TD><TD>16441</TD><TD>44</TD>
<TD>RHOU,TNIK,S100A10,PDLIM5,UNC13A</TD></TR>
<TR><TD>1.319e-02</TD><TD>-4.33</TD><TD>GSE28237_EARLY_VS_LATE_GC_BCELL_UP</TD><TD>MSigDB lists</TD><TD>GSE28237_EARLY_VS_LATE_GC_BCELL_UP</TD><TD>195</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>MMP16,PDE10A,NR2F1</TD></TR>
<TR><TD>1.319e-02</TD><TD>-4.33</TD><TD>HALLMARK_KRAS_SIGNALING_UP</TD><TD>MSigDB lists</TD><TD>HALLMARK_KRAS_SIGNALING_UP</TD><TD>195</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>FGF9,ETV1,ANGPTL4</TD></TR>
<TR><TD>1.319e-02</TD><TD>-4.33</TD><TD>urate biosynthesis/inosine 5'-phosphate degradation</TD><TD>BIOCYC pathways</TD><TD>META_PWY-5695</TD><TD>6</TD><TD>1</TD><TD>907</TD><TD>2</TD>
<TD>NT5E</TD></TR>
<TR><TD>1.321e-02</TD><TD>-4.33</TD><TD>cell surface receptor signaling pathway</TD><TD>biological process</TD><TD>GO:0007166</TD><TD>2257</TD><TD>12</TD><TD>16441</TD><TD>44</TD>
<TD>EFNB2,MSX2,TNIK,CAMK2D,FGF9,MSX1,GRHL3,RNF43,VIM,WNT16,ITGB4,CD44</TD></TR>
<TR><TD>1.323e-02</TD><TD>-4.33</TD><TD>KEGG_PPAR_SIGNALING_PATHWAY</TD><TD>MSigDB lists</TD><TD>KEGG_PPAR_SIGNALING_PATHWAY</TD><TD>69</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>PPARG,ANGPTL4</TD></TR>
<TR><TD>1.324e-02</TD><TD>-4.32</TD><TD>intracellular receptor signaling pathway</TD><TD>biological process</TD><TD>GO:0030522</TD><TD>185</TD><TD>3</TD><TD>16441</TD><TD>44</TD>
<TD>NR2F2,PPARG,NR2F1</TD></TR>
<TR><TD>1.324e-02</TD><TD>-4.32</TD><TD>MARTINEZ_TP53_TARGETS_DN</TD><TD>MSigDB lists</TD><TD>MARTINEZ_TP53_TARGETS_DN</TD><TD>560</TD><TD>5</TD><TD>17758</TD><TD>45</TD>
<TD>RHOU,MSX2,S100A10,PDE3A,NR2F1</TD></TR>
<TR><TD>1.324e-02</TD><TD>-4.32</TD><TD>ORGAN_DEVELOPMENT</TD><TD>MSigDB lists</TD><TD>ORGAN_DEVELOPMENT</TD><TD>560</TD><TD>5</TD><TD>17758</TD><TD>45</TD>
<TD>PBX1,MSX2,ZIC2,MSX1,ANGPTL4</TD></TR>
<TR><TD>1.326e-02</TD><TD>-4.32</TD><TD>human chr4p16.2</TD><TD>chromosome location</TD><TD>human chr4p16.2</TD><TD>7</TD><TD>1</TD><TD>26250</TD><TD>50</TD>
<TD>MSX1</TD></TR>
<TR><TD>1.326e-02</TD><TD>-4.32</TD><TD>human chr4q22</TD><TD>chromosome location</TD><TD>human chr4q22</TD><TD>7</TD><TD>1</TD><TD>26250</TD><TD>50</TD>
<TD>PDLIM5</TD></TR>
<TR><TD>1.331e-02</TD><TD>-4.32</TD><TD>ferrous iron transport</TD><TD>biological process</TD><TD>GO:0015684</TD><TD>5</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>SLC40A1</TD></TR>
<TR><TD>1.331e-02</TD><TD>-4.32</TD><TD>negative regulation of lipoprotein lipase activity</TD><TD>biological process</TD><TD>GO:0051005</TD><TD>5</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>ANGPTL4</TD></TR>
<TR><TD>1.331e-02</TD><TD>-4.32</TD><TD>regulation of hair follicle maturation</TD><TD>biological process</TD><TD>GO:0048819</TD><TD>5</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2</TD></TR>
<TR><TD>1.331e-02</TD><TD>-4.32</TD><TD>negative regulation of response to interferon-gamma</TD><TD>biological process</TD><TD>GO:0060331</TD><TD>5</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>PPARG</TD></TR>
<TR><TD>1.331e-02</TD><TD>-4.32</TD><TD>negative regulation of sequestering of triglyceride</TD><TD>biological process</TD><TD>GO:0010891</TD><TD>5</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>PPARG</TD></TR>
<TR><TD>1.331e-02</TD><TD>-4.32</TD><TD>response to aluminum ion</TD><TD>biological process</TD><TD>GO:0010044</TD><TD>5</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>NT5E</TD></TR>
<TR><TD>1.331e-02</TD><TD>-4.32</TD><TD>ribonucleoside monophosphate catabolic process</TD><TD>biological process</TD><TD>GO:0009158</TD><TD>5</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>NT5E</TD></TR>
<TR><TD>1.331e-02</TD><TD>-4.32</TD><TD>negative regulation of interferon-gamma-mediated signaling pathway</TD><TD>biological process</TD><TD>GO:0060336</TD><TD>5</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>PPARG</TD></TR>
<TR><TD>1.331e-02</TD><TD>-4.32</TD><TD>purine ribonucleoside monophosphate catabolic process</TD><TD>biological process</TD><TD>GO:0009169</TD><TD>5</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>NT5E</TD></TR>
<TR><TD>1.331e-02</TD><TD>-4.32</TD><TD>receptor biosynthetic process</TD><TD>biological process</TD><TD>GO:0032800</TD><TD>5</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>PPARG</TD></TR>
<TR><TD>1.331e-02</TD><TD>-4.32</TD><TD>hypoxanthine biosynthetic process</TD><TD>biological process</TD><TD>GO:0046101</TD><TD>5</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>PRPS1</TD></TR>
<TR><TD>1.331e-02</TD><TD>-4.32</TD><TD>regulation of histone deacetylase activity</TD><TD>biological process</TD><TD>GO:1901725</TD><TD>5</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>CAMK2D</TD></TR>
<TR><TD>1.331e-02</TD><TD>-4.32</TD><TD>Bergmann glial cell differentiation</TD><TD>biological process</TD><TD>GO:0060020</TD><TD>5</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>VIM</TD></TR>
<TR><TD>1.335e-02</TD><TD>-4.32</TD><TD>Amyotrophic lateral sclerosis(PMID:19734901)</TD><TD>GWAS genes</TD><TD>Amyotrophic lateral sclerosis(PMID:19734901)</TD><TD>2</TD><TD>1</TD><TD>2389</TD><TD>16</TD>
<TD>UNC13A</TD></TR>
<TR><TD>1.335e-02</TD><TD>-4.32</TD><TD>Brain imaging in schizophrenia (interaction)(PMID:19023125)</TD><TD>GWAS genes</TD><TD>Brain imaging in schizophrenia (interaction)(PMID:19023125)</TD><TD>2</TD><TD>1</TD><TD>2389</TD><TD>16</TD>
<TD>TNIK</TD></TR>
<TR><TD>1.335e-02</TD><TD>-4.32</TD><TD>Male infertility(PMID:19478329)</TD><TD>GWAS genes</TD><TD>Male infertility(PMID:19478329)</TD><TD>2</TD><TD>1</TD><TD>2389</TD><TD>16</TD>
<TD>PDE3A</TD></TR>
<TR><TD>1.337e-02</TD><TD>-4.31</TD><TD>GSE24142_EARLY_THYMIC_PROGENITOR_VS_DN3_THYMOCYTE_UP</TD><TD>MSigDB lists</TD><TD>GSE24142_EARLY_THYMIC_PROGENITOR_VS_DN3_THYMOCYTE_UP</TD><TD>196</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>CD44,KRT7,PKIB</TD></TR>
<TR><TD>1.337e-02</TD><TD>-4.31</TD><TD>GSE24142_EARLY_THYMIC_PROGENITOR_VS_DN3_THYMOCYTE_FETAL_UP</TD><TD>MSigDB lists</TD><TD>GSE24142_EARLY_THYMIC_PROGENITOR_VS_DN3_THYMOCYTE_FETAL_UP</TD><TD>196</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>VIM,CD44,PKIB</TD></TR>
<TR><TD>1.342e-02</TD><TD>-4.31</TD><TD>NEBULIN</TD><TD>prosite domains</TD><TD>PS51216</TD><TD>4</TD><TD>1</TD><TD>11866</TD><TD>40</TD>
<TD>NEBL</TD></TR>
<TR><TD>1.346e-02</TD><TD>-4.31</TD><TD>regulation of signal transduction</TD><TD>biological process</TD><TD>GO:0009966</TD><TD>2548</TD><TD>13</TD><TD>16441</TD><TD>44</TD>
<TD>RHOU,MSX2,TNIK,CAMK2D,FGF9,MSX1,PPARG,PDE10A,GPAT3,RNF43,ZIC2,WNT16,CD44</TD></TR>
<TR><TD>1.347e-02</TD><TD>-4.31</TD><TD>regulation of dendrite morphogenesis</TD><TD>biological process</TD><TD>GO:0048814</TD><TD>66</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>TNIK,PDLIM5</TD></TR>
<TR><TD>1.347e-02</TD><TD>-4.31</TD><TD>nephron tubule morphogenesis</TD><TD>biological process</TD><TD>GO:0072078</TD><TD>66</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>PBX1,CD44</TD></TR>
<TR><TD>1.348e-02</TD><TD>-4.31</TD><TD>contractile fiber part</TD><TD>cellular component</TD><TD>GO:0044449</TD><TD>199</TD><TD>3</TD><TD>17570</TD><TD>44</TD>
<TD>NEBL,PDLIM5,AHNAK2</TD></TR>
<TR><TD>1.350e-02</TD><TD>-4.31</TD><TD>organonitrogen compound catabolic process</TD><TD>biological process</TD><TD>GO:1901565</TD><TD>346</TD><TD>4</TD><TD>16441</TD><TD>44</TD>
<TD>CD44,PDE10A,PDE3A,NT5E</TD></TR>
<TR><TD>1.356e-02</TD><TD>-4.30</TD><TD>GSE30083_SP2_VS_SP3_THYMOCYTE_UP</TD><TD>MSigDB lists</TD><TD>GSE30083_SP2_VS_SP3_THYMOCYTE_UP</TD><TD>197</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>TNIK,CAMK2D,NR2F2</TD></TR>
<TR><TD>1.356e-02</TD><TD>-4.30</TD><TD>GSE24142_DN2_VS_DN3_THYMOCYTE_UP</TD><TD>MSigDB lists</TD><TD>GSE24142_DN2_VS_DN3_THYMOCYTE_UP</TD><TD>197</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>VIM,CD44,PKIB</TD></TR>
<TR><TD>1.358e-02</TD><TD>-4.30</TD><TD>negative regulation of nucleic acid-templated transcription</TD><TD>biological process</TD><TD>GO:1903507</TD><TD>1206</TD><TD>8</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2,FGF9,MSX1,PPARG,PBX1,ZIC2,NR2F2,NR2F1</TD></TR>
<TR><TD>1.363e-02</TD><TD>-4.30</TD><TD>cellular response to growth factor stimulus</TD><TD>biological process</TD><TD>GO:0071363</TD><TD>743</TD><TD>6</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2,CAMK2D,FGF9,MSX1,CD44,PDE3A</TD></TR>
<TR><TD>1.373e-02</TD><TD>-4.29</TD><TD>ANATOMICAL_STRUCTURE_MORPHOGENESIS</TD><TD>MSigDB lists</TD><TD>ANATOMICAL_STRUCTURE_MORPHOGENESIS</TD><TD>367</TD><TD>4</TD><TD>17758</TD><TD>45</TD>
<TD>EFNB2,SLC40A1,MSX1,ANGPTL4</TD></TR>
<TR><TD>1.374e-02</TD><TD>-4.29</TD><TD>FOSTER_KDM1A_TARGETS_DN</TD><TD>MSigDB lists</TD><TD>FOSTER_KDM1A_TARGETS_DN</TD><TD>198</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>ITGB4,KRT7,NT5E</TD></TR>
<TR><TD>1.374e-02</TD><TD>-4.29</TD><TD>GTATTAT,MIR-369-3P</TD><TD>MSigDB lists</TD><TD>GTATTAT,MIR-369-3P</TD><TD>198</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>EFNB2,NR2F2,VSNL1</TD></TR>
<TR><TD>1.374e-02</TD><TD>-4.29</TD><TD>HALLMARK_TNFA_SIGNALING_VIA_NFKB</TD><TD>MSigDB lists</TD><TD>HALLMARK_TNFA_SIGNALING_VIA_NFKB</TD><TD>198</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>CD44,PDLIM5,TANK</TD></TR>
<TR><TD>1.374e-02</TD><TD>-4.29</TD><TD>GSE39820_TGFBETA1_IL6_VS_TGFBETA1_IL6_IL23A_TREATED_CD4_TCELL_UP</TD><TD>MSigDB lists</TD><TD>GSE39820_TGFBETA1_IL6_VS_TGFBETA1_IL6_IL23A_TREATED_CD4_TCELL_UP</TD><TD>198</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>PRPS1,SLK,NT5E</TD></TR>
<TR><TD>1.380e-02</TD><TD>-4.28</TD><TD>MAP2K1 (mitogen-activated protein kinase kinase 1)</TD><TD>protein interactions</TD><TD>5604</TD><TD>70</TD><TD>2</TD><TD>16036</TD><TD>41</TD>
<TD>PPARG,PDLIM5</TD></TR>
<TR><TD>1.380e-02</TD><TD>-4.28</TD><TD>STX1A (syntaxin 1A (brain))</TD><TD>protein interactions</TD><TD>6804</TD><TD>70</TD><TD>2</TD><TD>16036</TD><TD>41</TD>
<TD>VIM,STXBP6</TD></TR>
<TR><TD>1.386e-02</TD><TD>-4.28</TD><TD>actin filament-based movement</TD><TD>biological process</TD><TD>GO:0030048</TD><TD>67</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>VIM,CAMK2D</TD></TR>
<TR><TD>1.397e-02</TD><TD>-4.27</TD><TD>MODULE_154</TD><TD>MSigDB lists</TD><TD>MODULE_154</TD><TD>71</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>ITGB4,ANGPTL4</TD></TR>
<TR><TD>1.397e-02</TD><TD>-4.27</TD><TD>YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_6</TD><TD>MSigDB lists</TD><TD>YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_6</TD><TD>71</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>EFNB2,ITGB4</TD></TR>
<TR><TD>1.402e-02</TD><TD>-4.27</TD><TD>protein autophosphorylation</TD><TD>biological process</TD><TD>GO:0046777</TD><TD>189</TD><TD>3</TD><TD>16441</TD><TD>44</TD>
<TD>TNIK,CAMK2D,SLK</TD></TR>
<TR><TD>1.414e-02</TD><TD>-4.26</TD><TD>Znf_LIM</TD><TD>interpro domains</TD><TD>IPR001781</TD><TD>72</TD><TD>2</TD><TD>18293</TD><TD>46</TD>
<TD>NEBL,PDLIM5</TD></TR>
<TR><TD>1.418e-02</TD><TD>-4.26</TD><TD>regulation of cell cycle process</TD><TD>biological process</TD><TD>GO:0010564</TD><TD>540</TD><TD>5</TD><TD>16441</TD><TD>44</TD>
<TD>PBX1,MSX2,CAMK2D,MSX1,PDE3A</TD></TR>
<TR><TD>1.420e-02</TD><TD>-4.25</TD><TD>SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4)</TD><TD>protein interactions</TD><TD>6597</TD><TD>199</TD><TD>3</TD><TD>16036</TD><TD>41</TD>
<TD>PBX1,PPARG,ANGPTL4</TD></TR>
<TR><TD>1.422e-02</TD><TD>-4.25</TD><TD>stem cell differentiation</TD><TD>biological process</TD><TD>GO:0048863</TD><TD>190</TD><TD>3</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2,MSX1,WNT16</TD></TR>
<TR><TD>1.422e-02</TD><TD>-4.25</TD><TD>response to estrogen</TD><TD>biological process</TD><TD>GO:0043627</TD><TD>190</TD><TD>3</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2,NR2F2,PPARG</TD></TR>
<TR><TD>1.426e-02</TD><TD>-4.25</TD><TD>developmental cell growth</TD><TD>biological process</TD><TD>GO:0048588</TD><TD>68</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>CAMK2D,PDLIM5</TD></TR>
<TR><TD>1.426e-02</TD><TD>-4.25</TD><TD>nephron epithelium morphogenesis</TD><TD>biological process</TD><TD>GO:0072088</TD><TD>68</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>PBX1,CD44</TD></TR>
<TR><TD>1.430e-02</TD><TD>-4.25</TD><TD>MANALO_HYPOXIA_UP</TD><TD>MSigDB lists</TD><TD>MANALO_HYPOXIA_UP</TD><TD>201</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>SLCO5A1,PPARG,ANGPTL4</TD></TR>
<TR><TD>1.434e-02</TD><TD>-4.24</TD><TD>RODRIGUES_THYROID_CARCINOMA_DN</TD><TD>MSigDB lists</TD><TD>RODRIGUES_THYROID_CARCINOMA_DN</TD><TD>72</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>CD44,S100A10</TD></TR>
<TR><TD>1.434e-02</TD><TD>-4.24</TD><TD>GAANYNYGACNY_UNKNOWN</TD><TD>MSigDB lists</TD><TD>GAANYNYGACNY_UNKNOWN</TD><TD>72</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>NR2F2,NR2F1</TD></TR>
<TR><TD>1.434e-02</TD><TD>-4.24</TD><TD>BRUECKNER_TARGETS_OF_MIRLET7A3_DN</TD><TD>MSigDB lists</TD><TD>BRUECKNER_TARGETS_OF_MIRLET7A3_DN</TD><TD>72</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>VIM,PPARG</TD></TR>
<TR><TD>1.439e-02</TD><TD>-4.24</TD><TD>Hedgehog signaling pathway</TD><TD>KEGG pathways</TD><TD>hsa04340</TD><TD>51</TD><TD>2</TD><TD>6908</TD><TD>25</TD>
<TD>ZIC2,WNT16</TD></TR>
<TR><TD>1.439e-02</TD><TD>-4.24</TD><TD>Hedgehog signaling pathway</TD><TD>KEGG pathways</TD><TD>ko04340</TD><TD>51</TD><TD>2</TD><TD>6908</TD><TD>25</TD>
<TD>ZIC2,WNT16</TD></TR>
<TR><TD>1.439e-02</TD><TD>-4.24</TD><TD>SUMO2 (small ubiquitin-like modifier 2)</TD><TD>protein interactions</TD><TD>6613</TD><TD>200</TD><TD>3</TD><TD>16036</TD><TD>41</TD>
<TD>VIM,MSX1,TANK</TD></TR>
<TR><TD>1.445e-02</TD><TD>-4.24</TD><TD>regulation of catalytic activity</TD><TD>biological process</TD><TD>GO:0050790</TD><TD>2284</TD><TD>12</TD><TD>16441</TD><TD>44</TD>
<TD>TNIK,CAMK2D,FGF9,S100A10,PPARG,SLK,GRHL3,CD44,NR2F2,ANGPTL4,MMP16,PKIB</TD></TR>
<TR><TD>1.455e-02</TD><TD>-4.23</TD><TD>negative regulation of RNA biosynthetic process</TD><TD>biological process</TD><TD>GO:1902679</TD><TD>1221</TD><TD>8</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2,FGF9,MSX1,PPARG,PBX1,ZIC2,NR2F2,NR2F1</TD></TR>
<TR><TD>1.459e-02</TD><TD>-4.23</TD><TD>myofibril</TD><TD>cellular component</TD><TD>GO:0030016</TD><TD>205</TD><TD>3</TD><TD>17570</TD><TD>44</TD>
<TD>NEBL,PDLIM5,AHNAK2</TD></TR>
<TR><TD>1.462e-02</TD><TD>-4.23</TD><TD>MODULE_2</TD><TD>MSigDB lists</TD><TD>MODULE_2</TD><TD>374</TD><TD>4</TD><TD>17758</TD><TD>45</TD>
<TD>LAMA4,ITGB4,CD44,VSNL1</TD></TR>
<TR><TD>1.466e-02</TD><TD>-4.22</TD><TD>nephron morphogenesis</TD><TD>biological process</TD><TD>GO:0072028</TD><TD>69</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>PBX1,CD44</TD></TR>
<TR><TD>1.466e-02</TD><TD>-4.22</TD><TD>nucleobase metabolic process</TD><TD>biological process</TD><TD>GO:0009112</TD><TD>69</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>PRPS1,NT5E</TD></TR>
<TR><TD>1.468e-02</TD><TD>-4.22</TD><TD>haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-plasma_cell_myeloma</TD><TD>COSMIC cancer mutations</TD><TD>haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-plasma_cell_myeloma</TD><TD>1322</TD><TD>8</TD><TD>17775</TD><TD>44</TD>
<TD>EFNB2,LAMA4,MSX2,TNIK,NEBL,CSMD3,SORCS2,ETV1</TD></TR>
<TR><TD>1.468e-02</TD><TD>-4.22</TD><TD>plasma_cell_myeloma</TD><TD>COSMIC cancer mutations</TD><TD>plasma_cell_myeloma</TD><TD>1322</TD><TD>8</TD><TD>17775</TD><TD>44</TD>
<TD>EFNB2,LAMA4,MSX2,TNIK,NEBL,CSMD3,SORCS2,ETV1</TD></TR>
<TR><TD>1.469e-02</TD><TD>-4.22</TD><TD>V$OCT1_02</TD><TD>MSigDB lists</TD><TD>V$OCT1_02</TD><TD>203</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>CSMD3,ZIC2,HFM1</TD></TR>
<TR><TD>1.472e-02</TD><TD>-4.22</TD><TD>MODULE_139</TD><TD>MSigDB lists</TD><TD>MODULE_139</TD><TD>73</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>MSX2,NEBL</TD></TR>
<TR><TD>1.474e-02</TD><TD>-4.22</TD><TD>LIM</TD><TD>pfam domains</TD><TD>PF00412</TD><TD>70</TD><TD>2</TD><TD>16629</TD><TD>44</TD>
<TD>NEBL,PDLIM5</TD></TR>
<TR><TD>1.481e-02</TD><TD>-4.21</TD><TD>NEBU</TD><TD>smart domains</TD><TD>SM00227</TD><TD>4</TD><TD>1</TD><TD>9131</TD><TD>34</TD>
<TD>NEBL</TD></TR>
<TR><TD>1.481e-02</TD><TD>-4.21</TD><TD>Sec63</TD><TD>smart domains</TD><TD>SM00973</TD><TD>4</TD><TD>1</TD><TD>9131</TD><TD>34</TD>
<TD>HFM1</TD></TR>
<TR><TD>1.489e-02</TD><TD>-4.21</TD><TD>LINDGREN_BLADDER_CANCER_CLUSTER_2B</TD><TD>MSigDB lists</TD><TD>LINDGREN_BLADDER_CANCER_CLUSTER_2B</TD><TD>376</TD><TD>4</TD><TD>17758</TD><TD>45</TD>
<TD>LAMA4,ETV1,STXBP6,NR2F1</TD></TR>
<TR><TD>1.490e-02</TD><TD>-4.21</TD><TD>IF</TD><TD>interpro domains</TD><TD>IPR001664</TD><TD>74</TD><TD>2</TD><TD>18293</TD><TD>46</TD>
<TD>VIM,KRT7</TD></TR>
<TR><TD>1.496e-02</TD><TD>-4.20</TD><TD>regulation of transferase activity</TD><TD>biological process</TD><TD>GO:0051338</TD><TD>986</TD><TD>7</TD><TD>16441</TD><TD>44</TD>
<TD>TNIK,CAMK2D,FGF9,NR2F2,PPARG,SLK,PKIB</TD></TR>
<TR><TD>1.500e-02</TD><TD>-4.20</TD><TD>CP2</TD><TD>interpro domains</TD><TD>IPR007604</TD><TD>6</TD><TD>1</TD><TD>18293</TD><TD>46</TD>
<TD>GRHL3</TD></TR>
<TR><TD>1.500e-02</TD><TD>-4.20</TD><TD>DUF4749</TD><TD>interpro domains</TD><TD>IPR031847</TD><TD>6</TD><TD>1</TD><TD>18293</TD><TD>46</TD>
<TD>PDLIM5</TD></TR>
<TR><TD>1.506e-02</TD><TD>-4.20</TD><TD>renal tubule morphogenesis</TD><TD>biological process</TD><TD>GO:0061333</TD><TD>70</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>PBX1,CD44</TD></TR>
<TR><TD>1.507e-02</TD><TD>-4.19</TD><TD>MIKKELSEN_NPC_HCP_WITH_H3K4ME3_AND_H3K27ME3</TD><TD>MSigDB lists</TD><TD>MIKKELSEN_NPC_HCP_WITH_H3K4ME3_AND_H3K27ME3</TD><TD>205</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>FGF9,SLC40A1,MSX2</TD></TR>
<TR><TD>1.511e-02</TD><TD>-4.19</TD><TD>WALLACE_PROSTATE_CANCER_DN</TD><TD>MSigDB lists</TD><TD>WALLACE_PROSTATE_CANCER_DN</TD><TD>6</TD><TD>1</TD><TD>17758</TD><TD>45</TD>
<TD>LAMA4</TD></TR>
<TR><TD>1.511e-02</TD><TD>-4.19</TD><TD>CHOI_ATL_ACUTE_STAGE</TD><TD>MSigDB lists</TD><TD>CHOI_ATL_ACUTE_STAGE</TD><TD>6</TD><TD>1</TD><TD>17758</TD><TD>45</TD>
<TD>ETV1</TD></TR>
<TR><TD>1.511e-02</TD><TD>-4.19</TD><TD>JOHNSTONE_PARVB_TARGETS_1_UP</TD><TD>MSigDB lists</TD><TD>JOHNSTONE_PARVB_TARGETS_1_UP</TD><TD>6</TD><TD>1</TD><TD>17758</TD><TD>45</TD>
<TD>KRT7</TD></TR>
<TR><TD>1.511e-02</TD><TD>-4.19</TD><TD>WILLIAMS_ESR1_TARGETS_DN</TD><TD>MSigDB lists</TD><TD>WILLIAMS_ESR1_TARGETS_DN</TD><TD>6</TD><TD>1</TD><TD>17758</TD><TD>45</TD>
<TD>EFNB2</TD></TR>
<TR><TD>1.511e-02</TD><TD>-4.19</TD><TD>TSAI_DNAJB4_TARGETS_DN</TD><TD>MSigDB lists</TD><TD>TSAI_DNAJB4_TARGETS_DN</TD><TD>6</TD><TD>1</TD><TD>17758</TD><TD>45</TD>
<TD>CD44</TD></TR>
<TR><TD>1.514e-02</TD><TD>-4.19</TD><TD>human chr13q32</TD><TD>chromosome location</TD><TD>human chr13q32</TD><TD>8</TD><TD>1</TD><TD>26250</TD><TD>50</TD>
<TD>ZIC2</TD></TR>
<TR><TD>1.514e-02</TD><TD>-4.19</TD><TD>human chr4q21.23</TD><TD>chromosome location</TD><TD>human chr4q21.23</TD><TD>8</TD><TD>1</TD><TD>26250</TD><TD>50</TD>
<TD>GPAT3</TD></TR>
<TR><TD>1.517e-02</TD><TD>-4.19</TD><TD>basolateral plasma membrane</TD><TD>cellular component</TD><TD>GO:0016323</TD><TD>208</TD><TD>3</TD><TD>17570</TD><TD>44</TD>
<TD>SLC40A1,ITGB4,CD44</TD></TR>
<TR><TD>1.523e-02</TD><TD>-4.18</TD><TD>developmental maturation</TD><TD>biological process</TD><TD>GO:0021700</TD><TD>195</TD><TD>3</TD><TD>16441</TD><TD>44</TD>
<TD>PPARG,PDE3A,UNC13A</TD></TR>
<TR><TD>1.525e-02</TD><TD>-4.18</TD><TD>MAP6 (microtubule associated protein 6)</TD><TD>protein interactions</TD><TD>4135</TD><TD>6</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>NR2F1</TD></TR>
<TR><TD>1.525e-02</TD><TD>-4.18</TD><TD>HPS3 (Hermansky-Pudlak syndrome 3)</TD><TD>protein interactions</TD><TD>84343</TD><TD>6</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>EFNB2</TD></TR>
<TR><TD>1.525e-02</TD><TD>-4.18</TD><TD>HELZ2 (helicase with zinc finger 2, transcriptional coactivator)</TD><TD>protein interactions</TD><TD>85441</TD><TD>6</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>PPARG</TD></TR>
<TR><TD>1.525e-02</TD><TD>-4.18</TD><TD>BFSP1 (beaded filament structural protein 1, filensin)</TD><TD>protein interactions</TD><TD>631</TD><TD>6</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>VIM</TD></TR>
<TR><TD>1.525e-02</TD><TD>-4.18</TD><TD>GRHL3 (grainyhead-like transcription factor 3)</TD><TD>protein interactions</TD><TD>57822</TD><TD>6</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>GRHL3</TD></TR>
<TR><TD>1.525e-02</TD><TD>-4.18</TD><TD>SLC16A2 (solute carrier family 16, member 2 (thyroid hormone transporter))</TD><TD>protein interactions</TD><TD>6567</TD><TD>6</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>NT5E</TD></TR>
<TR><TD>1.525e-02</TD><TD>-4.18</TD><TD>SLC26A6 (solute carrier family 26 (anion exchanger), member 6)</TD><TD>protein interactions</TD><TD>65010</TD><TD>6</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>NT5E</TD></TR>
<TR><TD>1.525e-02</TD><TD>-4.18</TD><TD>DIP2B (disco-interacting protein 2 homolog B)</TD><TD>protein interactions</TD><TD>57609</TD><TD>6</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>EFNB2</TD></TR>
<TR><TD>1.525e-02</TD><TD>-4.18</TD><TD>ROBO4 (roundabout guidance receptor 4)</TD><TD>protein interactions</TD><TD>54538</TD><TD>6</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>PPARG</TD></TR>
<TR><TD>1.525e-02</TD><TD>-4.18</TD><TD>head_neck</TD><TD>COSMIC cancer mutations</TD><TD>head_neck</TD><TD>16165</TD><TD>44</TD><TD>17775</TD><TD>44</TD>
<TD>EFNB2,TNIK,CNTNAP3,STXBP6,HFM1,C1orf226,CLSTN2,PBX1,RNF43,ZIC2,PDE3A,S100A10,NEBL,PDE10A,UNC13A,TANK,WNT16,CD44,ETV1,PRPS1,NT5E,LAMA4,SLC40A1,FGF9,MSX1,KRT7,PPARG,VSNL1,GRHL3,VIM,ANGPTL4,NR2F1,RHOU,MSX2,CAMK2D,AHNAK2,SLCO5A1,CSMD3,SORCS2,NR2F2,ITGB4,PDLIM5,MMP16,PKIB</TD></TR>
<TR><TD>1.534e-02</TD><TD>-4.18</TD><TD>TAB2 (TGF-beta activated kinase 1/MAP3K7 binding protein 2)</TD><TD>protein interactions</TD><TD>23118</TD><TD>74</TD><TD>2</TD><TD>16036</TD><TD>41</TD>
<TD>VIM,TANK</TD></TR>
<TR><TD>1.534e-02</TD><TD>-4.18</TD><TD>SVIL (supervillin)</TD><TD>protein interactions</TD><TD>6840</TD><TD>74</TD><TD>2</TD><TD>16036</TD><TD>41</TD>
<TD>VIM,PPARG</TD></TR>
<TR><TD>1.538e-02</TD><TD>-4.17</TD><TD>adenosine nucleotides degradation</TD><TD>BIOCYC pathways</TD><TD>HUMAN_SALVADEHYPOX-PWY</TD><TD>7</TD><TD>1</TD><TD>907</TD><TD>2</TD>
<TD>NT5E</TD></TR>
<TR><TD>1.546e-02</TD><TD>-4.17</TD><TD>pharynx</TD><TD>COSMIC cancer mutations</TD><TD>pharynx</TD><TD>2803</TD><TD>13</TD><TD>17775</TD><TD>44</TD>
<TD>STXBP6,UNC13A,GRHL3,C1orf226,CLSTN2,CSMD3,PBX1,VIM,CD44,SORCS2,ITGB4,MMP16,PRPS1</TD></TR>
<TR><TD>1.547e-02</TD><TD>-4.17</TD><TD>organ regeneration</TD><TD>biological process</TD><TD>GO:0031100</TD><TD>71</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>PPARG,PRPS1</TD></TR>
<TR><TD>1.550e-02</TD><TD>-4.17</TD><TD>MODULE_411</TD><TD>MSigDB lists</TD><TD>MODULE_411</TD><TD>75</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>S100A10,PDE10A</TD></TR>
<TR><TD>1.555e-02</TD><TD>-4.16</TD><TD>icosanoid binding</TD><TD>molecular function</TD><TD>GO:0050542</TD><TD>6</TD><TD>1</TD><TD>16491</TD><TD>43</TD>
<TD>PPARG</TD></TR>
<TR><TD>1.555e-02</TD><TD>-4.16</TD><TD>icosatetraenoic acid binding</TD><TD>molecular function</TD><TD>GO:0050543</TD><TD>6</TD><TD>1</TD><TD>16491</TD><TD>43</TD>
<TD>PPARG</TD></TR>
<TR><TD>1.555e-02</TD><TD>-4.16</TD><TD>fatty acid derivative binding</TD><TD>molecular function</TD><TD>GO:1901567</TD><TD>6</TD><TD>1</TD><TD>16491</TD><TD>43</TD>
<TD>PPARG</TD></TR>
<TR><TD>1.555e-02</TD><TD>-4.16</TD><TD>response to growth factor</TD><TD>biological process</TD><TD>GO:0070848</TD><TD>765</TD><TD>6</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2,CAMK2D,FGF9,MSX1,CD44,PDE3A</TD></TR>
<TR><TD>1.562e-02</TD><TD>-4.16</TD><TD>NUYTTEN_NIPP1_TARGETS_DN</TD><TD>MSigDB lists</TD><TD>NUYTTEN_NIPP1_TARGETS_DN</TD><TD>808</TD><TD>6</TD><TD>17758</TD><TD>45</TD>
<TD>PBX1,SLC40A1,NEBL,S100A10,NR2F2,PRPS1</TD></TR>
<TR><TD>1.577e-02</TD><TD>-4.15</TD><TD>DUF4749</TD><TD>pfam domains</TD><TD>PF15936</TD><TD>6</TD><TD>1</TD><TD>16629</TD><TD>44</TD>
<TD>PDLIM5</TD></TR>
<TR><TD>1.577e-02</TD><TD>-4.15</TD><TD>Integrin_B_tail</TD><TD>pfam domains</TD><TD>PF07965</TD><TD>6</TD><TD>1</TD><TD>16629</TD><TD>44</TD>
<TD>ITGB4</TD></TR>
<TR><TD>1.577e-02</TD><TD>-4.15</TD><TD>CP2</TD><TD>pfam domains</TD><TD>PF04516</TD><TD>6</TD><TD>1</TD><TD>16629</TD><TD>44</TD>
<TD>GRHL3</TD></TR>
<TR><TD>1.580e-02</TD><TD>-4.15</TD><TD>RNA polymerase II regulatory region DNA binding</TD><TD>molecular function</TD><TD>GO:0001012</TD><TD>570</TD><TD>5</TD><TD>16491</TD><TD>43</TD>
<TD>PBX1,MSX2,MSX1,PPARG,ETV1</TD></TR>
<TR><TD>1.583e-02</TD><TD>-4.15</TD><TD>AAGCACA,MIR-218</TD><TD>MSigDB lists</TD><TD>AAGCACA,MIR-218</TD><TD>383</TD><TD>4</TD><TD>17758</TD><TD>45</TD>
<TD>EFNB2,SLCO5A1,CSMD3,NEBL</TD></TR>
<TR><TD>1.584e-02</TD><TD>-4.15</TD><TD>regulation of sequence-specific DNA binding transcription factor activity</TD><TD>biological process</TD><TD>GO:0051090</TD><TD>363</TD><TD>4</TD><TD>16441</TD><TD>44</TD>
<TD>PBX1,MSX2,ZIC2,PPARG</TD></TR>
<TR><TD>1.587e-02</TD><TD>-4.14</TD><TD>KIM_WT1_TARGETS_UP</TD><TD>MSigDB lists</TD><TD>KIM_WT1_TARGETS_UP</TD><TD>209</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>CD44,PDLIM5,PDE10A</TD></TR>
<TR><TD>1.587e-02</TD><TD>-4.14</TD><TD>V$VDR_Q3</TD><TD>MSigDB lists</TD><TD>V$VDR_Q3</TD><TD>209</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>PBX1,FGF9,NR2F1</TD></TR>
<TR><TD>1.587e-02</TD><TD>-4.14</TD><TD>ion binding</TD><TD>molecular function</TD><TD>GO:0043167</TD><TD>5991</TD><TD>23</TD><TD>16491</TD><TD>43</TD>
<TD>TNIK,FGF9,PPARG,STXBP6,SLK,HFM1,VSNL1,CLSTN2,RNF43,ZIC2,PDE3A,NR2F1,RHOU,CAMK2D,S100A10,PDE10A,UNC13A,TANK,NR2F2,PDLIM5,MMP16,PRPS1,NT5E</TD></TR>
<TR><TD>1.589e-02</TD><TD>-4.14</TD><TD>MODULE_357</TD><TD>MSigDB lists</TD><TD>MODULE_357</TD><TD>76</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>ITGB4,ANGPTL4</TD></TR>
<TR><TD>1.589e-02</TD><TD>-4.14</TD><TD>NAKAYAMA_SOFT_TISSUE_TUMORS_PCA2_DN</TD><TD>MSigDB lists</TD><TD>NAKAYAMA_SOFT_TISSUE_TUMORS_PCA2_DN</TD><TD>76</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>PPARG,ANGPTL4</TD></TR>
<TR><TD>1.589e-02</TD><TD>-4.14</TD><TD>REACTOME_PLATELET_HOMEOSTASIS</TD><TD>MSigDB lists</TD><TD>REACTOME_PLATELET_HOMEOSTASIS</TD><TD>76</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>PDE10A,PDE3A</TD></TR>
<TR><TD>1.589e-02</TD><TD>-4.14</TD><TD>MODULE_297</TD><TD>MSigDB lists</TD><TD>MODULE_297</TD><TD>76</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>ITGB4,ANGPTL4</TD></TR>
<TR><TD>1.589e-02</TD><TD>-4.14</TD><TD>THEILGAARD_NEUTROPHIL_AT_SKIN_WOUND_UP</TD><TD>MSigDB lists</TD><TD>THEILGAARD_NEUTROPHIL_AT_SKIN_WOUND_UP</TD><TD>76</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>CD44,TANK</TD></TR>
<TR><TD>1.589e-02</TD><TD>-4.14</TD><TD>GGARNTKYCCA_UNKNOWN</TD><TD>MSigDB lists</TD><TD>GGARNTKYCCA_UNKNOWN</TD><TD>76</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>CSMD3,MSX1</TD></TR>
<TR><TD>1.595e-02</TD><TD>-4.14</TD><TD>wound healing involved in inflammatory response</TD><TD>biological process</TD><TD>GO:0002246</TD><TD>6</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>CD44</TD></TR>
<TR><TD>1.595e-02</TD><TD>-4.14</TD><TD>inflammatory response to wounding</TD><TD>biological process</TD><TD>GO:0090594</TD><TD>6</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>CD44</TD></TR>
<TR><TD>1.595e-02</TD><TD>-4.14</TD><TD>negative regulation of receptor biosynthetic process</TD><TD>biological process</TD><TD>GO:0010871</TD><TD>6</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>PPARG</TD></TR>
<TR><TD>1.595e-02</TD><TD>-4.14</TD><TD>iron ion transmembrane transport</TD><TD>biological process</TD><TD>GO:0034755</TD><TD>6</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>SLC40A1</TD></TR>
<TR><TD>1.595e-02</TD><TD>-4.14</TD><TD>purine nucleoside monophosphate catabolic process</TD><TD>biological process</TD><TD>GO:0009128</TD><TD>6</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>NT5E</TD></TR>
<TR><TD>1.595e-02</TD><TD>-4.14</TD><TD>negative regulation of CREB transcription factor activity</TD><TD>biological process</TD><TD>GO:0032792</TD><TD>6</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2</TD></TR>
<TR><TD>1.595e-02</TD><TD>-4.14</TD><TD>negative regulation of cholesterol storage</TD><TD>biological process</TD><TD>GO:0010887</TD><TD>6</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>PPARG</TD></TR>
<TR><TD>1.595e-02</TD><TD>-4.14</TD><TD>lymphatic endothelial cell differentiation</TD><TD>biological process</TD><TD>GO:0060836</TD><TD>6</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>NR2F2</TD></TR>
<TR><TD>1.595e-02</TD><TD>-4.14</TD><TD>hypoxanthine metabolic process</TD><TD>biological process</TD><TD>GO:0046100</TD><TD>6</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>PRPS1</TD></TR>
<TR><TD>1.595e-02</TD><TD>-4.14</TD><TD>positive regulation of striated muscle cell apoptotic process</TD><TD>biological process</TD><TD>GO:0010663</TD><TD>6</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>CAMK2D</TD></TR>
<TR><TD>1.595e-02</TD><TD>-4.14</TD><TD>cGMP catabolic process</TD><TD>biological process</TD><TD>GO:0046069</TD><TD>6</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>PDE10A</TD></TR>
<TR><TD>1.595e-02</TD><TD>-4.14</TD><TD>regulation of relaxation of cardiac muscle</TD><TD>biological process</TD><TD>GO:1901897</TD><TD>6</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>CAMK2D</TD></TR>
<TR><TD>1.595e-02</TD><TD>-4.14</TD><TD>positive regulation of mesoderm development</TD><TD>biological process</TD><TD>GO:2000382</TD><TD>6</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>ZIC2</TD></TR>
<TR><TD>1.595e-02</TD><TD>-4.14</TD><TD>peroxisome proliferator activated receptor signaling pathway</TD><TD>biological process</TD><TD>GO:0035357</TD><TD>6</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>PPARG</TD></TR>
<TR><TD>1.595e-02</TD><TD>-4.14</TD><TD>positive regulation of cardiac muscle cell apoptotic process</TD><TD>biological process</TD><TD>GO:0010666</TD><TD>6</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>CAMK2D</TD></TR>
<TR><TD>1.595e-02</TD><TD>-4.14</TD><TD>cellular response to cGMP</TD><TD>biological process</TD><TD>GO:0071321</TD><TD>6</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>PDE3A</TD></TR>
<TR><TD>1.597e-02</TD><TD>-4.14</TD><TD>Filament</TD><TD>pfam domains</TD><TD>PF00038</TD><TD>73</TD><TD>2</TD><TD>16629</TD><TD>44</TD>
<TD>VIM,KRT7</TD></TR>
<TR><TD>1.613e-02</TD><TD>-4.13</TD><TD>GFI1B (growth factor independent 1B transcription repressor)</TD><TD>protein interactions</TD><TD>8328</TD><TD>76</TD><TD>2</TD><TD>16036</TD><TD>41</TD>
<TD>PDLIM5,VSNL1</TD></TR>
<TR><TD>1.613e-02</TD><TD>-4.13</TD><TD>PLEC (plectin)</TD><TD>protein interactions</TD><TD>5339</TD><TD>76</TD><TD>2</TD><TD>16036</TD><TD>41</TD>
<TD>VIM,ITGB4</TD></TR>
<TR><TD>1.613e-02</TD><TD>-4.13</TD><TD>ATF7IP (activating transcription factor 7 interacting protein)</TD><TD>protein interactions</TD><TD>55729</TD><TD>76</TD><TD>2</TD><TD>16036</TD><TD>41</TD>
<TD>LAMA4,KRT7</TD></TR>
<TR><TD>1.613e-02</TD><TD>-4.13</TD><TD>regulation of neuron projection development</TD><TD>biological process</TD><TD>GO:0010975</TD><TD>365</TD><TD>4</TD><TD>16441</TD><TD>44</TD>
<TD>VIM,TNIK,PDLIM5,UNC13A</TD></TR>
<TR><TD>1.613e-02</TD><TD>-4.13</TD><TD>focal adhesion</TD><TD>cellular component</TD><TD>GO:0005925</TD><TD>390</TD><TD>4</TD><TD>17570</TD><TD>44</TD>
<TD>EFNB2,RHOU,VIM,CD44</TD></TR>
<TR><TD>1.628e-02</TD><TD>-4.12</TD><TD>cellular response to lipid</TD><TD>biological process</TD><TD>GO:0071396</TD><TD>366</TD><TD>4</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2,NR2F2,PPARG,NR2F1</TD></TR>
<TR><TD>1.629e-02</TD><TD>-4.12</TD><TD>LIEN_BREAST_CARCINOMA_METAPLASTIC_VS_DUCTAL_UP</TD><TD>MSigDB lists</TD><TD>LIEN_BREAST_CARCINOMA_METAPLASTIC_VS_DUCTAL_UP</TD><TD>77</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>VIM,ANGPTL4</TD></TR>
<TR><TD>1.629e-02</TD><TD>-4.12</TD><TD>FRIDMAN_SENESCENCE_UP</TD><TD>MSigDB lists</TD><TD>FRIDMAN_SENESCENCE_UP</TD><TD>77</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>VIM,CD44</TD></TR>
<TR><TD>1.629e-02</TD><TD>-4.12</TD><TD>CHANG_IMMORTALIZED_BY_HPV31_UP</TD><TD>MSigDB lists</TD><TD>CHANG_IMMORTALIZED_BY_HPV31_UP</TD><TD>77</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>KRT7,PPARG</TD></TR>
<TR><TD>1.634e-02</TD><TD>-4.11</TD><TD>chromatin DNA binding</TD><TD>molecular function</TD><TD>GO:0031490</TD><TD>75</TD><TD>2</TD><TD>16491</TD><TD>43</TD>
<TD>ZIC2,GRHL3</TD></TR>
<TR><TD>1.651e-02</TD><TD>-4.10</TD><TD>ear development</TD><TD>biological process</TD><TD>GO:0043583</TD><TD>201</TD><TD>3</TD><TD>16441</TD><TD>44</TD>
<TD>FGF9,MSX1,GRHL3</TD></TR>
<TR><TD>1.652e-02</TD><TD>-4.10</TD><TD>VECCHI_GASTRIC_CANCER_EARLY_UP</TD><TD>MSigDB lists</TD><TD>VECCHI_GASTRIC_CANCER_EARLY_UP</TD><TD>388</TD><TD>4</TD><TD>17758</TD><TD>45</TD>
<TD>MSX2,ZIC2,KRT7,S100A10</TD></TR>
<TR><TD>1.653e-02</TD><TD>-4.10</TD><TD>TRIM24 (tripartite motif containing 24)</TD><TD>protein interactions</TD><TD>8805</TD><TD>77</TD><TD>2</TD><TD>16036</TD><TD>41</TD>
<TD>NR2F2,PPARG</TD></TR>
<TR><TD>1.653e-02</TD><TD>-4.10</TD><TD>GTF2F1 (general transcription factor IIF subunit 1)</TD><TD>protein interactions</TD><TD>2962</TD><TD>77</TD><TD>2</TD><TD>16036</TD><TD>41</TD>
<TD>MSX2,PRPS1</TD></TR>
<TR><TD>1.653e-02</TD><TD>-4.10</TD><TD>NCOA2 (nuclear receptor coactivator 2)</TD><TD>protein interactions</TD><TD>10499</TD><TD>77</TD><TD>2</TD><TD>16036</TD><TD>41</TD>
<TD>PPARG,ETV1</TD></TR>
<TR><TD>1.656e-02</TD><TD>-4.10</TD><TD>contractile fiber</TD><TD>cellular component</TD><TD>GO:0043292</TD><TD>215</TD><TD>3</TD><TD>17570</TD><TD>44</TD>
<TD>NEBL,PDLIM5,AHNAK2</TD></TR>
<TR><TD>1.669e-02</TD><TD>-4.09</TD><TD>MODULE_341</TD><TD>MSigDB lists</TD><TD>MODULE_341</TD><TD>78</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>S100A10,PDE10A</TD></TR>
<TR><TD>1.673e-02</TD><TD>-4.09</TD><TD>extracellular matrix organization</TD><TD>biological process</TD><TD>GO:0030198</TD><TD>369</TD><TD>4</TD><TD>16441</TD><TD>44</TD>
<TD>LAMA4,ITGB4,CD44,MMP16</TD></TR>
<TR><TD>1.674e-02</TD><TD>-4.09</TD><TD>MHD2</TD><TD>prosite domains</TD><TD>PS51259</TD><TD>5</TD><TD>1</TD><TD>11866</TD><TD>40</TD>
<TD>UNC13A</TD></TR>
<TR><TD>1.683e-02</TD><TD>-4.08</TD><TD>cell-substrate adherens junction</TD><TD>cellular component</TD><TD>GO:0005924</TD><TD>395</TD><TD>4</TD><TD>17570</TD><TD>44</TD>
<TD>EFNB2,RHOU,VIM,CD44</TD></TR>
<TR><TD>1.688e-02</TD><TD>-4.08</TD><TD>extracellular structure organization</TD><TD>biological process</TD><TD>GO:0043062</TD><TD>370</TD><TD>4</TD><TD>16441</TD><TD>44</TD>
<TD>LAMA4,ITGB4,CD44,MMP16</TD></TR>
<TR><TD>1.689e-02</TD><TD>-4.08</TD><TD>V$IK3_01</TD><TD>MSigDB lists</TD><TD>V$IK3_01</TD><TD>214</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>RNF43,MSX1,VSNL1</TD></TR>
<TR><TD>1.699e-02</TD><TD>-4.07</TD><TD>PEREZ_TP53_TARGETS</TD><TD>MSigDB lists</TD><TD>PEREZ_TP53_TARGETS</TD><TD>1067</TD><TD>7</TD><TD>17758</TD><TD>45</TD>
<TD>MSX2,ZIC2,MSX1,CNTNAP3,PDE10A,VSNL1,AHNAK2</TD></TR>
<TR><TD>1.710e-02</TD><TD>-4.07</TD><TD>HARRIS_HYPOXIA</TD><TD>MSigDB lists</TD><TD>HARRIS_HYPOXIA</TD><TD>79</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>VIM,PRPS1</TD></TR>
<TR><TD>1.716e-02</TD><TD>-4.06</TD><TD>regulation of synapse assembly</TD><TD>biological process</TD><TD>GO:0051963</TD><TD>75</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>CLSTN2,PDLIM5</TD></TR>
<TR><TD>1.718e-02</TD><TD>-4.06</TD><TD>blood vessel morphogenesis</TD><TD>biological process</TD><TD>GO:0048514</TD><TD>372</TD><TD>4</TD><TD>16441</TD><TD>44</TD>
<TD>EFNB2,FGF9,NR2F2,ANGPTL4</TD></TR>
<TR><TD>1.718e-02</TD><TD>-4.06</TD><TD>purine-containing compound metabolic process</TD><TD>biological process</TD><TD>GO:0072521</TD><TD>372</TD><TD>4</TD><TD>16441</TD><TD>44</TD>
<TD>PRPS1,PDE10A,PDE3A,NT5E</TD></TR>
<TR><TD>1.720e-02</TD><TD>-4.06</TD><TD>Krukenberg_tumour</TD><TD>COSMIC cancer mutations</TD><TD>Krukenberg_tumour</TD><TD>7</TD><TD>1</TD><TD>17775</TD><TD>44</TD>
<TD>RNF43</TD></TR>
<TR><TD>1.730e-02</TD><TD>-4.06</TD><TD>positive regulation of molecular function</TD><TD>biological process</TD><TD>GO:0044093</TD><TD>1782</TD><TD>10</TD><TD>16441</TD><TD>44</TD>
<TD>TNIK,CAMK2D,FGF9,S100A10,PPARG,SLK,GRHL3,ZIC2,MMP16,PKIB</TD></TR>
<TR><TD>1.739e-02</TD><TD>-4.05</TD><TD>plasma membrane organization</TD><TD>biological process</TD><TD>GO:0007009</TD><TD>205</TD><TD>3</TD><TD>16441</TD><TD>44</TD>
<TD>TNIK,S100A10,AHNAK2</TD></TR>
<TR><TD>1.739e-02</TD><TD>-4.05</TD><TD>negative regulation of RNA metabolic process</TD><TD>biological process</TD><TD>GO:0051253</TD><TD>1261</TD><TD>8</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2,FGF9,MSX1,PPARG,PBX1,ZIC2,NR2F2,NR2F1</TD></TR>
<TR><TD>1.740e-02</TD><TD>-4.05</TD><TD>hemidesmosome</TD><TD>cellular component</TD><TD>GO:0030056</TD><TD>7</TD><TD>1</TD><TD>17570</TD><TD>44</TD>
<TD>ITGB4</TD></TR>
<TR><TD>1.747e-02</TD><TD>-4.05</TD><TD>Integrin_bsu_tail</TD><TD>interpro domains</TD><TD>IPR012896</TD><TD>7</TD><TD>1</TD><TD>18293</TD><TD>46</TD>
<TD>ITGB4</TD></TR>
<TR><TD>1.747e-02</TD><TD>-4.05</TD><TD>Munc13_1</TD><TD>interpro domains</TD><TD>IPR014770</TD><TD>7</TD><TD>1</TD><TD>18293</TD><TD>46</TD>
<TD>UNC13A</TD></TR>
<TR><TD>1.747e-02</TD><TD>-4.05</TD><TD>Intermed_filament_DNA-bd</TD><TD>interpro domains</TD><TD>IPR006821</TD><TD>7</TD><TD>1</TD><TD>18293</TD><TD>46</TD>
<TD>VIM</TD></TR>
<TR><TD>1.751e-02</TD><TD>-4.05</TD><TD>CROMER_METASTASIS_DN</TD><TD>MSigDB lists</TD><TD>CROMER_METASTASIS_DN</TD><TD>80</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>ITGB4,VSNL1</TD></TR>
<TR><TD>1.751e-02</TD><TD>-4.05</TD><TD>FRASOR_RESPONSE_TO_ESTRADIOL_DN</TD><TD>MSigDB lists</TD><TD>FRASOR_RESPONSE_TO_ESTRADIOL_DN</TD><TD>80</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>KRT7,PRPS1</TD></TR>
<TR><TD>1.756e-02</TD><TD>-4.04</TD><TD>TGANTCA_V$AP1_C</TD><TD>MSigDB lists</TD><TD>TGANTCA_V$AP1_C</TD><TD>1074</TD><TD>7</TD><TD>17758</TD><TD>45</TD>
<TD>SLCO5A1,CSMD3,FGF9,ITGB4,NEBL,S100A10,ANGPTL4</TD></TR>
<TR><TD>1.761e-02</TD><TD>-4.04</TD><TD>BEGUM_TARGETS_OF_PAX3_FOXO1_FUSION_AND_PAX3</TD><TD>MSigDB lists</TD><TD>BEGUM_TARGETS_OF_PAX3_FOXO1_FUSION_AND_PAX3</TD><TD>7</TD><TD>1</TD><TD>17758</TD><TD>45</TD>
<TD>NR2F1</TD></TR>
<TR><TD>1.761e-02</TD><TD>-4.04</TD><TD>MIKHAYLOVA_OXIDATIVE_STRESS_RESPONSE_VIA_VHL_UP</TD><TD>MSigDB lists</TD><TD>MIKHAYLOVA_OXIDATIVE_STRESS_RESPONSE_VIA_VHL_UP</TD><TD>7</TD><TD>1</TD><TD>17758</TD><TD>45</TD>
<TD>VIM</TD></TR>
<TR><TD>1.761e-02</TD><TD>-4.04</TD><TD>LUDWICZEK_TREATING_IRON_OVERLOAD</TD><TD>MSigDB lists</TD><TD>LUDWICZEK_TREATING_IRON_OVERLOAD</TD><TD>7</TD><TD>1</TD><TD>17758</TD><TD>45</TD>
<TD>SLC40A1</TD></TR>
<TR><TD>1.761e-02</TD><TD>-4.04</TD><TD>TESAR_ALK_TARGETS_EPISC_3D_UP</TD><TD>MSigDB lists</TD><TD>TESAR_ALK_TARGETS_EPISC_3D_UP</TD><TD>7</TD><TD>1</TD><TD>17758</TD><TD>45</TD>
<TD>MSX1</TD></TR>
<TR><TD>1.761e-02</TD><TD>-4.04</TD><TD>BUSA_SAM68_TARGETS_UP</TD><TD>MSigDB lists</TD><TD>BUSA_SAM68_TARGETS_UP</TD><TD>7</TD><TD>1</TD><TD>17758</TD><TD>45</TD>
<TD>NR2F1</TD></TR>
<TR><TD>1.761e-02</TD><TD>-4.04</TD><TD>TESAR_ALK_TARGETS_EPISC_4D_UP</TD><TD>MSigDB lists</TD><TD>TESAR_ALK_TARGETS_EPISC_4D_UP</TD><TD>7</TD><TD>1</TD><TD>17758</TD><TD>45</TD>
<TD>MSX1</TD></TR>
<TR><TD>1.765e-02</TD><TD>-4.04</TD><TD>positive regulation of catalytic activity</TD><TD>biological process</TD><TD>GO:0043085</TD><TD>1521</TD><TD>9</TD><TD>16441</TD><TD>44</TD>
<TD>TNIK,CAMK2D,FGF9,S100A10,PPARG,SLK,GRHL3,MMP16,PKIB</TD></TR>
<TR><TD>1.776e-02</TD><TD>-4.03</TD><TD>Homeobox</TD><TD>pfam domains</TD><TD>PF00046</TD><TD>209</TD><TD>3</TD><TD>16629</TD><TD>44</TD>
<TD>PBX1,MSX2,MSX1</TD></TR>
<TR><TD>1.776e-02</TD><TD>-4.03</TD><TD>RPS4Y1 (ribosomal protein S4, Y-linked 1)</TD><TD>protein interactions</TD><TD>6192</TD><TD>7</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>PRPS1</TD></TR>
<TR><TD>1.776e-02</TD><TD>-4.03</TD><TD>XIRP1 (xin actin binding repeat containing 1)</TD><TD>protein interactions</TD><TD>165904</TD><TD>7</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>NEBL</TD></TR>
<TR><TD>1.776e-02</TD><TD>-4.03</TD><TD>CHRNA4 (cholinergic receptor, nicotinic alpha 4)</TD><TD>protein interactions</TD><TD>1137</TD><TD>7</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>VSNL1</TD></TR>
<TR><TD>1.776e-02</TD><TD>-4.03</TD><TD>MAP7D3 (MAP7 domain containing 3)</TD><TD>protein interactions</TD><TD>79649</TD><TD>7</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>EFNB2</TD></TR>
<TR><TD>1.776e-02</TD><TD>-4.03</TD><TD>Rxra (retinoid X receptor alpha)</TD><TD>protein interactions</TD><TD>20181</TD><TD>7</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>PPARG</TD></TR>
<TR><TD>1.776e-02</TD><TD>-4.03</TD><TD>HOXD10 (homeobox D10)</TD><TD>protein interactions</TD><TD>3236</TD><TD>7</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>PBX1</TD></TR>
<TR><TD>1.776e-02</TD><TD>-4.03</TD><TD>FAM171A2 (family with sequence similarity 171, member A2)</TD><TD>protein interactions</TD><TD>284069</TD><TD>7</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>EFNB2</TD></TR>
<TR><TD>1.776e-02</TD><TD>-4.03</TD><TD>Gadd45b (growth arrest and DNA-damage-inducible 45 beta)</TD><TD>protein interactions</TD><TD>17873</TD><TD>7</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>PPARG</TD></TR>
<TR><TD>1.776e-02</TD><TD>-4.03</TD><TD>KISS1 (KiSS-1 metastasis-suppressor)</TD><TD>protein interactions</TD><TD>3814</TD><TD>7</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>MMP16</TD></TR>
<TR><TD>1.782e-02</TD><TD>-4.03</TD><TD>ConA-like_dom</TD><TD>interpro domains</TD><TD>IPR013320</TD><TD>220</TD><TD>3</TD><TD>18293</TD><TD>46</TD>
<TD>CLSTN2,LAMA4,CNTNAP3</TD></TR>
<TR><TD>1.792e-02</TD><TD>-4.02</TD><TD>TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_6HR_UP</TD><TD>MSigDB lists</TD><TD>TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_6HR_UP</TD><TD>81</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>MSX1,S100A10</TD></TR>
<TR><TD>1.804e-02</TD><TD>-4.02</TD><TD>interferon-gamma-mediated signaling pathway</TD><TD>biological process</TD><TD>GO:0060333</TD><TD>77</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>CAMK2D,CD44</TD></TR>
<TR><TD>1.809e-02</TD><TD>-4.01</TD><TD>WAKABAYASHI_ADIPOGENESIS_PPARG_RXRA_BOUND_8D</TD><TD>MSigDB lists</TD><TD>WAKABAYASHI_ADIPOGENESIS_PPARG_RXRA_BOUND_8D</TD><TD>835</TD><TD>6</TD><TD>17758</TD><TD>45</TD>
<TD>LAMA4,NR2F2,PPARG,ANGPTL4,TANK,NR2F1</TD></TR>
<TR><TD>1.811e-02</TD><TD>-4.01</TD><TD>diphosphotransferase activity</TD><TD>molecular function</TD><TD>GO:0016778</TD><TD>7</TD><TD>1</TD><TD>16491</TD><TD>43</TD>
<TD>PRPS1</TD></TR>
<TR><TD>1.811e-02</TD><TD>-4.01</TD><TD>iron ion transmembrane transporter activity</TD><TD>molecular function</TD><TD>GO:0005381</TD><TD>7</TD><TD>1</TD><TD>16491</TD><TD>43</TD>
<TD>SLC40A1</TD></TR>
<TR><TD>1.812e-02</TD><TD>-4.01</TD><TD>MODULE_6</TD><TD>MSigDB lists</TD><TD>MODULE_6</TD><TD>399</TD><TD>4</TD><TD>17758</TD><TD>45</TD>
<TD>ZIC2,ITGB4,CD44,KRT7</TD></TR>
<TR><TD>1.817e-02</TD><TD>-4.01</TD><TD>V$PU1_Q6</TD><TD>MSigDB lists</TD><TD>V$PU1_Q6</TD><TD>220</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>PBX1,ZIC2,ETV1</TD></TR>
<TR><TD>1.827e-02</TD><TD>-4.00</TD><TD>REN_ALVEOLAR_RHABDOMYOSARCOMA_DN</TD><TD>MSigDB lists</TD><TD>REN_ALVEOLAR_RHABDOMYOSARCOMA_DN</TD><TD>400</TD><TD>4</TD><TD>17758</TD><TD>45</TD>
<TD>LAMA4,S100A10,PDLIM5,NT5E</TD></TR>
<TR><TD>1.836e-02</TD><TD>-4.00</TD><TD>lower_third</TD><TD>COSMIC cancer mutations</TD><TD>lower_third</TD><TD>8323</TD><TD>28</TD><TD>17775</TD><TD>44</TD>
<TD>EFNB2,SLC40A1,MSX1,KRT7,CNTNAP3,HFM1,VSNL1,CLSTN2,RNF43,VIM,NR2F1,PDE3A,NEBL,PDE10A,UNC13A,TANK,AHNAK2,SLCO5A1,CSMD3,WNT16,CD44,SORCS2,NR2F2,ITGB4,PDLIM5,ETV1,MMP16,PRPS1</TD></TR>
<TR><TD>1.838e-02</TD><TD>-4.00</TD><TD>PKD</TD><TD>pfam domains</TD><TD>PF00801</TD><TD>7</TD><TD>1</TD><TD>16629</TD><TD>44</TD>
<TD>SORCS2</TD></TR>
<TR><TD>1.838e-02</TD><TD>-4.00</TD><TD>GAF</TD><TD>pfam domains</TD><TD>PF01590</TD><TD>7</TD><TD>1</TD><TD>16629</TD><TD>44</TD>
<TD>PDE10A</TD></TR>
<TR><TD>1.838e-02</TD><TD>-4.00</TD><TD>Filament_head</TD><TD>pfam domains</TD><TD>PF04732</TD><TD>7</TD><TD>1</TD><TD>16629</TD><TD>44</TD>
<TD>VIM</TD></TR>
<TR><TD>1.838e-02</TD><TD>-4.00</TD><TD>V$FOXJ2_02</TD><TD>MSigDB lists</TD><TD>V$FOXJ2_02</TD><TD>221</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>PBX1,CSMD3,NR2F1</TD></TR>
<TR><TD>1.848e-02</TD><TD>-3.99</TD><TD>pyrimidine-containing compound metabolic process</TD><TD>biological process</TD><TD>GO:0072527</TD><TD>78</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>PRPS1,NT5E</TD></TR>
<TR><TD>1.848e-02</TD><TD>-3.99</TD><TD>VPS10</TD><TD>smart domains</TD><TD>SM00602</TD><TD>5</TD><TD>1</TD><TD>9131</TD><TD>34</TD>
<TD>SORCS2</TD></TR>
<TR><TD>1.852e-02</TD><TD>-3.99</TD><TD>oesophagus-carcinoma-adenocarcinoma</TD><TD>COSMIC cancer mutations</TD><TD>oesophagus-carcinoma-adenocarcinoma</TD><TD>13776</TD><TD>40</TD><TD>17775</TD><TD>44</TD>
<TD>EFNB2,TNIK,CNTNAP3,STXBP6,HFM1,C1orf226,CLSTN2,RNF43,ZIC2,PDE3A,NEBL,PDE10A,UNC13A,TANK,WNT16,CD44,ETV1,PRPS1,NT5E,LAMA4,SLC40A1,FGF9,MSX1,KRT7,PPARG,VSNL1,GRHL3,VIM,ANGPTL4,NR2F1,RHOU,CAMK2D,CSMD3,SLCO5A1,NR2F2,SORCS2,ITGB4,PDLIM5,MMP16,PKIB</TD></TR>
<TR><TD>1.857e-02</TD><TD>-3.99</TD><TD>positive regulation of cell differentiation</TD><TD>biological process</TD><TD>GO:0045597</TD><TD>796</TD><TD>6</TD><TD>16441</TD><TD>44</TD>
<TD>EFNB2,MSX2,S100A10,PPARG,UNC13A,PDE3A</TD></TR>
<TR><TD>1.859e-02</TD><TD>-3.99</TD><TD>cerebral cortex regionalization</TD><TD>biological process</TD><TD>GO:0021796</TD><TD>7</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>NR2F1</TD></TR>
<TR><TD>1.859e-02</TD><TD>-3.99</TD><TD>response to cGMP</TD><TD>biological process</TD><TD>GO:0070305</TD><TD>7</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>PDE3A</TD></TR>
<TR><TD>1.859e-02</TD><TD>-3.99</TD><TD>negative regulation of collagen biosynthetic process</TD><TD>biological process</TD><TD>GO:0032966</TD><TD>7</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>PPARG</TD></TR>
<TR><TD>1.859e-02</TD><TD>-3.99</TD><TD>AMP biosynthetic process</TD><TD>biological process</TD><TD>GO:0006167</TD><TD>7</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>PRPS1</TD></TR>
<TR><TD>1.859e-02</TD><TD>-3.99</TD><TD>endothelial cell fate commitment</TD><TD>biological process</TD><TD>GO:0060839</TD><TD>7</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>NR2F2</TD></TR>
<TR><TD>1.876e-02</TD><TD>-3.98</TD><TD>skeletal system morphogenesis</TD><TD>biological process</TD><TD>GO:0048705</TD><TD>211</TD><TD>3</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2,MSX1,MMP16</TD></TR>
<TR><TD>1.876e-02</TD><TD>-3.98</TD><TD>HINATA_NFKB_TARGETS_FIBROBLAST_UP</TD><TD>MSigDB lists</TD><TD>HINATA_NFKB_TARGETS_FIBROBLAST_UP</TD><TD>83</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>VIM,KRT7</TD></TR>
<TR><TD>1.878e-02</TD><TD>-3.98</TD><TD>SYSTEM_DEVELOPMENT</TD><TD>MSigDB lists</TD><TD>SYSTEM_DEVELOPMENT</TD><TD>842</TD><TD>6</TD><TD>17758</TD><TD>45</TD>
<TD>PBX1,MSX2,ZIC2,MSX1,PRPS1,ANGPTL4</TD></TR>
<TR><TD>1.889e-02</TD><TD>-3.97</TD><TD>human chr8q13.3</TD><TD>chromosome location</TD><TD>human chr8q13.3</TD><TD>10</TD><TD>1</TD><TD>26250</TD><TD>50</TD>
<TD>SLCO5A1</TD></TR>
<TR><TD>1.889e-02</TD><TD>-3.97</TD><TD>human chr2p24.3</TD><TD>chromosome location</TD><TD>human chr2p24.3</TD><TD>10</TD><TD>1</TD><TD>26250</TD><TD>50</TD>
<TD>VSNL1</TD></TR>
<TR><TD>1.889e-02</TD><TD>-3.97</TD><TD>human chr15q26</TD><TD>chromosome location</TD><TD>human chr15q26</TD><TD>10</TD><TD>1</TD><TD>26250</TD><TD>50</TD>
<TD>NR2F2</TD></TR>
<TR><TD>1.891e-02</TD><TD>-3.97</TD><TD>regulation of cell growth</TD><TD>biological process</TD><TD>GO:0001558</TD><TD>383</TD><TD>4</TD><TD>16441</TD><TD>44</TD>
<TD>CAMK2D,MSX1,PPARG,UNC13A</TD></TR>
<TR><TD>1.893e-02</TD><TD>-3.97</TD><TD>nephron tubule development</TD><TD>biological process</TD><TD>GO:0072080</TD><TD>79</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>PBX1,CD44</TD></TR>
<TR><TD>1.893e-02</TD><TD>-3.97</TD><TD>BMP signaling pathway</TD><TD>biological process</TD><TD>GO:0030509</TD><TD>79</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2,MSX1</TD></TR>
<TR><TD>1.900e-02</TD><TD>-3.96</TD><TD>heart morphogenesis</TD><TD>biological process</TD><TD>GO:0003007</TD><TD>212</TD><TD>3</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2,MSX1,WNT16</TD></TR>
<TR><TD>1.901e-02</TD><TD>-3.96</TD><TD>IF</TD><TD>prosite domains</TD><TD>PS00226</TD><TD>63</TD><TD>2</TD><TD>11866</TD><TD>40</TD>
<TD>VIM,KRT7</TD></TR>
<TR><TD>1.905e-02</TD><TD>-3.96</TD><TD>PFDN1 (prefoldin subunit 1)</TD><TD>protein interactions</TD><TD>5201</TD><TD>83</TD><TD>2</TD><TD>16036</TD><TD>41</TD>
<TD>PRPS1,NR2F1</TD></TR>
<TR><TD>1.905e-02</TD><TD>-3.96</TD><TD>V$SOX9_B1</TD><TD>MSigDB lists</TD><TD>V$SOX9_B1</TD><TD>224</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>PBX1,ZIC2,ETV1</TD></TR>
<TR><TD>1.905e-02</TD><TD>-3.96</TD><TD>central_nervous_system-brain-primitive_neuroectodermal_tumour-medulloblastoma</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-brain-primitive_neuroectodermal_tumour-medulloblastoma</TD><TD>7542</TD><TD>26</TD><TD>17775</TD><TD>44</TD>
<TD>EFNB2,LAMA4,TNIK,PPARG,STXBP6,HFM1,GRHL3,VSNL1,CLSTN2,RNF43,PDE3A,RHOU,CAMK2D,NEBL,PDE10A,UNC13A,TANK,SLCO5A1,CSMD3,CD44,SORCS2,ITGB4,PDLIM5,MMP16,PKIB,NT5E</TD></TR>
<TR><TD>1.912e-02</TD><TD>-3.96</TD><TD>SMID_BREAST_CANCER_BASAL_UP</TD><TD>MSigDB lists</TD><TD>SMID_BREAST_CANCER_BASAL_UP</TD><TD>615</TD><TD>5</TD><TD>17758</TD><TD>45</TD>
<TD>FGF9,CD44,S100A10,STXBP6,ANGPTL4</TD></TR>
<TR><TD>1.915e-02</TD><TD>-3.96</TD><TD>cell adhesion</TD><TD>biological process</TD><TD>GO:0007155</TD><TD>1036</TD><TD>7</TD><TD>16441</TD><TD>44</TD>
<TD>EFNB2,CLSTN2,LAMA4,ITGB4,CD44,CNTNAP3,NT5E</TD></TR>
<TR><TD>1.919e-02</TD><TD>-3.95</TD><TD>KIM_GLIS2_TARGETS_UP</TD><TD>MSigDB lists</TD><TD>KIM_GLIS2_TARGETS_UP</TD><TD>84</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>VIM,ANGPTL4</TD></TR>
<TR><TD>1.919e-02</TD><TD>-3.95</TD><TD>RUAN_RESPONSE_TO_TNF_DN</TD><TD>MSigDB lists</TD><TD>RUAN_RESPONSE_TO_TNF_DN</TD><TD>84</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>LAMA4,PPARG</TD></TR>
<TR><TD>1.927e-02</TD><TD>-3.95</TD><TD>V$TITF1_Q3</TD><TD>MSigDB lists</TD><TD>V$TITF1_Q3</TD><TD>225</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>CSMD3,WNT16,ETV1</TD></TR>
<TR><TD>1.927e-02</TD><TD>-3.95</TD><TD>V$OCT1_04</TD><TD>MSigDB lists</TD><TD>V$OCT1_04</TD><TD>225</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>PBX1,ETV1,HFM1</TD></TR>
<TR><TD>1.927e-02</TD><TD>-3.95</TD><TD>V$FOXO4_01</TD><TD>MSigDB lists</TD><TD>V$FOXO4_01</TD><TD>225</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>CSMD3,FGF9,ETV1</TD></TR>
<TR><TD>1.927e-02</TD><TD>-3.95</TD><TD>V$POU1F1_Q6</TD><TD>MSigDB lists</TD><TD>V$POU1F1_Q6</TD><TD>225</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>FGF9,ZIC2,PDLIM5</TD></TR>
<TR><TD>1.937e-02</TD><TD>-3.94</TD><TD>response to endogenous stimulus</TD><TD>biological process</TD><TD>GO:0009719</TD><TD>1545</TD><TD>9</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2,CAMK2D,FGF9,MSX1,PPARG,NR2F2,CD44,PDE3A,NR2F1</TD></TR>
<TR><TD>1.938e-02</TD><TD>-3.94</TD><TD>regulation of BMP signaling pathway</TD><TD>biological process</TD><TD>GO:0030510</TD><TD>80</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2,MSX1</TD></TR>
<TR><TD>1.941e-02</TD><TD>-3.94</TD><TD>metal ion binding</TD><TD>molecular function</TD><TD>GO:0046872</TD><TD>4013</TD><TD>17</TD><TD>16491</TD><TD>43</TD>
<TD>PPARG,VSNL1,CLSTN2,RNF43,ZIC2,PDE3A,NR2F1,RHOU,S100A10,PDE10A,TANK,UNC13A,NR2F2,PDLIM5,MMP16,PRPS1,NT5E</TD></TR>
<TR><TD>1.946e-02</TD><TD>-3.94</TD><TD>BLALOCK_ALZHEIMERS_DISEASE_UP</TD><TD>MSigDB lists</TD><TD>BLALOCK_ALZHEIMERS_DISEASE_UP</TD><TD>1631</TD><TD>9</TD><TD>17758</TD><TD>45</TD>
<TD>LAMA4,MSX1,NEBL,SLK,CD44,ITGB4,MMP16,NR2F1,PDE3A</TD></TR>
<TR><TD>1.948e-02</TD><TD>-3.94</TD><TD>MYOD1 (myogenic differentiation 1)</TD><TD>protein interactions</TD><TD>4654</TD><TD>84</TD><TD>2</TD><TD>16036</TD><TD>41</TD>
<TD>PBX1,NR2F2</TD></TR>
<TR><TD>1.949e-02</TD><TD>-3.94</TD><TD>MODULE_60</TD><TD>MSigDB lists</TD><TD>MODULE_60</TD><TD>408</TD><TD>4</TD><TD>17758</TD><TD>45</TD>
<TD>PBX1,ZIC2,ITGB4,PDLIM5</TD></TR>
<TR><TD>1.950e-02</TD><TD>-3.94</TD><TD>MORF_IL13</TD><TD>MSigDB lists</TD><TD>MORF_IL13</TD><TD>226</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>TNIK,MSX1,NR2F1</TD></TR>
<TR><TD>1.952e-02</TD><TD>-3.94</TD><TD>biological adhesion</TD><TD>biological process</TD><TD>GO:0022610</TD><TD>1040</TD><TD>7</TD><TD>16441</TD><TD>44</TD>
<TD>EFNB2,CLSTN2,LAMA4,ITGB4,CD44,CNTNAP3,NT5E</TD></TR>
<TR><TD>1.962e-02</TD><TD>-3.93</TD><TD>LIU_VAV3_PROSTATE_CARCINOGENESIS_UP</TD><TD>MSigDB lists</TD><TD>LIU_VAV3_PROSTATE_CARCINOGENESIS_UP</TD><TD>85</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>KRT7,PPARG</TD></TR>
<TR><TD>1.962e-02</TD><TD>-3.93</TD><TD>SCHLESINGER_METHYLATED_DE_NOVO_IN_CANCER</TD><TD>MSigDB lists</TD><TD>SCHLESINGER_METHYLATED_DE_NOVO_IN_CANCER</TD><TD>85</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>CD44,NR2F2</TD></TR>
<TR><TD>1.962e-02</TD><TD>-3.93</TD><TD>KMCATNNWGGA_UNKNOWN</TD><TD>MSigDB lists</TD><TD>KMCATNNWGGA_UNKNOWN</TD><TD>85</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>NR2F2,NR2F1</TD></TR>
<TR><TD>1.962e-02</TD><TD>-3.93</TD><TD>chr1q23</TD><TD>MSigDB lists</TD><TD>chr1q23</TD><TD>85</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>PBX1,C1orf226</TD></TR>
<TR><TD>1.962e-02</TD><TD>-3.93</TD><TD>whole membrane</TD><TD>cellular component</TD><TD>GO:0098805</TD><TD>1942</TD><TD>10</TD><TD>17570</TD><TD>44</TD>
<TD>TNIK,SLC40A1,CAMK2D,S100A10,UNC13A,CLSTN2,ITGB4,CD44,PDLIM5,NT5E</TD></TR>
<TR><TD>1.976e-02</TD><TD>-3.92</TD><TD>purine nucleotides degradation II (aerobic)</TD><TD>BIOCYC pathways</TD><TD>META_PWY-6353</TD><TD>9</TD><TD>1</TD><TD>907</TD><TD>2</TD>
<TD>NT5E</TD></TR>
<TR><TD>1.976e-02</TD><TD>-3.92</TD><TD>purine nucleotides degradation</TD><TD>BIOCYC pathways</TD><TD>HUMAN_PWY-6353</TD><TD>9</TD><TD>1</TD><TD>907</TD><TD>2</TD>
<TD>NT5E</TD></TR>
<TR><TD>1.978e-02</TD><TD>-3.92</TD><TD>skin-extremity-malignant_melanoma</TD><TD>COSMIC cancer mutations</TD><TD>skin-extremity-malignant_melanoma</TD><TD>1967</TD><TD>10</TD><TD>17775</TD><TD>44</TD>
<TD>NEBL,HFM1,AHNAK2,CLSTN2,CSMD3,RNF43,SORCS2,ETV1,ANGPTL4,PDE3A</TD></TR>
<TR><TD>1.984e-02</TD><TD>-3.92</TD><TD>midbrain development</TD><TD>biological process</TD><TD>GO:0030901</TD><TD>81</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>FGF9,MSX1</TD></TR>
<TR><TD>1.984e-02</TD><TD>-3.92</TD><TD>extremity</TD><TD>COSMIC cancer mutations</TD><TD>extremity</TD><TD>1968</TD><TD>10</TD><TD>17775</TD><TD>44</TD>
<TD>NEBL,HFM1,AHNAK2,CLSTN2,CSMD3,RNF43,SORCS2,ETV1,ANGPTL4,PDE3A</TD></TR>
<TR><TD>1.992e-02</TD><TD>-3.92</TD><TD>SERPINH1 (serpin peptidase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1))</TD><TD>protein interactions</TD><TD>871</TD><TD>85</TD><TD>2</TD><TD>16036</TD><TD>41</TD>
<TD>VIM,PPARG</TD></TR>
<TR><TD>1.994e-02</TD><TD>-3.91</TD><TD>Ephrin</TD><TD>interpro domains</TD><TD>IPR031328</TD><TD>8</TD><TD>1</TD><TD>18293</TD><TD>46</TD>
<TD>EFNB2</TD></TR>
<TR><TD>1.994e-02</TD><TD>-3.91</TD><TD>Ephrin_CS</TD><TD>interpro domains</TD><TD>IPR019765</TD><TD>8</TD><TD>1</TD><TD>18293</TD><TD>46</TD>
<TD>EFNB2</TD></TR>
<TR><TD>1.994e-02</TD><TD>-3.91</TD><TD>GAF_dom-like</TD><TD>interpro domains</TD><TD>IPR029016</TD><TD>8</TD><TD>1</TD><TD>18293</TD><TD>46</TD>
<TD>PDE10A</TD></TR>
<TR><TD>1.994e-02</TD><TD>-3.91</TD><TD>GAF</TD><TD>interpro domains</TD><TD>IPR003018</TD><TD>8</TD><TD>1</TD><TD>18293</TD><TD>46</TD>
<TD>PDE10A</TD></TR>
<TR><TD>1.994e-02</TD><TD>-3.91</TD><TD>Integrin_bsu_N</TD><TD>interpro domains</TD><TD>IPR002369</TD><TD>8</TD><TD>1</TD><TD>18293</TD><TD>46</TD>
<TD>ITGB4</TD></TR>
<TR><TD>1.994e-02</TD><TD>-3.91</TD><TD>Ephrin_RBD</TD><TD>interpro domains</TD><TD>IPR001799</TD><TD>8</TD><TD>1</TD><TD>18293</TD><TD>46</TD>
<TD>EFNB2</TD></TR>
<TR><TD>1.995e-02</TD><TD>-3.91</TD><TD>V$FOXO1_02</TD><TD>MSigDB lists</TD><TD>V$FOXO1_02</TD><TD>228</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>FGF9,ETV1,NR2F1</TD></TR>
<TR><TD>1.995e-02</TD><TD>-3.91</TD><TD>V$POU6F1_01</TD><TD>MSigDB lists</TD><TD>V$POU6F1_01</TD><TD>228</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>CAMK2D,ETV1,NR2F1</TD></TR>
<TR><TD>1.995e-02</TD><TD>-3.91</TD><TD>V$ZF5_01</TD><TD>MSigDB lists</TD><TD>V$ZF5_01</TD><TD>228</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>EFNB2,ZIC2,NR2F2</TD></TR>
<TR><TD>1.995e-02</TD><TD>-3.91</TD><TD>V$NFKAPPAB65_01</TD><TD>MSigDB lists</TD><TD>V$NFKAPPAB65_01</TD><TD>228</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>RNF43,MSX1,NR2F2</TD></TR>
<TR><TD>2.005e-02</TD><TD>-3.91</TD><TD>negative regulation of cell differentiation</TD><TD>biological process</TD><TD>GO:0045596</TD><TD>590</TD><TD>5</TD><TD>16441</TD><TD>44</TD>
<TD>PBX1,MSX2,VIM,MSX1,PPARG</TD></TR>
<TR><TD>2.006e-02</TD><TD>-3.91</TD><TD>KYNG_DNA_DAMAGE_BY_GAMMA_AND_UV_RADIATION</TD><TD>MSigDB lists</TD><TD>KYNG_DNA_DAMAGE_BY_GAMMA_AND_UV_RADIATION</TD><TD>86</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>PBX1,MSX2</TD></TR>
<TR><TD>2.006e-02</TD><TD>-3.91</TD><TD>GGCCAGT,MIR-193A,MIR-193B</TD><TD>MSigDB lists</TD><TD>GGCCAGT,MIR-193A,MIR-193B</TD><TD>86</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>ETV1,MMP16</TD></TR>
<TR><TD>2.010e-02</TD><TD>-3.91</TD><TD>chr6q26</TD><TD>MSigDB lists</TD><TD>chr6q26</TD><TD>8</TD><TD>1</TD><TD>17758</TD><TD>45</TD>
<TD>PDE10A</TD></TR>
<TR><TD>2.010e-02</TD><TD>-3.91</TD><TD>RANKIN_ANGIOGENIC_TARGETS_OF_VHL_HIF2A_DN</TD><TD>MSigDB lists</TD><TD>RANKIN_ANGIOGENIC_TARGETS_OF_VHL_HIF2A_DN</TD><TD>8</TD><TD>1</TD><TD>17758</TD><TD>45</TD>
<TD>NR2F2</TD></TR>
<TR><TD>2.010e-02</TD><TD>-3.91</TD><TD>MILICIC_FAMILIAL_ADENOMATOUS_POLYPOSIS_UP</TD><TD>MSigDB lists</TD><TD>MILICIC_FAMILIAL_ADENOMATOUS_POLYPOSIS_UP</TD><TD>8</TD><TD>1</TD><TD>17758</TD><TD>45</TD>
<TD>MSX2</TD></TR>
<TR><TD>2.010e-02</TD><TD>-3.91</TD><TD>MIKKELSEN_PLURIPOTENT_STATE_DN</TD><TD>MSigDB lists</TD><TD>MIKKELSEN_PLURIPOTENT_STATE_DN</TD><TD>8</TD><TD>1</TD><TD>17758</TD><TD>45</TD>
<TD>CAMK2D</TD></TR>
<TR><TD>2.010e-02</TD><TD>-3.91</TD><TD>MYLLYKANGAS_AMPLIFICATION_HOT_SPOT_29</TD><TD>MSigDB lists</TD><TD>MYLLYKANGAS_AMPLIFICATION_HOT_SPOT_29</TD><TD>8</TD><TD>1</TD><TD>17758</TD><TD>45</TD>
<TD>ETV1</TD></TR>
<TR><TD>2.010e-02</TD><TD>-3.91</TD><TD>SCHMIDT_POR_TARGETS_IN_LIMB_BUD_DN</TD><TD>MSigDB lists</TD><TD>SCHMIDT_POR_TARGETS_IN_LIMB_BUD_DN</TD><TD>8</TD><TD>1</TD><TD>17758</TD><TD>45</TD>
<TD>MSX2</TD></TR>
<TR><TD>2.018e-02</TD><TD>-3.90</TD><TD>TAGCTTT,MIR-9</TD><TD>MSigDB lists</TD><TD>TAGCTTT,MIR-9</TD><TD>229</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>ZIC2,NR2F2,MMP16</TD></TR>
<TR><TD>2.019e-02</TD><TD>-3.90</TD><TD>regulation of synapse structure or activity</TD><TD>biological process</TD><TD>GO:0050803</TD><TD>217</TD><TD>3</TD><TD>16441</TD><TD>44</TD>
<TD>CLSTN2,PDLIM5,UNC13A</TD></TR>
<TR><TD>2.028e-02</TD><TD>-3.90</TD><TD>MTMR1 (myotubularin related protein 1)</TD><TD>protein interactions</TD><TD>8776</TD><TD>8</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>EFNB2</TD></TR>
<TR><TD>2.028e-02</TD><TD>-3.90</TD><TD>KIAA0391 (KIAA0391)</TD><TD>protein interactions</TD><TD>9692</TD><TD>8</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>EFNB2</TD></TR>
<TR><TD>2.028e-02</TD><TD>-3.90</TD><TD>METTL6 (methyltransferase like 6)</TD><TD>protein interactions</TD><TD>131965</TD><TD>8</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>PDLIM5</TD></TR>
<TR><TD>2.028e-02</TD><TD>-3.90</TD><TD>DENND6A (DENN/MADD domain containing 6A)</TD><TD>protein interactions</TD><TD>201627</TD><TD>8</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>EFNB2</TD></TR>
<TR><TD>2.028e-02</TD><TD>-3.90</TD><TD>TMEM65 (transmembrane protein 65)</TD><TD>protein interactions</TD><TD>157378</TD><TD>8</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>S100A10</TD></TR>
<TR><TD>2.028e-02</TD><TD>-3.90</TD><TD>SLC47A1 (solute carrier family 47 (multidrug and toxin extrusion), member 1)</TD><TD>protein interactions</TD><TD>55244</TD><TD>8</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>NT5E</TD></TR>
<TR><TD>2.028e-02</TD><TD>-3.90</TD><TD>PLEKHH3 (pleckstrin homology domain containing, family H (with MyTH4 domain) member 3)</TD><TD>protein interactions</TD><TD>79990</TD><TD>8</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>EFNB2</TD></TR>
<TR><TD>2.028e-02</TD><TD>-3.90</TD><TD>JSRP1 (junctional sarcoplasmic reticulum protein 1)</TD><TD>protein interactions</TD><TD>126306</TD><TD>8</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>AHNAK2</TD></TR>
<TR><TD>2.028e-02</TD><TD>-3.90</TD><TD>SLC44A1 (solute carrier family 44 (choline transporter), member 1)</TD><TD>protein interactions</TD><TD>23446</TD><TD>8</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>NT5E</TD></TR>
<TR><TD>2.028e-02</TD><TD>-3.90</TD><TD>PLEKHG4 (pleckstrin homology domain containing, family G (with RhoGef domain) member 4)</TD><TD>protein interactions</TD><TD>25894</TD><TD>8</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>EFNB2</TD></TR>
<TR><TD>2.028e-02</TD><TD>-3.90</TD><TD>FNDC3B (fibronectin type III domain containing 3B)</TD><TD>protein interactions</TD><TD>64778</TD><TD>8</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>CAMK2D</TD></TR>
<TR><TD>2.028e-02</TD><TD>-3.90</TD><TD>ARL8A (ADP-ribosylation factor like GTPase 8A)</TD><TD>protein interactions</TD><TD>127829</TD><TD>8</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>NT5E</TD></TR>
<TR><TD>2.028e-02</TD><TD>-3.90</TD><TD>SH3YL1 (SH3 and SYLF domain containing 1)</TD><TD>protein interactions</TD><TD>26751</TD><TD>8</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>VIM</TD></TR>
<TR><TD>2.028e-02</TD><TD>-3.90</TD><TD>HSDL1 (hydroxysteroid dehydrogenase like 1)</TD><TD>protein interactions</TD><TD>83693</TD><TD>8</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>NT5E</TD></TR>
<TR><TD>2.030e-02</TD><TD>-3.90</TD><TD>renal tubule development</TD><TD>biological process</TD><TD>GO:0061326</TD><TD>82</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>PBX1,CD44</TD></TR>
<TR><TD>2.030e-02</TD><TD>-3.90</TD><TD>receptor metabolic process</TD><TD>biological process</TD><TD>GO:0043112</TD><TD>82</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>RNF43,PPARG</TD></TR>
<TR><TD>2.033e-02</TD><TD>-3.90</TD><TD>VIM (vimentin)</TD><TD>protein interactions</TD><TD>7431</TD><TD>228</TD><TD>3</TD><TD>16036</TD><TD>41</TD>
<TD>VIM,CAMK2D,ITGB4</TD></TR>
<TR><TD>2.041e-02</TD><TD>-3.89</TD><TD>SENESE_HDAC1_TARGETS_DN</TD><TD>MSigDB lists</TD><TD>SENESE_HDAC1_TARGETS_DN</TD><TD>230</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>PBX1,KRT7,S100A10</TD></TR>
<TR><TD>2.041e-02</TD><TD>-3.89</TD><TD>STRUCTURAL_MOLECULE_ACTIVITY</TD><TD>MSigDB lists</TD><TD>STRUCTURAL_MOLECULE_ACTIVITY</TD><TD>230</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>LAMA4,VIM,NEBL</TD></TR>
<TR><TD>2.041e-02</TD><TD>-3.89</TD><TD>V$IRF_Q6</TD><TD>MSigDB lists</TD><TD>V$IRF_Q6</TD><TD>230</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>FGF9,SLC40A1,MSX1</TD></TR>
<TR><TD>2.044e-02</TD><TD>-3.89</TD><TD>skin development</TD><TD>biological process</TD><TD>GO:0043588</TD><TD>218</TD><TD>3</TD><TD>16441</TD><TD>44</TD>
<TD>WNT16,ITGB4,GRHL3</TD></TR>
<TR><TD>2.048e-02</TD><TD>-3.89</TD><TD>Homeobox_dom</TD><TD>interpro domains</TD><TD>IPR001356</TD><TD>232</TD><TD>3</TD><TD>18293</TD><TD>46</TD>
<TD>PBX1,MSX2,MSX1</TD></TR>
<TR><TD>2.057e-02</TD><TD>-3.88</TD><TD>ABCE1 (ATP binding cassette subfamily E member 1)</TD><TD>protein interactions</TD><TD>6059</TD><TD>229</TD><TD>3</TD><TD>16036</TD><TD>41</TD>
<TD>VIM,CD44,S100A10</TD></TR>
<TR><TD>2.064e-02</TD><TD>-3.88</TD><TD>WINTER_HYPOXIA_METAGENE</TD><TD>MSigDB lists</TD><TD>WINTER_HYPOXIA_METAGENE</TD><TD>231</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>VIM,ANGPTL4,NT5E</TD></TR>
<TR><TD>2.064e-02</TD><TD>-3.88</TD><TD>MASSARWEH_TAMOXIFEN_RESISTANCE_DN</TD><TD>MSigDB lists</TD><TD>MASSARWEH_TAMOXIFEN_RESISTANCE_DN</TD><TD>231</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>CD44,PKIB,C1orf226</TD></TR>
<TR><TD>2.067e-02</TD><TD>-3.88</TD><TD>cAMP-dependent protein kinase inhibitor activity</TD><TD>molecular function</TD><TD>GO:0004862</TD><TD>8</TD><TD>1</TD><TD>16491</TD><TD>43</TD>
<TD>PKIB</TD></TR>
<TR><TD>2.067e-02</TD><TD>-3.88</TD><TD>hyalurononglucosaminidase activity</TD><TD>molecular function</TD><TD>GO:0004415</TD><TD>8</TD><TD>1</TD><TD>16491</TD><TD>43</TD>
<TD>CD44</TD></TR>
<TR><TD>2.067e-02</TD><TD>-3.88</TD><TD>MAP kinase kinase kinase kinase activity</TD><TD>molecular function</TD><TD>GO:0008349</TD><TD>8</TD><TD>1</TD><TD>16491</TD><TD>43</TD>
<TD>TNIK</TD></TR>
<TR><TD>2.074e-02</TD><TD>-3.88</TD><TD>gland development</TD><TD>biological process</TD><TD>GO:0048732</TD><TD>394</TD><TD>4</TD><TD>16441</TD><TD>44</TD>
<TD>PBX1,MSX2,MSX1,CD44</TD></TR>
<TR><TD>2.076e-02</TD><TD>-3.87</TD><TD>human chr9p13.1</TD><TD>chromosome location</TD><TD>human chr9p13.1</TD><TD>11</TD><TD>1</TD><TD>26250</TD><TD>50</TD>
<TD>CNTNAP3</TD></TR>
<TR><TD>2.076e-02</TD><TD>-3.87</TD><TD>human chr12p12</TD><TD>chromosome location</TD><TD>human chr12p12</TD><TD>11</TD><TD>1</TD><TD>26250</TD><TD>50</TD>
<TD>PDE3A</TD></TR>
<TR><TD>2.076e-02</TD><TD>-3.87</TD><TD>human chr2q32</TD><TD>chromosome location</TD><TD>human chr2q32</TD><TD>11</TD><TD>1</TD><TD>26250</TD><TD>50</TD>
<TD>SLC40A1</TD></TR>
<TR><TD>2.077e-02</TD><TD>-3.87</TD><TD>regulation of striated muscle cell differentiation</TD><TD>biological process</TD><TD>GO:0051153</TD><TD>83</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>EFNB2,MSX1</TD></TR>
<TR><TD>2.080e-02</TD><TD>-3.87</TD><TD>TFAP4 (transcription factor AP-4 (activating enhancer binding protein 4))</TD><TD>protein interactions</TD><TD>7023</TD><TD>87</TD><TD>2</TD><TD>16036</TD><TD>41</TD>
<TD>NR2F2,NR2F1</TD></TR>
<TR><TD>2.082e-02</TD><TD>-3.87</TD><TD>-</TD><TD>gene3d domains</TD><TD>2.10.110.10</TD><TD>72</TD><TD>2</TD><TD>9988</TD><TD>31</TD>
<TD>NEBL,PDLIM5</TD></TR>
<TR><TD>2.085e-02</TD><TD>-3.87</TD><TD>positive regulation of MAPK cascade</TD><TD>biological process</TD><TD>GO:0043410</TD><TD>596</TD><TD>5</TD><TD>16441</TD><TD>44</TD>
<TD>TNIK,CAMK2D,FGF9,WNT16,CD44</TD></TR>
<TR><TD>2.090e-02</TD><TD>-3.87</TD><TD>soft_tissue-fibrous_tissue_and_uncertain_origin-synovial_sarcoma</TD><TD>COSMIC cancer mutations</TD><TD>soft_tissue-fibrous_tissue_and_uncertain_origin-synovial_sarcoma</TD><TD>90</TD><TD>2</TD><TD>17775</TD><TD>44</TD>
<TD>CAMK2D,PDE3A</TD></TR>
<TR><TD>2.093e-02</TD><TD>-3.87</TD><TD>GCANCTGNY_V$MYOD_Q6</TD><TD>MSigDB lists</TD><TD>GCANCTGNY_V$MYOD_Q6</TD><TD>863</TD><TD>6</TD><TD>17758</TD><TD>45</TD>
<TD>CSMD3,ITGB4,NEBL,NR2F2,ETV1,GRHL3</TD></TR>
<TR><TD>2.094e-02</TD><TD>-3.87</TD><TD>LEE_AGING_NEOCORTEX_UP</TD><TD>MSigDB lists</TD><TD>LEE_AGING_NEOCORTEX_UP</TD><TD>88</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>VIM,S100A10</TD></TR>
<TR><TD>2.094e-02</TD><TD>-3.87</TD><TD>HUMMERICH_SKIN_CANCER_PROGRESSION_UP</TD><TD>MSigDB lists</TD><TD>HUMMERICH_SKIN_CANCER_PROGRESSION_UP</TD><TD>88</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>ITGB4,CD44</TD></TR>
<TR><TD>2.094e-02</TD><TD>-3.87</TD><TD>WINTER_HYPOXIA_UP</TD><TD>MSigDB lists</TD><TD>WINTER_HYPOXIA_UP</TD><TD>88</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>S100A10,ANGPTL4</TD></TR>
<TR><TD>2.094e-02</TD><TD>-3.87</TD><TD>ELVIDGE_HIF1A_TARGETS_DN</TD><TD>MSigDB lists</TD><TD>ELVIDGE_HIF1A_TARGETS_DN</TD><TD>88</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>ANGPTL4,AHNAK2</TD></TR>
<TR><TD>2.098e-02</TD><TD>-3.86</TD><TD>regulation of intracellular signal transduction</TD><TD>biological process</TD><TD>GO:1902531</TD><TD>1566</TD><TD>9</TD><TD>16441</TD><TD>44</TD>
<TD>RHOU,TNIK,CAMK2D,FGF9,MSX1,PDE10A,GPAT3,WNT16,CD44</TD></TR>
<TR><TD>2.098e-02</TD><TD>-3.86</TD><TD>Ephrin</TD><TD>pfam domains</TD><TD>PF00812</TD><TD>8</TD><TD>1</TD><TD>16629</TD><TD>44</TD>
<TD>EFNB2</TD></TR>
<TR><TD>2.098e-02</TD><TD>-3.86</TD><TD>Integrin_beta</TD><TD>pfam domains</TD><TD>PF00362</TD><TD>8</TD><TD>1</TD><TD>16629</TD><TD>44</TD>
<TD>ITGB4</TD></TR>
<TR><TD>2.107e-02</TD><TD>-3.86</TD><TD>lung-middle_lobe-carcinoma-adenocarcinoma</TD><TD>COSMIC cancer mutations</TD><TD>lung-middle_lobe-carcinoma-adenocarcinoma</TD><TD>1412</TD><TD>8</TD><TD>17775</TD><TD>44</TD>
<TD>PDE10A,STXBP6,HFM1,UNC13A,GRHL3,CSMD3,SLCO5A1,VIM</TD></TR>
<TR><TD>2.109e-02</TD><TD>-3.86</TD><TD>Homeobox_metazoa</TD><TD>interpro domains</TD><TD>IPR020479</TD><TD>89</TD><TD>2</TD><TD>18293</TD><TD>46</TD>
<TD>MSX2,MSX1</TD></TR>
<TR><TD>2.111e-02</TD><TD>-3.86</TD><TD>V$CDC5_01</TD><TD>MSigDB lists</TD><TD>V$CDC5_01</TD><TD>233</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>PBX1,MSX1,PRPS1</TD></TR>
<TR><TD>2.114e-02</TD><TD>-3.86</TD><TD>single-organism process</TD><TD>biological process</TD><TD>GO:0044699</TD><TD>12803</TD><TD>40</TD><TD>16441</TD><TD>44</TD>
<TD>EFNB2,TNIK,CNTNAP3,STXBP6,SLK,HFM1,GPAT3,PBX1,RNF43,ZIC2,PDE3A,NEBL,S100A10,PDE10A,UNC13A,TANK,WNT16,CD44,ETV1,PRPS1,NT5E,LAMA4,FGF9,SLC40A1,MSX1,PPARG,GRHL3,VIM,ANGPTL4,NR2F1,RHOU,MSX2,CAMK2D,AHNAK2,SLCO5A1,ITGB4,SORCS2,NR2F2,PDLIM5,MMP16</TD></TR>
<TR><TD>2.115e-02</TD><TD>-3.86</TD><TD>FGFR3b ligand binding and activation</TD><TD>REACTOME pathways</TD><TD>R-HSA-190371</TD><TD>7</TD><TD>1</TD><TD>8202</TD><TD>25</TD>
<TD>FGF9</TD></TR>
<TR><TD>2.121e-02</TD><TD>-3.85</TD><TD>plasma membrane repair</TD><TD>biological process</TD><TD>GO:0001778</TD><TD>8</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>AHNAK2</TD></TR>
<TR><TD>2.121e-02</TD><TD>-3.85</TD><TD>synaptic vesicle docking</TD><TD>biological process</TD><TD>GO:0016081</TD><TD>8</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>UNC13A</TD></TR>
<TR><TD>2.121e-02</TD><TD>-3.85</TD><TD>regulation of SNARE complex assembly</TD><TD>biological process</TD><TD>GO:0035542</TD><TD>8</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>STXBP6</TD></TR>
<TR><TD>2.121e-02</TD><TD>-3.85</TD><TD>nucleoside monophosphate catabolic process</TD><TD>biological process</TD><TD>GO:0009125</TD><TD>8</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>NT5E</TD></TR>
<TR><TD>2.121e-02</TD><TD>-3.85</TD><TD>negative regulation of keratinocyte differentiation</TD><TD>biological process</TD><TD>GO:0045617</TD><TD>8</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2</TD></TR>
<TR><TD>2.121e-02</TD><TD>-3.85</TD><TD>regulation of nodal signaling pathway</TD><TD>biological process</TD><TD>GO:1900107</TD><TD>8</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>ZIC2</TD></TR>
<TR><TD>2.121e-02</TD><TD>-3.85</TD><TD>cellular response to hyperoxia</TD><TD>biological process</TD><TD>GO:0071455</TD><TD>8</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>PPARG</TD></TR>
<TR><TD>2.121e-02</TD><TD>-3.85</TD><TD>cellular response to increased oxygen levels</TD><TD>biological process</TD><TD>GO:0036295</TD><TD>8</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>PPARG</TD></TR>
<TR><TD>2.121e-02</TD><TD>-3.85</TD><TD>stress-induced premature senescence</TD><TD>biological process</TD><TD>GO:0090400</TD><TD>8</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>WNT16</TD></TR>
<TR><TD>2.121e-02</TD><TD>-3.85</TD><TD>adenosine metabolic process</TD><TD>biological process</TD><TD>GO:0046085</TD><TD>8</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>NT5E</TD></TR>
<TR><TD>2.121e-02</TD><TD>-3.85</TD><TD>optic cup morphogenesis involved in camera-type eye development</TD><TD>biological process</TD><TD>GO:0002072</TD><TD>8</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>WNT16</TD></TR>
<TR><TD>2.121e-02</TD><TD>-3.85</TD><TD>negative regulation of cAMP-dependent protein kinase activity</TD><TD>biological process</TD><TD>GO:2000480</TD><TD>8</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>PKIB</TD></TR>
<TR><TD>2.121e-02</TD><TD>-3.85</TD><TD>negative regulation of collagen metabolic process</TD><TD>biological process</TD><TD>GO:0010713</TD><TD>8</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>PPARG</TD></TR>
<TR><TD>2.121e-02</TD><TD>-3.85</TD><TD>exocyst localization</TD><TD>biological process</TD><TD>GO:0051601</TD><TD>8</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>STXBP6</TD></TR>
<TR><TD>2.121e-02</TD><TD>-3.85</TD><TD>activation of JNKK activity</TD><TD>biological process</TD><TD>GO:0007256</TD><TD>8</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>TNIK</TD></TR>
<TR><TD>2.121e-02</TD><TD>-3.85</TD><TD>bone trabecula formation</TD><TD>biological process</TD><TD>GO:0060346</TD><TD>8</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2</TD></TR>
<TR><TD>2.135e-02</TD><TD>-3.85</TD><TD>V$HNF1_01</TD><TD>MSigDB lists</TD><TD>V$HNF1_01</TD><TD>234</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>MSX2,ZIC2,NR2F1</TD></TR>
<TR><TD>2.139e-02</TD><TD>-3.85</TD><TD>soft_tissue</TD><TD>COSMIC cancer mutations</TD><TD>soft_tissue</TD><TD>6065</TD><TD>22</TD><TD>17775</TD><TD>44</TD>
<TD>CNTNAP3,PPARG,HFM1,GRHL3,CLSTN2,RNF43,VIM,ANGPTL4,NR2F1,PDE3A,CAMK2D,NEBL,PDE10A,UNC13A,CSMD3,SLCO5A1,CD44,NR2F2,SORCS2,PDLIM5,MMP16,NT5E</TD></TR>
<TR><TD>2.139e-02</TD><TD>-3.85</TD><TD>WNT_SIGNALING</TD><TD>MSigDB lists</TD><TD>WNT_SIGNALING</TD><TD>89</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>RHOU,WNT16</TD></TR>
<TR><TD>2.139e-02</TD><TD>-3.85</TD><TD>SHETH_LIVER_CANCER_VS_TXNIP_LOSS_PAM5</TD><TD>MSigDB lists</TD><TD>SHETH_LIVER_CANCER_VS_TXNIP_LOSS_PAM5</TD><TD>89</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>SORCS2,PKIB</TD></TR>
<TR><TD>2.139e-02</TD><TD>-3.85</TD><TD>HINATA_NFKB_TARGETS_KERATINOCYTE_UP</TD><TD>MSigDB lists</TD><TD>HINATA_NFKB_TARGETS_KERATINOCYTE_UP</TD><TD>89</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>VIM,KRT7</TD></TR>
<TR><TD>2.140e-02</TD><TD>-3.84</TD><TD>negative regulation of cellular macromolecule biosynthetic process</TD><TD>biological process</TD><TD>GO:2000113</TD><TD>1310</TD><TD>8</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2,FGF9,MSX1,PPARG,PBX1,ZIC2,NR2F2,NR2F1</TD></TR>
<TR><TD>2.145e-02</TD><TD>-3.84</TD><TD>pancreas-carcinoid-endocrine_tumour</TD><TD>COSMIC cancer mutations</TD><TD>pancreas-carcinoid-endocrine_tumour</TD><TD>7606</TD><TD>26</TD><TD>17775</TD><TD>44</TD>
<TD>EFNB2,LAMA4,FGF9,CNTNAP3,PPARG,STXBP6,HFM1,VSNL1,CLSTN2,RNF43,ANGPTL4,NR2F1,PDE3A,RHOU,CAMK2D,NEBL,UNC13A,SLCO5A1,CSMD3,WNT16,CD44,ITGB4,PDLIM5,MMP16,PKIB,NT5E</TD></TR>
<TR><TD>2.153e-02</TD><TD>-3.84</TD><TD>-</TD><TD>gene3d domains</TD><TD>3.30.450.40</TD><TD>7</TD><TD>1</TD><TD>9988</TD><TD>31</TD>
<TD>PDE10A</TD></TR>
<TR><TD>2.157e-02</TD><TD>-3.84</TD><TD>skin-scalp-malignant_melanoma</TD><TD>COSMIC cancer mutations</TD><TD>skin-scalp-malignant_melanoma</TD><TD>650</TD><TD>5</TD><TD>17775</TD><TD>44</TD>
<TD>LAMA4,NEBL,NR2F2,MMP16,PDE3A</TD></TR>
<TR><TD>2.159e-02</TD><TD>-3.84</TD><TD>V$ICSBP_Q6</TD><TD>MSigDB lists</TD><TD>V$ICSBP_Q6</TD><TD>235</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>FGF9,MSX1,ANGPTL4</TD></TR>
<TR><TD>2.159e-02</TD><TD>-3.84</TD><TD>V$GATA4_Q3</TD><TD>MSigDB lists</TD><TD>V$GATA4_Q3</TD><TD>235</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>SLCO5A1,WNT16,NR2F2</TD></TR>
<TR><TD>2.171e-02</TD><TD>-3.83</TD><TD>regulation of smooth muscle cell proliferation</TD><TD>biological process</TD><TD>GO:0048660</TD><TD>85</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>CAMK2D,PPARG</TD></TR>
<TR><TD>2.171e-02</TD><TD>-3.83</TD><TD>kidney morphogenesis</TD><TD>biological process</TD><TD>GO:0060993</TD><TD>85</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>PBX1,CD44</TD></TR>
<TR><TD>2.177e-02</TD><TD>-3.83</TD><TD>synovial_sarcoma</TD><TD>COSMIC cancer mutations</TD><TD>synovial_sarcoma</TD><TD>92</TD><TD>2</TD><TD>17775</TD><TD>44</TD>
<TD>CAMK2D,PDE3A</TD></TR>
<TR><TD>2.179e-02</TD><TD>-3.83</TD><TD>reproductive structure development</TD><TD>biological process</TD><TD>GO:0048608</TD><TD>400</TD><TD>4</TD><TD>16441</TD><TD>44</TD>
<TD>FGF9,CD44,NR2F2,PPARG</TD></TR>
<TR><TD>2.179e-02</TD><TD>-3.83</TD><TD>RTAAACA_V$FREAC2_01</TD><TD>MSigDB lists</TD><TD>RTAAACA_V$FREAC2_01</TD><TD>871</TD><TD>6</TD><TD>17758</TD><TD>45</TD>
<TD>PBX1,CSMD3,FGF9,NEBL,ETV1,MMP16</TD></TR>
<TR><TD>2.183e-02</TD><TD>-3.82</TD><TD>V$FOXM1_01</TD><TD>MSigDB lists</TD><TD>V$FOXM1_01</TD><TD>236</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>STXBP6,NR2F1,VSNL1</TD></TR>
<TR><TD>2.183e-02</TD><TD>-3.82</TD><TD>V$P300_01</TD><TD>MSigDB lists</TD><TD>V$P300_01</TD><TD>236</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>CSMD3,CAMK2D,NR2F1</TD></TR>
<TR><TD>2.183e-02</TD><TD>-3.82</TD><TD>V$PITX2_Q2</TD><TD>MSigDB lists</TD><TD>V$PITX2_Q2</TD><TD>236</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>PBX1,RNF43,MSX1</TD></TR>
<TR><TD>2.184e-02</TD><TD>-3.82</TD><TD>GAVIN_FOXP3_TARGETS_CLUSTER_T4</TD><TD>MSigDB lists</TD><TD>GAVIN_FOXP3_TARGETS_CLUSTER_T4</TD><TD>90</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>CD44,NT5E</TD></TR>
<TR><TD>2.186e-02</TD><TD>-3.82</TD><TD>negative regulation of apoptotic process</TD><TD>biological process</TD><TD>GO:0043066</TD><TD>826</TD><TD>6</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2,SLC40A1,MSX1,CD44,ANGPTL4,PDE3A</TD></TR>
<TR><TD>2.206e-02</TD><TD>-3.81</TD><TD>Sertoli-Leydig_cell_tumour</TD><TD>COSMIC cancer mutations</TD><TD>Sertoli-Leydig_cell_tumour</TD><TD>9</TD><TD>1</TD><TD>17775</TD><TD>44</TD>
<TD>RNF43</TD></TR>
<TR><TD>2.206e-02</TD><TD>-3.81</TD><TD>ovary-sex_cord-stromal_tumour-Sertoli-Leydig_cell_tumour</TD><TD>COSMIC cancer mutations</TD><TD>ovary-sex_cord-stromal_tumour-Sertoli-Leydig_cell_tumour</TD><TD>9</TD><TD>1</TD><TD>17775</TD><TD>44</TD>
<TD>RNF43</TD></TR>
<TR><TD>2.214e-02</TD><TD>-3.81</TD><TD>response to steroid hormone</TD><TD>biological process</TD><TD>GO:0048545</TD><TD>402</TD><TD>4</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2,NR2F2,PPARG,NR2F1</TD></TR>
<TR><TD>2.217e-02</TD><TD>-3.81</TD><TD>EPB41L3 (erythrocyte membrane protein band 4.1-like 3)</TD><TD>protein interactions</TD><TD>23136</TD><TD>90</TD><TD>2</TD><TD>16036</TD><TD>41</TD>
<TD>CD44,UNC13A</TD></TR>
<TR><TD>2.217e-02</TD><TD>-3.81</TD><TD>NCK1 (NCK adaptor protein 1)</TD><TD>protein interactions</TD><TD>4690</TD><TD>90</TD><TD>2</TD><TD>16036</TD><TD>41</TD>
<TD>RHOU,TNIK</TD></TR>
<TR><TD>2.221e-02</TD><TD>-3.81</TD><TD>regulation of protein kinase activity</TD><TD>biological process</TD><TD>GO:0045859</TD><TD>829</TD><TD>6</TD><TD>16441</TD><TD>44</TD>
<TD>TNIK,CAMK2D,FGF9,NR2F2,SLK,PKIB</TD></TR>
<TR><TD>2.222e-02</TD><TD>-3.81</TD><TD>middle_lobe</TD><TD>COSMIC cancer mutations</TD><TD>middle_lobe</TD><TD>1426</TD><TD>8</TD><TD>17775</TD><TD>44</TD>
<TD>STXBP6,PDE10A,HFM1,UNC13A,GRHL3,CSMD3,SLCO5A1,VIM</TD></TR>
<TR><TD>2.231e-02</TD><TD>-3.80</TD><TD>V$ISRE_01</TD><TD>MSigDB lists</TD><TD>V$ISRE_01</TD><TD>238</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>FGF9,MSX1,ANGPTL4</TD></TR>
<TR><TD>2.231e-02</TD><TD>-3.80</TD><TD>V$FREAC3_01</TD><TD>MSigDB lists</TD><TD>V$FREAC3_01</TD><TD>238</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>FGF9,ZIC2,ETV1</TD></TR>
<TR><TD>2.231e-02</TD><TD>-3.80</TD><TD>V$SRY_02</TD><TD>MSigDB lists</TD><TD>V$SRY_02</TD><TD>238</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>RNF43,FGF9,ZIC2</TD></TR>
<TR><TD>2.237e-02</TD><TD>-3.80</TD><TD>carbohydrate derivative binding</TD><TD>molecular function</TD><TD>GO:0097367</TD><TD>2195</TD><TD>11</TD><TD>16491</TD><TD>43</TD>
<TD>RHOU,TNIK,CAMK2D,FGF9,SLK,PDE10A,HFM1,VIM,CD44,PRPS1,PDE3A</TD></TR>
<TR><TD>2.241e-02</TD><TD>-3.80</TD><TD>PKD/Chitinase_dom</TD><TD>interpro domains</TD><TD>IPR022409</TD><TD>9</TD><TD>1</TD><TD>18293</TD><TD>46</TD>
<TD>SORCS2</TD></TR>
<TR><TD>2.241e-02</TD><TD>-3.80</TD><TD>Integrin_bsu</TD><TD>interpro domains</TD><TD>IPR015812</TD><TD>9</TD><TD>1</TD><TD>18293</TD><TD>46</TD>
<TD>ITGB4</TD></TR>
<TR><TD>2.241e-02</TD><TD>-3.80</TD><TD>Calx_beta</TD><TD>interpro domains</TD><TD>IPR003644</TD><TD>9</TD><TD>1</TD><TD>18293</TD><TD>46</TD>
<TD>ITGB4</TD></TR>
<TR><TD>2.245e-02</TD><TD>-3.80</TD><TD>transmembrane receptor protein serine/threonine kinase signaling pathway</TD><TD>biological process</TD><TD>GO:0007178</TD><TD>226</TD><TD>3</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2,VIM,MSX1</TD></TR>
<TR><TD>2.248e-02</TD><TD>-3.80</TD><TD>central_nervous_system-brain-primitive_neuroectodermal_tumour-medulloblastoma-large_cell</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-brain-primitive_neuroectodermal_tumour-medulloblastoma-large_cell</TD><TD>1157</TD><TD>7</TD><TD>17775</TD><TD>44</TD>
<TD>CLSTN2,CSMD3,SORCS2,CNTNAP3,UNC13A,GRHL3,C1orf226</TD></TR>
<TR><TD>2.250e-02</TD><TD>-3.79</TD><TD>reproductive system development</TD><TD>biological process</TD><TD>GO:0061458</TD><TD>404</TD><TD>4</TD><TD>16441</TD><TD>44</TD>
<TD>FGF9,CD44,NR2F2,PPARG</TD></TR>
<TR><TD>2.253e-02</TD><TD>-3.79</TD><TD>cervix-carcinoma-squamous_cell_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>cervix-carcinoma-squamous_cell_carcinoma</TD><TD>12377</TD><TD>37</TD><TD>17775</TD><TD>44</TD>
<TD>EFNB2,TNIK,CNTNAP3,HFM1,C1orf226,CLSTN2,RNF43,ZIC2,PDE3A,NEBL,PDE10A,UNC13A,TANK,WNT16,CD44,ETV1,NT5E,LAMA4,SLC40A1,FGF9,MSX1,KRT7,PPARG,GRHL3,VIM,NR2F1,RHOU,CAMK2D,AHNAK2,CSMD3,SLCO5A1,NR2F2,SORCS2,ITGB4,PDLIM5,MMP16,PKIB</TD></TR>
<TR><TD>2.253e-02</TD><TD>-3.79</TD><TD>phosphoric diester hydrolase activity</TD><TD>molecular function</TD><TD>GO:0008081</TD><TD>89</TD><TD>2</TD><TD>16491</TD><TD>43</TD>
<TD>PDE10A,PDE3A</TD></TR>
<TR><TD>2.256e-02</TD><TD>-3.79</TD><TD>AAAYWAACM_V$HFH4_01</TD><TD>MSigDB lists</TD><TD>AAAYWAACM_V$HFH4_01</TD><TD>239</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>PBX1,CSMD3,NR2F2</TD></TR>
<TR><TD>2.258e-02</TD><TD>-3.79</TD><TD>PEDERSEN_METASTASIS_BY_ERBB2_ISOFORM_5</TD><TD>MSigDB lists</TD><TD>PEDERSEN_METASTASIS_BY_ERBB2_ISOFORM_5</TD><TD>9</TD><TD>1</TD><TD>17758</TD><TD>45</TD>
<TD>S100A10</TD></TR>
<TR><TD>2.258e-02</TD><TD>-3.79</TD><TD>THILLAINADESAN_ZNF217_TARGETS_DN</TD><TD>MSigDB lists</TD><TD>THILLAINADESAN_ZNF217_TARGETS_DN</TD><TD>9</TD><TD>1</TD><TD>17758</TD><TD>45</TD>
<TD>EFNB2</TD></TR>
<TR><TD>2.258e-02</TD><TD>-3.79</TD><TD>SHIRAISHI_PLZF_TARGETS_DN</TD><TD>MSigDB lists</TD><TD>SHIRAISHI_PLZF_TARGETS_DN</TD><TD>9</TD><TD>1</TD><TD>17758</TD><TD>45</TD>
<TD>PBX1</TD></TR>
<TR><TD>2.258e-02</TD><TD>-3.79</TD><TD>XU_HGF_TARGETS_REPRESSED_BY_AKT1_UP</TD><TD>MSigDB lists</TD><TD>XU_HGF_TARGETS_REPRESSED_BY_AKT1_UP</TD><TD>9</TD><TD>1</TD><TD>17758</TD><TD>45</TD>
<TD>ANGPTL4</TD></TR>
<TR><TD>2.258e-02</TD><TD>-3.79</TD><TD>chr2p</TD><TD>MSigDB lists</TD><TD>chr2p</TD><TD>9</TD><TD>1</TD><TD>17758</TD><TD>45</TD>
<TD>VSNL1</TD></TR>
<TR><TD>2.258e-02</TD><TD>-3.79</TD><TD>OHASHI_AURKB_TARGETS</TD><TD>MSigDB lists</TD><TD>OHASHI_AURKB_TARGETS</TD><TD>9</TD><TD>1</TD><TD>17758</TD><TD>45</TD>
<TD>VIM</TD></TR>
<TR><TD>2.258e-02</TD><TD>-3.79</TD><TD>RAFFEL_VEGFA_TARGETS_UP</TD><TD>MSigDB lists</TD><TD>RAFFEL_VEGFA_TARGETS_UP</TD><TD>9</TD><TD>1</TD><TD>17758</TD><TD>45</TD>
<TD>PBX1</TD></TR>
<TR><TD>2.262e-02</TD><TD>-3.79</TD><TD>human chr15q26.2</TD><TD>chromosome location</TD><TD>human chr15q26.2</TD><TD>12</TD><TD>1</TD><TD>26250</TD><TD>50</TD>
<TD>NR2F2-AS1</TD></TR>
<TR><TD>2.262e-02</TD><TD>-3.79</TD><TD>human chr3q26.31</TD><TD>chromosome location</TD><TD>human chr3q26.31</TD><TD>12</TD><TD>1</TD><TD>26250</TD><TD>50</TD>
<TD>TNIK</TD></TR>
<TR><TD>2.262e-02</TD><TD>-3.79</TD><TD>human chr10q24.33</TD><TD>chromosome location</TD><TD>human chr10q24.33</TD><TD>12</TD><TD>1</TD><TD>26250</TD><TD>50</TD>
<TD>SLK</TD></TR>
<TR><TD>2.263e-02</TD><TD>-3.79</TD><TD>germ_cell_tumour</TD><TD>COSMIC cancer mutations</TD><TD>germ_cell_tumour</TD><TD>900</TD><TD>6</TD><TD>17775</TD><TD>44</TD>
<TD>CSMD3,LAMA4,RNF43,TNIK,CAMK2D,PDE10A</TD></TR>
<TR><TD>2.268e-02</TD><TD>-3.79</TD><TD>neural tube closure</TD><TD>biological process</TD><TD>GO:0001843</TD><TD>87</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>ZIC2,GRHL3</TD></TR>
<TR><TD>2.268e-02</TD><TD>-3.79</TD><TD>regulation of DNA binding</TD><TD>biological process</TD><TD>GO:0051101</TD><TD>87</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2,MSX1</TD></TR>
<TR><TD>2.270e-02</TD><TD>-3.79</TD><TD>cervix</TD><TD>COSMIC cancer mutations</TD><TD>cervix</TD><TD>12381</TD><TD>37</TD><TD>17775</TD><TD>44</TD>
<TD>EFNB2,TNIK,CNTNAP3,HFM1,C1orf226,CLSTN2,RNF43,ZIC2,PDE3A,NEBL,PDE10A,UNC13A,TANK,WNT16,CD44,ETV1,NT5E,LAMA4,SLC40A1,FGF9,MSX1,KRT7,PPARG,GRHL3,VIM,NR2F1,RHOU,CAMK2D,AHNAK2,CSMD3,SLCO5A1,NR2F2,SORCS2,ITGB4,PDLIM5,MMP16,PKIB</TD></TR>
<TR><TD>2.278e-02</TD><TD>-3.78</TD><TD>SLC7A2 (solute carrier family 7 (cationic amino acid transporter, y+ system), member 2)</TD><TD>protein interactions</TD><TD>6542</TD><TD>9</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>NT5E</TD></TR>
<TR><TD>2.278e-02</TD><TD>-3.78</TD><TD>FLVCR1 (feline leukemia virus subgroup C cellular receptor 1)</TD><TD>protein interactions</TD><TD>28982</TD><TD>9</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>NT5E</TD></TR>
<TR><TD>2.278e-02</TD><TD>-3.78</TD><TD>OSBP2 (oxysterol binding protein 2)</TD><TD>protein interactions</TD><TD>23762</TD><TD>9</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>VIM</TD></TR>
<TR><TD>2.278e-02</TD><TD>-3.78</TD><TD>DIS3L2 (DIS3 like 3'-5' exoribonuclease 2)</TD><TD>protein interactions</TD><TD>129563</TD><TD>9</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>VIM</TD></TR>
<TR><TD>2.278e-02</TD><TD>-3.78</TD><TD>KCNK3 (potassium channel, two pore domain subfamily K, member 3)</TD><TD>protein interactions</TD><TD>3777</TD><TD>9</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>S100A10</TD></TR>
<TR><TD>2.278e-02</TD><TD>-3.78</TD><TD>HOXD9 (homeobox D9)</TD><TD>protein interactions</TD><TD>3235</TD><TD>9</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>PBX1</TD></TR>
<TR><TD>2.278e-02</TD><TD>-3.78</TD><TD>ALOX12 (arachidonate 12-lipoxygenase)</TD><TD>protein interactions</TD><TD>239</TD><TD>9</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>ITGB4</TD></TR>
<TR><TD>2.278e-02</TD><TD>-3.78</TD><TD>EPHA5 (EPH receptor A5)</TD><TD>protein interactions</TD><TD>2044</TD><TD>9</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>EFNB2</TD></TR>
<TR><TD>2.278e-02</TD><TD>-3.78</TD><TD>LOR (loricrin)</TD><TD>protein interactions</TD><TD>4014</TD><TD>9</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>VIM</TD></TR>
<TR><TD>2.278e-02</TD><TD>-3.78</TD><TD>PPM1E (protein phosphatase, Mg2+/Mn2+ dependent, 1E)</TD><TD>protein interactions</TD><TD>22843</TD><TD>9</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>TNIK</TD></TR>
<TR><TD>2.278e-02</TD><TD>-3.78</TD><TD>PDZRN3 (PDZ domain containing ring finger 3)</TD><TD>protein interactions</TD><TD>23024</TD><TD>9</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>EFNB2</TD></TR>
<TR><TD>2.278e-02</TD><TD>-3.78</TD><TD>DNAL4 (dynein, axonemal, light chain 4)</TD><TD>protein interactions</TD><TD>10126</TD><TD>9</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>CAMK2D</TD></TR>
<TR><TD>2.278e-02</TD><TD>-3.78</TD><TD>TNP1 (transition protein 1 (during histone to protamine replacement))</TD><TD>protein interactions</TD><TD>7141</TD><TD>9</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>PPARG</TD></TR>
<TR><TD>2.278e-02</TD><TD>-3.78</TD><TD>IFNGR2 (interferon gamma receptor 2 (interferon gamma transducer 1))</TD><TD>protein interactions</TD><TD>3460</TD><TD>9</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>CAMK2D</TD></TR>
<TR><TD>2.278e-02</TD><TD>-3.78</TD><TD>EPHB4 (EPH receptor B4)</TD><TD>protein interactions</TD><TD>2050</TD><TD>9</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>EFNB2</TD></TR>
<TR><TD>2.280e-02</TD><TD>-3.78</TD><TD>cell junction</TD><TD>cellular component</TD><TD>GO:0030054</TD><TD>1147</TD><TD>7</TD><TD>17570</TD><TD>44</TD>
<TD>EFNB2,RHOU,VIM,ITGB4,CD44,PDLIM5,UNC13A</TD></TR>
<TR><TD>2.280e-02</TD><TD>-3.78</TD><TD>MODULE_123</TD><TD>MSigDB lists</TD><TD>MODULE_123</TD><TD>240</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>MSX1,PPARG,ETV1</TD></TR>
<TR><TD>2.292e-02</TD><TD>-3.78</TD><TD>negative regulation of programmed cell death</TD><TD>biological process</TD><TD>GO:0043069</TD><TD>835</TD><TD>6</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2,SLC40A1,MSX1,CD44,ANGPTL4,PDE3A</TD></TR>
<TR><TD>2.299e-02</TD><TD>-3.77</TD><TD>central_nervous_system-brainstem-glioma-astrocytoma_Grade_IV</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-brainstem-glioma-astrocytoma_Grade_IV</TD><TD>2630</TD><TD>12</TD><TD>17775</TD><TD>44</TD>
<TD>EFNB2,TNIK,CAMK2D,STXBP6,UNC13A,CLSTN2,CSMD3,SLCO5A1,VIM,PDLIM5,MMP16,PDE3A</TD></TR>
<TR><TD>2.305e-02</TD><TD>-3.77</TD><TD>V$TFIIA_Q6</TD><TD>MSigDB lists</TD><TD>V$TFIIA_Q6</TD><TD>241</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>ZIC2,PRPS1,NR2F1</TD></TR>
<TR><TD>2.305e-02</TD><TD>-3.77</TD><TD>BILD_HRAS_ONCOGENIC_SIGNATURE</TD><TD>MSigDB lists</TD><TD>BILD_HRAS_ONCOGENIC_SIGNATURE</TD><TD>241</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>ANGPTL4,NT5E,AHNAK2</TD></TR>
<TR><TD>2.313e-02</TD><TD>-3.77</TD><TD>CHARAFE_BREAST_CANCER_LUMINAL_VS_BASAL_DN</TD><TD>MSigDB lists</TD><TD>CHARAFE_BREAST_CANCER_LUMINAL_VS_BASAL_DN</TD><TD>430</TD><TD>4</TD><TD>17758</TD><TD>45</TD>
<TD>S100A10,CD44,VSNL1,NT5E</TD></TR>
<TR><TD>2.317e-02</TD><TD>-3.77</TD><TD>tube closure</TD><TD>biological process</TD><TD>GO:0060606</TD><TD>88</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>ZIC2,GRHL3</TD></TR>
<TR><TD>2.317e-02</TD><TD>-3.77</TD><TD>ureteric bud development</TD><TD>biological process</TD><TD>GO:0001657</TD><TD>88</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>PBX1,CD44</TD></TR>
<TR><TD>2.317e-02</TD><TD>-3.77</TD><TD>purine ribonucleoside biosynthetic process</TD><TD>biological process</TD><TD>GO:0046129</TD><TD>88</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>PRPS1,NT5E</TD></TR>
<TR><TD>2.317e-02</TD><TD>-3.77</TD><TD>purine nucleoside biosynthetic process</TD><TD>biological process</TD><TD>GO:0042451</TD><TD>88</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>PRPS1,NT5E</TD></TR>
<TR><TD>2.317e-02</TD><TD>-3.77</TD><TD>endothelium development</TD><TD>biological process</TD><TD>GO:0003158</TD><TD>88</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>SLC40A1,NR2F2</TD></TR>
<TR><TD>2.321e-02</TD><TD>-3.76</TD><TD>ATGGYGGA_UNKNOWN</TD><TD>MSigDB lists</TD><TD>ATGGYGGA_UNKNOWN</TD><TD>93</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>PBX1,PRPS1</TD></TR>
<TR><TD>2.321e-02</TD><TD>-3.76</TD><TD>RICKMAN_HEAD_AND_NECK_CANCER_A</TD><TD>MSigDB lists</TD><TD>RICKMAN_HEAD_AND_NECK_CANCER_A</TD><TD>93</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>ZIC2,STXBP6</TD></TR>
<TR><TD>2.323e-02</TD><TD>-3.76</TD><TD>filamin binding</TD><TD>molecular function</TD><TD>GO:0031005</TD><TD>9</TD><TD>1</TD><TD>16491</TD><TD>43</TD>
<TD>NEBL</TD></TR>
<TR><TD>2.323e-02</TD><TD>-3.76</TD><TD>prostaglandin receptor activity</TD><TD>molecular function</TD><TD>GO:0004955</TD><TD>9</TD><TD>1</TD><TD>16491</TD><TD>43</TD>
<TD>PPARG</TD></TR>
<TR><TD>2.324e-02</TD><TD>-3.76</TD><TD>PRKACA (protein kinase, cAMP-dependent, catalytic, alpha)</TD><TD>protein interactions</TD><TD>5566</TD><TD>240</TD><TD>3</TD><TD>16036</TD><TD>41</TD>
<TD>VIM,ETV1,PDE3A</TD></TR>
<TR><TD>2.325e-02</TD><TD>-3.76</TD><TD>Platelet homeostasis</TD><TD>REACTOME pathways</TD><TD>R-HSA-418346</TD><TD>78</TD><TD>2</TD><TD>8202</TD><TD>25</TD>
<TD>PDE10A,PDE3A</TD></TR>
<TR><TD>2.330e-02</TD><TD>-3.76</TD><TD>V$SF1_Q6</TD><TD>MSigDB lists</TD><TD>V$SF1_Q6</TD><TD>242</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>FGF9,NEBL,VSNL1</TD></TR>
<TR><TD>2.330e-02</TD><TD>-3.76</TD><TD>V$PAX4_03</TD><TD>MSigDB lists</TD><TD>V$PAX4_03</TD><TD>242</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>PBX1,ZIC2,NR2F1</TD></TR>
<TR><TD>2.330e-02</TD><TD>-3.76</TD><TD>KOBAYASHI_EGFR_SIGNALING_24HR_DN</TD><TD>MSigDB lists</TD><TD>KOBAYASHI_EGFR_SIGNALING_24HR_DN</TD><TD>242</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>ETV1,PRPS1,NT5E</TD></TR>
<TR><TD>2.330e-02</TD><TD>-3.76</TD><TD>V$DR1_Q3</TD><TD>MSigDB lists</TD><TD>V$DR1_Q3</TD><TD>242</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>FGF9,NR2F2,NR2F1</TD></TR>
<TR><TD>2.330e-02</TD><TD>-3.76</TD><TD>V$NFKAPPAB_01</TD><TD>MSigDB lists</TD><TD>V$NFKAPPAB_01</TD><TD>242</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>MSX1,ITGB4,NR2F2</TD></TR>
<TR><TD>2.337e-02</TD><TD>-3.76</TD><TD>MHD1</TD><TD>prosite domains</TD><TD>PS51258</TD><TD>7</TD><TD>1</TD><TD>11866</TD><TD>40</TD>
<TD>UNC13A</TD></TR>
<TR><TD>2.337e-02</TD><TD>-3.76</TD><TD>MARTINEZ_RB1_TARGETS_UP</TD><TD>MSigDB lists</TD><TD>MARTINEZ_RB1_TARGETS_UP</TD><TD>648</TD><TD>5</TD><TD>17758</TD><TD>45</TD>
<TD>CD44,S100A10,PDLIM5,PDE3A,NT5E</TD></TR>
<TR><TD>2.355e-02</TD><TD>-3.75</TD><TD>V$TST1_01</TD><TD>MSigDB lists</TD><TD>V$TST1_01</TD><TD>243</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>LAMA4,CSMD3,NR2F2</TD></TR>
<TR><TD>2.357e-02</TD><TD>-3.75</TD><TD>Calx-beta</TD><TD>pfam domains</TD><TD>PF03160</TD><TD>9</TD><TD>1</TD><TD>16629</TD><TD>44</TD>
<TD>ITGB4</TD></TR>
<TR><TD>2.357e-02</TD><TD>-3.75</TD><TD>Synaptobrevin</TD><TD>pfam domains</TD><TD>PF00957</TD><TD>9</TD><TD>1</TD><TD>16629</TD><TD>44</TD>
<TD>STXBP6</TD></TR>
<TR><TD>2.359e-02</TD><TD>-3.75</TD><TD>regulation of protein phosphorylation</TD><TD>biological process</TD><TD>GO:0001932</TD><TD>1334</TD><TD>8</TD><TD>16441</TD><TD>44</TD>
<TD>TNIK,CAMK2D,FGF9,SLK,WNT16,NR2F2,CD44,PKIB</TD></TR>
<TR><TD>2.366e-02</TD><TD>-3.74</TD><TD>response to BMP</TD><TD>biological process</TD><TD>GO:0071772</TD><TD>89</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2,MSX1</TD></TR>
<TR><TD>2.366e-02</TD><TD>-3.74</TD><TD>cellular response to BMP stimulus</TD><TD>biological process</TD><TD>GO:0071773</TD><TD>89</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2,MSX1</TD></TR>
<TR><TD>2.366e-02</TD><TD>-3.74</TD><TD>mesonephric epithelium development</TD><TD>biological process</TD><TD>GO:0072163</TD><TD>89</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>PBX1,CD44</TD></TR>
<TR><TD>2.366e-02</TD><TD>-3.74</TD><TD>mesonephric tubule development</TD><TD>biological process</TD><TD>GO:0072164</TD><TD>89</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>PBX1,CD44</TD></TR>
<TR><TD>2.367e-02</TD><TD>-3.74</TD><TD>pulmonary_blastoma</TD><TD>COSMIC cancer mutations</TD><TD>pulmonary_blastoma</TD><TD>666</TD><TD>5</TD><TD>17775</TD><TD>44</TD>
<TD>CSMD3,LAMA4,WNT16,ITGB4,NEBL</TD></TR>
<TR><TD>2.367e-02</TD><TD>-3.74</TD><TD>pleura-pulmonary_blastoma</TD><TD>COSMIC cancer mutations</TD><TD>pleura-pulmonary_blastoma</TD><TD>666</TD><TD>5</TD><TD>17775</TD><TD>44</TD>
<TD>CSMD3,LAMA4,WNT16,ITGB4,NEBL</TD></TR>
<TR><TD>2.368e-02</TD><TD>-3.74</TD><TD>GAVIN_FOXP3_TARGETS_CLUSTER_T7</TD><TD>MSigDB lists</TD><TD>GAVIN_FOXP3_TARGETS_CLUSTER_T7</TD><TD>94</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>VIM,PRPS1</TD></TR>
<TR><TD>2.380e-02</TD><TD>-3.74</TD><TD>V$TEF_Q6</TD><TD>MSigDB lists</TD><TD>V$TEF_Q6</TD><TD>244</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>PBX1,FGF9,ZIC2</TD></TR>
<TR><TD>2.384e-02</TD><TD>-3.74</TD><TD>cGMP-mediated signaling</TD><TD>biological process</TD><TD>GO:0019934</TD><TD>9</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>PDE3A</TD></TR>
<TR><TD>2.384e-02</TD><TD>-3.74</TD><TD>multicellular organismal iron ion homeostasis</TD><TD>biological process</TD><TD>GO:0060586</TD><TD>9</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>SLC40A1</TD></TR>
<TR><TD>2.384e-02</TD><TD>-3.74</TD><TD>diet induced thermogenesis</TD><TD>biological process</TD><TD>GO:0002024</TD><TD>9</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>PPARG</TD></TR>
<TR><TD>2.384e-02</TD><TD>-3.74</TD><TD>regulation of oocyte development</TD><TD>biological process</TD><TD>GO:0060281</TD><TD>9</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>PDE3A</TD></TR>
<TR><TD>2.384e-02</TD><TD>-3.74</TD><TD>negative regulation of multicellular organismal metabolic process</TD><TD>biological process</TD><TD>GO:0044252</TD><TD>9</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>PPARG</TD></TR>
<TR><TD>2.384e-02</TD><TD>-3.74</TD><TD>regulation of cell communication by electrical coupling involved in cardiac conduction</TD><TD>biological process</TD><TD>GO:1901844</TD><TD>9</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>CAMK2D</TD></TR>
<TR><TD>2.384e-02</TD><TD>-3.74</TD><TD>adaptive thermogenesis</TD><TD>biological process</TD><TD>GO:1990845</TD><TD>9</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>PPARG</TD></TR>
<TR><TD>2.384e-02</TD><TD>-3.74</TD><TD>regulation of relaxation of muscle</TD><TD>biological process</TD><TD>GO:1901077</TD><TD>9</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>CAMK2D</TD></TR>
<TR><TD>2.384e-02</TD><TD>-3.74</TD><TD>enamel mineralization</TD><TD>biological process</TD><TD>GO:0070166</TD><TD>9</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2</TD></TR>
<TR><TD>2.397e-02</TD><TD>-3.73</TD><TD>large_cell</TD><TD>COSMIC cancer mutations</TD><TD>large_cell</TD><TD>15622</TD><TD>43</TD><TD>17775</TD><TD>44</TD>
<TD>EFNB2,TNIK,CNTNAP3,STXBP6,HFM1,C1orf226,CLSTN2,PBX1,RNF43,ZIC2,PDE3A,S100A10,NEBL,PDE10A,UNC13A,TANK,WNT16,CD44,ETV1,PRPS1,NT5E,LAMA4,SLC40A1,FGF9,MSX1,KRT7,PPARG,VSNL1,GRHL3,VIM,ANGPTL4,NR2F1,RHOU,MSX2,CAMK2D,SLCO5A1,CSMD3,NR2F2,SORCS2,ITGB4,PDLIM5,MMP16,PKIB</TD></TR>
<TR><TD>2.398e-02</TD><TD>-3.73</TD><TD>adenoma</TD><TD>COSMIC cancer mutations</TD><TD>adenoma</TD><TD>2966</TD><TD>13</TD><TD>17775</TD><TD>44</TD>
<TD>LAMA4,RHOU,NEBL,HFM1,UNC13A,CLSTN2,CSMD3,RNF43,ANGPTL4,MMP16,PDE3A,NR2F1,NT5E</TD></TR>
<TR><TD>2.405e-02</TD><TD>-3.73</TD><TD>BROWNE_HCMV_INFECTION_4HR_DN</TD><TD>MSigDB lists</TD><TD>BROWNE_HCMV_INFECTION_4HR_DN</TD><TD>245</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>NEBL,NR2F2,ETV1</TD></TR>
<TR><TD>2.412e-02</TD><TD>-3.72</TD><TD>cation binding</TD><TD>molecular function</TD><TD>GO:0043169</TD><TD>4106</TD><TD>17</TD><TD>16491</TD><TD>43</TD>
<TD>PPARG,VSNL1,CLSTN2,RNF43,ZIC2,PDE3A,NR2F1,RHOU,S100A10,PDE10A,TANK,UNC13A,NR2F2,PDLIM5,MMP16,PRPS1,NT5E</TD></TR>
<TR><TD>2.414e-02</TD><TD>-3.72</TD><TD>RNF mutants show enhanced WNT signaling and proliferation</TD><TD>REACTOME pathways</TD><TD>R-HSA-5340588</TD><TD>8</TD><TD>1</TD><TD>8202</TD><TD>25</TD>
<TD>RNF43</TD></TR>
<TR><TD>2.415e-02</TD><TD>-3.72</TD><TD>HOMEOBOX_1</TD><TD>prosite domains</TD><TD>PS00027</TD><TD>185</TD><TD>3</TD><TD>11866</TD><TD>40</TD>
<TD>PBX1,MSX2,MSX1</TD></TR>
<TR><TD>2.415e-02</TD><TD>-3.72</TD><TD>CAHOY_NEURONAL</TD><TD>MSigDB lists</TD><TD>CAHOY_NEURONAL</TD><TD>95</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>CLSTN2,FGF9</TD></TR>
<TR><TD>2.416e-02</TD><TD>-3.72</TD><TD>signal transduction by protein phosphorylation</TD><TD>biological process</TD><TD>GO:0023014</TD><TD>413</TD><TD>4</TD><TD>16441</TD><TD>44</TD>
<TD>TNIK,CAMK2D,FGF9,SLK</TD></TR>
<TR><TD>2.418e-02</TD><TD>-3.72</TD><TD>HELLER_HDAC_TARGETS_SILENCED_BY_METHYLATION_UP</TD><TD>MSigDB lists</TD><TD>HELLER_HDAC_TARGETS_SILENCED_BY_METHYLATION_UP</TD><TD>436</TD><TD>4</TD><TD>17758</TD><TD>45</TD>
<TD>EFNB2,MSX1,PDLIM5,AHNAK2</TD></TR>
<TR><TD>2.418e-02</TD><TD>-3.72</TD><TD>CREIGHTON_ENDOCRINE_THERAPY_RESISTANCE_5</TD><TD>MSigDB lists</TD><TD>CREIGHTON_ENDOCRINE_THERAPY_RESISTANCE_5</TD><TD>436</TD><TD>4</TD><TD>17758</TD><TD>45</TD>
<TD>RHOU,EFNB2,PBX1,NEBL</TD></TR>
<TR><TD>2.425e-02</TD><TD>-3.72</TD><TD>regulation of cellular response to stress</TD><TD>biological process</TD><TD>GO:0080135</TD><TD>620</TD><TD>5</TD><TD>16441</TD><TD>44</TD>
<TD>TNIK,CAMK2D,WNT16,MSX1,CD44</TD></TR>
<TR><TD>2.431e-02</TD><TD>-3.72</TD><TD>V$OCT_Q6</TD><TD>MSigDB lists</TD><TD>V$OCT_Q6</TD><TD>246</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>ETV1,GRHL3,VSNL1</TD></TR>
<TR><TD>2.431e-02</TD><TD>-3.72</TD><TD>ONDER_CDH1_TARGETS_2_UP</TD><TD>MSigDB lists</TD><TD>ONDER_CDH1_TARGETS_2_UP</TD><TD>246</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>NEBL,PPARG,NR2F1</TD></TR>
<TR><TD>2.431e-02</TD><TD>-3.72</TD><TD>V$NRF2_Q4</TD><TD>MSigDB lists</TD><TD>V$NRF2_Q4</TD><TD>246</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>CSMD3,FGF9,CD44</TD></TR>
<TR><TD>2.441e-02</TD><TD>-3.71</TD><TD>LIM_DOMAIN_1</TD><TD>prosite domains</TD><TD>PS00478</TD><TD>72</TD><TD>2</TD><TD>11866</TD><TD>40</TD>
<TD>NEBL,PDLIM5</TD></TR>
<TR><TD>2.441e-02</TD><TD>-3.71</TD><TD>LIM_DOMAIN_2</TD><TD>prosite domains</TD><TD>PS50023</TD><TD>72</TD><TD>2</TD><TD>11866</TD><TD>40</TD>
<TD>NEBL,PDLIM5</TD></TR>
<TR><TD>2.449e-02</TD><TD>-3.71</TD><TD>ovary-germ_cell_tumour-mixed</TD><TD>COSMIC cancer mutations</TD><TD>ovary-germ_cell_tumour-mixed</TD><TD>10</TD><TD>1</TD><TD>17775</TD><TD>44</TD>
<TD>RNF43</TD></TR>
<TR><TD>2.449e-02</TD><TD>-3.71</TD><TD>human chr6q26</TD><TD>chromosome location</TD><TD>human chr6q26</TD><TD>13</TD><TD>1</TD><TD>26250</TD><TD>50</TD>
<TD>PDE10A</TD></TR>
<TR><TD>2.454e-02</TD><TD>-3.71</TD><TD>DELYS_THYROID_CANCER_UP</TD><TD>MSigDB lists</TD><TD>DELYS_THYROID_CANCER_UP</TD><TD>438</TD><TD>4</TD><TD>17758</TD><TD>45</TD>
<TD>CD44,S100A10,AHNAK2,NT5E</TD></TR>
<TR><TD>2.456e-02</TD><TD>-3.71</TD><TD>V$NFKB_Q6</TD><TD>MSigDB lists</TD><TD>V$NFKB_Q6</TD><TD>247</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>RNF43,NR2F2,TANK</TD></TR>
<TR><TD>2.456e-02</TD><TD>-3.71</TD><TD>V$GATA6_01</TD><TD>MSigDB lists</TD><TD>V$GATA6_01</TD><TD>247</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>NR2F2,NR2F1,VSNL1</TD></TR>
<TR><TD>2.456e-02</TD><TD>-3.71</TD><TD>V$HNF4_Q6</TD><TD>MSigDB lists</TD><TD>V$HNF4_Q6</TD><TD>247</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>ZIC2,ETV1,MMP16</TD></TR>
<TR><TD>2.463e-02</TD><TD>-3.70</TD><TD>CHAUHAN_RESPONSE_TO_METHOXYESTRADIOL_DN</TD><TD>MSigDB lists</TD><TD>CHAUHAN_RESPONSE_TO_METHOXYESTRADIOL_DN</TD><TD>96</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>VIM,S100A10</TD></TR>
<TR><TD>2.463e-02</TD><TD>-3.70</TD><TD>NAKAMURA_ADIPOGENESIS_LATE_UP</TD><TD>MSigDB lists</TD><TD>NAKAMURA_ADIPOGENESIS_LATE_UP</TD><TD>96</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>PPARG,PDE10A</TD></TR>
<TR><TD>2.472e-02</TD><TD>-3.70</TD><TD>transcription regulatory region sequence-specific DNA binding</TD><TD>molecular function</TD><TD>GO:0000976</TD><TD>640</TD><TD>5</TD><TD>16491</TD><TD>43</TD>
<TD>PBX1,MSX2,MSX1,PPARG,ETV1</TD></TR>
<TR><TD>2.479e-02</TD><TD>-3.70</TD><TD>cellular component organization</TD><TD>biological process</TD><TD>GO:0016043</TD><TD>5336</TD><TD>21</TD><TD>16441</TD><TD>44</TD>
<TD>EFNB2,LAMA4,TNIK,FGF9,MSX1,HFM1,VIM,ZIC2,ANGPTL4,RHOU,MSX2,CAMK2D,S100A10,NEBL,UNC13A,AHNAK2,WNT16,ITGB4,CD44,ETV1,MMP16</TD></TR>
<TR><TD>2.482e-02</TD><TD>-3.70</TD><TD>V$PPAR_DR1_Q2</TD><TD>MSigDB lists</TD><TD>V$PPAR_DR1_Q2</TD><TD>248</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>FGF9,NR2F2,NR2F1</TD></TR>
<TR><TD>2.491e-02</TD><TD>-3.69</TD><TD>MODULE_18</TD><TD>MSigDB lists</TD><TD>MODULE_18</TD><TD>440</TD><TD>4</TD><TD>17758</TD><TD>45</TD>
<TD>ZIC2,MSX1,CD44,VSNL1</TD></TR>
<TR><TD>2.501e-02</TD><TD>-3.69</TD><TD>lipid binding</TD><TD>molecular function</TD><TD>GO:0008289</TD><TD>642</TD><TD>5</TD><TD>16491</TD><TD>43</TD>
<TD>NR2F2,S100A10,PPARG,STXBP6,UNC13A</TD></TR>
<TR><TD>2.506e-02</TD><TD>-3.69</TD><TD>LOPEZ_MESOTHELIOMA_SURVIVAL_DN</TD><TD>MSigDB lists</TD><TD>LOPEZ_MESOTHELIOMA_SURVIVAL_DN</TD><TD>10</TD><TD>1</TD><TD>17758</TD><TD>45</TD>
<TD>TNIK</TD></TR>
<TR><TD>2.506e-02</TD><TD>-3.69</TD><TD>CAFFAREL_RESPONSE_TO_THC_8HR_3_DN</TD><TD>MSigDB lists</TD><TD>CAFFAREL_RESPONSE_TO_THC_8HR_3_DN</TD><TD>10</TD><TD>1</TD><TD>17758</TD><TD>45</TD>
<TD>PRPS1</TD></TR>
<TR><TD>2.506e-02</TD><TD>-3.69</TD><TD>POSITIVE_REGULATION_OF_ANGIOGENESIS</TD><TD>MSigDB lists</TD><TD>POSITIVE_REGULATION_OF_ANGIOGENESIS</TD><TD>10</TD><TD>1</TD><TD>17758</TD><TD>45</TD>
<TD>ANGPTL4</TD></TR>
<TR><TD>2.506e-02</TD><TD>-3.69</TD><TD>REACTOME_HYALURONAN_UPTAKE_AND_DEGRADATION</TD><TD>MSigDB lists</TD><TD>REACTOME_HYALURONAN_UPTAKE_AND_DEGRADATION</TD><TD>10</TD><TD>1</TD><TD>17758</TD><TD>45</TD>
<TD>CD44</TD></TR>
<TR><TD>2.506e-02</TD><TD>-3.69</TD><TD>TRANSITION_METAL_ION_TRANSMEMBRANE_TRANSPORTER_ACTIVITY</TD><TD>MSigDB lists</TD><TD>TRANSITION_METAL_ION_TRANSMEMBRANE_TRANSPORTER_ACTIVITY</TD><TD>10</TD><TD>1</TD><TD>17758</TD><TD>45</TD>
<TD>SLC40A1</TD></TR>
<TR><TD>2.506e-02</TD><TD>-3.69</TD><TD>REACTOME_PURINE_CATABOLISM</TD><TD>MSigDB lists</TD><TD>REACTOME_PURINE_CATABOLISM</TD><TD>10</TD><TD>1</TD><TD>17758</TD><TD>45</TD>
<TD>NT5E</TD></TR>
<TR><TD>2.506e-02</TD><TD>-3.69</TD><TD>HINATA_NFKB_MATRIX</TD><TD>MSigDB lists</TD><TD>HINATA_NFKB_MATRIX</TD><TD>10</TD><TD>1</TD><TD>17758</TD><TD>45</TD>
<TD>KRT7</TD></TR>
<TR><TD>2.508e-02</TD><TD>-3.69</TD><TD>JAEGER_METASTASIS_DN</TD><TD>MSigDB lists</TD><TD>JAEGER_METASTASIS_DN</TD><TD>249</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>ITGB4,NEBL,VSNL1</TD></TR>
<TR><TD>2.511e-02</TD><TD>-3.68</TD><TD>LIM_MAMMARY_LUMINAL_MATURE_DN</TD><TD>MSigDB lists</TD><TD>LIM_MAMMARY_LUMINAL_MATURE_DN</TD><TD>97</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>CAMK2D,VIM</TD></TR>
<TR><TD>2.514e-02</TD><TD>-3.68</TD><TD>localization of cell</TD><TD>biological process</TD><TD>GO:0051674</TD><TD>853</TD><TD>6</TD><TD>16441</TD><TD>44</TD>
<TD>EFNB2,MSX2,ITGB4,CD44,NR2F2,NR2F1</TD></TR>
<TR><TD>2.514e-02</TD><TD>-3.68</TD><TD>cell motility</TD><TD>biological process</TD><TD>GO:0048870</TD><TD>853</TD><TD>6</TD><TD>16441</TD><TD>44</TD>
<TD>EFNB2,MSX2,ITGB4,CD44,NR2F2,NR2F1</TD></TR>
<TR><TD>2.516e-02</TD><TD>-3.68</TD><TD>primary neural tube formation</TD><TD>biological process</TD><TD>GO:0014020</TD><TD>92</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>ZIC2,GRHL3</TD></TR>
<TR><TD>2.528e-02</TD><TD>-3.68</TD><TD>PDYN (prodynorphin)</TD><TD>protein interactions</TD><TD>5173</TD><TD>10</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>S100A10</TD></TR>
<TR><TD>2.528e-02</TD><TD>-3.68</TD><TD>GLI2 (GLI family zinc finger 2)</TD><TD>protein interactions</TD><TD>2736</TD><TD>10</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>ZIC2</TD></TR>
<TR><TD>2.528e-02</TD><TD>-3.68</TD><TD>TIAM2 (T-cell lymphoma invasion and metastasis 2)</TD><TD>protein interactions</TD><TD>26230</TD><TD>10</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>TNIK</TD></TR>
<TR><TD>2.528e-02</TD><TD>-3.68</TD><TD>VANGL2 (VANGL planar cell polarity protein 2)</TD><TD>protein interactions</TD><TD>57216</TD><TD>10</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>NT5E</TD></TR>
<TR><TD>2.528e-02</TD><TD>-3.68</TD><TD>ZBTB5 (zinc finger and BTB domain containing 5)</TD><TD>protein interactions</TD><TD>9925</TD><TD>10</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>PPARG</TD></TR>
<TR><TD>2.528e-02</TD><TD>-3.68</TD><TD>NFE2L3 (nuclear factor, erythroid 2-like 3)</TD><TD>protein interactions</TD><TD>9603</TD><TD>10</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>PPARG</TD></TR>
<TR><TD>2.528e-02</TD><TD>-3.68</TD><TD>AGTPBP1 (ATP/GTP binding protein 1)</TD><TD>protein interactions</TD><TD>23287</TD><TD>10</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>TNIK</TD></TR>
<TR><TD>2.528e-02</TD><TD>-3.68</TD><TD>TIGD5 (tigger transposable element derived 5)</TD><TD>protein interactions</TD><TD>84948</TD><TD>10</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>EFNB2</TD></TR>
<TR><TD>2.528e-02</TD><TD>-3.68</TD><TD>DAD1 (defender against cell death 1)</TD><TD>protein interactions</TD><TD>1603</TD><TD>10</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>EFNB2</TD></TR>
<TR><TD>2.528e-02</TD><TD>-3.68</TD><TD>WASF3 (WAS protein family, member 3)</TD><TD>protein interactions</TD><TD>10810</TD><TD>10</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>CAMK2D</TD></TR>
<TR><TD>2.528e-02</TD><TD>-3.68</TD><TD>APBA3 (amyloid beta (A4) precursor protein-binding, family A, member 3)</TD><TD>protein interactions</TD><TD>9546</TD><TD>10</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>TANK</TD></TR>
<TR><TD>2.528e-02</TD><TD>-3.68</TD><TD>UPP1 (uridine phosphorylase 1)</TD><TD>protein interactions</TD><TD>7378</TD><TD>10</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>VIM</TD></TR>
<TR><TD>2.528e-02</TD><TD>-3.68</TD><TD>HOXB1 (homeobox B1)</TD><TD>protein interactions</TD><TD>3211</TD><TD>10</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>PBX1</TD></TR>
<TR><TD>2.528e-02</TD><TD>-3.68</TD><TD>MAB21L1 (mab-21-like 1 (C. elegans))</TD><TD>protein interactions</TD><TD>4081</TD><TD>10</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>PBX1</TD></TR>
<TR><TD>2.528e-02</TD><TD>-3.68</TD><TD>ZNF384 (zinc finger protein 384)</TD><TD>protein interactions</TD><TD>171017</TD><TD>10</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>VIM</TD></TR>
<TR><TD>2.534e-02</TD><TD>-3.68</TD><TD>RACCACAR_V$AML_Q6</TD><TD>MSigDB lists</TD><TD>RACCACAR_V$AML_Q6</TD><TD>250</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>RNF43,PPARG,GRHL3</TD></TR>
<TR><TD>2.539e-02</TD><TD>-3.67</TD><TD>activation of MAPKK activity</TD><TD>biological process</TD><TD>GO:0000186</TD><TD>237</TD><TD>3</TD><TD>16441</TD><TD>44</TD>
<TD>TNIK,CAMK2D,FGF9</TD></TR>
<TR><TD>2.544e-02</TD><TD>-3.67</TD><TD>PPAR signaling pathway</TD><TD>KEGG pathways</TD><TD>ko03320</TD><TD>69</TD><TD>2</TD><TD>6908</TD><TD>25</TD>
<TD>PPARG,ANGPTL4</TD></TR>
<TR><TD>2.544e-02</TD><TD>-3.67</TD><TD>PPAR signaling pathway</TD><TD>KEGG pathways</TD><TD>hsa03320</TD><TD>69</TD><TD>2</TD><TD>6908</TD><TD>25</TD>
<TD>PPARG,ANGPTL4</TD></TR>
<TR><TD>2.548e-02</TD><TD>-3.67</TD><TD>EEF1D (eukaryotic translation elongation factor 1 delta (guanine nucleotide exchange protein))</TD><TD>protein interactions</TD><TD>1936</TD><TD>97</TD><TD>2</TD><TD>16036</TD><TD>41</TD>
<TD>VIM,NR2F1</TD></TR>
<TR><TD>2.559e-02</TD><TD>-3.67</TD><TD>BASSO_CD40_SIGNALING_UP</TD><TD>MSigDB lists</TD><TD>BASSO_CD40_SIGNALING_UP</TD><TD>98</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>CD44,KRT7</TD></TR>
<TR><TD>2.559e-02</TD><TD>-3.67</TD><TD>MCCLUNG_CREB1_TARGETS_UP</TD><TD>MSigDB lists</TD><TD>MCCLUNG_CREB1_TARGETS_UP</TD><TD>98</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>MMP16,NR2F1</TD></TR>
<TR><TD>2.560e-02</TD><TD>-3.67</TD><TD>V$BACH1_01</TD><TD>MSigDB lists</TD><TD>V$BACH1_01</TD><TD>251</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>CSMD3,ITGB4,S100A10</TD></TR>
<TR><TD>2.560e-02</TD><TD>-3.67</TD><TD>V$GFI1_01</TD><TD>MSigDB lists</TD><TD>V$GFI1_01</TD><TD>251</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>PBX1,CAMK2D,NR2F2</TD></TR>
<TR><TD>2.567e-02</TD><TD>-3.66</TD><TD>mesonephros development</TD><TD>biological process</TD><TD>GO:0001823</TD><TD>93</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>PBX1,CD44</TD></TR>
<TR><TD>2.576e-02</TD><TD>-3.66</TD><TD>Fatty acid, triacylglycerol, and ketone body metabolism</TD><TD>REACTOME pathways</TD><TD>R-HSA-535734</TD><TD>212</TD><TD>3</TD><TD>8202</TD><TD>25</TD>
<TD>PPARG,ANGPTL4,GPAT3</TD></TR>
<TR><TD>2.578e-02</TD><TD>-3.66</TD><TD>prostanoid receptor activity</TD><TD>molecular function</TD><TD>GO:0004954</TD><TD>10</TD><TD>1</TD><TD>16491</TD><TD>43</TD>
<TD>PPARG</TD></TR>
<TR><TD>2.578e-02</TD><TD>-3.66</TD><TD>3',5'-cyclic-AMP phosphodiesterase activity</TD><TD>molecular function</TD><TD>GO:0004115</TD><TD>10</TD><TD>1</TD><TD>16491</TD><TD>43</TD>
<TD>PDE3A</TD></TR>
<TR><TD>2.578e-02</TD><TD>-3.66</TD><TD>3',5'-cyclic-GMP phosphodiesterase activity</TD><TD>molecular function</TD><TD>GO:0047555</TD><TD>10</TD><TD>1</TD><TD>16491</TD><TD>43</TD>
<TD>PDE10A</TD></TR>
<TR><TD>2.578e-02</TD><TD>-3.66</TD><TD>CREIGHTON_ENDOCRINE_THERAPY_RESISTANCE_3</TD><TD>MSigDB lists</TD><TD>CREIGHTON_ENDOCRINE_THERAPY_RESISTANCE_3</TD><TD>665</TD><TD>5</TD><TD>17758</TD><TD>45</TD>
<TD>PPARG,PDLIM5,SLK,TANK,NR2F1</TD></TR>
<TR><TD>2.587e-02</TD><TD>-3.65</TD><TD>V$OCT1_Q5_01</TD><TD>MSigDB lists</TD><TD>V$OCT1_Q5_01</TD><TD>252</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>ETV1,GRHL3,VSNL1</TD></TR>
<TR><TD>2.594e-02</TD><TD>-3.65</TD><TD>regulation of cellular response to growth factor stimulus</TD><TD>biological process</TD><TD>GO:0090287</TD><TD>239</TD><TD>3</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2,FGF9,MSX1</TD></TR>
<TR><TD>2.597e-02</TD><TD>-3.65</TD><TD>CD4 (CD4 molecule)</TD><TD>protein interactions</TD><TD>920</TD><TD>98</TD><TD>2</TD><TD>16036</TD><TD>41</TD>
<TD>VIM,CD44</TD></TR>
<TR><TD>2.607e-02</TD><TD>-3.65</TD><TD>GTGTTGA,MIR-505</TD><TD>MSigDB lists</TD><TD>GTGTTGA,MIR-505</TD><TD>99</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>CAMK2D,ZIC2</TD></TR>
<TR><TD>2.613e-02</TD><TD>-3.64</TD><TD>V$CP2_01</TD><TD>MSigDB lists</TD><TD>V$CP2_01</TD><TD>253</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>CLSTN2,ZIC2,GRHL3</TD></TR>
<TR><TD>2.620e-02</TD><TD>-3.64</TD><TD>TRANSCRIPTION_FROM_RNA_POLYMERASE_II_PROMOTER</TD><TD>MSigDB lists</TD><TD>TRANSCRIPTION_FROM_RNA_POLYMERASE_II_PROMOTER</TD><TD>447</TD><TD>4</TD><TD>17758</TD><TD>45</TD>
<TD>PBX1,NR2F2,ETV1,PPARG</TD></TR>
<TR><TD>2.623e-02</TD><TD>-3.64</TD><TD>negative regulation of cell proliferation</TD><TD>biological process</TD><TD>GO:0008285</TD><TD>633</TD><TD>5</TD><TD>16441</TD><TD>44</TD>
<TD>EFNB2,MSX2,MSX1,NR2F2,PPARG</TD></TR>
<TR><TD>2.635e-02</TD><TD>-3.64</TD><TD>human chr3p25</TD><TD>chromosome location</TD><TD>human chr3p25</TD><TD>14</TD><TD>1</TD><TD>26250</TD><TD>50</TD>
<TD>PPARG</TD></TR>
<TR><TD>2.635e-02</TD><TD>-3.64</TD><TD>human chr12q14.3</TD><TD>chromosome location</TD><TD>human chr12q14.3</TD><TD>14</TD><TD>1</TD><TD>26250</TD><TD>50</TD>
<TD>LOC100507065</TD></TR>
<TR><TD>2.639e-02</TD><TD>-3.63</TD><TD>ACTGTGA,MIR-27A,MIR-27B</TD><TD>MSigDB lists</TD><TD>ACTGTGA,MIR-27A,MIR-27B</TD><TD>448</TD><TD>4</TD><TD>17758</TD><TD>45</TD>
<TD>SLCO5A1,PPARG,PDLIM5,PDE3A</TD></TR>
<TR><TD>2.640e-02</TD><TD>-3.63</TD><TD>V$MYCMAX_02</TD><TD>MSigDB lists</TD><TD>V$MYCMAX_02</TD><TD>254</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>CSMD3,ETV1,GRHL3</TD></TR>
<TR><TD>2.645e-02</TD><TD>-3.63</TD><TD>cranial suture morphogenesis</TD><TD>biological process</TD><TD>GO:0060363</TD><TD>10</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2</TD></TR>
<TR><TD>2.645e-02</TD><TD>-3.63</TD><TD>positive regulation of cardiac muscle cell differentiation</TD><TD>biological process</TD><TD>GO:2000727</TD><TD>10</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>EFNB2</TD></TR>
<TR><TD>2.645e-02</TD><TD>-3.63</TD><TD>cellular response to iron ion</TD><TD>biological process</TD><TD>GO:0071281</TD><TD>10</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>SLC40A1</TD></TR>
<TR><TD>2.645e-02</TD><TD>-3.63</TD><TD>membrane raft assembly</TD><TD>biological process</TD><TD>GO:0001765</TD><TD>10</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>S100A10</TD></TR>
<TR><TD>2.645e-02</TD><TD>-3.63</TD><TD>negative regulation of vascular permeability</TD><TD>biological process</TD><TD>GO:0043116</TD><TD>10</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>PDE3A</TD></TR>
<TR><TD>2.645e-02</TD><TD>-3.63</TD><TD>positive regulation of phagocytosis, engulfment</TD><TD>biological process</TD><TD>GO:0060100</TD><TD>10</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>PPARG</TD></TR>
<TR><TD>2.645e-02</TD><TD>-3.63</TD><TD>synaptic vesicle maturation</TD><TD>biological process</TD><TD>GO:0016188</TD><TD>10</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>UNC13A</TD></TR>
<TR><TD>2.645e-02</TD><TD>-3.63</TD><TD>resolution of meiotic recombination intermediates</TD><TD>biological process</TD><TD>GO:0000712</TD><TD>10</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>HFM1</TD></TR>
<TR><TD>2.645e-02</TD><TD>-3.63</TD><TD>positive regulation of hair follicle development</TD><TD>biological process</TD><TD>GO:0051798</TD><TD>10</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2</TD></TR>
<TR><TD>2.645e-02</TD><TD>-3.63</TD><TD>chondrocyte proliferation</TD><TD>biological process</TD><TD>GO:0035988</TD><TD>10</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>MMP16</TD></TR>
<TR><TD>2.645e-02</TD><TD>-3.63</TD><TD>negative regulation of sodium ion transmembrane transporter activity</TD><TD>biological process</TD><TD>GO:2000650</TD><TD>10</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>CAMK2D</TD></TR>
<TR><TD>2.645e-02</TD><TD>-3.63</TD><TD>positive regulation of heterotypic cell-cell adhesion</TD><TD>biological process</TD><TD>GO:0034116</TD><TD>10</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>CD44</TD></TR>
<TR><TD>2.654e-02</TD><TD>-3.63</TD><TD>Insulin-like growth factors(PMID:21216879)</TD><TD>GWAS genes</TD><TD>Insulin-like growth factors(PMID:21216879)</TD><TD>4</TD><TD>1</TD><TD>2389</TD><TD>16</TD>
<TD>SORCS2</TD></TR>
<TR><TD>2.654e-02</TD><TD>-3.63</TD><TD>regulation of growth</TD><TD>biological process</TD><TD>GO:0040008</TD><TD>635</TD><TD>5</TD><TD>16441</TD><TD>44</TD>
<TD>CAMK2D,FGF9,MSX1,PPARG,UNC13A</TD></TR>
<TR><TD>2.656e-02</TD><TD>-3.63</TD><TD>ZHANG_RESPONSE_TO_IKK_INHIBITOR_AND_TNF_DN</TD><TD>MSigDB lists</TD><TD>ZHANG_RESPONSE_TO_IKK_INHIBITOR_AND_TNF_DN</TD><TD>100</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>ZIC2,NR2F2</TD></TR>
<TR><TD>2.656e-02</TD><TD>-3.63</TD><TD>MIKKELSEN_IPS_WITH_HCP_H3K27ME3</TD><TD>MSigDB lists</TD><TD>MIKKELSEN_IPS_WITH_HCP_H3K27ME3</TD><TD>100</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>NR2F2,VSNL1</TD></TR>
<TR><TD>2.661e-02</TD><TD>-3.63</TD><TD>synapse</TD><TD>cellular component</TD><TD>GO:0045202</TD><TD>679</TD><TD>5</TD><TD>17570</TD><TD>44</TD>
<TD>CLSTN2,SLC40A1,PDLIM5,UNC13A,NT5E</TD></TR>
<TR><TD>2.666e-02</TD><TD>-3.62</TD><TD>EPHRIN_RBD_1</TD><TD>prosite domains</TD><TD>PS01299</TD><TD>8</TD><TD>1</TD><TD>11866</TD><TD>40</TD>
<TD>EFNB2</TD></TR>
<TR><TD>2.666e-02</TD><TD>-3.62</TD><TD>EPHRIN_RBD_2</TD><TD>prosite domains</TD><TD>PS51551</TD><TD>8</TD><TD>1</TD><TD>11866</TD><TD>40</TD>
<TD>EFNB2</TD></TR>
<TR><TD>2.667e-02</TD><TD>-3.62</TD><TD>LU_AGING_BRAIN_UP</TD><TD>MSigDB lists</TD><TD>LU_AGING_BRAIN_UP</TD><TD>255</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>VIM,NEBL,PDLIM5</TD></TR>
<TR><TD>2.667e-02</TD><TD>-3.62</TD><TD>V$NFKB_C</TD><TD>MSigDB lists</TD><TD>V$NFKB_C</TD><TD>255</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>MSX1,ITGB4,S100A10</TD></TR>
<TR><TD>2.677e-02</TD><TD>-3.62</TD><TD>carcinoid-endocrine_tumour</TD><TD>COSMIC cancer mutations</TD><TD>carcinoid-endocrine_tumour</TD><TD>8129</TD><TD>27</TD><TD>17775</TD><TD>44</TD>
<TD>EFNB2,LAMA4,TNIK,FGF9,CNTNAP3,PPARG,STXBP6,HFM1,VSNL1,CLSTN2,RNF43,ANGPTL4,NR2F1,PDE3A,RHOU,CAMK2D,NEBL,UNC13A,SLCO5A1,CSMD3,WNT16,CD44,ITGB4,PDLIM5,MMP16,PKIB,NT5E</TD></TR>
<TR><TD>2.686e-02</TD><TD>-3.62</TD><TD>large_intestine-rectum-adenoma</TD><TD>COSMIC cancer mutations</TD><TD>large_intestine-rectum-adenoma</TD><TD>103</TD><TD>2</TD><TD>17775</TD><TD>44</TD>
<TD>LAMA4,ANGPTL4</TD></TR>
<TR><TD>2.691e-02</TD><TD>-3.62</TD><TD>chronic_lymphocytic_leukaemia-small_lymphocytic_lymphoma</TD><TD>COSMIC cancer mutations</TD><TD>chronic_lymphocytic_leukaemia-small_lymphocytic_lymphoma</TD><TD>3677</TD><TD>15</TD><TD>17775</TD><TD>44</TD>
<TD>LAMA4,TNIK,CAMK2D,CNTNAP3,HFM1,UNC13A,VSNL1,CLSTN2,CSMD3,ZIC2,NR2F2,ITGB4,ETV1,MMP16,PDE3A</TD></TR>
<TR><TD>2.691e-02</TD><TD>-3.62</TD><TD>haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-chronic_lymphocytic_leukaemia-small_lymphocytic_lymphoma</TD><TD>COSMIC cancer mutations</TD><TD>haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-chronic_lymphocytic_leukaemia-small_lymphocytic_lymphoma</TD><TD>3677</TD><TD>15</TD><TD>17775</TD><TD>44</TD>
<TD>LAMA4,TNIK,CAMK2D,CNTNAP3,HFM1,UNC13A,VSNL1,CLSTN2,CSMD3,ZIC2,NR2F2,ITGB4,ETV1,MMP16,PDE3A</TD></TR>
<TR><TD>2.706e-02</TD><TD>-3.61</TD><TD>KEGG_MELANOGENESIS</TD><TD>MSigDB lists</TD><TD>KEGG_MELANOGENESIS</TD><TD>101</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>CAMK2D,WNT16</TD></TR>
<TR><TD>2.706e-02</TD><TD>-3.61</TD><TD>ACTGCAG,MIR-17-3P</TD><TD>MSigDB lists</TD><TD>ACTGCAG,MIR-17-3P</TD><TD>101</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>CAMK2D,SORCS2</TD></TR>
<TR><TD>2.706e-02</TD><TD>-3.61</TD><TD>ELVIDGE_HIF1A_AND_HIF2A_TARGETS_DN</TD><TD>MSigDB lists</TD><TD>ELVIDGE_HIF1A_AND_HIF2A_TARGETS_DN</TD><TD>101</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>ANGPTL4,AHNAK2</TD></TR>
<TR><TD>2.711e-02</TD><TD>-3.61</TD><TD>Type I hemidesmosome assembly</TD><TD>REACTOME pathways</TD><TD>R-HSA-446107</TD><TD>9</TD><TD>1</TD><TD>8202</TD><TD>25</TD>
<TD>ITGB4</TD></TR>
<TR><TD>2.732e-02</TD><TD>-3.60</TD><TD>PKD_dom</TD><TD>interpro domains</TD><TD>IPR000601</TD><TD>11</TD><TD>1</TD><TD>18293</TD><TD>46</TD>
<TD>SORCS2</TD></TR>
<TR><TD>2.746e-02</TD><TD>-3.59</TD><TD>TUBB2A (tubulin, beta 2A class IIa)</TD><TD>protein interactions</TD><TD>7280</TD><TD>101</TD><TD>2</TD><TD>16036</TD><TD>41</TD>
<TD>LAMA4,TNIK</TD></TR>
<TR><TD>2.753e-02</TD><TD>-3.59</TD><TD>WHITESIDE_CISPLATIN_RESISTANCE_UP</TD><TD>MSigDB lists</TD><TD>WHITESIDE_CISPLATIN_RESISTANCE_UP</TD><TD>11</TD><TD>1</TD><TD>17758</TD><TD>45</TD>
<TD>ITGB4</TD></TR>
<TR><TD>2.753e-02</TD><TD>-3.59</TD><TD>REACTOME_SIGNALING_BY_ACTIVATED_POINT_MUTANTS_OF_FGFR1</TD><TD>MSigDB lists</TD><TD>REACTOME_SIGNALING_BY_ACTIVATED_POINT_MUTANTS_OF_FGFR1</TD><TD>11</TD><TD>1</TD><TD>17758</TD><TD>45</TD>
<TD>FGF9</TD></TR>
<TR><TD>2.753e-02</TD><TD>-3.59</TD><TD>GHANDHI_BYSTANDER_IRRADIATION_DN</TD><TD>MSigDB lists</TD><TD>GHANDHI_BYSTANDER_IRRADIATION_DN</TD><TD>11</TD><TD>1</TD><TD>17758</TD><TD>45</TD>
<TD>CNTNAP3</TD></TR>
<TR><TD>2.753e-02</TD><TD>-3.59</TD><TD>PID_INTEGRIN4_PATHWAY</TD><TD>MSigDB lists</TD><TD>PID_INTEGRIN4_PATHWAY</TD><TD>11</TD><TD>1</TD><TD>17758</TD><TD>45</TD>
<TD>ITGB4</TD></TR>
<TR><TD>2.753e-02</TD><TD>-3.59</TD><TD>REACTOME_SIGNALING_BY_FGFR3_MUTANTS</TD><TD>MSigDB lists</TD><TD>REACTOME_SIGNALING_BY_FGFR3_MUTANTS</TD><TD>11</TD><TD>1</TD><TD>17758</TD><TD>45</TD>
<TD>FGF9</TD></TR>
<TR><TD>2.753e-02</TD><TD>-3.59</TD><TD>REACTOME_PYRIMIDINE_CATABOLISM</TD><TD>MSigDB lists</TD><TD>REACTOME_PYRIMIDINE_CATABOLISM</TD><TD>11</TD><TD>1</TD><TD>17758</TD><TD>45</TD>
<TD>NT5E</TD></TR>
<TR><TD>2.753e-02</TD><TD>-3.59</TD><TD>IIZUKA_LIVER_CANCER_EARLY_RECURRENCE</TD><TD>MSigDB lists</TD><TD>IIZUKA_LIVER_CANCER_EARLY_RECURRENCE</TD><TD>11</TD><TD>1</TD><TD>17758</TD><TD>45</TD>
<TD>VIM</TD></TR>
<TR><TD>2.753e-02</TD><TD>-3.59</TD><TD>BIOCARTA_MONOCYTE_PATHWAY</TD><TD>MSigDB lists</TD><TD>BIOCARTA_MONOCYTE_PATHWAY</TD><TD>11</TD><TD>1</TD><TD>17758</TD><TD>45</TD>
<TD>CD44</TD></TR>
<TR><TD>2.753e-02</TD><TD>-3.59</TD><TD>IIZUKA_LIVER_CANCER_PROGRESSION_G1_G2_UP</TD><TD>MSigDB lists</TD><TD>IIZUKA_LIVER_CANCER_PROGRESSION_G1_G2_UP</TD><TD>11</TD><TD>1</TD><TD>17758</TD><TD>45</TD>
<TD>PDLIM5</TD></TR>
<TR><TD>2.755e-02</TD><TD>-3.59</TD><TD>WESTON_VEGFA_TARGETS</TD><TD>MSigDB lists</TD><TD>WESTON_VEGFA_TARGETS</TD><TD>102</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>VIM,KRT7</TD></TR>
<TR><TD>2.765e-02</TD><TD>-3.59</TD><TD>positive regulation of cell cycle process</TD><TD>biological process</TD><TD>GO:0090068</TD><TD>245</TD><TD>3</TD><TD>16441</TD><TD>44</TD>
<TD>PBX1,MSX2,MSX1</TD></TR>
<TR><TD>2.771e-02</TD><TD>-3.59</TD><TD>response to inorganic substance</TD><TD>biological process</TD><TD>GO:0010035</TD><TD>431</TD><TD>4</TD><TD>16441</TD><TD>44</TD>
<TD>SLC40A1,CAMK2D,PPARG,NT5E</TD></TR>
<TR><TD>2.772e-02</TD><TD>-3.59</TD><TD>ATXN1 (ataxin 1)</TD><TD>protein interactions</TD><TD>6310</TD><TD>257</TD><TD>3</TD><TD>16036</TD><TD>41</TD>
<TD>MSX2,ITGB4,VSNL1</TD></TR>
<TR><TD>2.775e-02</TD><TD>-3.58</TD><TD>V$HOXA4_Q2</TD><TD>MSigDB lists</TD><TD>V$HOXA4_Q2</TD><TD>259</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>RNF43,CAMK2D,NR2F1</TD></TR>
<TR><TD>2.775e-02</TD><TD>-3.58</TD><TD>nephron epithelium development</TD><TD>biological process</TD><TD>GO:0072009</TD><TD>97</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>PBX1,CD44</TD></TR>
<TR><TD>2.778e-02</TD><TD>-3.58</TD><TD>SYT11 (synaptotagmin XI)</TD><TD>protein interactions</TD><TD>23208</TD><TD>11</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>PDLIM5</TD></TR>
<TR><TD>2.778e-02</TD><TD>-3.58</TD><TD>ADIPOR1 (adiponectin receptor 1)</TD><TD>protein interactions</TD><TD>51094</TD><TD>11</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>NT5E</TD></TR>
<TR><TD>2.778e-02</TD><TD>-3.58</TD><TD>NCOA4 (nuclear receptor coactivator 4)</TD><TD>protein interactions</TD><TD>8031</TD><TD>11</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>PPARG</TD></TR>
<TR><TD>2.778e-02</TD><TD>-3.58</TD><TD>KDM4C (lysine (K)-specific demethylase 4C)</TD><TD>protein interactions</TD><TD>23081</TD><TD>11</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>PPARG</TD></TR>
<TR><TD>2.778e-02</TD><TD>-3.58</TD><TD>PI4K2B (phosphatidylinositol 4-kinase type 2 beta)</TD><TD>protein interactions</TD><TD>55300</TD><TD>11</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>EFNB2</TD></TR>
<TR><TD>2.778e-02</TD><TD>-3.58</TD><TD>EML4 (echinoderm microtubule associated protein like 4)</TD><TD>protein interactions</TD><TD>27436</TD><TD>11</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>PRPS1</TD></TR>
<TR><TD>2.778e-02</TD><TD>-3.58</TD><TD>TRIOBP (TRIO and F-actin binding protein)</TD><TD>protein interactions</TD><TD>11078</TD><TD>11</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>VIM</TD></TR>
<TR><TD>2.778e-02</TD><TD>-3.58</TD><TD>ARL2BP (ADP-ribosylation factor like GTPase 2 binding protein)</TD><TD>protein interactions</TD><TD>23568</TD><TD>11</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>CAMK2D</TD></TR>
<TR><TD>2.778e-02</TD><TD>-3.58</TD><TD>MYPN (myopalladin)</TD><TD>protein interactions</TD><TD>84665</TD><TD>11</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>NEBL</TD></TR>
<TR><TD>2.778e-02</TD><TD>-3.58</TD><TD>FAM131C (family with sequence similarity 131, member C)</TD><TD>protein interactions</TD><TD>348487</TD><TD>11</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>VSNL1</TD></TR>
<TR><TD>2.778e-02</TD><TD>-3.58</TD><TD>PAX9 (paired box 9)</TD><TD>protein interactions</TD><TD>5083</TD><TD>11</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>MSX1</TD></TR>
<TR><TD>2.778e-02</TD><TD>-3.58</TD><TD>AAAS (achalasia, adrenocortical insufficiency, alacrimia)</TD><TD>protein interactions</TD><TD>8086</TD><TD>11</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>EFNB2</TD></TR>
<TR><TD>2.778e-02</TD><TD>-3.58</TD><TD>BRD1 (bromodomain containing 1)</TD><TD>protein interactions</TD><TD>23774</TD><TD>11</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>VIM</TD></TR>
<TR><TD>2.778e-02</TD><TD>-3.58</TD><TD>EPHB3 (EPH receptor B3)</TD><TD>protein interactions</TD><TD>2049</TD><TD>11</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>EFNB2</TD></TR>
<TR><TD>2.778e-02</TD><TD>-3.58</TD><TD>G-protein coupled receptor binding</TD><TD>molecular function</TD><TD>GO:0001664</TD><TD>252</TD><TD>3</TD><TD>16491</TD><TD>43</TD>
<TD>RNF43,WNT16,ITGB4</TD></TR>
<TR><TD>2.791e-02</TD><TD>-3.58</TD><TD>regulation of kinase activity</TD><TD>biological process</TD><TD>GO:0043549</TD><TD>874</TD><TD>6</TD><TD>16441</TD><TD>44</TD>
<TD>TNIK,CAMK2D,FGF9,NR2F2,SLK,PKIB</TD></TR>
<TR><TD>2.798e-02</TD><TD>-3.58</TD><TD>protein N-terminus binding</TD><TD>molecular function</TD><TD>GO:0047485</TD><TD>100</TD><TD>2</TD><TD>16491</TD><TD>43</TD>
<TD>PDLIM5,UNC13A</TD></TR>
<TR><TD>2.803e-02</TD><TD>-3.57</TD><TD>ROZANOV_MMP14_TARGETS_UP</TD><TD>MSigDB lists</TD><TD>ROZANOV_MMP14_TARGETS_UP</TD><TD>260</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>LAMA4,MSX1,PPARG</TD></TR>
<TR><TD>2.803e-02</TD><TD>-3.57</TD><TD>V$AP1_C</TD><TD>MSigDB lists</TD><TD>V$AP1_C</TD><TD>260</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>SLCO5A1,CSMD3,FGF9</TD></TR>
<TR><TD>2.806e-02</TD><TD>-3.57</TD><TD>IZADPANAH_STEM_CELL_ADIPOSE_VS_BONE_DN</TD><TD>MSigDB lists</TD><TD>IZADPANAH_STEM_CELL_ADIPOSE_VS_BONE_DN</TD><TD>103</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>LAMA4,PBX1</TD></TR>
<TR><TD>2.829e-02</TD><TD>-3.57</TD><TD>inner ear morphogenesis</TD><TD>biological process</TD><TD>GO:0042472</TD><TD>98</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>FGF9,GRHL3</TD></TR>
<TR><TD>2.830e-02</TD><TD>-3.56</TD><TD>HYDROLASE_ACTIVITY_ACTING_ON_ESTER_BONDS</TD><TD>MSigDB lists</TD><TD>HYDROLASE_ACTIVITY_ACTING_ON_ESTER_BONDS</TD><TD>261</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>PDE10A,PDE3A,NT5E</TD></TR>
<TR><TD>2.831e-02</TD><TD>-3.56</TD><TD>SCHAEFFER_PROSTATE_DEVELOPMENT_48HR_UP</TD><TD>MSigDB lists</TD><TD>SCHAEFFER_PROSTATE_DEVELOPMENT_48HR_UP</TD><TD>458</TD><TD>4</TD><TD>17758</TD><TD>45</TD>
<TD>SLC40A1,ITGB4,KRT7,NT5E</TD></TR>
<TR><TD>2.832e-02</TD><TD>-3.56</TD><TD>1-acylglycerol-3-phosphate O-acyltransferase activity</TD><TD>molecular function</TD><TD>GO:0003841</TD><TD>11</TD><TD>1</TD><TD>16491</TD><TD>43</TD>
<TD>GPAT3</TD></TR>
<TR><TD>2.832e-02</TD><TD>-3.56</TD><TD>diacylglycerol binding</TD><TD>molecular function</TD><TD>GO:0019992</TD><TD>11</TD><TD>1</TD><TD>16491</TD><TD>43</TD>
<TD>UNC13A</TD></TR>
<TR><TD>2.832e-02</TD><TD>-3.56</TD><TD>AMP binding</TD><TD>molecular function</TD><TD>GO:0016208</TD><TD>11</TD><TD>1</TD><TD>16491</TD><TD>43</TD>
<TD>PRPS1</TD></TR>
<TR><TD>2.832e-02</TD><TD>-3.56</TD><TD>lysophosphatidic acid acyltransferase activity</TD><TD>molecular function</TD><TD>GO:0042171</TD><TD>11</TD><TD>1</TD><TD>16491</TD><TD>43</TD>
<TD>GPAT3</TD></TR>
<TR><TD>2.848e-02</TD><TD>-3.56</TD><TD>ATR (ATR serine/threonine kinase)</TD><TD>protein interactions</TD><TD>545</TD><TD>103</TD><TD>2</TD><TD>16036</TD><TD>41</TD>
<TD>ETV1,NT5E</TD></TR>
<TR><TD>2.848e-02</TD><TD>-3.56</TD><TD>KAT2A (K(lysine) acetyltransferase 2A)</TD><TD>protein interactions</TD><TD>2648</TD><TD>103</TD><TD>2</TD><TD>16036</TD><TD>41</TD>
<TD>PBX1,PPARG</TD></TR>
<TR><TD>2.882e-02</TD><TD>-3.55</TD><TD>ossification</TD><TD>biological process</TD><TD>GO:0001503</TD><TD>249</TD><TD>3</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2,FGF9,MMP16</TD></TR>
<TR><TD>2.882e-02</TD><TD>-3.55</TD><TD>regulation of striated muscle tissue development</TD><TD>biological process</TD><TD>GO:0016202</TD><TD>99</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>EFNB2,FGF9</TD></TR>
<TR><TD>2.906e-02</TD><TD>-3.54</TD><TD>positive regulation of vascular permeability</TD><TD>biological process</TD><TD>GO:0043117</TD><TD>11</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>PDE3A</TD></TR>
<TR><TD>2.906e-02</TD><TD>-3.54</TD><TD>lipoprotein transport</TD><TD>biological process</TD><TD>GO:0042953</TD><TD>11</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>PPARG</TD></TR>
<TR><TD>2.906e-02</TD><TD>-3.54</TD><TD>bone trabecula morphogenesis</TD><TD>biological process</TD><TD>GO:0061430</TD><TD>11</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2</TD></TR>
<TR><TD>2.906e-02</TD><TD>-3.54</TD><TD>negative regulation of acute inflammatory response</TD><TD>biological process</TD><TD>GO:0002674</TD><TD>11</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>PPARG</TD></TR>
<TR><TD>2.906e-02</TD><TD>-3.54</TD><TD>positive regulation of neurotransmitter secretion</TD><TD>biological process</TD><TD>GO:0001956</TD><TD>11</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>UNC13A</TD></TR>
<TR><TD>2.906e-02</TD><TD>-3.54</TD><TD>negative regulation of sodium ion transmembrane transport</TD><TD>biological process</TD><TD>GO:1902306</TD><TD>11</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>CAMK2D</TD></TR>
<TR><TD>2.906e-02</TD><TD>-3.54</TD><TD>mechanosensory behavior</TD><TD>biological process</TD><TD>GO:0007638</TD><TD>11</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>ETV1</TD></TR>
<TR><TD>2.906e-02</TD><TD>-3.54</TD><TD>lung-associated mesenchyme development</TD><TD>biological process</TD><TD>GO:0060484</TD><TD>11</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>FGF9</TD></TR>
<TR><TD>2.906e-02</TD><TD>-3.54</TD><TD>positive regulation of hair cycle</TD><TD>biological process</TD><TD>GO:0042635</TD><TD>11</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2</TD></TR>
<TR><TD>2.906e-02</TD><TD>-3.54</TD><TD>lipoprotein localization</TD><TD>biological process</TD><TD>GO:0044872</TD><TD>11</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>PPARG</TD></TR>
<TR><TD>2.906e-02</TD><TD>-3.54</TD><TD>replicative senescence</TD><TD>biological process</TD><TD>GO:0090399</TD><TD>11</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>WNT16</TD></TR>
<TR><TD>2.906e-02</TD><TD>-3.54</TD><TD>endometrium-carcinoma-serous_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>endometrium-carcinoma-serous_carcinoma</TD><TD>1500</TD><TD>8</TD><TD>17775</TD><TD>44</TD>
<TD>EFNB2,TNIK,CNTNAP3,PDE10A,HFM1,CSMD3,ETV1,NR2F1</TD></TR>
<TR><TD>2.907e-02</TD><TD>-3.54</TD><TD>COULOUARN_TEMPORAL_TGFB1_SIGNATURE_UP</TD><TD>MSigDB lists</TD><TD>COULOUARN_TEMPORAL_TGFB1_SIGNATURE_UP</TD><TD>105</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>SLC40A1,VIM</TD></TR>
<TR><TD>2.907e-02</TD><TD>-3.54</TD><TD>REACTOME_PPARA_ACTIVATES_GENE_EXPRESSION</TD><TD>MSigDB lists</TD><TD>REACTOME_PPARA_ACTIVATES_GENE_EXPRESSION</TD><TD>105</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>PPARG,ANGPTL4</TD></TR>
<TR><TD>2.907e-02</TD><TD>-3.54</TD><TD>LABBE_TARGETS_OF_TGFB1_AND_WNT3A_DN</TD><TD>MSigDB lists</TD><TD>LABBE_TARGETS_OF_TGFB1_AND_WNT3A_DN</TD><TD>105</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>SLC40A1,CAMK2D</TD></TR>
<TR><TD>2.916e-02</TD><TD>-3.53</TD><TD>blood vessel development</TD><TD>biological process</TD><TD>GO:0001568</TD><TD>438</TD><TD>4</TD><TD>16441</TD><TD>44</TD>
<TD>EFNB2,FGF9,NR2F2,ANGPTL4</TD></TR>
<TR><TD>2.922e-02</TD><TD>-3.53</TD><TD>negative regulation of nucleobase-containing compound metabolic process</TD><TD>biological process</TD><TD>GO:0045934</TD><TD>1389</TD><TD>8</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2,FGF9,MSX1,PPARG,PBX1,ZIC2,NR2F2,NR2F1</TD></TR>
<TR><TD>2.924e-02</TD><TD>-3.53</TD><TD>LIM</TD><TD>smart domains</TD><TD>SM00132</TD><TD>72</TD><TD>2</TD><TD>9131</TD><TD>34</TD>
<TD>NEBL,PDLIM5</TD></TR>
<TR><TD>2.936e-02</TD><TD>-3.53</TD><TD>negative regulation of inflammatory response</TD><TD>biological process</TD><TD>GO:0050728</TD><TD>100</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>PPARG,NT5E</TD></TR>
<TR><TD>2.936e-02</TD><TD>-3.53</TD><TD>positive regulation of synaptic transmission</TD><TD>biological process</TD><TD>GO:0050806</TD><TD>100</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>CLSTN2,UNC13A</TD></TR>
<TR><TD>2.938e-02</TD><TD>-3.53</TD><TD>sequence-specific double-stranded DNA binding</TD><TD>molecular function</TD><TD>GO:1990837</TD><TD>670</TD><TD>5</TD><TD>16491</TD><TD>43</TD>
<TD>PBX1,MSX2,MSX1,PPARG,ETV1</TD></TR>
<TR><TD>2.941e-02</TD><TD>-3.53</TD><TD>cell fate commitment</TD><TD>biological process</TD><TD>GO:0045165</TD><TD>251</TD><TD>3</TD><TD>16441</TD><TD>44</TD>
<TD>WNT16,NR2F2,PPARG</TD></TR>
<TR><TD>2.941e-02</TD><TD>-3.53</TD><TD>Calx_beta</TD><TD>smart domains</TD><TD>SM00237</TD><TD>8</TD><TD>1</TD><TD>9131</TD><TD>34</TD>
<TD>ITGB4</TD></TR>
<TR><TD>2.941e-02</TD><TD>-3.53</TD><TD>GAF</TD><TD>smart domains</TD><TD>SM00065</TD><TD>8</TD><TD>1</TD><TD>9131</TD><TD>34</TD>
<TD>PDE10A</TD></TR>
<TR><TD>2.941e-02</TD><TD>-3.53</TD><TD>INB</TD><TD>smart domains</TD><TD>SM00187</TD><TD>8</TD><TD>1</TD><TD>9131</TD><TD>34</TD>
<TD>ITGB4</TD></TR>
<TR><TD>2.950e-02</TD><TD>-3.52</TD><TD>response to stimulus</TD><TD>biological process</TD><TD>GO:0050896</TD><TD>7571</TD><TD>27</TD><TD>16441</TD><TD>44</TD>
<TD>EFNB2,SLC40A1,TNIK,FGF9,MSX1,PPARG,SLK,GRHL3,VIM,RNF43,ANGPTL4,PDE3A,NR2F1,RHOU,MSX2,CAMK2D,PDE10A,TANK,UNC13A,AHNAK2,WNT16,ITGB4,CD44,NR2F2,SORCS2,ETV1,NT5E</TD></TR>
<TR><TD>2.950e-02</TD><TD>-3.52</TD><TD>RAD23B (RAD23 homolog B, nucleotide excision repair protein)</TD><TD>protein interactions</TD><TD>5887</TD><TD>105</TD><TD>2</TD><TD>16036</TD><TD>41</TD>
<TD>VIM,PDLIM5</TD></TR>
<TR><TD>2.958e-02</TD><TD>-3.52</TD><TD>PEDERSEN_METASTASIS_BY_ERBB2_ISOFORM_4</TD><TD>MSigDB lists</TD><TD>PEDERSEN_METASTASIS_BY_ERBB2_ISOFORM_4</TD><TD>106</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>PPARG,C1orf226</TD></TR>
<TR><TD>2.962e-02</TD><TD>-3.52</TD><TD>GTGCCTT,MIR-506</TD><TD>MSigDB lists</TD><TD>GTGCCTT,MIR-506</TD><TD>690</TD><TD>5</TD><TD>17758</TD><TD>45</TD>
<TD>RHOU,SLCO5A1,VIM,NEBL,PRPS1</TD></TR>
<TR><TD>2.971e-02</TD><TD>-3.52</TD><TD>KRAS.600.LUNG.BREAST_UP.V1_UP</TD><TD>MSigDB lists</TD><TD>KRAS.600.LUNG.BREAST_UP.V1_UP</TD><TD>266</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>CLSTN2,SLCO5A1,ANGPTL4</TD></TR>
<TR><TD>2.971e-02</TD><TD>-3.52</TD><TD>Degradation of the extracellular matrix</TD><TD>REACTOME pathways</TD><TD>R-HSA-1474228</TD><TD>89</TD><TD>2</TD><TD>8202</TD><TD>25</TD>
<TD>CD44,MMP16</TD></TR>
<TR><TD>2.972e-02</TD><TD>-3.52</TD><TD>Ser/Thr_dual-sp_kinase</TD><TD>interpro domains</TD><TD>IPR002290</TD><TD>268</TD><TD>3</TD><TD>18293</TD><TD>46</TD>
<TD>TNIK,CAMK2D,SLK</TD></TR>
<TR><TD>2.976e-02</TD><TD>-3.51</TD><TD>adherens junction</TD><TD>cellular component</TD><TD>GO:0005912</TD><TD>471</TD><TD>4</TD><TD>17570</TD><TD>44</TD>
<TD>EFNB2,RHOU,VIM,CD44</TD></TR>
<TR><TD>2.977e-02</TD><TD>-3.51</TD><TD>OA_transporter</TD><TD>interpro domains</TD><TD>IPR004156</TD><TD>12</TD><TD>1</TD><TD>18293</TD><TD>46</TD>
<TD>SLCO5A1</TD></TR>
<TR><TD>2.977e-02</TD><TD>-3.51</TD><TD>PRTase-like</TD><TD>interpro domains</TD><TD>IPR029057</TD><TD>12</TD><TD>1</TD><TD>18293</TD><TD>46</TD>
<TD>PRPS1</TD></TR>
<TR><TD>2.977e-02</TD><TD>-3.51</TD><TD>Synaptobrevin</TD><TD>interpro domains</TD><TD>IPR001388</TD><TD>12</TD><TD>1</TD><TD>18293</TD><TD>46</TD>
<TD>STXBP6</TD></TR>
<TR><TD>2.988e-02</TD><TD>-3.51</TD><TD>EPHRIN</TD><TD>prints domains</TD><TD>PR01347</TD><TD>8</TD><TD>1</TD><TD>4759</TD><TD>18</TD>
<TD>EFNB2</TD></TR>
<TR><TD>2.988e-02</TD><TD>-3.51</TD><TD>INTEGRINB</TD><TD>prints domains</TD><TD>PR01186</TD><TD>8</TD><TD>1</TD><TD>4759</TD><TD>18</TD>
<TD>ITGB4</TD></TR>
<TR><TD>2.990e-02</TD><TD>-3.51</TD><TD>regulation of muscle tissue development</TD><TD>biological process</TD><TD>GO:1901861</TD><TD>101</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>EFNB2,FGF9</TD></TR>
<TR><TD>2.990e-02</TD><TD>-3.51</TD><TD>regulation of muscle organ development</TD><TD>biological process</TD><TD>GO:0048634</TD><TD>101</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>EFNB2,FGF9</TD></TR>
<TR><TD>2.994e-02</TD><TD>-3.51</TD><TD>INTEGRIN_BETA</TD><TD>prosite domains</TD><TD>PS00243</TD><TD>9</TD><TD>1</TD><TD>11866</TD><TD>40</TD>
<TD>ITGB4</TD></TR>
<TR><TD>3.000e-02</TD><TD>-3.51</TD><TD>REACTOME_CASPASE_MEDIATED_CLEAVAGE_OF_CYTOSKELETAL_PROTEINS</TD><TD>MSigDB lists</TD><TD>REACTOME_CASPASE_MEDIATED_CLEAVAGE_OF_CYTOSKELETAL_PROTEINS</TD><TD>12</TD><TD>1</TD><TD>17758</TD><TD>45</TD>
<TD>VIM</TD></TR>
<TR><TD>3.000e-02</TD><TD>-3.51</TD><TD>REGULATION_OF_ACTIN_FILAMENT_LENGTH</TD><TD>MSigDB lists</TD><TD>REGULATION_OF_ACTIN_FILAMENT_LENGTH</TD><TD>12</TD><TD>1</TD><TD>17758</TD><TD>45</TD>
<TD>NEBL</TD></TR>
<TR><TD>3.000e-02</TD><TD>-3.51</TD><TD>XU_RESPONSE_TO_TRETINOIN_DN</TD><TD>MSigDB lists</TD><TD>XU_RESPONSE_TO_TRETINOIN_DN</TD><TD>12</TD><TD>1</TD><TD>17758</TD><TD>45</TD>
<TD>NR2F2</TD></TR>
<TR><TD>3.000e-02</TD><TD>-3.51</TD><TD>REACTOME_FGFR4_LIGAND_BINDING_AND_ACTIVATION</TD><TD>MSigDB lists</TD><TD>REACTOME_FGFR4_LIGAND_BINDING_AND_ACTIVATION</TD><TD>12</TD><TD>1</TD><TD>17758</TD><TD>45</TD>
<TD>FGF9</TD></TR>
<TR><TD>3.000e-02</TD><TD>-3.51</TD><TD>REACTOME_FGFR2C_LIGAND_BINDING_AND_ACTIVATION</TD><TD>MSigDB lists</TD><TD>REACTOME_FGFR2C_LIGAND_BINDING_AND_ACTIVATION</TD><TD>12</TD><TD>1</TD><TD>17758</TD><TD>45</TD>
<TD>FGF9</TD></TR>
<TR><TD>3.000e-02</TD><TD>-3.51</TD><TD>chr13q11</TD><TD>MSigDB lists</TD><TD>chr13q11</TD><TD>12</TD><TD>1</TD><TD>17758</TD><TD>45</TD>
<TD>FGF9</TD></TR>
<TR><TD>3.000e-02</TD><TD>-3.51</TD><TD>TRANSITION_METAL_ION_TRANSPORT</TD><TD>MSigDB lists</TD><TD>TRANSITION_METAL_ION_TRANSPORT</TD><TD>12</TD><TD>1</TD><TD>17758</TD><TD>45</TD>
<TD>SLC40A1</TD></TR>
<TR><TD>3.000e-02</TD><TD>-3.51</TD><TD>SUZUKI_CTCFL_TARGETS_UP</TD><TD>MSigDB lists</TD><TD>SUZUKI_CTCFL_TARGETS_UP</TD><TD>12</TD><TD>1</TD><TD>17758</TD><TD>45</TD>
<TD>CAMK2D</TD></TR>
<TR><TD>3.000e-02</TD><TD>-3.51</TD><TD>MODULE_56</TD><TD>MSigDB lists</TD><TD>MODULE_56</TD><TD>12</TD><TD>1</TD><TD>17758</TD><TD>45</TD>
<TD>PRPS1</TD></TR>
<TR><TD>3.002e-02</TD><TD>-3.51</TD><TD>positive regulation of cell development</TD><TD>biological process</TD><TD>GO:0010720</TD><TD>442</TD><TD>4</TD><TD>16441</TD><TD>44</TD>
<TD>S100A10,PPARG,UNC13A,PDE3A</TD></TR>
<TR><TD>3.002e-02</TD><TD>-3.51</TD><TD>TLE1 (transducin-like enhancer of split 1 (E(sp1) homolog, Drosophila))</TD><TD>protein interactions</TD><TD>7088</TD><TD>106</TD><TD>2</TD><TD>16036</TD><TD>41</TD>
<TD>MSX2,MSX1</TD></TR>
<TR><TD>3.002e-02</TD><TD>-3.51</TD><TD>NCOA1 (nuclear receptor coactivator 1)</TD><TD>protein interactions</TD><TD>8648</TD><TD>106</TD><TD>2</TD><TD>16036</TD><TD>41</TD>
<TD>PPARG,NR2F1</TD></TR>
<TR><TD>3.005e-02</TD><TD>-3.50</TD><TD>human chr7p21.3</TD><TD>chromosome location</TD><TD>human chr7p21.3</TD><TD>16</TD><TD>1</TD><TD>26250</TD><TD>50</TD>
<TD>ETV1</TD></TR>
<TR><TD>3.008e-02</TD><TD>-3.50</TD><TD>Purine catabolism</TD><TD>REACTOME pathways</TD><TD>R-HSA-74259</TD><TD>10</TD><TD>1</TD><TD>8202</TD><TD>25</TD>
<TD>NT5E</TD></TR>
<TR><TD>3.010e-02</TD><TD>-3.50</TD><TD>WANG_HCP_PROSTATE_CANCER</TD><TD>MSigDB lists</TD><TD>WANG_HCP_PROSTATE_CANCER</TD><TD>107</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>NEBL,PDLIM5</TD></TR>
<TR><TD>3.010e-02</TD><TD>-3.50</TD><TD>DOANE_BREAST_CANCER_ESR1_UP</TD><TD>MSigDB lists</TD><TD>DOANE_BREAST_CANCER_ESR1_UP</TD><TD>107</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>CLSTN2,PBX1</TD></TR>
<TR><TD>3.010e-02</TD><TD>-3.50</TD><TD>positive regulation of response to stimulus</TD><TD>biological process</TD><TD>GO:0048584</TD><TD>1946</TD><TD>10</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2,TNIK,CAMK2D,FGF9,MSX1,TANK,VSNL1,ZIC2,WNT16,CD44</TD></TR>
<TR><TD>3.011e-02</TD><TD>-3.50</TD><TD>regulation of response to stress</TD><TD>biological process</TD><TD>GO:0080134</TD><TD>1397</TD><TD>8</TD><TD>16441</TD><TD>44</TD>
<TD>TNIK,CAMK2D,MSX1,PPARG,TANK,WNT16,CD44,NT5E</TD></TR>
<TR><TD>3.016e-02</TD><TD>-3.50</TD><TD>oligoastrocytoma_Grade_III</TD><TD>COSMIC cancer mutations</TD><TD>oligoastrocytoma_Grade_III</TD><TD>274</TD><TD>3</TD><TD>17775</TD><TD>44</TD>
<TD>CSMD3,PDE10A,GRHL3</TD></TR>
<TR><TD>3.022e-02</TD><TD>-3.50</TD><TD>negative regulation of macromolecule biosynthetic process</TD><TD>biological process</TD><TD>GO:0010558</TD><TD>1398</TD><TD>8</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2,FGF9,MSX1,PPARG,PBX1,ZIC2,NR2F2,NR2F1</TD></TR>
<TR><TD>3.023e-02</TD><TD>-3.50</TD><TD>nucleotide metabolic process</TD><TD>biological process</TD><TD>GO:0009117</TD><TD>443</TD><TD>4</TD><TD>16441</TD><TD>44</TD>
<TD>PDE10A,PRPS1,PDE3A,NT5E</TD></TR>
<TR><TD>3.026e-02</TD><TD>-3.50</TD><TD>WONG_ADULT_TISSUE_STEM_MODULE</TD><TD>MSigDB lists</TD><TD>WONG_ADULT_TISSUE_STEM_MODULE</TD><TD>694</TD><TD>5</TD><TD>17758</TD><TD>45</TD>
<TD>RHOU,EFNB2,PBX1,SORCS2,NR2F1</TD></TR>
<TR><TD>3.026e-02</TD><TD>-3.50</TD><TD>RSPO1 (R-spondin 1)</TD><TD>protein interactions</TD><TD>284654</TD><TD>12</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>RNF43</TD></TR>
<TR><TD>3.026e-02</TD><TD>-3.50</TD><TD>SCRN2 (secernin 2)</TD><TD>protein interactions</TD><TD>90507</TD><TD>12</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>CAMK2D</TD></TR>
<TR><TD>3.026e-02</TD><TD>-3.50</TD><TD>ZNF703 (zinc finger protein 703)</TD><TD>protein interactions</TD><TD>80139</TD><TD>12</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>MSX2</TD></TR>
<TR><TD>3.026e-02</TD><TD>-3.50</TD><TD>MCAM (melanoma cell adhesion molecule)</TD><TD>protein interactions</TD><TD>4162</TD><TD>12</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>LAMA4</TD></TR>
<TR><TD>3.026e-02</TD><TD>-3.50</TD><TD>PKN3 (protein kinase N3)</TD><TD>protein interactions</TD><TD>29941</TD><TD>12</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>EFNB2</TD></TR>
<TR><TD>3.026e-02</TD><TD>-3.50</TD><TD>SRGN (serglycin)</TD><TD>protein interactions</TD><TD>5552</TD><TD>12</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>CD44</TD></TR>
<TR><TD>3.026e-02</TD><TD>-3.50</TD><TD>SLC27A6 (solute carrier family 27 (fatty acid transporter), member 6)</TD><TD>protein interactions</TD><TD>28965</TD><TD>12</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>VIM</TD></TR>
<TR><TD>3.026e-02</TD><TD>-3.50</TD><TD>ITGB1BP1 (integrin beta 1 binding protein 1)</TD><TD>protein interactions</TD><TD>9270</TD><TD>12</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>TANK</TD></TR>
<TR><TD>3.026e-02</TD><TD>-3.50</TD><TD>ELF2 (E74-like factor 2 (ets domain transcription factor))</TD><TD>protein interactions</TD><TD>1998</TD><TD>12</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>PRPS1</TD></TR>
<TR><TD>3.026e-02</TD><TD>-3.50</TD><TD>KIF15 (kinesin family member 15)</TD><TD>protein interactions</TD><TD>56992</TD><TD>12</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>VIM</TD></TR>
<TR><TD>3.045e-02</TD><TD>-3.49</TD><TD>ribonucleoside biosynthetic process</TD><TD>biological process</TD><TD>GO:0042455</TD><TD>102</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>PRPS1,NT5E</TD></TR>
<TR><TD>3.045e-02</TD><TD>-3.49</TD><TD>regulation of fat cell differentiation</TD><TD>biological process</TD><TD>GO:0045598</TD><TD>102</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2,PPARG</TD></TR>
<TR><TD>3.045e-02</TD><TD>-3.49</TD><TD>multicellular organismal metabolic process</TD><TD>biological process</TD><TD>GO:0044236</TD><TD>102</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>PPARG,MMP16</TD></TR>
<TR><TD>3.056e-02</TD><TD>-3.49</TD><TD>HDAC1 (histone deacetylase 1)</TD><TD>protein interactions</TD><TD>3065</TD><TD>466</TD><TD>4</TD><TD>16036</TD><TD>41</TD>
<TD>PBX1,VIM,NR2F2,PPARG</TD></TR>
<TR><TD>3.057e-02</TD><TD>-3.49</TD><TD>skin-face-carcinoma-squamous_cell_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>skin-face-carcinoma-squamous_cell_carcinoma</TD><TD>2109</TD><TD>10</TD><TD>17775</TD><TD>44</TD>
<TD>LAMA4,NEBL,PPARG,HFM1,CSMD3,RNF43,PDLIM5,ANGPTL4,PDE3A,NT5E</TD></TR>
<TR><TD>3.057e-02</TD><TD>-3.49</TD><TD>STK33_NOMO_UP</TD><TD>MSigDB lists</TD><TD>STK33_NOMO_UP</TD><TD>269</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>EFNB2,CAMK2D,ZIC2</TD></TR>
<TR><TD>3.061e-02</TD><TD>-3.49</TD><TD>ion channel binding</TD><TD>molecular function</TD><TD>GO:0044325</TD><TD>105</TD><TD>2</TD><TD>16491</TD><TD>43</TD>
<TD>CAMK2D,S100A10</TD></TR>
<TR><TD>3.062e-02</TD><TD>-3.49</TD><TD>CCANNAGRKGGC_UNKNOWN</TD><TD>MSigDB lists</TD><TD>CCANNAGRKGGC_UNKNOWN</TD><TD>108</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>CSMD3,SORCS2</TD></TR>
<TR><TD>3.062e-02</TD><TD>-3.49</TD><TD>ATGCTGG,MIR-338</TD><TD>MSigDB lists</TD><TD>ATGCTGG,MIR-338</TD><TD>108</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>FGF9,SLK</TD></TR>
<TR><TD>3.062e-02</TD><TD>-3.49</TD><TD>ZHANG_TLX_TARGETS_DN</TD><TD>MSigDB lists</TD><TD>ZHANG_TLX_TARGETS_DN</TD><TD>108</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>S100A10,SORCS2</TD></TR>
<TR><TD>3.086e-02</TD><TD>-3.48</TD><TD>5'-nucleotidase activity</TD><TD>molecular function</TD><TD>GO:0008253</TD><TD>12</TD><TD>1</TD><TD>16491</TD><TD>43</TD>
<TD>NT5E</TD></TR>
<TR><TD>3.086e-02</TD><TD>-3.48</TD><TD>IVANOVA_HEMATOPOIESIS_MATURE_CELL</TD><TD>MSigDB lists</TD><TD>IVANOVA_HEMATOPOIESIS_MATURE_CELL</TD><TD>270</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>RHOU,SLC40A1,SLK</TD></TR>
<TR><TD>3.093e-02</TD><TD>-3.48</TD><TD>kidney development</TD><TD>biological process</TD><TD>GO:0001822</TD><TD>256</TD><TD>3</TD><TD>16441</TD><TD>44</TD>
<TD>PBX1,EFNB2,CD44</TD></TR>
<TR><TD>3.094e-02</TD><TD>-3.48</TD><TD>ZHOU_INFLAMMATORY_RESPONSE_FIMA_UP</TD><TD>MSigDB lists</TD><TD>ZHOU_INFLAMMATORY_RESPONSE_FIMA_UP</TD><TD>471</TD><TD>4</TD><TD>17758</TD><TD>45</TD>
<TD>FGF9,CD44,STXBP6,ANGPTL4</TD></TR>
<TR><TD>3.114e-02</TD><TD>-3.47</TD><TD>MODULE_321</TD><TD>MSigDB lists</TD><TD>MODULE_321</TD><TD>109</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>CD44,S100A10</TD></TR>
<TR><TD>3.114e-02</TD><TD>-3.47</TD><TD>MODULE_180</TD><TD>MSigDB lists</TD><TD>MODULE_180</TD><TD>109</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>MSX2,NEBL</TD></TR>
<TR><TD>3.115e-02</TD><TD>-3.47</TD><TD>MORF_NOS2A</TD><TD>MSigDB lists</TD><TD>MORF_NOS2A</TD><TD>271</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>TNIK,MSX1,NR2F1</TD></TR>
<TR><TD>3.124e-02</TD><TD>-3.47</TD><TD>muscle cell differentiation</TD><TD>biological process</TD><TD>GO:0042692</TD><TD>257</TD><TD>3</TD><TD>16441</TD><TD>44</TD>
<TD>CAMK2D,NEBL,PDLIM5</TD></TR>
<TR><TD>3.130e-02</TD><TD>-3.46</TD><TD>OATP</TD><TD>pfam domains</TD><TD>PF03137</TD><TD>12</TD><TD>1</TD><TD>16629</TD><TD>44</TD>
<TD>SLCO5A1</TD></TR>
<TR><TD>3.134e-02</TD><TD>-3.46</TD><TD>bone-humerus-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour</TD><TD>COSMIC cancer mutations</TD><TD>bone-humerus-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour</TD><TD>112</TD><TD>2</TD><TD>17775</TD><TD>44</TD>
<TD>NEBL,UNC13A</TD></TR>
<TR><TD>3.144e-02</TD><TD>-3.46</TD><TD>NAKAMURA_TUMOR_ZONE_PERIPHERAL_VS_CENTRAL_UP</TD><TD>MSigDB lists</TD><TD>NAKAMURA_TUMOR_ZONE_PERIPHERAL_VS_CENTRAL_UP</TD><TD>272</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>LAMA4,KRT7,VSNL1</TD></TR>
<TR><TD>3.155e-02</TD><TD>-3.46</TD><TD>muscle system process</TD><TD>biological process</TD><TD>GO:0003012</TD><TD>258</TD><TD>3</TD><TD>16441</TD><TD>44</TD>
<TD>VIM,CAMK2D,PDLIM5</TD></TR>
<TR><TD>3.156e-02</TD><TD>-3.46</TD><TD>regulation of synapse organization</TD><TD>biological process</TD><TD>GO:0050807</TD><TD>104</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>CLSTN2,PDLIM5</TD></TR>
<TR><TD>3.156e-02</TD><TD>-3.46</TD><TD>neural tube formation</TD><TD>biological process</TD><TD>GO:0001841</TD><TD>104</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>ZIC2,GRHL3</TD></TR>
<TR><TD>3.159e-02</TD><TD>-3.46</TD><TD>Interferon gamma signaling</TD><TD>REACTOME pathways</TD><TD>R-HSA-877300</TD><TD>92</TD><TD>2</TD><TD>8202</TD><TD>25</TD>
<TD>CAMK2D,CD44</TD></TR>
<TR><TD>3.160e-02</TD><TD>-3.45</TD><TD>SIRT6 (sirtuin 6)</TD><TD>protein interactions</TD><TD>51548</TD><TD>109</TD><TD>2</TD><TD>16036</TD><TD>41</TD>
<TD>VIM,PDLIM5</TD></TR>
<TR><TD>3.166e-02</TD><TD>-3.45</TD><TD>hemidesmosome assembly</TD><TD>biological process</TD><TD>GO:0031581</TD><TD>12</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>ITGB4</TD></TR>
<TR><TD>3.166e-02</TD><TD>-3.45</TD><TD>tooth mineralization</TD><TD>biological process</TD><TD>GO:0034505</TD><TD>12</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2</TD></TR>
<TR><TD>3.166e-02</TD><TD>-3.45</TD><TD>eyelid development in camera-type eye</TD><TD>biological process</TD><TD>GO:0061029</TD><TD>12</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>GRHL3</TD></TR>
<TR><TD>3.166e-02</TD><TD>-3.45</TD><TD>regulation of cardiac muscle cell action potential involved in regulation of contraction</TD><TD>biological process</TD><TD>GO:0098909</TD><TD>12</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>CAMK2D</TD></TR>
<TR><TD>3.166e-02</TD><TD>-3.45</TD><TD>negative regulation of epidermal cell differentiation</TD><TD>biological process</TD><TD>GO:0045605</TD><TD>12</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2</TD></TR>
<TR><TD>3.166e-02</TD><TD>-3.45</TD><TD>embryonic camera-type eye formation</TD><TD>biological process</TD><TD>GO:0060900</TD><TD>12</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>WNT16</TD></TR>
<TR><TD>3.166e-02</TD><TD>-3.45</TD><TD>regulation of phagocytosis, engulfment</TD><TD>biological process</TD><TD>GO:0060099</TD><TD>12</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>PPARG</TD></TR>
<TR><TD>3.166e-02</TD><TD>-3.45</TD><TD>meiotic chromosome separation</TD><TD>biological process</TD><TD>GO:0051307</TD><TD>12</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>HFM1</TD></TR>
<TR><TD>3.166e-02</TD><TD>-3.45</TD><TD>regulation of sequestering of triglyceride</TD><TD>biological process</TD><TD>GO:0010889</TD><TD>12</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>PPARG</TD></TR>
<TR><TD>3.166e-02</TD><TD>-3.45</TD><TD>cartilage morphogenesis</TD><TD>biological process</TD><TD>GO:0060536</TD><TD>12</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>MSX1</TD></TR>
<TR><TD>3.166e-02</TD><TD>-3.45</TD><TD>wound healing, spreading of epidermal cells</TD><TD>biological process</TD><TD>GO:0035313</TD><TD>12</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2</TD></TR>
<TR><TD>3.166e-02</TD><TD>-3.45</TD><TD>keratinocyte proliferation</TD><TD>biological process</TD><TD>GO:0043616</TD><TD>12</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>WNT16</TD></TR>
<TR><TD>3.166e-02</TD><TD>-3.45</TD><TD>positive regulation of receptor biosynthetic process</TD><TD>biological process</TD><TD>GO:0010870</TD><TD>12</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>NR2F1</TD></TR>
<TR><TD>3.166e-02</TD><TD>-3.45</TD><TD>cellular potassium ion homeostasis</TD><TD>biological process</TD><TD>GO:0030007</TD><TD>12</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>CAMK2D</TD></TR>
<TR><TD>3.166e-02</TD><TD>-3.45</TD><TD>relaxation of cardiac muscle</TD><TD>biological process</TD><TD>GO:0055119</TD><TD>12</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>CAMK2D</TD></TR>
<TR><TD>3.166e-02</TD><TD>-3.45</TD><TD>peripheral nervous system neuron differentiation</TD><TD>biological process</TD><TD>GO:0048934</TD><TD>12</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>ETV1</TD></TR>
<TR><TD>3.166e-02</TD><TD>-3.45</TD><TD>purine nucleobase biosynthetic process</TD><TD>biological process</TD><TD>GO:0009113</TD><TD>12</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>PRPS1</TD></TR>
<TR><TD>3.166e-02</TD><TD>-3.45</TD><TD>peripheral nervous system neuron development</TD><TD>biological process</TD><TD>GO:0048935</TD><TD>12</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>ETV1</TD></TR>
<TR><TD>3.166e-02</TD><TD>-3.45</TD><TD>negative regulation of sodium ion transport</TD><TD>biological process</TD><TD>GO:0010766</TD><TD>12</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>CAMK2D</TD></TR>
<TR><TD>3.166e-02</TD><TD>-3.45</TD><TD>regulation of timing of cell differentiation</TD><TD>biological process</TD><TD>GO:0048505</TD><TD>12</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>FGF9</TD></TR>
<TR><TD>3.166e-02</TD><TD>-3.45</TD><TD>planar cell polarity pathway involved in neural tube closure</TD><TD>biological process</TD><TD>GO:0090179</TD><TD>12</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>GRHL3</TD></TR>
<TR><TD>3.166e-02</TD><TD>-3.45</TD><TD>regulation of Rac protein signal transduction</TD><TD>biological process</TD><TD>GO:0035020</TD><TD>12</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>CAMK2D</TD></TR>
<TR><TD>3.166e-02</TD><TD>-3.45</TD><TD>nephric duct morphogenesis</TD><TD>biological process</TD><TD>GO:0072178</TD><TD>12</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>EFNB2</TD></TR>
<TR><TD>3.169e-02</TD><TD>-3.45</TD><TD>drug binding</TD><TD>molecular function</TD><TD>GO:0008144</TD><TD>107</TD><TD>2</TD><TD>16491</TD><TD>43</TD>
<TD>PPARG,PDE10A</TD></TR>
<TR><TD>3.172e-02</TD><TD>-3.45</TD><TD>ovary-carcinoma-transitional_cell_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>ovary-carcinoma-transitional_cell_carcinoma</TD><TD>13</TD><TD>1</TD><TD>17775</TD><TD>44</TD>
<TD>RNF43</TD></TR>
<TR><TD>3.177e-02</TD><TD>-3.45</TD><TD>nucleoside phosphate metabolic process</TD><TD>biological process</TD><TD>GO:0006753</TD><TD>450</TD><TD>4</TD><TD>16441</TD><TD>44</TD>
<TD>PDE10A,PRPS1,PDE3A,NT5E</TD></TR>
<TR><TD>3.190e-02</TD><TD>-3.45</TD><TD>human chr1q23</TD><TD>chromosome location</TD><TD>human chr1q23</TD><TD>17</TD><TD>1</TD><TD>26250</TD><TD>50</TD>
<TD>PBX1</TD></TR>
<TR><TD>3.193e-02</TD><TD>-3.44</TD><TD>EphrinB-EPHB pathway</TD><TD>Pathway Interaction DB</TD><TD>ephrinb_ephbpathway</TD><TD>6</TD><TD>1</TD><TD>2227</TD><TD>12</TD>
<TD>EFNB2</TD></TR>
<TR><TD>3.194e-02</TD><TD>-3.44</TD><TD>clear_cell_renal_cell_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>clear_cell_renal_cell_carcinoma</TD><TD>14582</TD><TD>41</TD><TD>17775</TD><TD>44</TD>
<TD>EFNB2,TNIK,CNTNAP3,STXBP6,HFM1,C1orf226,CLSTN2,PBX1,RNF43,ZIC2,PDE3A,S100A10,NEBL,PDE10A,UNC13A,TANK,WNT16,CD44,ETV1,PRPS1,LAMA4,SLC40A1,FGF9,KRT7,PPARG,VSNL1,GRHL3,VIM,ANGPTL4,NR2F1,RHOU,MSX2,CAMK2D,AHNAK2,SLCO5A1,CSMD3,NR2F2,SORCS2,ITGB4,PDLIM5,MMP16</TD></TR>
<TR><TD>3.194e-02</TD><TD>-3.44</TD><TD>kidney-carcinoma-clear_cell_renal_cell_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>kidney-carcinoma-clear_cell_renal_cell_carcinoma</TD><TD>14582</TD><TD>41</TD><TD>17775</TD><TD>44</TD>
<TD>EFNB2,TNIK,CNTNAP3,STXBP6,HFM1,C1orf226,CLSTN2,PBX1,RNF43,ZIC2,PDE3A,S100A10,NEBL,PDE10A,UNC13A,TANK,WNT16,CD44,ETV1,PRPS1,LAMA4,SLC40A1,FGF9,KRT7,PPARG,VSNL1,GRHL3,VIM,ANGPTL4,NR2F1,RHOU,MSX2,CAMK2D,AHNAK2,SLCO5A1,CSMD3,NR2F2,SORCS2,ITGB4,PDLIM5,MMP16</TD></TR>
<TR><TD>3.202e-02</TD><TD>-3.44</TD><TD>sarcolemma</TD><TD>cellular component</TD><TD>GO:0042383</TD><TD>112</TD><TD>2</TD><TD>17570</TD><TD>44</TD>
<TD>CAMK2D,AHNAK2</TD></TR>
<TR><TD>3.207e-02</TD><TD>-3.44</TD><TD>prostate</TD><TD>COSMIC cancer mutations</TD><TD>prostate</TD><TD>14584</TD><TD>41</TD><TD>17775</TD><TD>44</TD>
<TD>EFNB2,TNIK,CNTNAP3,STXBP6,HFM1,C1orf226,CLSTN2,PBX1,RNF43,ZIC2,PDE3A,NEBL,PDE10A,UNC13A,TANK,WNT16,CD44,ETV1,NT5E,LAMA4,SLC40A1,FGF9,MSX1,KRT7,PPARG,VSNL1,GRHL3,ANGPTL4,NR2F1,RHOU,MSX2,CAMK2D,AHNAK2,CSMD3,SLCO5A1,NR2F2,SORCS2,ITGB4,PDLIM5,MMP16,PKIB</TD></TR>
<TR><TD>3.209e-02</TD><TD>-3.44</TD><TD>haematopoietic_and_lymphoid_tissue-lymph_node-lymphoid_neoplasm-mantle_cell_lymphoma</TD><TD>COSMIC cancer mutations</TD><TD>haematopoietic_and_lymphoid_tissue-lymph_node-lymphoid_neoplasm-mantle_cell_lymphoma</TD><TD>488</TD><TD>4</TD><TD>17775</TD><TD>44</TD>
<TD>CSMD3,SORCS2,PDLIM5,PDE3A</TD></TR>
<TR><TD>3.211e-02</TD><TD>-3.44</TD><TD>regulation of dendrite development</TD><TD>biological process</TD><TD>GO:0050773</TD><TD>105</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>TNIK,PDLIM5</TD></TR>
<TR><TD>3.214e-02</TD><TD>-3.44</TD><TD>JUP (junction plakoglobin)</TD><TD>protein interactions</TD><TD>3728</TD><TD>110</TD><TD>2</TD><TD>16036</TD><TD>41</TD>
<TD>ITGB4,PDE3A</TD></TR>
<TR><TD>3.219e-02</TD><TD>-3.44</TD><TD>KEGG_OOCYTE_MEIOSIS</TD><TD>MSigDB lists</TD><TD>KEGG_OOCYTE_MEIOSIS</TD><TD>111</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>CAMK2D,SLK</TD></TR>
<TR><TD>3.234e-02</TD><TD>-3.43</TD><TD>TGGAAA_V$NFAT_Q4_01</TD><TD>MSigDB lists</TD><TD>TGGAAA_V$NFAT_Q4_01</TD><TD>1781</TD><TD>9</TD><TD>17758</TD><TD>45</TD>
<TD>S100A10,SLK,GRHL3,VSNL1,ZIC2,VIM,RNF43,ETV1,PDLIM5</TD></TR>
<TR><TD>3.243e-02</TD><TD>-3.43</TD><TD>cellular component organization or biogenesis</TD><TD>biological process</TD><TD>GO:0071840</TD><TD>5468</TD><TD>21</TD><TD>16441</TD><TD>44</TD>
<TD>EFNB2,LAMA4,TNIK,FGF9,MSX1,HFM1,VIM,ZIC2,ANGPTL4,RHOU,MSX2,CAMK2D,S100A10,NEBL,UNC13A,AHNAK2,WNT16,ITGB4,CD44,ETV1,MMP16</TD></TR>
<TR><TD>3.246e-02</TD><TD>-3.43</TD><TD>NEGATIVE_REGULATION_OF_HYDROLASE_ACTIVITY</TD><TD>MSigDB lists</TD><TD>NEGATIVE_REGULATION_OF_HYDROLASE_ACTIVITY</TD><TD>13</TD><TD>1</TD><TD>17758</TD><TD>45</TD>
<TD>ANGPTL4</TD></TR>
<TR><TD>3.246e-02</TD><TD>-3.43</TD><TD>MYLLYKANGAS_AMPLIFICATION_HOT_SPOT_24</TD><TD>MSigDB lists</TD><TD>MYLLYKANGAS_AMPLIFICATION_HOT_SPOT_24</TD><TD>13</TD><TD>1</TD><TD>17758</TD><TD>45</TD>
<TD>PBX1</TD></TR>
<TR><TD>3.246e-02</TD><TD>-3.43</TD><TD>BIOCARTA_CACAM_PATHWAY</TD><TD>MSigDB lists</TD><TD>BIOCARTA_CACAM_PATHWAY</TD><TD>13</TD><TD>1</TD><TD>17758</TD><TD>45</TD>
<TD>CAMK2D</TD></TR>
<TR><TD>3.246e-02</TD><TD>-3.43</TD><TD>REGULATION_OF_CELLULAR_COMPONENT_SIZE</TD><TD>MSigDB lists</TD><TD>REGULATION_OF_CELLULAR_COMPONENT_SIZE</TD><TD>13</TD><TD>1</TD><TD>17758</TD><TD>45</TD>
<TD>NEBL</TD></TR>
<TR><TD>3.246e-02</TD><TD>-3.43</TD><TD>GERHOLD_RESPONSE_TO_TZD_DN</TD><TD>MSigDB lists</TD><TD>GERHOLD_RESPONSE_TO_TZD_DN</TD><TD>13</TD><TD>1</TD><TD>17758</TD><TD>45</TD>
<TD>PPARG</TD></TR>
<TR><TD>3.246e-02</TD><TD>-3.43</TD><TD>IVANOV_MUTATED_IN_COLON_CANCER</TD><TD>MSigDB lists</TD><TD>IVANOV_MUTATED_IN_COLON_CANCER</TD><TD>13</TD><TD>1</TD><TD>17758</TD><TD>45</TD>
<TD>RNF43</TD></TR>
<TR><TD>3.246e-02</TD><TD>-3.43</TD><TD>INAMURA_LUNG_CANCER_SCC_DN</TD><TD>MSigDB lists</TD><TD>INAMURA_LUNG_CANCER_SCC_DN</TD><TD>13</TD><TD>1</TD><TD>17758</TD><TD>45</TD>
<TD>NR2F1</TD></TR>
<TR><TD>3.248e-02</TD><TD>-3.43</TD><TD>anion binding</TD><TD>molecular function</TD><TD>GO:0043168</TD><TD>2626</TD><TD>12</TD><TD>16491</TD><TD>43</TD>
<TD>RHOU,TNIK,CAMK2D,FGF9,PPARG,STXBP6,SLK,PDE10A,HFM1,NR2F2,PRPS1,PDE3A</TD></TR>
<TR><TD>3.253e-02</TD><TD>-3.43</TD><TD>positive regulation of signal transduction</TD><TD>biological process</TD><TD>GO:0009967</TD><TD>1418</TD><TD>8</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2,TNIK,CAMK2D,FGF9,MSX1,ZIC2,WNT16,CD44</TD></TR>
<TR><TD>3.263e-02</TD><TD>-3.42</TD><TD>TATTATA,MIR-374</TD><TD>MSigDB lists</TD><TD>TATTATA,MIR-374</TD><TD>276</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>MSX1,WNT16,NR2F2</TD></TR>
<TR><TD>3.273e-02</TD><TD>-3.42</TD><TD>seminoma</TD><TD>COSMIC cancer mutations</TD><TD>seminoma</TD><TD>726</TD><TD>5</TD><TD>17775</TD><TD>44</TD>
<TD>CSMD3,LAMA4,TNIK,CAMK2D,PDE10A</TD></TR>
<TR><TD>3.273e-02</TD><TD>-3.42</TD><TD>SCHAEFFER_PROSTATE_DEVELOPMENT_12HR_UP</TD><TD>MSigDB lists</TD><TD>SCHAEFFER_PROSTATE_DEVELOPMENT_12HR_UP</TD><TD>112</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>ITGB4,NT5E</TD></TR>
<TR><TD>3.274e-02</TD><TD>-3.42</TD><TD>STEAP3 (STEAP family member 3, metalloreductase)</TD><TD>protein interactions</TD><TD>55240</TD><TD>13</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>NT5E</TD></TR>
<TR><TD>3.274e-02</TD><TD>-3.42</TD><TD>JMJD1C (jumonji domain containing 1C)</TD><TD>protein interactions</TD><TD>221037</TD><TD>13</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>PPARG</TD></TR>
<TR><TD>3.274e-02</TD><TD>-3.42</TD><TD>PCDH7 (protocadherin 7)</TD><TD>protein interactions</TD><TD>5099</TD><TD>13</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>NT5E</TD></TR>
<TR><TD>3.274e-02</TD><TD>-3.42</TD><TD>PITHD1 (PITH (C-terminal proteasome-interacting domain of thioredoxin-like) domain containing 1)</TD><TD>protein interactions</TD><TD>57095</TD><TD>13</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>SLK</TD></TR>
<TR><TD>3.274e-02</TD><TD>-3.42</TD><TD>FABP4 (fatty acid binding protein 4, adipocyte)</TD><TD>protein interactions</TD><TD>2167</TD><TD>13</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>VIM</TD></TR>
<TR><TD>3.274e-02</TD><TD>-3.42</TD><TD>RETSAT (retinol saturase (all-trans-retinol 13,14-reductase))</TD><TD>protein interactions</TD><TD>54884</TD><TD>13</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>EFNB2</TD></TR>
<TR><TD>3.274e-02</TD><TD>-3.42</TD><TD>LMBR1 (limb development membrane protein 1)</TD><TD>protein interactions</TD><TD>64327</TD><TD>13</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>EFNB2</TD></TR>
<TR><TD>3.274e-02</TD><TD>-3.42</TD><TD>HBEGF (heparin-binding EGF-like growth factor)</TD><TD>protein interactions</TD><TD>1839</TD><TD>13</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>CD44</TD></TR>
<TR><TD>3.274e-02</TD><TD>-3.42</TD><TD>COL17A1 (collagen, type XVII, alpha 1)</TD><TD>protein interactions</TD><TD>1308</TD><TD>13</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>ITGB4</TD></TR>
<TR><TD>3.280e-02</TD><TD>-3.42</TD><TD>regulation of binding</TD><TD>biological process</TD><TD>GO:0051098</TD><TD>262</TD><TD>3</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2,MSX1,S100A10</TD></TR>
<TR><TD>3.290e-02</TD><TD>-3.41</TD><TD>EP300 (E1A binding protein p300)</TD><TD>protein interactions</TD><TD>2033</TD><TD>477</TD><TD>4</TD><TD>16036</TD><TD>41</TD>
<TD>CD44,NR2F2,PPARG,ETV1</TD></TR>
<TR><TD>3.296e-02</TD><TD>-3.41</TD><TD>cell surface</TD><TD>cellular component</TD><TD>GO:0009986</TD><TD>719</TD><TD>5</TD><TD>17570</TD><TD>44</TD>
<TD>CLSTN2,ITGB4,CD44,MMP16,NT5E</TD></TR>
<TR><TD>3.303e-02</TD><TD>-3.41</TD><TD>PKD</TD><TD>smart domains</TD><TD>SM00089</TD><TD>9</TD><TD>1</TD><TD>9131</TD><TD>34</TD>
<TD>SORCS2</TD></TR>
<TR><TD>3.304e-02</TD><TD>-3.41</TD><TD>Signaling by activated point mutants of FGFR1</TD><TD>REACTOME pathways</TD><TD>R-HSA-1839122</TD><TD>11</TD><TD>1</TD><TD>8202</TD><TD>25</TD>
<TD>FGF9</TD></TR>
<TR><TD>3.306e-02</TD><TD>-3.41</TD><TD>RODRIGUES_THYROID_CARCINOMA_ANAPLASTIC_DN</TD><TD>MSigDB lists</TD><TD>RODRIGUES_THYROID_CARCINOMA_ANAPLASTIC_DN</TD><TD>481</TD><TD>4</TD><TD>17758</TD><TD>45</TD>
<TD>PBX1,NEBL,PDLIM5,STXBP6</TD></TR>
<TR><TD>3.307e-02</TD><TD>-3.41</TD><TD>Prostate cancer(PMID:19767753)</TD><TD>GWAS genes</TD><TD>Prostate cancer(PMID:19767753)</TD><TD>5</TD><TD>1</TD><TD>2389</TD><TD>16</TD>
<TD>PDLIM5</TD></TR>
<TR><TD>3.312e-02</TD><TD>-3.41</TD><TD>activation of protein kinase activity</TD><TD>biological process</TD><TD>GO:0032147</TD><TD>456</TD><TD>4</TD><TD>16441</TD><TD>44</TD>
<TD>TNIK,CAMK2D,FGF9,SLK</TD></TR>
<TR><TD>3.313e-02</TD><TD>-3.41</TD><TD>positive regulation of nucleic acid-templated transcription</TD><TD>biological process</TD><TD>GO:1903508</TD><TD>1423</TD><TD>8</TD><TD>16441</TD><TD>44</TD>
<TD>SLC40A1,MSX1,PPARG,GRHL3,PBX1,ZIC2,NR2F2,ETV1</TD></TR>
<TR><TD>3.313e-02</TD><TD>-3.41</TD><TD>positive regulation of transcription, DNA-templated</TD><TD>biological process</TD><TD>GO:0045893</TD><TD>1423</TD><TD>8</TD><TD>16441</TD><TD>44</TD>
<TD>SLC40A1,MSX1,PPARG,GRHL3,PBX1,ZIC2,NR2F2,ETV1</TD></TR>
<TR><TD>3.319e-02</TD><TD>-3.41</TD><TD>NUCLEOBASENUCLEOSIDENUCLEOTIDE_AND_NUCLEIC_ACID_METABOLIC_PROCESS</TD><TD>MSigDB lists</TD><TD>NUCLEOBASENUCLEOSIDENUCLEOTIDE_AND_NUCLEIC_ACID_METABOLIC_PROCESS</TD><TD>1225</TD><TD>7</TD><TD>17758</TD><TD>45</TD>
<TD>PBX1,KRT7,NR2F2,ETV1,PPARG,PRPS1,NT5E</TD></TR>
<TR><TD>3.326e-02</TD><TD>-3.40</TD><TD>HOSHIDA_LIVER_CANCER_SUBCLASS_S2</TD><TD>MSigDB lists</TD><TD>HOSHIDA_LIVER_CANCER_SUBCLASS_S2</TD><TD>113</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>PPARG,NT5E</TD></TR>
<TR><TD>3.329e-02</TD><TD>-3.40</TD><TD>positive regulation of nucleobase-containing compound metabolic process</TD><TD>biological process</TD><TD>GO:0045935</TD><TD>1697</TD><TD>9</TD><TD>16441</TD><TD>44</TD>
<TD>SLC40A1,MSX1,PPARG,GRHL3,PBX1,ZIC2,NR2F2,ETV1,PKIB</TD></TR>
<TR><TD>3.333e-02</TD><TD>-3.40</TD><TD>fibrous_tissue_and_uncertain_origin</TD><TD>COSMIC cancer mutations</TD><TD>fibrous_tissue_and_uncertain_origin</TD><TD>285</TD><TD>3</TD><TD>17775</TD><TD>44</TD>
<TD>CAMK2D,CD44,PDE3A</TD></TR>
<TR><TD>3.337e-02</TD><TD>-3.40</TD><TD>regulation of phosphorylation</TD><TD>biological process</TD><TD>GO:0042325</TD><TD>1425</TD><TD>8</TD><TD>16441</TD><TD>44</TD>
<TD>TNIK,CAMK2D,FGF9,SLK,WNT16,NR2F2,CD44,PKIB</TD></TR>
<TR><TD>3.338e-02</TD><TD>-3.40</TD><TD>long-chain fatty acid binding</TD><TD>molecular function</TD><TD>GO:0036041</TD><TD>13</TD><TD>1</TD><TD>16491</TD><TD>43</TD>
<TD>PPARG</TD></TR>
<TR><TD>3.338e-02</TD><TD>-3.40</TD><TD>lysophospholipid acyltransferase activity</TD><TD>molecular function</TD><TD>GO:0071617</TD><TD>13</TD><TD>1</TD><TD>16491</TD><TD>43</TD>
<TD>GPAT3</TD></TR>
<TR><TD>3.338e-02</TD><TD>-3.40</TD><TD>intermediate filament binding</TD><TD>molecular function</TD><TD>GO:0019215</TD><TD>13</TD><TD>1</TD><TD>16491</TD><TD>43</TD>
<TD>VIM</TD></TR>
<TR><TD>3.363e-02</TD><TD>-3.39</TD><TD>-</TD><TD>gene3d domains</TD><TD>2.60.40.670</TD><TD>11</TD><TD>1</TD><TD>9988</TD><TD>31</TD>
<TD>SORCS2</TD></TR>
<TR><TD>3.375e-02</TD><TD>-3.39</TD><TD>human chr6q22.31</TD><TD>chromosome location</TD><TD>human chr6q22.31</TD><TD>18</TD><TD>1</TD><TD>26250</TD><TD>50</TD>
<TD>PKIB</TD></TR>
<TR><TD>3.381e-02</TD><TD>-3.39</TD><TD>gland morphogenesis</TD><TD>biological process</TD><TD>GO:0022612</TD><TD>108</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2,CD44</TD></TR>
<TR><TD>3.384e-02</TD><TD>-3.39</TD><TD>WANG_MLL_TARGETS</TD><TD>MSigDB lists</TD><TD>WANG_MLL_TARGETS</TD><TD>280</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>ZIC2,ETV1,STXBP6</TD></TR>
<TR><TD>3.393e-02</TD><TD>-3.38</TD><TD>BROWNE_HCMV_INFECTION_48HR_DN</TD><TD>MSigDB lists</TD><TD>BROWNE_HCMV_INFECTION_48HR_DN</TD><TD>485</TD><TD>4</TD><TD>17758</TD><TD>45</TD>
<TD>PBX1,PPARG,ETV1,MMP16</TD></TR>
<TR><TD>3.393e-02</TD><TD>-3.38</TD><TD>anchoring junction</TD><TD>cellular component</TD><TD>GO:0070161</TD><TD>491</TD><TD>4</TD><TD>17570</TD><TD>44</TD>
<TD>EFNB2,RHOU,VIM,CD44</TD></TR>
<TR><TD>3.415e-02</TD><TD>-3.38</TD><TD>MODULE_205</TD><TD>MSigDB lists</TD><TD>MODULE_205</TD><TD>281</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>MSX1,NEBL,STXBP6</TD></TR>
<TR><TD>3.425e-02</TD><TD>-3.37</TD><TD>trophoblast giant cell differentiation</TD><TD>biological process</TD><TD>GO:0060707</TD><TD>13</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>NR2F2</TD></TR>
<TR><TD>3.425e-02</TD><TD>-3.37</TD><TD>telencephalon regionalization</TD><TD>biological process</TD><TD>GO:0021978</TD><TD>13</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>NR2F1</TD></TR>
<TR><TD>3.425e-02</TD><TD>-3.37</TD><TD>white fat cell differentiation</TD><TD>biological process</TD><TD>GO:0050872</TD><TD>13</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>PPARG</TD></TR>
<TR><TD>3.425e-02</TD><TD>-3.37</TD><TD>regulation of development, heterochronic</TD><TD>biological process</TD><TD>GO:0040034</TD><TD>13</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>FGF9</TD></TR>
<TR><TD>3.425e-02</TD><TD>-3.37</TD><TD>regulation of cholesterol storage</TD><TD>biological process</TD><TD>GO:0010885</TD><TD>13</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>PPARG</TD></TR>
<TR><TD>3.425e-02</TD><TD>-3.37</TD><TD>male sex determination</TD><TD>biological process</TD><TD>GO:0030238</TD><TD>13</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>FGF9</TD></TR>
<TR><TD>3.425e-02</TD><TD>-3.37</TD><TD>CDP-diacylglycerol biosynthetic process</TD><TD>biological process</TD><TD>GO:0016024</TD><TD>13</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>GPAT3</TD></TR>
<TR><TD>3.425e-02</TD><TD>-3.37</TD><TD>negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator</TD><TD>biological process</TD><TD>GO:1902166</TD><TD>13</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>CD44</TD></TR>
<TR><TD>3.425e-02</TD><TD>-3.37</TD><TD>positive regulation of DNA damage response, signal transduction by p53 class mediator</TD><TD>biological process</TD><TD>GO:0043517</TD><TD>13</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>MSX1</TD></TR>
<TR><TD>3.425e-02</TD><TD>-3.37</TD><TD>branching involved in prostate gland morphogenesis</TD><TD>biological process</TD><TD>GO:0060442</TD><TD>13</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>CD44</TD></TR>
<TR><TD>3.425e-02</TD><TD>-3.37</TD><TD>negative regulation of macrophage derived foam cell differentiation</TD><TD>biological process</TD><TD>GO:0010745</TD><TD>13</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>PPARG</TD></TR>
<TR><TD>3.425e-02</TD><TD>-3.37</TD><TD>negative regulation of keratinocyte proliferation</TD><TD>biological process</TD><TD>GO:0010839</TD><TD>13</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>EFNB2</TD></TR>
<TR><TD>3.425e-02</TD><TD>-3.37</TD><TD>regulation of cAMP-dependent protein kinase activity</TD><TD>biological process</TD><TD>GO:2000479</TD><TD>13</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>PKIB</TD></TR>
<TR><TD>3.425e-02</TD><TD>-3.37</TD><TD>mesenchymal cell proliferation</TD><TD>biological process</TD><TD>GO:0010463</TD><TD>13</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>MSX1</TD></TR>
<TR><TD>3.425e-02</TD><TD>-3.37</TD><TD>urate metabolic process</TD><TD>biological process</TD><TD>GO:0046415</TD><TD>13</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>PRPS1</TD></TR>
<TR><TD>3.425e-02</TD><TD>-3.37</TD><TD>positive regulation of muscle cell apoptotic process</TD><TD>biological process</TD><TD>GO:0010661</TD><TD>13</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>CAMK2D</TD></TR>
<TR><TD>3.425e-02</TD><TD>-3.37</TD><TD>outflow tract septum morphogenesis</TD><TD>biological process</TD><TD>GO:0003148</TD><TD>13</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2</TD></TR>
<TR><TD>3.425e-02</TD><TD>-3.37</TD><TD>negative regulation of DNA damage response, signal transduction by p53 class mediator</TD><TD>biological process</TD><TD>GO:0043518</TD><TD>13</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>CD44</TD></TR>
<TR><TD>3.425e-02</TD><TD>-3.37</TD><TD>regulation of cell communication by electrical coupling</TD><TD>biological process</TD><TD>GO:0010649</TD><TD>13</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>CAMK2D</TD></TR>
<TR><TD>3.425e-02</TD><TD>-3.37</TD><TD>response to low-density lipoprotein particle</TD><TD>biological process</TD><TD>GO:0055098</TD><TD>13</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>PPARG</TD></TR>
<TR><TD>3.425e-02</TD><TD>-3.37</TD><TD>regulation of establishment of planar polarity involved in neural tube closure</TD><TD>biological process</TD><TD>GO:0090178</TD><TD>13</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>GRHL3</TD></TR>
<TR><TD>3.425e-02</TD><TD>-3.37</TD><TD>negative regulation of telomerase activity</TD><TD>biological process</TD><TD>GO:0051974</TD><TD>13</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>PPARG</TD></TR>
<TR><TD>3.447e-02</TD><TD>-3.37</TD><TD>kidney-carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>kidney-carcinoma</TD><TD>3789</TD><TD>15</TD><TD>17775</TD><TD>44</TD>
<TD>RHOU,TNIK,CAMK2D,PPARG,TANK,CSMD3,PBX1,VIM,CD44,ITGB4,NR2F2,ETV1,MMP16,PRPS1,NR2F1</TD></TR>
<TR><TD>3.451e-02</TD><TD>-3.37</TD><TD>vasculature development</TD><TD>biological process</TD><TD>GO:0001944</TD><TD>462</TD><TD>4</TD><TD>16441</TD><TD>44</TD>
<TD>EFNB2,FGF9,NR2F2,ANGPTL4</TD></TR>
<TR><TD>3.452e-02</TD><TD>-3.37</TD><TD>cellular response to stimulus</TD><TD>biological process</TD><TD>GO:0051716</TD><TD>6201</TD><TD>23</TD><TD>16441</TD><TD>44</TD>
<TD>EFNB2,SLC40A1,TNIK,FGF9,MSX1,PPARG,SLK,GRHL3,VIM,RNF43,PDE3A,NR2F1,RHOU,MSX2,CAMK2D,PDE10A,TANK,UNC13A,WNT16,ITGB4,CD44,SORCS2,NR2F2</TD></TR>
<TR><TD>3.465e-02</TD><TD>-3.36</TD><TD>Link_dom</TD><TD>interpro domains</TD><TD>IPR000538</TD><TD>14</TD><TD>1</TD><TD>18293</TD><TD>46</TD>
<TD>CD44</TD></TR>
<TR><TD>3.476e-02</TD><TD>-3.36</TD><TD>BROWNE_HCMV_INFECTION_14HR_DN</TD><TD>MSigDB lists</TD><TD>BROWNE_HCMV_INFECTION_14HR_DN</TD><TD>283</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>ETV1,MMP16,AHNAK2</TD></TR>
<TR><TD>3.476e-02</TD><TD>-3.36</TD><TD>REGULATION_OF_TRANSCRIPTION_FROM_RNA_POLYMERASE_II_PROMOTER</TD><TD>MSigDB lists</TD><TD>REGULATION_OF_TRANSCRIPTION_FROM_RNA_POLYMERASE_II_PROMOTER</TD><TD>283</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>PBX1,NR2F2,PPARG</TD></TR>
<TR><TD>3.490e-02</TD><TD>-3.36</TD><TD>chr4p16</TD><TD>MSigDB lists</TD><TD>chr4p16</TD><TD>116</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>MSX1,SORCS2</TD></TR>
<TR><TD>3.491e-02</TD><TD>-3.35</TD><TD>MATZUK_OVULATION</TD><TD>MSigDB lists</TD><TD>MATZUK_OVULATION</TD><TD>14</TD><TD>1</TD><TD>17758</TD><TD>45</TD>
<TD>PDE3A</TD></TR>
<TR><TD>3.491e-02</TD><TD>-3.35</TD><TD>chr13q33</TD><TD>MSigDB lists</TD><TD>chr13q33</TD><TD>14</TD><TD>1</TD><TD>17758</TD><TD>45</TD>
<TD>EFNB2</TD></TR>
<TR><TD>3.491e-02</TD><TD>-3.35</TD><TD>VERRECCHIA_RESPONSE_TO_TGFB1_C3</TD><TD>MSigDB lists</TD><TD>VERRECCHIA_RESPONSE_TO_TGFB1_C3</TD><TD>14</TD><TD>1</TD><TD>17758</TD><TD>45</TD>
<TD>LAMA4</TD></TR>
<TR><TD>3.491e-02</TD><TD>-3.35</TD><TD>HUMMEL_BURKITTS_LYMPHOMA_DN</TD><TD>MSigDB lists</TD><TD>HUMMEL_BURKITTS_LYMPHOMA_DN</TD><TD>14</TD><TD>1</TD><TD>17758</TD><TD>45</TD>
<TD>CD44</TD></TR>
<TR><TD>3.491e-02</TD><TD>-3.35</TD><TD>WORSCHECH_TUMOR_EVASION_AND_TOLEROGENICITY_DN</TD><TD>MSigDB lists</TD><TD>WORSCHECH_TUMOR_EVASION_AND_TOLEROGENICITY_DN</TD><TD>14</TD><TD>1</TD><TD>17758</TD><TD>45</TD>
<TD>TANK</TD></TR>
<TR><TD>3.491e-02</TD><TD>-3.35</TD><TD>SA_MMP_CYTOKINE_CONNECTION</TD><TD>MSigDB lists</TD><TD>SA_MMP_CYTOKINE_CONNECTION</TD><TD>14</TD><TD>1</TD><TD>17758</TD><TD>45</TD>
<TD>CD44</TD></TR>
<TR><TD>3.491e-02</TD><TD>-3.35</TD><TD>REACTOME_FGFR1_LIGAND_BINDING_AND_ACTIVATION</TD><TD>MSigDB lists</TD><TD>REACTOME_FGFR1_LIGAND_BINDING_AND_ACTIVATION</TD><TD>14</TD><TD>1</TD><TD>17758</TD><TD>45</TD>
<TD>FGF9</TD></TR>
<TR><TD>3.491e-02</TD><TD>-3.35</TD><TD>REACTOME_HYALURONAN_METABOLISM</TD><TD>MSigDB lists</TD><TD>REACTOME_HYALURONAN_METABOLISM</TD><TD>14</TD><TD>1</TD><TD>17758</TD><TD>45</TD>
<TD>CD44</TD></TR>
<TR><TD>3.491e-02</TD><TD>-3.35</TD><TD>BIOCARTA_NUCLEARRS_PATHWAY</TD><TD>MSigDB lists</TD><TD>BIOCARTA_NUCLEARRS_PATHWAY</TD><TD>14</TD><TD>1</TD><TD>17758</TD><TD>45</TD>
<TD>PPARG</TD></TR>
<TR><TD>3.502e-02</TD><TD>-3.35</TD><TD>structure-specific DNA binding</TD><TD>molecular function</TD><TD>GO:0043566</TD><TD>113</TD><TD>2</TD><TD>16491</TD><TD>43</TD>
<TD>ZIC2,GRHL3</TD></TR>
<TR><TD>3.522e-02</TD><TD>-3.35</TD><TD>ASB11 (ankyrin repeat and SOCS box containing 11, E3 ubiquitin protein ligase)</TD><TD>protein interactions</TD><TD>140456</TD><TD>14</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>PRPS1</TD></TR>
<TR><TD>3.522e-02</TD><TD>-3.35</TD><TD>CACNA1B (calcium channel, voltage-dependent, N type, alpha 1B subunit)</TD><TD>protein interactions</TD><TD>774</TD><TD>14</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>PDLIM5</TD></TR>
<TR><TD>3.522e-02</TD><TD>-3.35</TD><TD>SELE (selectin E)</TD><TD>protein interactions</TD><TD>6401</TD><TD>14</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>CD44</TD></TR>
<TR><TD>3.522e-02</TD><TD>-3.35</TD><TD>RGS7 (regulator of G-protein signaling 7)</TD><TD>protein interactions</TD><TD>6000</TD><TD>14</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>MSX1</TD></TR>
<TR><TD>3.522e-02</TD><TD>-3.35</TD><TD>SPATA24 (spermatogenesis associated 24)</TD><TD>protein interactions</TD><TD>202051</TD><TD>14</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>CAMK2D</TD></TR>
<TR><TD>3.522e-02</TD><TD>-3.35</TD><TD>ELMSAN1 (ELM2 and Myb/SANT-like domain containing 1)</TD><TD>protein interactions</TD><TD>91748</TD><TD>14</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>PDLIM5</TD></TR>
<TR><TD>3.522e-02</TD><TD>-3.35</TD><TD>POU1F1 (POU class 1 homeobox 1)</TD><TD>protein interactions</TD><TD>5449</TD><TD>14</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>PPARG</TD></TR>
<TR><TD>3.522e-02</TD><TD>-3.35</TD><TD>TRIM16 (tripartite motif containing 16)</TD><TD>protein interactions</TD><TD>10626</TD><TD>14</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>VIM</TD></TR>
<TR><TD>3.522e-02</TD><TD>-3.35</TD><TD>MAB21L2 (mab-21-like 2 (C. elegans))</TD><TD>protein interactions</TD><TD>10586</TD><TD>14</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>PBX1</TD></TR>
<TR><TD>3.522e-02</TD><TD>-3.35</TD><TD>HECW1 (HECT, C2 and WW domain containing E3 ubiquitin protein ligase 1)</TD><TD>protein interactions</TD><TD>23072</TD><TD>14</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>RNF43</TD></TR>
<TR><TD>3.522e-02</TD><TD>-3.35</TD><TD>KIF14 (kinesin family member 14)</TD><TD>protein interactions</TD><TD>9928</TD><TD>14</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>EFNB2</TD></TR>
<TR><TD>3.522e-02</TD><TD>-3.35</TD><TD>SAR1B (secretion associated, Ras related GTPase 1B)</TD><TD>protein interactions</TD><TD>51128</TD><TD>14</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>NT5E</TD></TR>
<TR><TD>3.522e-02</TD><TD>-3.35</TD><TD>DLC1 (DLC1 Rho GTPase activating protein)</TD><TD>protein interactions</TD><TD>10395</TD><TD>14</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>S100A10</TD></TR>
<TR><TD>3.526e-02</TD><TD>-3.35</TD><TD>BONOME_OVARIAN_CANCER_SURVIVAL_SUBOPTIMAL_DEBULKING</TD><TD>MSigDB lists</TD><TD>BONOME_OVARIAN_CANCER_SURVIVAL_SUBOPTIMAL_DEBULKING</TD><TD>491</TD><TD>4</TD><TD>17758</TD><TD>45</TD>
<TD>ITGB4,NR2F2,NR2F1,NT5E</TD></TR>
<TR><TD>3.538e-02</TD><TD>-3.34</TD><TD>MORF_ARL3</TD><TD>MSigDB lists</TD><TD>MORF_ARL3</TD><TD>285</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>MSX1,PDE10A,NR2F1</TD></TR>
<TR><TD>3.545e-02</TD><TD>-3.34</TD><TD>CHIARADONNA_NEOPLASTIC_TRANSFORMATION_CDC25_UP</TD><TD>MSigDB lists</TD><TD>CHIARADONNA_NEOPLASTIC_TRANSFORMATION_CDC25_UP</TD><TD>117</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>LAMA4,EFNB2</TD></TR>
<TR><TD>3.545e-02</TD><TD>-3.34</TD><TD>BURTON_ADIPOGENESIS_5</TD><TD>MSigDB lists</TD><TD>BURTON_ADIPOGENESIS_5</TD><TD>117</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>PPARG,PRPS1</TD></TR>
<TR><TD>3.555e-02</TD><TD>-3.34</TD><TD>nucleoside biosynthetic process</TD><TD>biological process</TD><TD>GO:0009163</TD><TD>111</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>PRPS1,NT5E</TD></TR>
<TR><TD>3.559e-02</TD><TD>-3.34</TD><TD>human chr7q31</TD><TD>chromosome location</TD><TD>human chr7q31</TD><TD>19</TD><TD>1</TD><TD>26250</TD><TD>50</TD>
<TD>WNT16</TD></TR>
<TR><TD>3.559e-02</TD><TD>-3.34</TD><TD>human chr8q21.3</TD><TD>chromosome location</TD><TD>human chr8q21.3</TD><TD>19</TD><TD>1</TD><TD>26250</TD><TD>50</TD>
<TD>MMP16</TD></TR>
<TR><TD>3.559e-02</TD><TD>-3.34</TD><TD>human chr2q24.2</TD><TD>chromosome location</TD><TD>human chr2q24.2</TD><TD>19</TD><TD>1</TD><TD>26250</TD><TD>50</TD>
<TD>TANK</TD></TR>
<TR><TD>3.575e-02</TD><TD>-3.33</TD><TD>Proteoglycans in cancer</TD><TD>KEGG pathways</TD><TD>ko05205</TD><TD>203</TD><TD>3</TD><TD>6908</TD><TD>25</TD>
<TD>CAMK2D,WNT16,CD44</TD></TR>
<TR><TD>3.575e-02</TD><TD>-3.33</TD><TD>Proteoglycans in cancer</TD><TD>KEGG pathways</TD><TD>hsa05205</TD><TD>203</TD><TD>3</TD><TD>6908</TD><TD>25</TD>
<TD>CAMK2D,WNT16,CD44</TD></TR>
<TR><TD>3.577e-02</TD><TD>-3.33</TD><TD>positive regulation of transferase activity</TD><TD>biological process</TD><TD>GO:0051347</TD><TD>688</TD><TD>5</TD><TD>16441</TD><TD>44</TD>
<TD>TNIK,CAMK2D,FGF9,SLK,PKIB</TD></TR>
<TR><TD>3.585e-02</TD><TD>-3.33</TD><TD>protein homodimerization activity</TD><TD>molecular function</TD><TD>GO:0042803</TD><TD>707</TD><TD>5</TD><TD>16491</TD><TD>43</TD>
<TD>CAMK2D,NR2F2,S100A10,PRPS1,SLK</TD></TR>
<TR><TD>3.591e-02</TD><TD>-3.33</TD><TD>nucleotidase activity</TD><TD>molecular function</TD><TD>GO:0008252</TD><TD>14</TD><TD>1</TD><TD>16491</TD><TD>43</TD>
<TD>NT5E</TD></TR>
<TR><TD>3.591e-02</TD><TD>-3.33</TD><TD>titin binding</TD><TD>molecular function</TD><TD>GO:0031432</TD><TD>14</TD><TD>1</TD><TD>16491</TD><TD>43</TD>
<TD>CAMK2D</TD></TR>
<TR><TD>3.591e-02</TD><TD>-3.33</TD><TD>tropomyosin binding</TD><TD>molecular function</TD><TD>GO:0005523</TD><TD>14</TD><TD>1</TD><TD>16491</TD><TD>43</TD>
<TD>NEBL</TD></TR>
<TR><TD>3.599e-02</TD><TD>-3.32</TD><TD>FGFR3 mutant receptor activation</TD><TD>REACTOME pathways</TD><TD>R-HSA-2033514</TD><TD>12</TD><TD>1</TD><TD>8202</TD><TD>25</TD>
<TD>FGF9</TD></TR>
<TR><TD>3.599e-02</TD><TD>-3.32</TD><TD>FGFR3 ligand binding and activation</TD><TD>REACTOME pathways</TD><TD>R-HSA-190239</TD><TD>12</TD><TD>1</TD><TD>8202</TD><TD>25</TD>
<TD>FGF9</TD></TR>
<TR><TD>3.599e-02</TD><TD>-3.32</TD><TD>FGFR3c ligand binding and activation</TD><TD>REACTOME pathways</TD><TD>R-HSA-190372</TD><TD>12</TD><TD>1</TD><TD>8202</TD><TD>25</TD>
<TD>FGF9</TD></TR>
<TR><TD>3.599e-02</TD><TD>-3.32</TD><TD>Pyrimidine catabolism</TD><TD>REACTOME pathways</TD><TD>R-HSA-73621</TD><TD>12</TD><TD>1</TD><TD>8202</TD><TD>25</TD>
<TD>NT5E</TD></TR>
<TR><TD>3.599e-02</TD><TD>-3.32</TD><TD>Hyaluronan uptake and degradation</TD><TD>REACTOME pathways</TD><TD>R-HSA-2160916</TD><TD>12</TD><TD>1</TD><TD>8202</TD><TD>25</TD>
<TD>CD44</TD></TR>
<TR><TD>3.599e-02</TD><TD>-3.32</TD><TD>Signaling by activated point mutants of FGFR3</TD><TD>REACTOME pathways</TD><TD>R-HSA-1839130</TD><TD>12</TD><TD>1</TD><TD>8202</TD><TD>25</TD>
<TD>FGF9</TD></TR>
<TR><TD>3.599e-02</TD><TD>-3.32</TD><TD>Caspase-mediated cleavage of cytoskeletal proteins</TD><TD>REACTOME pathways</TD><TD>R-HSA-264870</TD><TD>12</TD><TD>1</TD><TD>8202</TD><TD>25</TD>
<TD>VIM</TD></TR>
<TR><TD>3.599e-02</TD><TD>-3.32</TD><TD>FGFR1c ligand binding and activation</TD><TD>REACTOME pathways</TD><TD>R-HSA-190373</TD><TD>12</TD><TD>1</TD><TD>8202</TD><TD>25</TD>
<TD>FGF9</TD></TR>
<TR><TD>3.613e-02</TD><TD>-3.32</TD><TD>neuron migration</TD><TD>biological process</TD><TD>GO:0001764</TD><TD>112</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>NR2F2,NR2F1</TD></TR>
<TR><TD>3.613e-02</TD><TD>-3.32</TD><TD>regulation of embryonic development</TD><TD>biological process</TD><TD>GO:0045995</TD><TD>112</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>LAMA4,GRHL3</TD></TR>
<TR><TD>3.626e-02</TD><TD>-3.32</TD><TD>DODD_NASOPHARYNGEAL_CARCINOMA_UP</TD><TD>MSigDB lists</TD><TD>DODD_NASOPHARYNGEAL_CARCINOMA_UP</TD><TD>1528</TD><TD>8</TD><TD>17758</TD><TD>45</TD>
<TD>RHOU,FGF9,KRT7,NEBL,PPARG,HFM1,GRHL3,AHNAK2</TD></TR>
<TR><TD>3.633e-02</TD><TD>-3.32</TD><TD>TGANNYRGCA_V$TCF11MAFG_01</TD><TD>MSigDB lists</TD><TD>TGANNYRGCA_V$TCF11MAFG_01</TD><TD>288</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>FGF9,PPARG,ANGPTL4</TD></TR>
<TR><TD>3.633e-02</TD><TD>-3.32</TD><TD>ZHANG_TLX_TARGETS_60HR_UP</TD><TD>MSigDB lists</TD><TD>ZHANG_TLX_TARGETS_60HR_UP</TD><TD>288</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>EFNB2,S100A10,SORCS2</TD></TR>
<TR><TD>3.643e-02</TD><TD>-3.31</TD><TD>EF-hand_1</TD><TD>pfam domains</TD><TD>PF00036</TD><TD>14</TD><TD>1</TD><TD>16629</TD><TD>44</TD>
<TD>VSNL1</TD></TR>
<TR><TD>3.643e-02</TD><TD>-3.31</TD><TD>Xlink</TD><TD>pfam domains</TD><TD>PF00193</TD><TD>14</TD><TD>1</TD><TD>16629</TD><TD>44</TD>
<TD>CD44</TD></TR>
<TR><TD>3.648e-02</TD><TD>-3.31</TD><TD>PKD</TD><TD>prosite domains</TD><TD>PS50093</TD><TD>11</TD><TD>1</TD><TD>11866</TD><TD>40</TD>
<TD>SORCS2</TD></TR>
<TR><TD>3.651e-02</TD><TD>-3.31</TD><TD>dysgerminoma</TD><TD>COSMIC cancer mutations</TD><TD>dysgerminoma</TD><TD>15</TD><TD>1</TD><TD>17775</TD><TD>44</TD>
<TD>RNF43</TD></TR>
<TR><TD>3.651e-02</TD><TD>-3.31</TD><TD>ovary-germ_cell_tumour-dysgerminoma</TD><TD>COSMIC cancer mutations</TD><TD>ovary-germ_cell_tumour-dysgerminoma</TD><TD>15</TD><TD>1</TD><TD>17775</TD><TD>44</TD>
<TD>RNF43</TD></TR>
<TR><TD>3.651e-02</TD><TD>-3.31</TD><TD>ovary-germ_cell_tumour-yolk_sac_tumour</TD><TD>COSMIC cancer mutations</TD><TD>ovary-germ_cell_tumour-yolk_sac_tumour</TD><TD>15</TD><TD>1</TD><TD>17775</TD><TD>44</TD>
<TD>RNF43</TD></TR>
<TR><TD>3.656e-02</TD><TD>-3.31</TD><TD>TCTCTCC,MIR-185</TD><TD>MSigDB lists</TD><TD>TCTCTCC,MIR-185</TD><TD>119</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>PBX1,CAMK2D</TD></TR>
<TR><TD>3.656e-02</TD><TD>-3.31</TD><TD>IZADPANAH_STEM_CELL_ADIPOSE_VS_BONE_UP</TD><TD>MSigDB lists</TD><TD>IZADPANAH_STEM_CELL_ADIPOSE_VS_BONE_UP</TD><TD>119</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>CD44,NR2F2</TD></TR>
<TR><TD>3.656e-02</TD><TD>-3.31</TD><TD>IWANAGA_CARCINOGENESIS_BY_KRAS_DN</TD><TD>MSigDB lists</TD><TD>IWANAGA_CARCINOGENESIS_BY_KRAS_DN</TD><TD>119</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>ITGB4,NR2F2</TD></TR>
<TR><TD>3.656e-02</TD><TD>-3.31</TD><TD>V$CDPCR1_01</TD><TD>MSigDB lists</TD><TD>V$CDPCR1_01</TD><TD>119</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>CSMD3,ETV1</TD></TR>
<TR><TD>3.662e-02</TD><TD>-3.31</TD><TD>positive regulation of RNA biosynthetic process</TD><TD>biological process</TD><TD>GO:1902680</TD><TD>1451</TD><TD>8</TD><TD>16441</TD><TD>44</TD>
<TD>SLC40A1,MSX1,PPARG,GRHL3,PBX1,ZIC2,NR2F2,ETV1</TD></TR>
<TR><TD>3.664e-02</TD><TD>-3.31</TD><TD>-</TD><TD>gene3d domains</TD><TD>3.40.50.2020</TD><TD>12</TD><TD>1</TD><TD>9988</TD><TD>31</TD>
<TD>PRPS1</TD></TR>
<TR><TD>3.664e-02</TD><TD>-3.31</TD><TD>CNH</TD><TD>smart domains</TD><TD>SM00036</TD><TD>10</TD><TD>1</TD><TD>9131</TD><TD>34</TD>
<TD>TNIK</TD></TR>
<TR><TD>3.672e-02</TD><TD>-3.30</TD><TD>negative regulation of epithelial cell proliferation</TD><TD>biological process</TD><TD>GO:0050680</TD><TD>113</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>EFNB2,NR2F2</TD></TR>
<TR><TD>3.672e-02</TD><TD>-3.30</TD><TD>glycosyl compound biosynthetic process</TD><TD>biological process</TD><TD>GO:1901659</TD><TD>113</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>PRPS1,NT5E</TD></TR>
<TR><TD>3.684e-02</TD><TD>-3.30</TD><TD>lens fiber cell development</TD><TD>biological process</TD><TD>GO:0070307</TD><TD>14</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>VIM</TD></TR>
<TR><TD>3.684e-02</TD><TD>-3.30</TD><TD>purine ribonucleoside catabolic process</TD><TD>biological process</TD><TD>GO:0046130</TD><TD>14</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>NT5E</TD></TR>
<TR><TD>3.684e-02</TD><TD>-3.30</TD><TD>regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator</TD><TD>biological process</TD><TD>GO:1902165</TD><TD>14</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>CD44</TD></TR>
<TR><TD>3.684e-02</TD><TD>-3.30</TD><TD>positive regulation of fatty acid oxidation</TD><TD>biological process</TD><TD>GO:0046321</TD><TD>14</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>PPARG</TD></TR>
<TR><TD>3.684e-02</TD><TD>-3.30</TD><TD>CDP-diacylglycerol metabolic process</TD><TD>biological process</TD><TD>GO:0046341</TD><TD>14</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>GPAT3</TD></TR>
<TR><TD>3.684e-02</TD><TD>-3.30</TD><TD>purine nucleoside catabolic process</TD><TD>biological process</TD><TD>GO:0006152</TD><TD>14</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>NT5E</TD></TR>
<TR><TD>3.684e-02</TD><TD>-3.30</TD><TD>beta-amyloid metabolic process</TD><TD>biological process</TD><TD>GO:0050435</TD><TD>14</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>UNC13A</TD></TR>
<TR><TD>3.684e-02</TD><TD>-3.30</TD><TD>positive regulation of oligodendrocyte differentiation</TD><TD>biological process</TD><TD>GO:0048714</TD><TD>14</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>PPARG</TD></TR>
<TR><TD>3.684e-02</TD><TD>-3.30</TD><TD>FORTSCHEGGER_PHF8_TARGETS_DN</TD><TD>MSigDB lists</TD><TD>FORTSCHEGGER_PHF8_TARGETS_DN</TD><TD>732</TD><TD>5</TD><TD>17758</TD><TD>45</TD>
<TD>PBX1,ITGB4,STXBP6,NT5E,AHNAK2</TD></TR>
<TR><TD>3.708e-02</TD><TD>-3.29</TD><TD>CNH_dom</TD><TD>interpro domains</TD><TD>IPR001180</TD><TD>15</TD><TD>1</TD><TD>18293</TD><TD>46</TD>
<TD>TNIK</TD></TR>
<TR><TD>3.708e-02</TD><TD>-3.29</TD><TD>Pept_M10A_Zn_BS</TD><TD>interpro domains</TD><TD>IPR021158</TD><TD>15</TD><TD>1</TD><TD>18293</TD><TD>46</TD>
<TD>MMP16</TD></TR>
<TR><TD>3.712e-02</TD><TD>-3.29</TD><TD>REACTOME_G_ALPHA_S_SIGNALLING_EVENTS</TD><TD>MSigDB lists</TD><TD>REACTOME_G_ALPHA_S_SIGNALLING_EVENTS</TD><TD>120</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>PDE10A,PDE3A</TD></TR>
<TR><TD>3.712e-02</TD><TD>-3.29</TD><TD>RB_DN.V1_DN</TD><TD>MSigDB lists</TD><TD>RB_DN.V1_DN</TD><TD>120</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>CD44,KRT7</TD></TR>
<TR><TD>3.712e-02</TD><TD>-3.29</TD><TD>ARGGGTTAA_UNKNOWN</TD><TD>MSigDB lists</TD><TD>ARGGGTTAA_UNKNOWN</TD><TD>120</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>CSMD3,FGF9</TD></TR>
<TR><TD>3.732e-02</TD><TD>-3.29</TD><TD>positive regulation of JNK cascade</TD><TD>biological process</TD><TD>GO:0046330</TD><TD>114</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>TNIK,WNT16</TD></TR>
<TR><TD>3.736e-02</TD><TD>-3.29</TD><TD>OZANNE_AP1_TARGETS_UP</TD><TD>MSigDB lists</TD><TD>OZANNE_AP1_TARGETS_UP</TD><TD>15</TD><TD>1</TD><TD>17758</TD><TD>45</TD>
<TD>CD44</TD></TR>
<TR><TD>3.736e-02</TD><TD>-3.29</TD><TD>REACTOME_UNBLOCKING_OF_NMDA_RECEPTOR_GLUTAMATE_BINDING_AND_ACTIVATION</TD><TD>MSigDB lists</TD><TD>REACTOME_UNBLOCKING_OF_NMDA_RECEPTOR_GLUTAMATE_BINDING_AND_ACTIVATION</TD><TD>15</TD><TD>1</TD><TD>17758</TD><TD>45</TD>
<TD>CAMK2D</TD></TR>
<TR><TD>3.736e-02</TD><TD>-3.29</TD><TD>REACTOME_CREB_PHOSPHORYLATION_THROUGH_THE_ACTIVATION_OF_CAMKII</TD><TD>MSigDB lists</TD><TD>REACTOME_CREB_PHOSPHORYLATION_THROUGH_THE_ACTIVATION_OF_CAMKII</TD><TD>15</TD><TD>1</TD><TD>17758</TD><TD>45</TD>
<TD>CAMK2D</TD></TR>
<TR><TD>3.736e-02</TD><TD>-3.29</TD><TD>FINETTI_BREAST_CANCERS_KINOME_GRAY</TD><TD>MSigDB lists</TD><TD>FINETTI_BREAST_CANCERS_KINOME_GRAY</TD><TD>15</TD><TD>1</TD><TD>17758</TD><TD>45</TD>
<TD>SLK</TD></TR>
<TR><TD>3.736e-02</TD><TD>-3.29</TD><TD>DAVICIONI_RHABDOMYOSARCOMA_PAX_FOXO1_FUSION_DN</TD><TD>MSigDB lists</TD><TD>DAVICIONI_RHABDOMYOSARCOMA_PAX_FOXO1_FUSION_DN</TD><TD>15</TD><TD>1</TD><TD>17758</TD><TD>45</TD>
<TD>FGF9</TD></TR>
<TR><TD>3.736e-02</TD><TD>-3.29</TD><TD>CARBOHYDRATE_KINASE_ACTIVITY</TD><TD>MSigDB lists</TD><TD>CARBOHYDRATE_KINASE_ACTIVITY</TD><TD>15</TD><TD>1</TD><TD>17758</TD><TD>45</TD>
<TD>PRPS1</TD></TR>
<TR><TD>3.736e-02</TD><TD>-3.29</TD><TD>RAY_TARGETS_OF_P210_BCR_ABL_FUSION_UP</TD><TD>MSigDB lists</TD><TD>RAY_TARGETS_OF_P210_BCR_ABL_FUSION_UP</TD><TD>15</TD><TD>1</TD><TD>17758</TD><TD>45</TD>
<TD>PDLIM5</TD></TR>
<TR><TD>3.736e-02</TD><TD>-3.29</TD><TD>NIELSEN_LEIOMYOSARCOMA_DN</TD><TD>MSigDB lists</TD><TD>NIELSEN_LEIOMYOSARCOMA_DN</TD><TD>15</TD><TD>1</TD><TD>17758</TD><TD>45</TD>
<TD>PBX1</TD></TR>
<TR><TD>3.736e-02</TD><TD>-3.29</TD><TD>SCHURINGA_STAT5A_TARGETS_DN</TD><TD>MSigDB lists</TD><TD>SCHURINGA_STAT5A_TARGETS_DN</TD><TD>15</TD><TD>1</TD><TD>17758</TD><TD>45</TD>
<TD>CD44</TD></TR>
<TR><TD>3.743e-02</TD><TD>-3.29</TD><TD>human chr1p22.2</TD><TD>chromosome location</TD><TD>human chr1p22.2</TD><TD>20</TD><TD>1</TD><TD>26250</TD><TD>50</TD>
<TD>HFM1</TD></TR>
<TR><TD>3.743e-02</TD><TD>-3.29</TD><TD>human chr17q24.3</TD><TD>chromosome location</TD><TD>human chr17q24.3</TD><TD>20</TD><TD>1</TD><TD>26250</TD><TD>50</TD>
<TD>LINC00511</TD></TR>
<TR><TD>3.763e-02</TD><TD>-3.28</TD><TD>regulation of mitotic cell cycle</TD><TD>biological process</TD><TD>GO:0007346</TD><TD>475</TD><TD>4</TD><TD>16441</TD><TD>44</TD>
<TD>PBX1,TNIK,CAMK2D,SLK</TD></TR>
<TR><TD>3.768e-02</TD><TD>-3.28</TD><TD>CENTRAL_NERVOUS_SYSTEM_DEVELOPMENT</TD><TD>MSigDB lists</TD><TD>CENTRAL_NERVOUS_SYSTEM_DEVELOPMENT</TD><TD>121</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>PBX1,ZIC2</TD></TR>
<TR><TD>3.769e-02</TD><TD>-3.28</TD><TD>STK40 (serine/threonine kinase 40)</TD><TD>protein interactions</TD><TD>83931</TD><TD>15</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>ETV1</TD></TR>
<TR><TD>3.769e-02</TD><TD>-3.28</TD><TD>GRM1 (glutamate receptor, metabotropic 1)</TD><TD>protein interactions</TD><TD>2911</TD><TD>15</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>EFNB2</TD></TR>
<TR><TD>3.769e-02</TD><TD>-3.28</TD><TD>ZC3H12A (zinc finger CCCH-type containing 12A)</TD><TD>protein interactions</TD><TD>80149</TD><TD>15</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>TANK</TD></TR>
<TR><TD>3.769e-02</TD><TD>-3.28</TD><TD>MAN2A2 (mannosidase, alpha, class 2A, member 2)</TD><TD>protein interactions</TD><TD>4122</TD><TD>15</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>VIM</TD></TR>
<TR><TD>3.769e-02</TD><TD>-3.28</TD><TD>GADD45B (growth arrest and DNA-damage-inducible, beta)</TD><TD>protein interactions</TD><TD>4616</TD><TD>15</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>PPARG</TD></TR>
<TR><TD>3.769e-02</TD><TD>-3.28</TD><TD>DET1 (de-etiolated homolog 1 (Arabidopsis))</TD><TD>protein interactions</TD><TD>55070</TD><TD>15</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>ETV1</TD></TR>
<TR><TD>3.769e-02</TD><TD>-3.28</TD><TD>PRPH (peripherin)</TD><TD>protein interactions</TD><TD>5630</TD><TD>15</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>VIM</TD></TR>
<TR><TD>3.769e-02</TD><TD>-3.28</TD><TD>GOLGA4 (golgin A4)</TD><TD>protein interactions</TD><TD>2803</TD><TD>15</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>TNIK</TD></TR>
<TR><TD>3.769e-02</TD><TD>-3.28</TD><TD>COL14A1 (collagen, type XIV, alpha 1)</TD><TD>protein interactions</TD><TD>7373</TD><TD>15</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>CD44</TD></TR>
<TR><TD>3.769e-02</TD><TD>-3.28</TD><TD>HSP90AB4P (heat shock protein 90kDa alpha (cytosolic), class B member 4, pseudogene)</TD><TD>protein interactions</TD><TD>664618</TD><TD>15</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>PRPS1</TD></TR>
<TR><TD>3.769e-02</TD><TD>-3.28</TD><TD>PILRA (paired immunoglobin-like type 2 receptor alpha)</TD><TD>protein interactions</TD><TD>29992</TD><TD>15</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>LAMA4</TD></TR>
<TR><TD>3.779e-02</TD><TD>-3.28</TD><TD>negative regulation of cellular biosynthetic process</TD><TD>biological process</TD><TD>GO:0031327</TD><TD>1460</TD><TD>8</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2,FGF9,MSX1,PPARG,PBX1,ZIC2,NR2F2,NR2F1</TD></TR>
<TR><TD>3.783e-02</TD><TD>-3.27</TD><TD>Mitochondrial DNA depletion syndrome</TD><TD>SMPDB pathways</TD><TD>SMP00536</TD><TD>37</TD><TD>1</TD><TD>978</TD><TD>1</TD>
<TD>PDE10A</TD></TR>
<TR><TD>3.783e-02</TD><TD>-3.27</TD><TD>Myoadenylate deaminase deficiency</TD><TD>SMPDB pathways</TD><TD>SMP00537</TD><TD>37</TD><TD>1</TD><TD>978</TD><TD>1</TD>
<TD>PDE10A</TD></TR>
<TR><TD>3.783e-02</TD><TD>-3.27</TD><TD>Adenosine Deaminase Deficiency</TD><TD>SMPDB pathways</TD><TD>SMP00144</TD><TD>37</TD><TD>1</TD><TD>978</TD><TD>1</TD>
<TD>PDE10A</TD></TR>
<TR><TD>3.783e-02</TD><TD>-3.27</TD><TD>Xanthine Dehydrogenase Deficiency (Xanthinuria)</TD><TD>SMPDB pathways</TD><TD>SMP00220</TD><TD>37</TD><TD>1</TD><TD>978</TD><TD>1</TD>
<TD>PDE10A</TD></TR>
<TR><TD>3.783e-02</TD><TD>-3.27</TD><TD>Lesch-Nyhan Syndrome (LNS)</TD><TD>SMPDB pathways</TD><TD>SMP00364</TD><TD>37</TD><TD>1</TD><TD>978</TD><TD>1</TD>
<TD>PDE10A</TD></TR>
<TR><TD>3.783e-02</TD><TD>-3.27</TD><TD>Adenine phosphoribosyltransferase deficiency (APRT)</TD><TD>SMPDB pathways</TD><TD>SMP00535</TD><TD>37</TD><TD>1</TD><TD>978</TD><TD>1</TD>
<TD>PDE10A</TD></TR>
<TR><TD>3.783e-02</TD><TD>-3.27</TD><TD>Xanthinuria type II</TD><TD>SMPDB pathways</TD><TD>SMP00513</TD><TD>37</TD><TD>1</TD><TD>978</TD><TD>1</TD>
<TD>PDE10A</TD></TR>
<TR><TD>3.783e-02</TD><TD>-3.27</TD><TD>Purine Nucleoside Phosphorylase Deficiency</TD><TD>SMPDB pathways</TD><TD>SMP00210</TD><TD>37</TD><TD>1</TD><TD>978</TD><TD>1</TD>
<TD>PDE10A</TD></TR>
<TR><TD>3.783e-02</TD><TD>-3.27</TD><TD>Purine Metabolism</TD><TD>SMPDB pathways</TD><TD>SMP00050</TD><TD>37</TD><TD>1</TD><TD>978</TD><TD>1</TD>
<TD>PDE10A</TD></TR>
<TR><TD>3.783e-02</TD><TD>-3.27</TD><TD>Molybdenum Cofactor Deficiency</TD><TD>SMPDB pathways</TD><TD>SMP00203</TD><TD>37</TD><TD>1</TD><TD>978</TD><TD>1</TD>
<TD>PDE10A</TD></TR>
<TR><TD>3.783e-02</TD><TD>-3.27</TD><TD>AICA-Ribosiduria</TD><TD>SMPDB pathways</TD><TD>SMP00168</TD><TD>37</TD><TD>1</TD><TD>978</TD><TD>1</TD>
<TD>PDE10A</TD></TR>
<TR><TD>3.783e-02</TD><TD>-3.27</TD><TD>Gout or Kelley-Seegmiller Syndrome</TD><TD>SMPDB pathways</TD><TD>SMP00365</TD><TD>37</TD><TD>1</TD><TD>978</TD><TD>1</TD>
<TD>PDE10A</TD></TR>
<TR><TD>3.783e-02</TD><TD>-3.27</TD><TD>Xanthinuria type I</TD><TD>SMPDB pathways</TD><TD>SMP00512</TD><TD>37</TD><TD>1</TD><TD>978</TD><TD>1</TD>
<TD>PDE10A</TD></TR>
<TR><TD>3.783e-02</TD><TD>-3.27</TD><TD>Adenylosuccinate Lyase Deficiency</TD><TD>SMPDB pathways</TD><TD>SMP00167</TD><TD>37</TD><TD>1</TD><TD>978</TD><TD>1</TD>
<TD>PDE10A</TD></TR>
<TR><TD>3.808e-02</TD><TD>-3.27</TD><TD>regulation of epithelial cell proliferation</TD><TD>biological process</TD><TD>GO:0050678</TD><TD>278</TD><TD>3</TD><TD>16441</TD><TD>44</TD>
<TD>EFNB2,FGF9,NR2F2</TD></TR>
<TR><TD>3.815e-02</TD><TD>-3.27</TD><TD>NABA_MATRISOME_ASSOCIATED</TD><TD>MSigDB lists</TD><TD>NABA_MATRISOME_ASSOCIATED</TD><TD>739</TD><TD>5</TD><TD>17758</TD><TD>45</TD>
<TD>FGF9,WNT16,S100A10,MMP16,ANGPTL4</TD></TR>
<TR><TD>3.816e-02</TD><TD>-3.27</TD><TD>scalp</TD><TD>COSMIC cancer mutations</TD><TD>scalp</TD><TD>2188</TD><TD>10</TD><TD>17775</TD><TD>44</TD>
<TD>EFNB2,LAMA4,FGF9,NEBL,CLSTN2,CSMD3,VIM,NR2F2,MMP16,PDE3A</TD></TR>
<TR><TD>3.824e-02</TD><TD>-3.26</TD><TD>RXRA (retinoid X receptor alpha)</TD><TD>protein interactions</TD><TD>6256</TD><TD>121</TD><TD>2</TD><TD>16036</TD><TD>41</TD>
<TD>PPARG,NR2F1</TD></TR>
<TR><TD>3.825e-02</TD><TD>-3.26</TD><TD>V$GRE_C</TD><TD>MSigDB lists</TD><TD>V$GRE_C</TD><TD>122</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>TANK,NR2F1</TD></TR>
<TR><TD>3.825e-02</TD><TD>-3.26</TD><TD>LI_INDUCED_T_TO_NATURAL_KILLER_UP</TD><TD>MSigDB lists</TD><TD>LI_INDUCED_T_TO_NATURAL_KILLER_UP</TD><TD>294</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>VIM,S100A10,NT5E</TD></TR>
<TR><TD>3.842e-02</TD><TD>-3.26</TD><TD>hexosaminidase activity</TD><TD>molecular function</TD><TD>GO:0015929</TD><TD>15</TD><TD>1</TD><TD>16491</TD><TD>43</TD>
<TD>CD44</TD></TR>
<TR><TD>3.842e-02</TD><TD>-3.26</TD><TD>icosanoid receptor activity</TD><TD>molecular function</TD><TD>GO:0004953</TD><TD>15</TD><TD>1</TD><TD>16491</TD><TD>43</TD>
<TD>PPARG</TD></TR>
<TR><TD>3.848e-02</TD><TD>-3.26</TD><TD>ONKEN_UVEAL_MELANOMA_DN</TD><TD>MSigDB lists</TD><TD>ONKEN_UVEAL_MELANOMA_DN</TD><TD>505</TD><TD>4</TD><TD>17758</TD><TD>45</TD>
<TD>LAMA4,PBX1,CD44,ETV1</TD></TR>
<TR><TD>3.852e-02</TD><TD>-3.26</TD><TD>positive regulation of lipid metabolic process</TD><TD>biological process</TD><TD>GO:0045834</TD><TD>116</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>PPARG,NT5E</TD></TR>
<TR><TD>3.877e-02</TD><TD>-3.25</TD><TD>muscle organ development</TD><TD>biological process</TD><TD>GO:0007517</TD><TD>280</TD><TD>3</TD><TD>16441</TD><TD>44</TD>
<TD>MSX1,NR2F2,ETV1</TD></TR>
<TR><TD>3.882e-02</TD><TD>-3.25</TD><TD>MIKKELSEN_IPS_ICP_WITH_H3K4ME3_AND_H327ME3</TD><TD>MSigDB lists</TD><TD>MIKKELSEN_IPS_ICP_WITH_H3K4ME3_AND_H327ME3</TD><TD>123</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>LAMA4,CD44</TD></TR>
<TR><TD>3.882e-02</TD><TD>-3.25</TD><TD>REGULATION_OF_CELLULAR_COMPONENT_ORGANIZATION_AND_BIOGENESIS</TD><TD>MSigDB lists</TD><TD>REGULATION_OF_CELLULAR_COMPONENT_ORGANIZATION_AND_BIOGENESIS</TD><TD>123</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>PBX1,NEBL</TD></TR>
<TR><TD>3.894e-02</TD><TD>-3.25</TD><TD>Dissolution of Fibrin Clot</TD><TD>REACTOME pathways</TD><TD>R-HSA-75205</TD><TD>13</TD><TD>1</TD><TD>8202</TD><TD>25</TD>
<TD>S100A10</TD></TR>
<TR><TD>3.894e-02</TD><TD>-3.25</TD><TD>FGFR2c ligand binding and activation</TD><TD>REACTOME pathways</TD><TD>R-HSA-190375</TD><TD>13</TD><TD>1</TD><TD>8202</TD><TD>25</TD>
<TD>FGF9</TD></TR>
<TR><TD>3.898e-02</TD><TD>-3.24</TD><TD>CNH</TD><TD>pfam domains</TD><TD>PF00780</TD><TD>15</TD><TD>1</TD><TD>16629</TD><TD>44</TD>
<TD>TNIK</TD></TR>
<TR><TD>3.912e-02</TD><TD>-3.24</TD><TD>response to estradiol</TD><TD>biological process</TD><TD>GO:0032355</TD><TD>117</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2,NR2F2</TD></TR>
<TR><TD>3.931e-02</TD><TD>-3.24</TD><TD>COPS6 (COP9 signalosome subunit 6)</TD><TD>protein interactions</TD><TD>10980</TD><TD>295</TD><TD>3</TD><TD>16036</TD><TD>41</TD>
<TD>LAMA4,VIM,S100A10</TD></TR>
<TR><TD>3.939e-02</TD><TD>-3.23</TD><TD>NIKOLSKY_BREAST_CANCER_8Q12_Q22_AMPLICON</TD><TD>MSigDB lists</TD><TD>NIKOLSKY_BREAST_CANCER_8Q12_Q22_AMPLICON</TD><TD>124</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>SLCO5A1,MMP16</TD></TR>
<TR><TD>3.942e-02</TD><TD>-3.23</TD><TD>positive regulation of neurotransmitter transport</TD><TD>biological process</TD><TD>GO:0051590</TD><TD>15</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>UNC13A</TD></TR>
<TR><TD>3.942e-02</TD><TD>-3.23</TD><TD>establishment of tissue polarity</TD><TD>biological process</TD><TD>GO:0007164</TD><TD>15</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>GRHL3</TD></TR>
<TR><TD>3.942e-02</TD><TD>-3.23</TD><TD>negative regulation of lipase activity</TD><TD>biological process</TD><TD>GO:0060192</TD><TD>15</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>ANGPTL4</TD></TR>
<TR><TD>3.942e-02</TD><TD>-3.23</TD><TD>positive regulation of telomere capping</TD><TD>biological process</TD><TD>GO:1904355</TD><TD>15</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>PKIB</TD></TR>
<TR><TD>3.942e-02</TD><TD>-3.23</TD><TD>cell migration involved in sprouting angiogenesis</TD><TD>biological process</TD><TD>GO:0002042</TD><TD>15</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>EFNB2</TD></TR>
<TR><TD>3.942e-02</TD><TD>-3.23</TD><TD>regulation of hair follicle development</TD><TD>biological process</TD><TD>GO:0051797</TD><TD>15</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2</TD></TR>
<TR><TD>3.942e-02</TD><TD>-3.23</TD><TD>establishment of planar polarity</TD><TD>biological process</TD><TD>GO:0001736</TD><TD>15</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>GRHL3</TD></TR>
<TR><TD>3.942e-02</TD><TD>-3.23</TD><TD>hyaluronan catabolic process</TD><TD>biological process</TD><TD>GO:0030214</TD><TD>15</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>CD44</TD></TR>
<TR><TD>3.942e-02</TD><TD>-3.23</TD><TD>response to vitamin E</TD><TD>biological process</TD><TD>GO:0033197</TD><TD>15</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>PPARG</TD></TR>
<TR><TD>3.942e-02</TD><TD>-3.23</TD><TD>nephric duct development</TD><TD>biological process</TD><TD>GO:0072176</TD><TD>15</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>EFNB2</TD></TR>
<TR><TD>3.942e-02</TD><TD>-3.23</TD><TD>regulation of lipoprotein lipase activity</TD><TD>biological process</TD><TD>GO:0051004</TD><TD>15</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>ANGPTL4</TD></TR>
<TR><TD>3.942e-02</TD><TD>-3.23</TD><TD>negative regulation of epidermis development</TD><TD>biological process</TD><TD>GO:0045683</TD><TD>15</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2</TD></TR>
<TR><TD>3.950e-02</TD><TD>-3.23</TD><TD>EGF_extracell</TD><TD>interpro domains</TD><TD>IPR013111</TD><TD>16</TD><TD>1</TD><TD>18293</TD><TD>46</TD>
<TD>ITGB4</TD></TR>
<TR><TD>3.956e-02</TD><TD>-3.23</TD><TD>Alzheimer&#39;s disease(PMID:22005930)</TD><TD>GWAS genes</TD><TD>Alzheimer&#39;s disease(PMID:22005930)</TD><TD>6</TD><TD>1</TD><TD>2389</TD><TD>16</TD>
<TD>VSNL1</TD></TR>
<TR><TD>3.956e-02</TD><TD>-3.23</TD><TD>Response to fenofibrate(PMID:22890011)</TD><TD>GWAS genes</TD><TD>Response to fenofibrate(PMID:22890011)</TD><TD>6</TD><TD>1</TD><TD>2389</TD><TD>16</TD>
<TD>PDE10A</TD></TR>
<TR><TD>3.956e-02</TD><TD>-3.23</TD><TD>Pancreatic cancer(PMID:20686608)</TD><TD>GWAS genes</TD><TD>Pancreatic cancer(PMID:20686608)</TD><TD>6</TD><TD>1</TD><TD>2389</TD><TD>16</TD>
<TD>RNF43</TD></TR>
<TR><TD>3.956e-02</TD><TD>-3.23</TD><TD>Type 2 diabetes(PMID:17463246)</TD><TD>GWAS genes</TD><TD>Type 2 diabetes(PMID:17463246)</TD><TD>6</TD><TD>1</TD><TD>2389</TD><TD>16</TD>
<TD>PPARG</TD></TR>
<TR><TD>3.956e-02</TD><TD>-3.23</TD><TD>Conduct disorder (symptom count)(PMID:20585324)</TD><TD>GWAS genes</TD><TD>Conduct disorder (symptom count)(PMID:20585324)</TD><TD>6</TD><TD>1</TD><TD>2389</TD><TD>16</TD>
<TD>PDE10A</TD></TR>
<TR><TD>3.956e-02</TD><TD>-3.23</TD><TD>Height(PMID:20966902)</TD><TD>GWAS genes</TD><TD>Height(PMID:20966902)</TD><TD>6</TD><TD>1</TD><TD>2389</TD><TD>16</TD>
<TD>PBX1</TD></TR>
<TR><TD>3.961e-02</TD><TD>-3.23</TD><TD>cell projection organization</TD><TD>biological process</TD><TD>GO:0030030</TD><TD>1206</TD><TD>7</TD><TD>16441</TD><TD>44</TD>
<TD>EFNB2,TNIK,CAMK2D,ZIC2,FGF9,ITGB4,ETV1</TD></TR>
<TR><TD>3.963e-02</TD><TD>-3.23</TD><TD>-</TD><TD>gene3d domains</TD><TD>2.60.40.420</TD><TD>13</TD><TD>1</TD><TD>9988</TD><TD>31</TD>
<TD>EFNB2</TD></TR>
<TR><TD>3.973e-02</TD><TD>-3.23</TD><TD>V_SNARE</TD><TD>prosite domains</TD><TD>PS50892</TD><TD>12</TD><TD>1</TD><TD>11866</TD><TD>40</TD>
<TD>STXBP6</TD></TR>
<TR><TD>3.973e-02</TD><TD>-3.23</TD><TD>LINK_1</TD><TD>prosite domains</TD><TD>PS01241</TD><TD>12</TD><TD>1</TD><TD>11866</TD><TD>40</TD>
<TD>CD44</TD></TR>
<TR><TD>3.973e-02</TD><TD>-3.23</TD><TD>lipid homeostasis</TD><TD>biological process</TD><TD>GO:0055088</TD><TD>118</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>PPARG,ANGPTL4</TD></TR>
<TR><TD>3.973e-02</TD><TD>-3.23</TD><TD>nephron development</TD><TD>biological process</TD><TD>GO:0072006</TD><TD>118</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>PBX1,CD44</TD></TR>
<TR><TD>3.980e-02</TD><TD>-3.22</TD><TD>DASU_IL6_SIGNALING_SCAR_DN</TD><TD>MSigDB lists</TD><TD>DASU_IL6_SIGNALING_SCAR_DN</TD><TD>16</TD><TD>1</TD><TD>17758</TD><TD>45</TD>
<TD>PRPS1</TD></TR>
<TR><TD>3.980e-02</TD><TD>-3.22</TD><TD>chr4q26</TD><TD>MSigDB lists</TD><TD>chr4q26</TD><TD>16</TD><TD>1</TD><TD>17758</TD><TD>45</TD>
<TD>CAMK2D</TD></TR>
<TR><TD>3.980e-02</TD><TD>-3.22</TD><TD>KANG_FLUOROURACIL_RESISTANCE_DN</TD><TD>MSigDB lists</TD><TD>KANG_FLUOROURACIL_RESISTANCE_DN</TD><TD>16</TD><TD>1</TD><TD>17758</TD><TD>45</TD>
<TD>ITGB4</TD></TR>
<TR><TD>3.980e-02</TD><TD>-3.22</TD><TD>REACTOME_ACTIVATED_POINT_MUTANTS_OF_FGFR2</TD><TD>MSigDB lists</TD><TD>REACTOME_ACTIVATED_POINT_MUTANTS_OF_FGFR2</TD><TD>16</TD><TD>1</TD><TD>17758</TD><TD>45</TD>
<TD>FGF9</TD></TR>
<TR><TD>3.980e-02</TD><TD>-3.22</TD><TD>NGO_MALIGNANT_GLIOMA_1P_LOH</TD><TD>MSigDB lists</TD><TD>NGO_MALIGNANT_GLIOMA_1P_LOH</TD><TD>16</TD><TD>1</TD><TD>17758</TD><TD>45</TD>
<TD>VIM</TD></TR>
<TR><TD>3.980e-02</TD><TD>-3.22</TD><TD>FARMER_BREAST_CANCER_CLUSTER_6</TD><TD>MSigDB lists</TD><TD>FARMER_BREAST_CANCER_CLUSTER_6</TD><TD>16</TD><TD>1</TD><TD>17758</TD><TD>45</TD>
<TD>RNF43</TD></TR>
<TR><TD>3.980e-02</TD><TD>-3.22</TD><TD>V$PAX5_02</TD><TD>MSigDB lists</TD><TD>V$PAX5_02</TD><TD>16</TD><TD>1</TD><TD>17758</TD><TD>45</TD>
<TD>GRHL3</TD></TR>
<TR><TD>3.995e-02</TD><TD>-3.22</TD><TD>diffuse_adenocarcinoma</TD><TD>COSMIC cancer mutations</TD><TD>diffuse_adenocarcinoma</TD><TD>4562</TD><TD>17</TD><TD>17775</TD><TD>44</TD>
<TD>EFNB2,LAMA4,SLC40A1,HFM1,CLSTN2,RNF43,VIM,NR2F1,PDE3A,PDE10A,UNC13A,CSMD3,SORCS2,ETV1,PDLIM5,PRPS1,MMP16</TD></TR>
<TR><TD>3.995e-02</TD><TD>-3.22</TD><TD>stomach-carcinoma-diffuse_adenocarcinoma</TD><TD>COSMIC cancer mutations</TD><TD>stomach-carcinoma-diffuse_adenocarcinoma</TD><TD>4562</TD><TD>17</TD><TD>17775</TD><TD>44</TD>
<TD>EFNB2,LAMA4,SLC40A1,HFM1,CLSTN2,RNF43,VIM,NR2F1,PDE3A,PDE10A,UNC13A,CSMD3,SORCS2,ETV1,PDLIM5,PRPS1,MMP16</TD></TR>
<TR><TD>3.997e-02</TD><TD>-3.22</TD><TD>RB_P107_DN.V1_DN</TD><TD>MSigDB lists</TD><TD>RB_P107_DN.V1_DN</TD><TD>125</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>RHOU,KRT7</TD></TR>
<TR><TD>3.997e-02</TD><TD>-3.22</TD><TD>ZHU_CMV_ALL_DN</TD><TD>MSigDB lists</TD><TD>ZHU_CMV_ALL_DN</TD><TD>125</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>LAMA4,NR2F2</TD></TR>
<TR><TD>3.997e-02</TD><TD>-3.22</TD><TD>GERY_CEBP_TARGETS</TD><TD>MSigDB lists</TD><TD>GERY_CEBP_TARGETS</TD><TD>125</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>PPARG,ANGPTL4</TD></TR>
<TR><TD>4.015e-02</TD><TD>-3.22</TD><TD>NR0B1 (nuclear receptor subfamily 0, group B, member 1)</TD><TD>protein interactions</TD><TD>190</TD><TD>16</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>PPARG</TD></TR>
<TR><TD>4.015e-02</TD><TD>-3.22</TD><TD>ARL2 (ADP-ribosylation factor like GTPase 2)</TD><TD>protein interactions</TD><TD>402</TD><TD>16</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>NT5E</TD></TR>
<TR><TD>4.015e-02</TD><TD>-3.22</TD><TD>PDIA2 (protein disulfide isomerase family A, member 2)</TD><TD>protein interactions</TD><TD>64714</TD><TD>16</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>PPARG</TD></TR>
<TR><TD>4.015e-02</TD><TD>-3.22</TD><TD>GDNF (glial cell derived neurotrophic factor)</TD><TD>protein interactions</TD><TD>2668</TD><TD>16</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>S100A10</TD></TR>
<TR><TD>4.015e-02</TD><TD>-3.22</TD><TD>BBOX1 (butyrobetaine (gamma), 2-oxoglutarate dioxygenase (gamma-butyrobetaine hydroxylase) 1)</TD><TD>protein interactions</TD><TD>8424</TD><TD>16</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>TANK</TD></TR>
<TR><TD>4.015e-02</TD><TD>-3.22</TD><TD>CNKSR2 (connector enhancer of kinase suppressor of Ras 2)</TD><TD>protein interactions</TD><TD>22866</TD><TD>16</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>TNIK</TD></TR>
<TR><TD>4.015e-02</TD><TD>-3.22</TD><TD>HOXA10 (homeobox A10)</TD><TD>protein interactions</TD><TD>3206</TD><TD>16</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>PBX1</TD></TR>
<TR><TD>4.015e-02</TD><TD>-3.22</TD><TD>GHITM (growth hormone inducible transmembrane protein)</TD><TD>protein interactions</TD><TD>27069</TD><TD>16</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>NT5E</TD></TR>
<TR><TD>4.015e-02</TD><TD>-3.22</TD><TD>RAB9A (RAB9A, member RAS oncogene family)</TD><TD>protein interactions</TD><TD>9367</TD><TD>16</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>NT5E</TD></TR>
<TR><TD>4.015e-02</TD><TD>-3.22</TD><TD>HGH1 (HGH1 homolog)</TD><TD>protein interactions</TD><TD>51236</TD><TD>16</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>SLK</TD></TR>
<TR><TD>4.015e-02</TD><TD>-3.22</TD><TD>IQCF1 (IQ motif containing F1)</TD><TD>protein interactions</TD><TD>132141</TD><TD>16</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>CAMK2D</TD></TR>
<TR><TD>4.015e-02</TD><TD>-3.22</TD><TD>PDX1 (pancreatic and duodenal homeobox 1)</TD><TD>protein interactions</TD><TD>3651</TD><TD>16</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>PBX1</TD></TR>
<TR><TD>4.015e-02</TD><TD>-3.22</TD><TD>ERC2 (ELKS/RAB6-interacting/CAST family member 2)</TD><TD>protein interactions</TD><TD>26059</TD><TD>16</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>UNC13A</TD></TR>
<TR><TD>4.015e-02</TD><TD>-3.22</TD><TD>RNF43 (ring finger protein 43)</TD><TD>protein interactions</TD><TD>54894</TD><TD>16</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>RNF43</TD></TR>
<TR><TD>4.015e-02</TD><TD>-3.22</TD><TD>TM2D3 (TM2 domain containing 3)</TD><TD>protein interactions</TD><TD>80213</TD><TD>16</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>NR2F2</TD></TR>
<TR><TD>4.023e-02</TD><TD>-3.21</TD><TD>JIANG_HYPOXIA_NORMAL</TD><TD>MSigDB lists</TD><TD>JIANG_HYPOXIA_NORMAL</TD><TD>300</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>ITGB4,ANGPTL4,NT5E</TD></TR>
<TR><TD>4.034e-02</TD><TD>-3.21</TD><TD>negative regulation of protein serine/threonine kinase activity</TD><TD>biological process</TD><TD>GO:0071901</TD><TD>119</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>NR2F2,PKIB</TD></TR>
<TR><TD>4.035e-02</TD><TD>-3.21</TD><TD>molecular transducer activity</TD><TD>molecular function</TD><TD>GO:0060089</TD><TD>1805</TD><TD>9</TD><TD>16491</TD><TD>43</TD>
<TD>EFNB2,TNIK,SLC40A1,PPARG,SORCS2,NR2F2,CD44,ITGB4,NR2F1</TD></TR>
<TR><TD>4.035e-02</TD><TD>-3.21</TD><TD>regulation of cell proliferation</TD><TD>biological process</TD><TD>GO:0042127</TD><TD>1479</TD><TD>8</TD><TD>16441</TD><TD>44</TD>
<TD>EFNB2,MSX2,CAMK2D,FGF9,MSX1,PPARG,PBX1,NR2F2</TD></TR>
<TR><TD>4.055e-02</TD><TD>-3.21</TD><TD>ELVIDGE_HYPOXIA_BY_DMOG_UP</TD><TD>MSigDB lists</TD><TD>ELVIDGE_HYPOXIA_BY_DMOG_UP</TD><TD>126</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>ANGPTL4,AHNAK2</TD></TR>
<TR><TD>4.056e-02</TD><TD>-3.20</TD><TD>ANXA7 (annexin A7)</TD><TD>protein interactions</TD><TD>310</TD><TD>125</TD><TD>2</TD><TD>16036</TD><TD>41</TD>
<TD>VIM,S100A10</TD></TR>
<TR><TD>4.063e-02</TD><TD>-3.20</TD><TD>negative regulation of biosynthetic process</TD><TD>biological process</TD><TD>GO:0009890</TD><TD>1481</TD><TD>8</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2,FGF9,MSX1,PPARG,PBX1,ZIC2,NR2F2,NR2F1</TD></TR>
<TR><TD>4.064e-02</TD><TD>-3.20</TD><TD>HOMEOBOX_2</TD><TD>prosite domains</TD><TD>PS50071</TD><TD>227</TD><TD>3</TD><TD>11866</TD><TD>40</TD>
<TD>PBX1,MSX2,MSX1</TD></TR>
<TR><TD>4.070e-02</TD><TD>-3.20</TD><TD>receptor activity</TD><TD>molecular function</TD><TD>GO:0004872</TD><TD>1522</TD><TD>8</TD><TD>16491</TD><TD>43</TD>
<TD>EFNB2,SLC40A1,PPARG,SORCS2,NR2F2,CD44,ITGB4,NR2F1</TD></TR>
<TR><TD>4.071e-02</TD><TD>-3.20</TD><TD>face</TD><TD>COSMIC cancer mutations</TD><TD>face</TD><TD>2212</TD><TD>10</TD><TD>17775</TD><TD>44</TD>
<TD>LAMA4,NEBL,PPARG,HFM1,CSMD3,RNF43,PDLIM5,ANGPTL4,PDE3A,NT5E</TD></TR>
<TR><TD>4.082e-02</TD><TD>-3.20</TD><TD>Homeodomain-like</TD><TD>interpro domains</TD><TD>IPR009057</TD><TD>304</TD><TD>3</TD><TD>18293</TD><TD>46</TD>
<TD>PBX1,MSX2,MSX1</TD></TR>
<TR><TD>4.087e-02</TD><TD>-3.20</TD><TD>LINKMODULE</TD><TD>prints domains</TD><TD>PR01265</TD><TD>11</TD><TD>1</TD><TD>4759</TD><TD>18</TD>
<TD>CD44</TD></TR>
<TR><TD>4.088e-02</TD><TD>-3.20</TD><TD>NABA_MATRISOME</TD><TD>MSigDB lists</TD><TD>NABA_MATRISOME</TD><TD>1010</TD><TD>6</TD><TD>17758</TD><TD>45</TD>
<TD>LAMA4,FGF9,WNT16,S100A10,MMP16,ANGPTL4</TD></TR>
<TR><TD>4.093e-02</TD><TD>-3.20</TD><TD>retinoid X receptor binding</TD><TD>molecular function</TD><TD>GO:0046965</TD><TD>16</TD><TD>1</TD><TD>16491</TD><TD>43</TD>
<TD>PPARG</TD></TR>
<TR><TD>4.093e-02</TD><TD>-3.20</TD><TD>cGMP binding</TD><TD>molecular function</TD><TD>GO:0030553</TD><TD>16</TD><TD>1</TD><TD>16491</TD><TD>43</TD>
<TD>PDE10A</TD></TR>
<TR><TD>4.093e-02</TD><TD>-3.20</TD><TD>GTP-Rho binding</TD><TD>molecular function</TD><TD>GO:0017049</TD><TD>16</TD><TD>1</TD><TD>16491</TD><TD>43</TD>
<TD>STXBP6</TD></TR>
<TR><TD>4.102e-02</TD><TD>-3.19</TD><TD>meninges</TD><TD>COSMIC cancer mutations</TD><TD>meninges</TD><TD>528</TD><TD>4</TD><TD>17775</TD><TD>44</TD>
<TD>CSMD3,CAMK2D,ITGB4,ETV1</TD></TR>
<TR><TD>4.102e-02</TD><TD>-3.19</TD><TD>meningioma</TD><TD>COSMIC cancer mutations</TD><TD>meningioma</TD><TD>528</TD><TD>4</TD><TD>17775</TD><TD>44</TD>
<TD>CSMD3,CAMK2D,ITGB4,ETV1</TD></TR>
<TR><TD>4.113e-02</TD><TD>-3.19</TD><TD>MODULE_11</TD><TD>MSigDB lists</TD><TD>MODULE_11</TD><TD>516</TD><TD>4</TD><TD>17758</TD><TD>45</TD>
<TD>FGF9,ZIC2,NEBL,VSNL1</TD></TR>
<TR><TD>4.113e-02</TD><TD>-3.19</TD><TD>positive regulation of cellular biosynthetic process</TD><TD>biological process</TD><TD>GO:0031328</TD><TD>1763</TD><TD>9</TD><TD>16441</TD><TD>44</TD>
<TD>SLC40A1,MSX1,PPARG,GRHL3,PBX1,ZIC2,NR2F2,ETV1,PKIB</TD></TR>
<TR><TD>4.115e-02</TD><TD>-3.19</TD><TD>NCK2 (NCK adaptor protein 2)</TD><TD>protein interactions</TD><TD>8440</TD><TD>126</TD><TD>2</TD><TD>16036</TD><TD>41</TD>
<TD>EFNB2,TNIK</TD></TR>
<TR><TD>4.123e-02</TD><TD>-3.19</TD><TD>camera-type eye development</TD><TD>biological process</TD><TD>GO:0043010</TD><TD>287</TD><TD>3</TD><TD>16441</TD><TD>44</TD>
<TD>VIM,WNT16,GRHL3</TD></TR>
<TR><TD>4.128e-02</TD><TD>-3.19</TD><TD>central_nervous_system-temporal_lobe-glioma-astrocytoma_Grade_II</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-temporal_lobe-glioma-astrocytoma_Grade_II</TD><TD>17</TD><TD>1</TD><TD>17775</TD><TD>44</TD>
<TD>RNF43</TD></TR>
<TR><TD>4.144e-02</TD><TD>-3.18</TD><TD>GGGAGGRR_V$MAZ_Q6</TD><TD>MSigDB lists</TD><TD>GGGAGGRR_V$MAZ_Q6</TD><TD>2165</TD><TD>10</TD><TD>17758</TD><TD>45</TD>
<TD>FGF9,MSX1,PPARG,STXBP6,ZIC2,VIM,NR2F2,CD44,ETV1,NR2F1</TD></TR>
<TR><TD>4.146e-02</TD><TD>-3.18</TD><TD>negative regulation of nitrogen compound metabolic process</TD><TD>biological process</TD><TD>GO:0051172</TD><TD>1487</TD><TD>8</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2,FGF9,MSX1,PPARG,PBX1,ZIC2,NR2F2,NR2F1</TD></TR>
<TR><TD>4.148e-02</TD><TD>-3.18</TD><TD>CDP-diacylglycerol biosynthesis</TD><TD>BIOCYC pathways</TD><TD>HUMAN_PWY-5667</TD><TD>19</TD><TD>1</TD><TD>907</TD><TD>2</TD>
<TD>GPAT3</TD></TR>
<TR><TD>4.152e-02</TD><TD>-3.18</TD><TD>EGF_2</TD><TD>pfam domains</TD><TD>PF07974</TD><TD>16</TD><TD>1</TD><TD>16629</TD><TD>44</TD>
<TD>ITGB4</TD></TR>
<TR><TD>4.152e-02</TD><TD>-3.18</TD><TD>Acyltransferase</TD><TD>pfam domains</TD><TD>PF01553</TD><TD>16</TD><TD>1</TD><TD>16629</TD><TD>44</TD>
<TD>GPAT3</TD></TR>
<TR><TD>4.157e-02</TD><TD>-3.18</TD><TD>extracellular matrix disassembly</TD><TD>biological process</TD><TD>GO:0022617</TD><TD>121</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>CD44,MMP16</TD></TR>
<TR><TD>4.157e-02</TD><TD>-3.18</TD><TD>negative regulation of binding</TD><TD>biological process</TD><TD>GO:0051100</TD><TD>121</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2,MSX1</TD></TR>
<TR><TD>4.160e-02</TD><TD>-3.18</TD><TD>positive regulation of RNA metabolic process</TD><TD>biological process</TD><TD>GO:0051254</TD><TD>1488</TD><TD>8</TD><TD>16441</TD><TD>44</TD>
<TD>SLC40A1,MSX1,PPARG,GRHL3,PBX1,ZIC2,NR2F2,ETV1</TD></TR>
<TR><TD>4.162e-02</TD><TD>-3.18</TD><TD>TGCGCANK_UNKNOWN</TD><TD>MSigDB lists</TD><TD>TGCGCANK_UNKNOWN</TD><TD>518</TD><TD>4</TD><TD>17758</TD><TD>45</TD>
<TD>FGF9,NR2F2,PKIB,VSNL1</TD></TR>
<TR><TD>4.172e-02</TD><TD>-3.18</TD><TD>KRAS.BREAST_UP.V1_UP</TD><TD>MSigDB lists</TD><TD>KRAS.BREAST_UP.V1_UP</TD><TD>128</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>CLSTN2,WNT16</TD></TR>
<TR><TD>4.172e-02</TD><TD>-3.18</TD><TD>PETROVA_ENDOTHELIUM_LYMPHATIC_VS_BLOOD_UP</TD><TD>MSigDB lists</TD><TD>PETROVA_ENDOTHELIUM_LYMPHATIC_VS_BLOOD_UP</TD><TD>128</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>PPARG,NR2F1</TD></TR>
<TR><TD>4.187e-02</TD><TD>-3.17</TD><TD>FGFR4 ligand binding and activation</TD><TD>REACTOME pathways</TD><TD>R-HSA-190322</TD><TD>14</TD><TD>1</TD><TD>8202</TD><TD>25</TD>
<TD>FGF9</TD></TR>
<TR><TD>4.192e-02</TD><TD>-3.17</TD><TD>Hemopexin_CS</TD><TD>interpro domains</TD><TD>IPR018486</TD><TD>17</TD><TD>1</TD><TD>18293</TD><TD>46</TD>
<TD>MMP16</TD></TR>
<TR><TD>4.192e-02</TD><TD>-3.17</TD><TD>Plipid/glycerol_acylTrfase</TD><TD>interpro domains</TD><TD>IPR002123</TD><TD>17</TD><TD>1</TD><TD>18293</TD><TD>46</TD>
<TD>GPAT3</TD></TR>
<TR><TD>4.199e-02</TD><TD>-3.17</TD><TD>regulation of short-term neuronal synaptic plasticity</TD><TD>biological process</TD><TD>GO:0048172</TD><TD>16</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>UNC13A</TD></TR>
<TR><TD>4.199e-02</TD><TD>-3.17</TD><TD>monocyte differentiation</TD><TD>biological process</TD><TD>GO:0030224</TD><TD>16</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>PPARG</TD></TR>
<TR><TD>4.199e-02</TD><TD>-3.17</TD><TD>cardiac myofibril assembly</TD><TD>biological process</TD><TD>GO:0055003</TD><TD>16</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>NEBL</TD></TR>
<TR><TD>4.199e-02</TD><TD>-3.17</TD><TD>negative regulation of lipid storage</TD><TD>biological process</TD><TD>GO:0010888</TD><TD>16</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>PPARG</TD></TR>
<TR><TD>4.199e-02</TD><TD>-3.17</TD><TD>cellular response to prostaglandin E stimulus</TD><TD>biological process</TD><TD>GO:0071380</TD><TD>16</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>PPARG</TD></TR>
<TR><TD>4.199e-02</TD><TD>-3.17</TD><TD>regulation of mesoderm development</TD><TD>biological process</TD><TD>GO:2000380</TD><TD>16</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>ZIC2</TD></TR>
<TR><TD>4.199e-02</TD><TD>-3.17</TD><TD>astrocyte development</TD><TD>biological process</TD><TD>GO:0014002</TD><TD>16</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>VIM</TD></TR>
<TR><TD>4.199e-02</TD><TD>-3.17</TD><TD>regulation of telomere capping</TD><TD>biological process</TD><TD>GO:1904353</TD><TD>16</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>PKIB</TD></TR>
<TR><TD>4.199e-02</TD><TD>-3.17</TD><TD>response to caffeine</TD><TD>biological process</TD><TD>GO:0031000</TD><TD>16</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>PPARG</TD></TR>
<TR><TD>4.199e-02</TD><TD>-3.17</TD><TD>positive regulation of G2/M transition of mitotic cell cycle</TD><TD>biological process</TD><TD>GO:0010971</TD><TD>16</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>PBX1</TD></TR>
<TR><TD>4.199e-02</TD><TD>-3.17</TD><TD>positive regulation of vascular endothelial growth factor receptor signaling pathway</TD><TD>biological process</TD><TD>GO:0030949</TD><TD>16</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>FGF9</TD></TR>
<TR><TD>4.220e-02</TD><TD>-3.17</TD><TD>regulation of cyclin-dependent protein kinase activity</TD><TD>biological process</TD><TD>GO:1904029</TD><TD>122</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>NR2F2,PKIB</TD></TR>
<TR><TD>4.220e-02</TD><TD>-3.17</TD><TD>cell-matrix adhesion</TD><TD>biological process</TD><TD>GO:0007160</TD><TD>122</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>ITGB4,CD44</TD></TR>
<TR><TD>4.222e-02</TD><TD>-3.16</TD><TD>pancreas-carcinoma-adenocarcinoma</TD><TD>COSMIC cancer mutations</TD><TD>pancreas-carcinoma-adenocarcinoma</TD><TD>533</TD><TD>4</TD><TD>17775</TD><TD>44</TD>
<TD>LAMA4,NEBL,PDE10A,GRHL3</TD></TR>
<TR><TD>4.224e-02</TD><TD>-3.16</TD><TD>FARMER_BREAST_CANCER_CLUSTER_7</TD><TD>MSigDB lists</TD><TD>FARMER_BREAST_CANCER_CLUSTER_7</TD><TD>17</TD><TD>1</TD><TD>17758</TD><TD>45</TD>
<TD>MSX2</TD></TR>
<TR><TD>4.224e-02</TD><TD>-3.16</TD><TD>ZEMBUTSU_SENSITIVITY_TO_FLUOROURACIL</TD><TD>MSigDB lists</TD><TD>ZEMBUTSU_SENSITIVITY_TO_FLUOROURACIL</TD><TD>17</TD><TD>1</TD><TD>17758</TD><TD>45</TD>
<TD>PRPS1</TD></TR>
<TR><TD>4.224e-02</TD><TD>-3.16</TD><TD>KOBAYASHI_RESPONSE_TO_ROMIDEPSIN</TD><TD>MSigDB lists</TD><TD>KOBAYASHI_RESPONSE_TO_ROMIDEPSIN</TD><TD>17</TD><TD>1</TD><TD>17758</TD><TD>45</TD>
<TD>EFNB2</TD></TR>
<TR><TD>4.224e-02</TD><TD>-3.16</TD><TD>RESPONSE_TO_NUTRIENT</TD><TD>MSigDB lists</TD><TD>RESPONSE_TO_NUTRIENT</TD><TD>17</TD><TD>1</TD><TD>17758</TD><TD>45</TD>
<TD>PPARG</TD></TR>
<TR><TD>4.224e-02</TD><TD>-3.16</TD><TD>LI_ADIPOGENESIS_BY_ACTIVATED_PPARG</TD><TD>MSigDB lists</TD><TD>LI_ADIPOGENESIS_BY_ACTIVATED_PPARG</TD><TD>17</TD><TD>1</TD><TD>17758</TD><TD>45</TD>
<TD>PPARG</TD></TR>
<TR><TD>4.224e-02</TD><TD>-3.16</TD><TD>NIELSEN_GIST_VS_SYNOVIAL_SARCOMA_UP</TD><TD>MSigDB lists</TD><TD>NIELSEN_GIST_VS_SYNOVIAL_SARCOMA_UP</TD><TD>17</TD><TD>1</TD><TD>17758</TD><TD>45</TD>
<TD>ZIC2</TD></TR>
<TR><TD>4.224e-02</TD><TD>-3.16</TD><TD>REACTOME_RAS_ACTIVATION_UOPN_CA2_INFUX_THROUGH_NMDA_RECEPTOR</TD><TD>MSigDB lists</TD><TD>REACTOME_RAS_ACTIVATION_UOPN_CA2_INFUX_THROUGH_NMDA_RECEPTOR</TD><TD>17</TD><TD>1</TD><TD>17758</TD><TD>45</TD>
<TD>CAMK2D</TD></TR>
<TR><TD>4.226e-02</TD><TD>-3.16</TD><TD>acute_myeloid_leukaemia</TD><TD>COSMIC cancer mutations</TD><TD>acute_myeloid_leukaemia</TD><TD>10922</TD><TD>33</TD><TD>17775</TD><TD>44</TD>
<TD>EFNB2,TNIK,CNTNAP3,STXBP6,HFM1,CLSTN2,PDE3A,NEBL,PDE10A,UNC13A,CD44,ETV1,PRPS1,LAMA4,SLC40A1,FGF9,MSX1,KRT7,PPARG,GRHL3,ANGPTL4,NR2F1,RHOU,MSX2,CAMK2D,AHNAK2,CSMD3,SLCO5A1,ITGB4,SORCS2,PDLIM5,MMP16,PKIB</TD></TR>
<TR><TD>4.226e-02</TD><TD>-3.16</TD><TD>haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-acute_myeloid_leukaemia</TD><TD>COSMIC cancer mutations</TD><TD>haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-acute_myeloid_leukaemia</TD><TD>10922</TD><TD>33</TD><TD>17775</TD><TD>44</TD>
<TD>EFNB2,TNIK,CNTNAP3,STXBP6,HFM1,CLSTN2,PDE3A,NEBL,PDE10A,UNC13A,CD44,ETV1,PRPS1,LAMA4,SLC40A1,FGF9,MSX1,KRT7,PPARG,GRHL3,ANGPTL4,NR2F1,RHOU,MSX2,CAMK2D,AHNAK2,CSMD3,SLCO5A1,ITGB4,SORCS2,PDLIM5,MMP16,PKIB</TD></TR>
<TR><TD>4.231e-02</TD><TD>-3.16</TD><TD>MULLIGHAN_NPM1_MUTATED_SIGNATURE_2_UP</TD><TD>MSigDB lists</TD><TD>MULLIGHAN_NPM1_MUTATED_SIGNATURE_2_UP</TD><TD>129</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>TANK,PDE3A</TD></TR>
<TR><TD>4.232e-02</TD><TD>-3.16</TD><TD>Morphine addiction</TD><TD>KEGG pathways</TD><TD>hsa05032</TD><TD>91</TD><TD>2</TD><TD>6908</TD><TD>25</TD>
<TD>PDE10A,PDE3A</TD></TR>
<TR><TD>4.232e-02</TD><TD>-3.16</TD><TD>Morphine addiction</TD><TD>KEGG pathways</TD><TD>ko05032</TD><TD>91</TD><TD>2</TD><TD>6908</TD><TD>25</TD>
<TD>PDE10A,PDE3A</TD></TR>
<TR><TD>4.233e-02</TD><TD>-3.16</TD><TD>double-stranded DNA binding</TD><TD>molecular function</TD><TD>GO:0003690</TD><TD>740</TD><TD>5</TD><TD>16491</TD><TD>43</TD>
<TD>PBX1,MSX2,MSX1,PPARG,ETV1</TD></TR>
<TR><TD>4.243e-02</TD><TD>-3.16</TD><TD>membrane-bounded vesicle</TD><TD>cellular component</TD><TD>GO:0031988</TD><TD>3503</TD><TD>14</TD><TD>17570</TD><TD>44</TD>
<TD>LAMA4,SLC40A1,TNIK,CAMK2D,FGF9,KRT7,NEBL,S100A10,SLK,AHNAK2,VIM,ITGB4,CD44,NT5E</TD></TR>
<TR><TD>4.251e-02</TD><TD>-3.16</TD><TD>Ser/Thr_kinase_AS</TD><TD>interpro domains</TD><TD>IPR008271</TD><TD>309</TD><TD>3</TD><TD>18293</TD><TD>46</TD>
<TD>TNIK,CAMK2D,SLK</TD></TR>
<TR><TD>4.257e-02</TD><TD>-3.16</TD><TD>MULTICELLULAR_ORGANISMAL_DEVELOPMENT</TD><TD>MSigDB lists</TD><TD>MULTICELLULAR_ORGANISMAL_DEVELOPMENT</TD><TD>1020</TD><TD>6</TD><TD>17758</TD><TD>45</TD>
<TD>PBX1,MSX2,ZIC2,MSX1,ANGPTL4,PRPS1</TD></TR>
<TR><TD>4.261e-02</TD><TD>-3.16</TD><TD>NR2E3 (nuclear receptor subfamily 2, group E, member 3)</TD><TD>protein interactions</TD><TD>10002</TD><TD>17</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>PPARG</TD></TR>
<TR><TD>4.261e-02</TD><TD>-3.16</TD><TD>POU2AF1 (POU class 2 associating factor 1)</TD><TD>protein interactions</TD><TD>5450</TD><TD>17</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>MSX2</TD></TR>
<TR><TD>4.261e-02</TD><TD>-3.16</TD><TD>NR2F6 (nuclear receptor subfamily 2, group F, member 6)</TD><TD>protein interactions</TD><TD>2063</TD><TD>17</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>NR2F2</TD></TR>
<TR><TD>4.261e-02</TD><TD>-3.16</TD><TD>RABL2A (RAB, member of RAS oncogene family-like 2A)</TD><TD>protein interactions</TD><TD>11159</TD><TD>17</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>SLK</TD></TR>
<TR><TD>4.261e-02</TD><TD>-3.16</TD><TD>DNTTIP2 (deoxynucleotidyltransferase, terminal, interacting protein 2)</TD><TD>protein interactions</TD><TD>30836</TD><TD>17</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>PPARG</TD></TR>
<TR><TD>4.261e-02</TD><TD>-3.16</TD><TD>ZNHIT3 (zinc finger, HIT-type containing 3)</TD><TD>protein interactions</TD><TD>9326</TD><TD>17</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>PPARG</TD></TR>
<TR><TD>4.261e-02</TD><TD>-3.16</TD><TD>PRPS2 (phosphoribosyl pyrophosphate synthetase 2)</TD><TD>protein interactions</TD><TD>5634</TD><TD>17</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>PRPS1</TD></TR>
<TR><TD>4.261e-02</TD><TD>-3.16</TD><TD>MIF4GD (MIF4G domain containing)</TD><TD>protein interactions</TD><TD>57409</TD><TD>17</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>PPARG</TD></TR>
<TR><TD>4.261e-02</TD><TD>-3.16</TD><TD>HOXB7 (homeobox B7)</TD><TD>protein interactions</TD><TD>3217</TD><TD>17</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>PBX1</TD></TR>
<TR><TD>4.261e-02</TD><TD>-3.16</TD><TD>RAD54L2 (RAD54-like 2 (S. cerevisiae))</TD><TD>protein interactions</TD><TD>23132</TD><TD>17</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>PPARG</TD></TR>
<TR><TD>4.261e-02</TD><TD>-3.16</TD><TD>LMX1B (LIM homeobox transcription factor 1, beta)</TD><TD>protein interactions</TD><TD>4010</TD><TD>17</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>PBX1</TD></TR>
<TR><TD>4.261e-02</TD><TD>-3.16</TD><TD>PITX2 (paired-like homeodomain 2)</TD><TD>protein interactions</TD><TD>5308</TD><TD>17</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>MSX2</TD></TR>
<TR><TD>4.261e-02</TD><TD>-3.16</TD><TD>SLC30A5 (solute carrier family 30 (zinc transporter), member 5)</TD><TD>protein interactions</TD><TD>64924</TD><TD>17</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>NT5E</TD></TR>
<TR><TD>4.261e-02</TD><TD>-3.16</TD><TD>CEP350 (centrosomal protein 350kDa)</TD><TD>protein interactions</TD><TD>9857</TD><TD>17</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>PPARG</TD></TR>
<TR><TD>4.261e-02</TD><TD>-3.16</TD><TD>TRPV6 (transient receptor potential cation channel, subfamily V, member 6)</TD><TD>protein interactions</TD><TD>55503</TD><TD>17</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>S100A10</TD></TR>
<TR><TD>4.261e-02</TD><TD>-3.16</TD><TD>FAM46A (family with sequence similarity 46, member A)</TD><TD>protein interactions</TD><TD>55603</TD><TD>17</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>NR2F2</TD></TR>
<TR><TD>4.261e-02</TD><TD>-3.16</TD><TD>UROD (uroporphyrinogen decarboxylase)</TD><TD>protein interactions</TD><TD>7389</TD><TD>17</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>VIM</TD></TR>
<TR><TD>4.261e-02</TD><TD>-3.16</TD><TD>SBF1 (SET binding factor 1)</TD><TD>protein interactions</TD><TD>6305</TD><TD>17</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>EFNB2</TD></TR>
<TR><TD>4.261e-02</TD><TD>-3.16</TD><TD>MAP4K5 (mitogen-activated protein kinase kinase kinase kinase 5)</TD><TD>protein interactions</TD><TD>11183</TD><TD>17</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>TANK</TD></TR>
<TR><TD>4.267e-02</TD><TD>-3.15</TD><TD>response to oxygen levels</TD><TD>biological process</TD><TD>GO:0070482</TD><TD>291</TD><TD>3</TD><TD>16441</TD><TD>44</TD>
<TD>CAMK2D,PPARG,ANGPTL4</TD></TR>
<TR><TD>4.282e-02</TD><TD>-3.15</TD><TD>osteoblast differentiation</TD><TD>biological process</TD><TD>GO:0001649</TD><TD>123</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2,FGF9</TD></TR>
<TR><TD>4.283e-02</TD><TD>-3.15</TD><TD>response to stress</TD><TD>biological process</TD><TD>GO:0006950</TD><TD>3601</TD><TD>15</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2,TNIK,CAMK2D,FGF9,PPARG,SLK,PDE10A,TANK,GRHL3,AHNAK2,WNT16,ITGB4,CD44,ANGPTL4,PDE3A</TD></TR>
<TR><TD>4.287e-02</TD><TD>-3.15</TD><TD>MODULE_100</TD><TD>MSigDB lists</TD><TD>MODULE_100</TD><TD>523</TD><TD>4</TD><TD>17758</TD><TD>45</TD>
<TD>FGF9,ZIC2,NEBL,VSNL1</TD></TR>
<TR><TD>4.291e-02</TD><TD>-3.15</TD><TD>V$TAXCREB_01</TD><TD>MSigDB lists</TD><TD>V$TAXCREB_01</TD><TD>130</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>CAMK2D,NR2F1</TD></TR>
<TR><TD>4.320e-02</TD><TD>-3.14</TD><TD>positive regulation of protein phosphorylation</TD><TD>biological process</TD><TD>GO:0001934</TD><TD>970</TD><TD>6</TD><TD>16441</TD><TD>44</TD>
<TD>TNIK,CAMK2D,FGF9,WNT16,CD44,SLK</TD></TR>
<TR><TD>4.330e-02</TD><TD>-3.14</TD><TD>YGCGYRCGC_UNKNOWN</TD><TD>MSigDB lists</TD><TD>YGCGYRCGC_UNKNOWN</TD><TD>309</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>ZIC2,NR2F2,MMP16</TD></TR>
<TR><TD>4.332e-02</TD><TD>-3.14</TD><TD>breast-carcinoma-lobular_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>breast-carcinoma-lobular_carcinoma</TD><TD>784</TD><TD>5</TD><TD>17775</TD><TD>44</TD>
<TD>TNIK,CAMK2D,VIM,SORCS2,UNC13A</TD></TR>
<TR><TD>4.332e-02</TD><TD>-3.14</TD><TD>lobular_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>lobular_carcinoma</TD><TD>784</TD><TD>5</TD><TD>17775</TD><TD>44</TD>
<TD>TNIK,CAMK2D,VIM,SORCS2,UNC13A</TD></TR>
<TR><TD>4.344e-02</TD><TD>-3.14</TD><TD>syntaxin-1 binding</TD><TD>molecular function</TD><TD>GO:0017075</TD><TD>17</TD><TD>1</TD><TD>16491</TD><TD>43</TD>
<TD>UNC13A</TD></TR>
<TR><TD>4.344e-02</TD><TD>-3.14</TD><TD>acylglycerol O-acyltransferase activity</TD><TD>molecular function</TD><TD>GO:0016411</TD><TD>17</TD><TD>1</TD><TD>16491</TD><TD>43</TD>
<TD>GPAT3</TD></TR>
<TR><TD>4.344e-02</TD><TD>-3.14</TD><TD>nitric-oxide synthase binding</TD><TD>molecular function</TD><TD>GO:0050998</TD><TD>17</TD><TD>1</TD><TD>16491</TD><TD>43</TD>
<TD>CAMK2D</TD></TR>
<TR><TD>4.345e-02</TD><TD>-3.14</TD><TD>mammary gland development</TD><TD>biological process</TD><TD>GO:0030879</TD><TD>124</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2,MSX1</TD></TR>
<TR><TD>4.345e-02</TD><TD>-3.14</TD><TD>embryonic epithelial tube formation</TD><TD>biological process</TD><TD>GO:0001838</TD><TD>124</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>ZIC2,GRHL3</TD></TR>
<TR><TD>4.348e-02</TD><TD>-3.14</TD><TD>positive regulation of nitrogen compound metabolic process</TD><TD>biological process</TD><TD>GO:0051173</TD><TD>1781</TD><TD>9</TD><TD>16441</TD><TD>44</TD>
<TD>SLC40A1,MSX1,PPARG,GRHL3,PBX1,ZIC2,NR2F2,ETV1,PKIB</TD></TR>
<TR><TD>4.354e-02</TD><TD>-3.13</TD><TD>ACTN1 (actinin, alpha 1)</TD><TD>protein interactions</TD><TD>87</TD><TD>130</TD><TD>2</TD><TD>16036</TD><TD>41</TD>
<TD>NEBL,PDLIM5</TD></TR>
<TR><TD>4.358e-02</TD><TD>-3.13</TD><TD>HOMEOBOX</TD><TD>prints domains</TD><TD>PR00024</TD><TD>89</TD><TD>2</TD><TD>4759</TD><TD>18</TD>
<TD>MSX2,MSX1</TD></TR>
<TR><TD>4.362e-02</TD><TD>-3.13</TD><TD>MODULE_137</TD><TD>MSigDB lists</TD><TD>MODULE_137</TD><TD>526</TD><TD>4</TD><TD>17758</TD><TD>45</TD>
<TD>FGF9,ZIC2,NEBL,VSNL1</TD></TR>
<TR><TD>4.375e-02</TD><TD>-3.13</TD><TD>positive regulation of intracellular signal transduction</TD><TD>biological process</TD><TD>GO:1902533</TD><TD>973</TD><TD>6</TD><TD>16441</TD><TD>44</TD>
<TD>TNIK,CAMK2D,FGF9,WNT16,MSX1,CD44</TD></TR>
<TR><TD>4.408e-02</TD><TD>-3.12</TD><TD>epithelial tube formation</TD><TD>biological process</TD><TD>GO:0072175</TD><TD>125</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>ZIC2,GRHL3</TD></TR>
<TR><TD>4.410e-02</TD><TD>-3.12</TD><TD>KRAS.LUNG_UP.V1_UP</TD><TD>MSigDB lists</TD><TD>KRAS.LUNG_UP.V1_UP</TD><TD>132</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>SLCO5A1,ANGPTL4</TD></TR>
<TR><TD>4.414e-02</TD><TD>-3.12</TD><TD>angiogenesis</TD><TD>biological process</TD><TD>GO:0001525</TD><TD>295</TD><TD>3</TD><TD>16441</TD><TD>44</TD>
<TD>EFNB2,FGF9,ANGPTL4</TD></TR>
<TR><TD>4.415e-02</TD><TD>-3.12</TD><TD>exocyst</TD><TD>cellular component</TD><TD>GO:0000145</TD><TD>18</TD><TD>1</TD><TD>17570</TD><TD>44</TD>
<TD>STXBP6</TD></TR>
<TR><TD>4.433e-02</TD><TD>-3.12</TD><TD>Pept_M10A_stromelysin-type</TD><TD>interpro domains</TD><TD>IPR016293</TD><TD>18</TD><TD>1</TD><TD>18293</TD><TD>46</TD>
<TD>MMP16</TD></TR>
<TR><TD>4.434e-02</TD><TD>-3.12</TD><TD>FARMER_BREAST_CANCER_APOCRINE_VS_LUMINAL</TD><TD>MSigDB lists</TD><TD>FARMER_BREAST_CANCER_APOCRINE_VS_LUMINAL</TD><TD>312</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>CLSTN2,MSX2,KRT7</TD></TR>
<TR><TD>4.434e-02</TD><TD>-3.12</TD><TD>TTGCCAA,MIR-182</TD><TD>MSigDB lists</TD><TD>TTGCCAA,MIR-182</TD><TD>312</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>EFNB2,FGF9,MMP16</TD></TR>
<TR><TD>4.448e-02</TD><TD>-3.11</TD><TD>negative regulation of gene expression</TD><TD>biological process</TD><TD>GO:0010629</TD><TD>1508</TD><TD>8</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2,FGF9,MSX1,PPARG,PBX1,ZIC2,NR2F2,NR2F1</TD></TR>
<TR><TD>4.456e-02</TD><TD>-3.11</TD><TD>membrane raft organization</TD><TD>biological process</TD><TD>GO:0031579</TD><TD>17</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>S100A10</TD></TR>
<TR><TD>4.456e-02</TD><TD>-3.11</TD><TD>positive regulation of cell cycle G2/M phase transition</TD><TD>biological process</TD><TD>GO:1902751</TD><TD>17</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>PBX1</TD></TR>
<TR><TD>4.456e-02</TD><TD>-3.11</TD><TD>receptor catabolic process</TD><TD>biological process</TD><TD>GO:0032801</TD><TD>17</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>RNF43</TD></TR>
<TR><TD>4.456e-02</TD><TD>-3.11</TD><TD>regulation of cardiac muscle cell action potential</TD><TD>biological process</TD><TD>GO:0098901</TD><TD>17</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>CAMK2D</TD></TR>
<TR><TD>4.456e-02</TD><TD>-3.11</TD><TD>positive regulation of telomere maintenance via telomerase</TD><TD>biological process</TD><TD>GO:0032212</TD><TD>17</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>PKIB</TD></TR>
<TR><TD>4.456e-02</TD><TD>-3.11</TD><TD>oocyte maturation</TD><TD>biological process</TD><TD>GO:0001556</TD><TD>17</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>PDE3A</TD></TR>
<TR><TD>4.456e-02</TD><TD>-3.11</TD><TD>establishment of skin barrier</TD><TD>biological process</TD><TD>GO:0061436</TD><TD>17</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>GRHL3</TD></TR>
<TR><TD>4.456e-02</TD><TD>-3.11</TD><TD>negative regulation of intrinsic apoptotic signaling pathway by p53 class mediator</TD><TD>biological process</TD><TD>GO:1902254</TD><TD>17</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>CD44</TD></TR>
<TR><TD>4.464e-02</TD><TD>-3.11</TD><TD>MASSARWEH_TAMOXIFEN_RESISTANCE_UP</TD><TD>MSigDB lists</TD><TD>MASSARWEH_TAMOXIFEN_RESISTANCE_UP</TD><TD>530</TD><TD>4</TD><TD>17758</TD><TD>45</TD>
<TD>PBX1,KRT7,NEBL,PRPS1</TD></TR>
<TR><TD>4.466e-02</TD><TD>-3.11</TD><TD>NIELSEN_SYNOVIAL_SARCOMA_UP</TD><TD>MSigDB lists</TD><TD>NIELSEN_SYNOVIAL_SARCOMA_UP</TD><TD>18</TD><TD>1</TD><TD>17758</TD><TD>45</TD>
<TD>ZIC2</TD></TR>
<TR><TD>4.466e-02</TD><TD>-3.11</TD><TD>MEINHOLD_OVARIAN_CANCER_LOW_GRADE_UP</TD><TD>MSigDB lists</TD><TD>MEINHOLD_OVARIAN_CANCER_LOW_GRADE_UP</TD><TD>18</TD><TD>1</TD><TD>17758</TD><TD>45</TD>
<TD>S100A10</TD></TR>
<TR><TD>4.466e-02</TD><TD>-3.11</TD><TD>MODULE_102</TD><TD>MSigDB lists</TD><TD>MODULE_102</TD><TD>18</TD><TD>1</TD><TD>17758</TD><TD>45</TD>
<TD>PRPS1</TD></TR>
<TR><TD>4.466e-02</TD><TD>-3.11</TD><TD>YIH_RESPONSE_TO_ARSENITE_C2</TD><TD>MSigDB lists</TD><TD>YIH_RESPONSE_TO_ARSENITE_C2</TD><TD>18</TD><TD>1</TD><TD>17758</TD><TD>45</TD>
<TD>TANK</TD></TR>
<TR><TD>4.466e-02</TD><TD>-3.11</TD><TD>NELSON_RESPONSE_TO_ANDROGEN_DN</TD><TD>MSigDB lists</TD><TD>NELSON_RESPONSE_TO_ANDROGEN_DN</TD><TD>18</TD><TD>1</TD><TD>17758</TD><TD>45</TD>
<TD>MMP16</TD></TR>
<TR><TD>4.466e-02</TD><TD>-3.11</TD><TD>VERNOCHET_ADIPOGENESIS</TD><TD>MSigDB lists</TD><TD>VERNOCHET_ADIPOGENESIS</TD><TD>18</TD><TD>1</TD><TD>17758</TD><TD>45</TD>
<TD>PPARG</TD></TR>
<TR><TD>4.466e-02</TD><TD>-3.11</TD><TD>LANDIS_ERBB2_BREAST_PRENEOPLASTIC_UP</TD><TD>MSigDB lists</TD><TD>LANDIS_ERBB2_BREAST_PRENEOPLASTIC_UP</TD><TD>18</TD><TD>1</TD><TD>17758</TD><TD>45</TD>
<TD>ETV1</TD></TR>
<TR><TD>4.466e-02</TD><TD>-3.11</TD><TD>HONRADO_BREAST_CANCER_BRCA1_VS_BRCA2</TD><TD>MSigDB lists</TD><TD>HONRADO_BREAST_CANCER_BRCA1_VS_BRCA2</TD><TD>18</TD><TD>1</TD><TD>17758</TD><TD>45</TD>
<TD>VIM</TD></TR>
<TR><TD>4.466e-02</TD><TD>-3.11</TD><TD>KANG_CISPLATIN_RESISTANCE_UP</TD><TD>MSigDB lists</TD><TD>KANG_CISPLATIN_RESISTANCE_UP</TD><TD>18</TD><TD>1</TD><TD>17758</TD><TD>45</TD>
<TD>AHNAK2</TD></TR>
<TR><TD>4.466e-02</TD><TD>-3.11</TD><TD>BIOCARTA_TNFR2_PATHWAY</TD><TD>MSigDB lists</TD><TD>BIOCARTA_TNFR2_PATHWAY</TD><TD>18</TD><TD>1</TD><TD>17758</TD><TD>45</TD>
<TD>TANK</TD></TR>
<TR><TD>4.470e-02</TD><TD>-3.11</TD><TD>SERVITJA_LIVER_HNF1A_TARGETS_UP</TD><TD>MSigDB lists</TD><TD>SERVITJA_LIVER_HNF1A_TARGETS_UP</TD><TD>133</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>FGF9,PPARG</TD></TR>
<TR><TD>4.470e-02</TD><TD>-3.11</TD><TD>MIKKELSEN_ES_ICP_WITH_H3K4ME3_AND_H3K27ME3</TD><TD>MSigDB lists</TD><TD>MIKKELSEN_ES_ICP_WITH_H3K4ME3_AND_H3K27ME3</TD><TD>133</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>LAMA4,CD44</TD></TR>
<TR><TD>4.470e-02</TD><TD>-3.11</TD><TD>KRAS.LUNG.BREAST_UP.V1_DN</TD><TD>MSigDB lists</TD><TD>KRAS.LUNG.BREAST_UP.V1_DN</TD><TD>133</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>PBX1,PDE3A</TD></TR>
<TR><TD>4.472e-02</TD><TD>-3.11</TD><TD>purine nucleotide biosynthetic process</TD><TD>biological process</TD><TD>GO:0006164</TD><TD>126</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>PRPS1,NT5E</TD></TR>
<TR><TD>4.474e-02</TD><TD>-3.11</TD><TD>Alpha6-Beta4 Integrin Signaling Pathway</TD><TD>WikiPathways</TD><TD>WP244</TD><TD>69</TD><TD>2</TD><TD>4455</TD><TD>22</TD>
<TD>VIM,ITGB4</TD></TR>
<TR><TD>4.475e-02</TD><TD>-3.11</TD><TD>human chr4q26</TD><TD>chromosome location</TD><TD>human chr4q26</TD><TD>24</TD><TD>1</TD><TD>26250</TD><TD>50</TD>
<TD>CAMK2D</TD></TR>
<TR><TD>4.490e-02</TD><TD>-3.10</TD><TD>MODULE_66</TD><TD>MSigDB lists</TD><TD>MODULE_66</TD><TD>531</TD><TD>4</TD><TD>17758</TD><TD>45</TD>
<TD>FGF9,ZIC2,NEBL,VSNL1</TD></TR>
<TR><TD>4.490e-02</TD><TD>-3.10</TD><TD>YCATTAA_UNKNOWN</TD><TD>MSigDB lists</TD><TD>YCATTAA_UNKNOWN</TD><TD>531</TD><TD>4</TD><TD>17758</TD><TD>45</TD>
<TD>CSMD3,NEBL,NR2F2,NR2F1</TD></TR>
<TR><TD>4.505e-02</TD><TD>-3.10</TD><TD>GRESHOCK_CANCER_COPY_NUMBER_UP</TD><TD>MSigDB lists</TD><TD>GRESHOCK_CANCER_COPY_NUMBER_UP</TD><TD>314</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>PBX1,ETV1,PPARG</TD></TR>
<TR><TD>4.506e-02</TD><TD>-3.10</TD><TD>NEFM (neurofilament, medium polypeptide)</TD><TD>protein interactions</TD><TD>4741</TD><TD>18</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>TNIK</TD></TR>
<TR><TD>4.506e-02</TD><TD>-3.10</TD><TD>FCGR3B (Fc fragment of IgG, low affinity IIIb, receptor (CD16b))</TD><TD>protein interactions</TD><TD>2215</TD><TD>18</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>NR2F2</TD></TR>
<TR><TD>4.506e-02</TD><TD>-3.10</TD><TD>NR4A2 (nuclear receptor subfamily 4, group A, member 2)</TD><TD>protein interactions</TD><TD>4929</TD><TD>18</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>PPARG</TD></TR>
<TR><TD>4.506e-02</TD><TD>-3.10</TD><TD>DPP8 (dipeptidyl-peptidase 8)</TD><TD>protein interactions</TD><TD>54878</TD><TD>18</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>CD44</TD></TR>
<TR><TD>4.506e-02</TD><TD>-3.10</TD><TD>GRM5 (glutamate receptor, metabotropic 5)</TD><TD>protein interactions</TD><TD>2915</TD><TD>18</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>EFNB2</TD></TR>
<TR><TD>4.506e-02</TD><TD>-3.10</TD><TD>NSMCE2 (NSE2/MMS21 homolog, SMC5-SMC6 complex SUMO ligase)</TD><TD>protein interactions</TD><TD>286053</TD><TD>18</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>ETV1</TD></TR>
<TR><TD>4.506e-02</TD><TD>-3.10</TD><TD>SRGAP3 (SLIT-ROBO Rho GTPase activating protein 3)</TD><TD>protein interactions</TD><TD>9901</TD><TD>18</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>TNIK</TD></TR>
<TR><TD>4.506e-02</TD><TD>-3.10</TD><TD>RDH13 (retinol dehydrogenase 13 (all-trans/9-cis))</TD><TD>protein interactions</TD><TD>112724</TD><TD>18</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>NT5E</TD></TR>
<TR><TD>4.506e-02</TD><TD>-3.10</TD><TD>MMP1 (matrix metallopeptidase 1)</TD><TD>protein interactions</TD><TD>4312</TD><TD>18</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>CD44</TD></TR>
<TR><TD>4.506e-02</TD><TD>-3.10</TD><TD>ALS2CR11 (amyotrophic lateral sclerosis 2 chromosome region candidate 11)</TD><TD>protein interactions</TD><TD>151254</TD><TD>18</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>VIM</TD></TR>
<TR><TD>4.506e-02</TD><TD>-3.10</TD><TD>EPHB6 (EPH receptor B6)</TD><TD>protein interactions</TD><TD>2051</TD><TD>18</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>EFNB2</TD></TR>
<TR><TD>4.506e-02</TD><TD>-3.10</TD><TD>NMNAT1 (nicotinamide nucleotide adenylyltransferase 1)</TD><TD>protein interactions</TD><TD>64802</TD><TD>18</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>MSX1</TD></TR>
<TR><TD>4.506e-02</TD><TD>-3.10</TD><TD>HOXA9 (homeobox A9)</TD><TD>protein interactions</TD><TD>3205</TD><TD>18</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>PBX1</TD></TR>
<TR><TD>4.506e-02</TD><TD>-3.10</TD><TD>PRPSAP2 (phosphoribosyl pyrophosphate synthetase-associated protein 2)</TD><TD>protein interactions</TD><TD>5636</TD><TD>18</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>PRPS1</TD></TR>
<TR><TD>4.512e-02</TD><TD>-3.10</TD><TD>brainstem</TD><TD>COSMIC cancer mutations</TD><TD>brainstem</TD><TD>3233</TD><TD>13</TD><TD>17775</TD><TD>44</TD>
<TD>EFNB2,TNIK,CAMK2D,PPARG,STXBP6,UNC13A,CLSTN2,SLCO5A1,CSMD3,VIM,PDLIM5,MMP16,PDE3A</TD></TR>
<TR><TD>4.516e-02</TD><TD>-3.10</TD><TD>nucleobase-containing small molecule metabolic process</TD><TD>biological process</TD><TD>GO:0055086</TD><TD>504</TD><TD>4</TD><TD>16441</TD><TD>44</TD>
<TD>PDE10A,PRPS1,PDE3A,NT5E</TD></TR>
<TR><TD>4.521e-02</TD><TD>-3.10</TD><TD>PPARA activates gene expression</TD><TD>REACTOME pathways</TD><TD>R-HSA-1989781</TD><TD>112</TD><TD>2</TD><TD>8202</TD><TD>25</TD>
<TD>PPARG,ANGPTL4</TD></TR>
<TR><TD>4.530e-02</TD><TD>-3.09</TD><TD>MFS_dom</TD><TD>interpro domains</TD><TD>IPR020846</TD><TD>135</TD><TD>2</TD><TD>18293</TD><TD>46</TD>
<TD>SLCO5A1,SLC40A1</TD></TR>
<TR><TD>4.531e-02</TD><TD>-3.09</TD><TD>PROVENZANI_METASTASIS_DN</TD><TD>MSigDB lists</TD><TD>PROVENZANI_METASTASIS_DN</TD><TD>134</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>CD44,STXBP6</TD></TR>
<TR><TD>4.531e-02</TD><TD>-3.09</TD><TD>KRAS.BREAST_UP.V1_DN</TD><TD>MSigDB lists</TD><TD>KRAS.BREAST_UP.V1_DN</TD><TD>134</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>PBX1,PDE3A</TD></TR>
<TR><TD>4.531e-02</TD><TD>-3.09</TD><TD>RUIZ_TNC_TARGETS_DN</TD><TD>MSigDB lists</TD><TD>RUIZ_TNC_TARGETS_DN</TD><TD>134</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>CD44,PRPS1</TD></TR>
<TR><TD>4.536e-02</TD><TD>-3.09</TD><TD>cellular response to interferon-gamma</TD><TD>biological process</TD><TD>GO:0071346</TD><TD>127</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>CAMK2D,CD44</TD></TR>
<TR><TD>4.589e-02</TD><TD>-3.08</TD><TD>TRAF2 (TNF receptor-associated factor 2)</TD><TD>protein interactions</TD><TD>7186</TD><TD>314</TD><TD>3</TD><TD>16036</TD><TD>41</TD>
<TD>TNIK,NEBL,TANK</TD></TR>
<TR><TD>4.592e-02</TD><TD>-3.08</TD><TD>WAKABAYASHI_ADIPOGENESIS_PPARG_RXRA_BOUND_WITH_H4K20ME1_MARK</TD><TD>MSigDB lists</TD><TD>WAKABAYASHI_ADIPOGENESIS_PPARG_RXRA_BOUND_WITH_H4K20ME1_MARK</TD><TD>135</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>PPARG,TANK</TD></TR>
<TR><TD>4.598e-02</TD><TD>-3.08</TD><TD>SETDB1 (SET domain, bifurcated 1)</TD><TD>protein interactions</TD><TD>9869</TD><TD>134</TD><TD>2</TD><TD>16036</TD><TD>41</TD>
<TD>VIM,S100A10</TD></TR>
<TR><TD>4.600e-02</TD><TD>-3.08</TD><TD>cell growth</TD><TD>biological process</TD><TD>GO:0016049</TD><TD>128</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>CAMK2D,PDLIM5</TD></TR>
<TR><TD>4.601e-02</TD><TD>-3.08</TD><TD>Type 2 diabetes(PMID:17463248)</TD><TD>GWAS genes</TD><TD>Type 2 diabetes(PMID:17463248)</TD><TD>7</TD><TD>1</TD><TD>2389</TD><TD>16</TD>
<TD>PPARG</TD></TR>
<TR><TD>4.601e-02</TD><TD>-3.08</TD><TD>QT interval(PMID:20031603)</TD><TD>GWAS genes</TD><TD>QT interval(PMID:20031603)</TD><TD>7</TD><TD>1</TD><TD>2389</TD><TD>16</TD>
<TD>PDE3A</TD></TR>
<TR><TD>4.620e-02</TD><TD>-3.07</TD><TD>LINK_2</TD><TD>prosite domains</TD><TD>PS50963</TD><TD>14</TD><TD>1</TD><TD>11866</TD><TD>40</TD>
<TD>CD44</TD></TR>
<TR><TD>4.620e-02</TD><TD>-3.07</TD><TD>DOUGLAS_BMI1_TARGETS_UP</TD><TD>MSigDB lists</TD><TD>DOUGLAS_BMI1_TARGETS_UP</TD><TD>536</TD><TD>4</TD><TD>17758</TD><TD>45</TD>
<TD>MSX2,ZIC2,S100A10,NR2F2</TD></TR>
<TR><TD>4.647e-02</TD><TD>-3.07</TD><TD>FARMER_BREAST_CANCER_APOCRINE_VS_BASAL</TD><TD>MSigDB lists</TD><TD>FARMER_BREAST_CANCER_APOCRINE_VS_BASAL</TD><TD>318</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>MSX2,KRT7,NR2F1</TD></TR>
<TR><TD>4.647e-02</TD><TD>-3.07</TD><TD>FARMER_BREAST_CANCER_BASAL_VS_LULMINAL</TD><TD>MSigDB lists</TD><TD>FARMER_BREAST_CANCER_BASAL_VS_LULMINAL</TD><TD>318</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>PBX1,RNF43,CD44</TD></TR>
<TR><TD>4.653e-02</TD><TD>-3.07</TD><TD>V$MEIS1BHOXA9_01</TD><TD>MSigDB lists</TD><TD>V$MEIS1BHOXA9_01</TD><TD>136</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>CSMD3,NR2F2</TD></TR>
<TR><TD>4.654e-02</TD><TD>-3.07</TD><TD>regulation of cell projection organization</TD><TD>biological process</TD><TD>GO:0031344</TD><TD>509</TD><TD>4</TD><TD>16441</TD><TD>44</TD>
<TD>VIM,TNIK,PDLIM5,UNC13A</TD></TR>
<TR><TD>4.656e-02</TD><TD>-3.07</TD><TD>thyroid-carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>thyroid-carcinoma</TD><TD>4286</TD><TD>16</TD><TD>17775</TD><TD>44</TD>
<TD>LAMA4,TNIK,SLC40A1,CNTNAP3,HFM1,CLSTN2,ZIC2,ANGPTL4,PDE3A,UNC13A,CSMD3,CD44,ETV1,PRPS1,MMP16,NT5E</TD></TR>
<TR><TD>4.660e-02</TD><TD>-3.07</TD><TD>LCK (LCK proto-oncogene, Src family tyrosine kinase)</TD><TD>protein interactions</TD><TD>3932</TD><TD>135</TD><TD>2</TD><TD>16036</TD><TD>41</TD>
<TD>CD44,NR2F2</TD></TR>
<TR><TD>4.673e-02</TD><TD>-3.06</TD><TD>FLECHNER_BIOPSY_KIDNEY_TRANSPLANT_OK_VS_DONOR_UP</TD><TD>MSigDB lists</TD><TD>FLECHNER_BIOPSY_KIDNEY_TRANSPLANT_OK_VS_DONOR_UP</TD><TD>538</TD><TD>4</TD><TD>17758</TD><TD>45</TD>
<TD>VIM,CD44,PDLIM5,TANK</TD></TR>
<TR><TD>4.673e-02</TD><TD>-3.06</TD><TD>Fibrinogen_CS</TD><TD>interpro domains</TD><TD>IPR020837</TD><TD>19</TD><TD>1</TD><TD>18293</TD><TD>46</TD>
<TD>ANGPTL4</TD></TR>
<TR><TD>4.673e-02</TD><TD>-3.06</TD><TD>Cupredoxin</TD><TD>interpro domains</TD><TD>IPR008972</TD><TD>19</TD><TD>1</TD><TD>18293</TD><TD>46</TD>
<TD>EFNB2</TD></TR>
<TR><TD>4.673e-02</TD><TD>-3.06</TD><TD>Wnt</TD><TD>interpro domains</TD><TD>IPR005817</TD><TD>19</TD><TD>1</TD><TD>18293</TD><TD>46</TD>
<TD>WNT16</TD></TR>
<TR><TD>4.673e-02</TD><TD>-3.06</TD><TD>PDEase</TD><TD>interpro domains</TD><TD>IPR023088</TD><TD>19</TD><TD>1</TD><TD>18293</TD><TD>46</TD>
<TD>PDE10A</TD></TR>
<TR><TD>4.673e-02</TD><TD>-3.06</TD><TD>Wnt_CS</TD><TD>interpro domains</TD><TD>IPR018161</TD><TD>19</TD><TD>1</TD><TD>18293</TD><TD>46</TD>
<TD>WNT16</TD></TR>
<TR><TD>4.679e-02</TD><TD>-3.06</TD><TD>neuron projection morphogenesis</TD><TD>biological process</TD><TD>GO:0048812</TD><TD>741</TD><TD>5</TD><TD>16441</TD><TD>44</TD>
<TD>EFNB2,TNIK,CAMK2D,FGF9,ETV1</TD></TR>
<TR><TD>4.693e-02</TD><TD>-3.06</TD><TD>GRB2 (growth factor receptor bound protein 2)</TD><TD>protein interactions</TD><TD>2885</TD><TD>535</TD><TD>4</TD><TD>16036</TD><TD>41</TD>
<TD>RHOU,VIM,ITGB4,KRT7</TD></TR>
<TR><TD>4.709e-02</TD><TD>-3.06</TD><TD>ZIRN_TRETINOIN_RESPONSE_UP</TD><TD>MSigDB lists</TD><TD>ZIRN_TRETINOIN_RESPONSE_UP</TD><TD>19</TD><TD>1</TD><TD>17758</TD><TD>45</TD>
<TD>LAMA4</TD></TR>
<TR><TD>4.709e-02</TD><TD>-3.06</TD><TD>VERRECCHIA_RESPONSE_TO_TGFB1_C1</TD><TD>MSigDB lists</TD><TD>VERRECCHIA_RESPONSE_TO_TGFB1_C1</TD><TD>19</TD><TD>1</TD><TD>17758</TD><TD>45</TD>
<TD>CD44</TD></TR>
<TR><TD>4.709e-02</TD><TD>-3.06</TD><TD>MASRI_RESISTANCE_TO_TAMOXIFEN_AND_AROMATASE_INHIBITORS_DN</TD><TD>MSigDB lists</TD><TD>MASRI_RESISTANCE_TO_TAMOXIFEN_AND_AROMATASE_INHIBITORS_DN</TD><TD>19</TD><TD>1</TD><TD>17758</TD><TD>45</TD>
<TD>NT5E</TD></TR>
<TR><TD>4.709e-02</TD><TD>-3.06</TD><TD>MYLLYKANGAS_AMPLIFICATION_HOT_SPOT_17</TD><TD>MSigDB lists</TD><TD>MYLLYKANGAS_AMPLIFICATION_HOT_SPOT_17</TD><TD>19</TD><TD>1</TD><TD>17758</TD><TD>45</TD>
<TD>PBX1</TD></TR>
<TR><TD>4.709e-02</TD><TD>-3.06</TD><TD>ALONSO_METASTASIS_NEURAL_UP</TD><TD>MSigDB lists</TD><TD>ALONSO_METASTASIS_NEURAL_UP</TD><TD>19</TD><TD>1</TD><TD>17758</TD><TD>45</TD>
<TD>S100A10</TD></TR>
<TR><TD>4.709e-02</TD><TD>-3.06</TD><TD>RUAN_RESPONSE_TO_TROGLITAZONE_DN</TD><TD>MSigDB lists</TD><TD>RUAN_RESPONSE_TO_TROGLITAZONE_DN</TD><TD>19</TD><TD>1</TD><TD>17758</TD><TD>45</TD>
<TD>PPARG</TD></TR>
<TR><TD>4.709e-02</TD><TD>-3.06</TD><TD>BIOCARTA_STATHMIN_PATHWAY</TD><TD>MSigDB lists</TD><TD>BIOCARTA_STATHMIN_PATHWAY</TD><TD>19</TD><TD>1</TD><TD>17758</TD><TD>45</TD>
<TD>CAMK2D</TD></TR>
<TR><TD>4.709e-02</TD><TD>-3.06</TD><TD>INTEGRIN_COMPLEX</TD><TD>MSigDB lists</TD><TD>INTEGRIN_COMPLEX</TD><TD>19</TD><TD>1</TD><TD>17758</TD><TD>45</TD>
<TD>ITGB4</TD></TR>
<TR><TD>4.710e-02</TD><TD>-3.06</TD><TD>epithelial cell differentiation</TD><TD>biological process</TD><TD>GO:0030855</TD><TD>511</TD><TD>4</TD><TD>16441</TD><TD>44</TD>
<TD>VIM,WNT16,NR2F2,PPARG</TD></TR>
<TR><TD>4.712e-02</TD><TD>-3.06</TD><TD>filopodium assembly</TD><TD>biological process</TD><TD>GO:0046847</TD><TD>18</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>ITGB4</TD></TR>
<TR><TD>4.712e-02</TD><TD>-3.06</TD><TD>regulation of cardiac muscle cell apoptotic process</TD><TD>biological process</TD><TD>GO:0010665</TD><TD>18</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>CAMK2D</TD></TR>
<TR><TD>4.712e-02</TD><TD>-3.06</TD><TD>positive regulation of dendrite extension</TD><TD>biological process</TD><TD>GO:1903861</TD><TD>18</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>UNC13A</TD></TR>
<TR><TD>4.712e-02</TD><TD>-3.06</TD><TD>regulation of protein kinase A signaling</TD><TD>biological process</TD><TD>GO:0010738</TD><TD>18</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>PDE10A</TD></TR>
<TR><TD>4.712e-02</TD><TD>-3.06</TD><TD>regulation of cardiac conduction</TD><TD>biological process</TD><TD>GO:1903779</TD><TD>18</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>CAMK2D</TD></TR>
<TR><TD>4.712e-02</TD><TD>-3.06</TD><TD>regulation of cardiac muscle cell differentiation</TD><TD>biological process</TD><TD>GO:2000725</TD><TD>18</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>EFNB2</TD></TR>
<TR><TD>4.712e-02</TD><TD>-3.06</TD><TD>epithelial cell fate commitment</TD><TD>biological process</TD><TD>GO:0072148</TD><TD>18</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>NR2F2</TD></TR>
<TR><TD>4.712e-02</TD><TD>-3.06</TD><TD>positive regulation of telomere maintenance via telomere lengthening</TD><TD>biological process</TD><TD>GO:1904358</TD><TD>18</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>PKIB</TD></TR>
<TR><TD>4.712e-02</TD><TD>-3.06</TD><TD>positive regulation of signal transduction by p53 class mediator</TD><TD>biological process</TD><TD>GO:1901798</TD><TD>18</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>MSX1</TD></TR>
<TR><TD>4.712e-02</TD><TD>-3.06</TD><TD>cellular response to vitamin</TD><TD>biological process</TD><TD>GO:0071295</TD><TD>18</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>PPARG</TD></TR>
<TR><TD>4.712e-02</TD><TD>-3.06</TD><TD>endochondral bone developmental growth</TD><TD>biological process</TD><TD>GO:0003416</TD><TD>18</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2</TD></TR>
<TR><TD>4.712e-02</TD><TD>-3.06</TD><TD>bone growth</TD><TD>biological process</TD><TD>GO:0098868</TD><TD>18</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2</TD></TR>
<TR><TD>4.712e-02</TD><TD>-3.06</TD><TD>positive regulation of muscle hypertrophy</TD><TD>biological process</TD><TD>GO:0014742</TD><TD>18</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>CAMK2D</TD></TR>
<TR><TD>4.712e-02</TD><TD>-3.06</TD><TD>microvillus assembly</TD><TD>biological process</TD><TD>GO:0030033</TD><TD>18</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>TNIK</TD></TR>
<TR><TD>4.712e-02</TD><TD>-3.06</TD><TD>nucleobase biosynthetic process</TD><TD>biological process</TD><TD>GO:0046112</TD><TD>18</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>PRPS1</TD></TR>
<TR><TD>4.712e-02</TD><TD>-3.06</TD><TD>positive regulation of cardiac muscle hypertrophy</TD><TD>biological process</TD><TD>GO:0010613</TD><TD>18</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>CAMK2D</TD></TR>
<TR><TD>4.712e-02</TD><TD>-3.06</TD><TD>cellular response to lithium ion</TD><TD>biological process</TD><TD>GO:0071285</TD><TD>18</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>PPARG</TD></TR>
<TR><TD>4.712e-02</TD><TD>-3.06</TD><TD>regulation of dendrite extension</TD><TD>biological process</TD><TD>GO:1903859</TD><TD>18</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>UNC13A</TD></TR>
<TR><TD>4.712e-02</TD><TD>-3.06</TD><TD>regulation of heterotypic cell-cell adhesion</TD><TD>biological process</TD><TD>GO:0034114</TD><TD>18</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>CD44</TD></TR>
<TR><TD>4.712e-02</TD><TD>-3.06</TD><TD>positive regulation of cardiac muscle cell proliferation</TD><TD>biological process</TD><TD>GO:0060045</TD><TD>18</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>FGF9</TD></TR>
<TR><TD>4.720e-02</TD><TD>-3.05</TD><TD>LIPID_METABOLIC_PROCESS</TD><TD>MSigDB lists</TD><TD>LIPID_METABOLIC_PROCESS</TD><TD>320</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>NR2F2,PPARG,PDE3A</TD></TR>
<TR><TD>4.722e-02</TD><TD>-3.05</TD><TD>IKBKB (inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta)</TD><TD>protein interactions</TD><TD>3551</TD><TD>136</TD><TD>2</TD><TD>16036</TD><TD>41</TD>
<TD>PPARG,TANK</TD></TR>
<TR><TD>4.722e-02</TD><TD>-3.05</TD><TD>PPARG (peroxisome proliferator-activated receptor gamma)</TD><TD>protein interactions</TD><TD>5468</TD><TD>136</TD><TD>2</TD><TD>16036</TD><TD>41</TD>
<TD>MSX2,PPARG</TD></TR>
<TR><TD>4.741e-02</TD><TD>-3.05</TD><TD>Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)</TD><TD>REACTOME pathways</TD><TD>R-HSA-400206</TD><TD>115</TD><TD>2</TD><TD>8202</TD><TD>25</TD>
<TD>PPARG,ANGPTL4</TD></TR>
<TR><TD>4.750e-02</TD><TD>-3.05</TD><TD>SDC4 (syndecan 4)</TD><TD>protein interactions</TD><TD>6385</TD><TD>19</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>TANK</TD></TR>
<TR><TD>4.750e-02</TD><TD>-3.05</TD><TD>HOXA5 (homeobox A5)</TD><TD>protein interactions</TD><TD>3202</TD><TD>19</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>PBX1</TD></TR>
<TR><TD>4.750e-02</TD><TD>-3.05</TD><TD>SDCCAG3 (serologically defined colon cancer antigen 3)</TD><TD>protein interactions</TD><TD>10807</TD><TD>19</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>VIM</TD></TR>
<TR><TD>4.750e-02</TD><TD>-3.05</TD><TD>FSHR (follicle stimulating hormone receptor)</TD><TD>protein interactions</TD><TD>2492</TD><TD>19</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>S100A10</TD></TR>
<TR><TD>4.750e-02</TD><TD>-3.05</TD><TD>MICAL1 (microtubule associated monooxygenase, calponin and LIM domain containing 1)</TD><TD>protein interactions</TD><TD>64780</TD><TD>19</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>VIM</TD></TR>
<TR><TD>4.750e-02</TD><TD>-3.05</TD><TD>ASB15 (ankyrin repeat and SOCS box containing 15)</TD><TD>protein interactions</TD><TD>142685</TD><TD>19</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>VIM</TD></TR>
<TR><TD>4.750e-02</TD><TD>-3.05</TD><TD>HOXD4 (homeobox D4)</TD><TD>protein interactions</TD><TD>3233</TD><TD>19</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>PBX1</TD></TR>
<TR><TD>4.750e-02</TD><TD>-3.05</TD><TD>TLE4 (transducin-like enhancer of split 4)</TD><TD>protein interactions</TD><TD>7091</TD><TD>19</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>MSX1</TD></TR>
<TR><TD>4.750e-02</TD><TD>-3.05</TD><TD>FGFR4 (fibroblast growth factor receptor 4)</TD><TD>protein interactions</TD><TD>2264</TD><TD>19</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>FGF9</TD></TR>
<TR><TD>4.750e-02</TD><TD>-3.05</TD><TD>HMMR (hyaluronan-mediated motility receptor (RHAMM))</TD><TD>protein interactions</TD><TD>3161</TD><TD>19</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>CD44</TD></TR>
<TR><TD>4.750e-02</TD><TD>-3.05</TD><TD>MAGEB4 (MAGE family member B4)</TD><TD>protein interactions</TD><TD>4115</TD><TD>19</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>CAMK2D</TD></TR>
<TR><TD>4.750e-02</TD><TD>-3.05</TD><TD>EPHB1 (EPH receptor B1)</TD><TD>protein interactions</TD><TD>2047</TD><TD>19</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>EFNB2</TD></TR>
<TR><TD>4.771e-02</TD><TD>-3.04</TD><TD>FGFR1 ligand binding and activation</TD><TD>REACTOME pathways</TD><TD>R-HSA-190242</TD><TD>16</TD><TD>1</TD><TD>8202</TD><TD>25</TD>
<TD>FGF9</TD></TR>
<TR><TD>4.776e-02</TD><TD>-3.04</TD><TD>TTGGAGA,MIR-515-5P,MIR-519E</TD><TD>MSigDB lists</TD><TD>TTGGAGA,MIR-515-5P,MIR-519E</TD><TD>138</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>CLSTN2,ETV1</TD></TR>
<TR><TD>4.776e-02</TD><TD>-3.04</TD><TD>GROSS_HYPOXIA_VIA_ELK3_AND_HIF1A_UP</TD><TD>MSigDB lists</TD><TD>GROSS_HYPOXIA_VIA_ELK3_AND_HIF1A_UP</TD><TD>138</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>CD44,ANGPTL4</TD></TR>
<TR><TD>4.784e-02</TD><TD>-3.04</TD><TD>DYNLL1 (dynein, light chain, LC8-type 1)</TD><TD>protein interactions</TD><TD>8655</TD><TD>137</TD><TD>2</TD><TD>16036</TD><TD>41</TD>
<TD>VIM,PKIB</TD></TR>
<TR><TD>4.790e-02</TD><TD>-3.04</TD><TD>lung-carcinoma-adenocarcinoma</TD><TD>COSMIC cancer mutations</TD><TD>lung-carcinoma-adenocarcinoma</TD><TD>15921</TD><TD>43</TD><TD>17775</TD><TD>44</TD>
<TD>EFNB2,TNIK,CNTNAP3,STXBP6,HFM1,C1orf226,CLSTN2,PBX1,RNF43,ZIC2,PDE3A,S100A10,NEBL,PDE10A,UNC13A,TANK,WNT16,CD44,ETV1,PRPS1,NT5E,LAMA4,SLC40A1,FGF9,MSX1,KRT7,PPARG,VSNL1,GRHL3,VIM,ANGPTL4,NR2F1,RHOU,MSX2,CAMK2D,AHNAK2,SLCO5A1,CSMD3,NR2F2,SORCS2,ITGB4,PDLIM5,MMP16</TD></TR>
<TR><TD>4.795e-02</TD><TD>-3.04</TD><TD>positive regulation of stress-activated MAPK cascade</TD><TD>biological process</TD><TD>GO:0032874</TD><TD>131</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>TNIK,WNT16</TD></TR>
<TR><TD>4.806e-02</TD><TD>-3.04</TD><TD>Azathioprine Action Pathway</TD><TD>SMPDB pathways</TD><TD>SMP00427</TD><TD>47</TD><TD>1</TD><TD>978</TD><TD>1</TD>
<TD>PDE10A</TD></TR>
<TR><TD>4.806e-02</TD><TD>-3.04</TD><TD>Mercaptopurine Action Pathway</TD><TD>SMPDB pathways</TD><TD>SMP00428</TD><TD>47</TD><TD>1</TD><TD>978</TD><TD>1</TD>
<TD>PDE10A</TD></TR>
<TR><TD>4.806e-02</TD><TD>-3.04</TD><TD>Thioguanine Action Pathway</TD><TD>SMPDB pathways</TD><TD>SMP00430</TD><TD>47</TD><TD>1</TD><TD>978</TD><TD>1</TD>
<TD>PDE10A</TD></TR>
<TR><TD>4.838e-02</TD><TD>-3.03</TD><TD>BMI1_DN_MEL18_DN.V1_DN</TD><TD>MSigDB lists</TD><TD>BMI1_DN_MEL18_DN.V1_DN</TD><TD>139</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>PDLIM5,PDE3A</TD></TR>
<TR><TD>4.838e-02</TD><TD>-3.03</TD><TD>V$STAT3_02</TD><TD>MSigDB lists</TD><TD>V$STAT3_02</TD><TD>139</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>SLCO5A1,VSNL1</TD></TR>
<TR><TD>4.838e-02</TD><TD>-3.03</TD><TD>human chrXq22.3</TD><TD>chromosome location</TD><TD>human chrXq22.3</TD><TD>26</TD><TD>1</TD><TD>26250</TD><TD>50</TD>
<TD>PRPS1</TD></TR>
<TR><TD>4.861e-02</TD><TD>-3.02</TD><TD>positive regulation of stress-activated protein kinase signaling cascade</TD><TD>biological process</TD><TD>GO:0070304</TD><TD>132</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>TNIK,WNT16</TD></TR>
<TR><TD>4.861e-02</TD><TD>-3.02</TD><TD>cell maturation</TD><TD>biological process</TD><TD>GO:0048469</TD><TD>132</TD><TD>2</TD><TD>16441</TD><TD>44</TD>
<TD>PPARG,PDE3A</TD></TR>
<TR><TD>4.902e-02</TD><TD>-3.02</TD><TD>MODULE_220</TD><TD>MSigDB lists</TD><TD>MODULE_220</TD><TD>325</TD><TD>3</TD><TD>17758</TD><TD>45</TD>
<TD>PBX1,EFNB2,MSX1</TD></TR>
<TR><TD>4.908e-02</TD><TD>-3.01</TD><TD>blood circulation</TD><TD>biological process</TD><TD>GO:0008015</TD><TD>308</TD><TD>3</TD><TD>16441</TD><TD>44</TD>
<TD>CAMK2D,PPARG,PDE3A</TD></TR>
<TR><TD>4.908e-02</TD><TD>-3.01</TD><TD>angiosarcoma</TD><TD>COSMIC cancer mutations</TD><TD>angiosarcoma</TD><TD>2284</TD><TD>10</TD><TD>17775</TD><TD>44</TD>
<TD>CAMK2D,NEBL,CNTNAP3,HFM1,CSMD3,SLCO5A1,CLSTN2,CD44,SORCS2,MMP16</TD></TR>
<TR><TD>4.908e-02</TD><TD>-3.01</TD><TD>soft_tissue-blood_vessel-angiosarcoma</TD><TD>COSMIC cancer mutations</TD><TD>soft_tissue-blood_vessel-angiosarcoma</TD><TD>2284</TD><TD>10</TD><TD>17775</TD><TD>44</TD>
<TD>CAMK2D,NEBL,CNTNAP3,HFM1,CSMD3,SLCO5A1,CLSTN2,CD44,SORCS2,MMP16</TD></TR>
<TR><TD>4.910e-02</TD><TD>-3.01</TD><TD>HDAC4 (histone deacetylase 4)</TD><TD>protein interactions</TD><TD>9759</TD><TD>139</TD><TD>2</TD><TD>16036</TD><TD>41</TD>
<TD>CAMK2D,PPARG</TD></TR>
<TR><TD>4.912e-02</TD><TD>-3.01</TD><TD>wnt</TD><TD>pfam domains</TD><TD>PF00110</TD><TD>19</TD><TD>1</TD><TD>16629</TD><TD>44</TD>
<TD>WNT16</TD></TR>
<TR><TD>4.913e-02</TD><TD>-3.01</TD><TD>Peptidoglycan-bd-like</TD><TD>interpro domains</TD><TD>IPR002477</TD><TD>20</TD><TD>1</TD><TD>18293</TD><TD>46</TD>
<TD>MMP16</TD></TR>
<TR><TD>4.942e-02</TD><TD>-3.01</TD><TD>CNH</TD><TD>prosite domains</TD><TD>PS50219</TD><TD>15</TD><TD>1</TD><TD>11866</TD><TD>40</TD>
<TD>TNIK</TD></TR>
<TR><TD>4.942e-02</TD><TD>-3.01</TD><TD>CYSTEINE_SWITCH</TD><TD>prosite domains</TD><TD>PS00546</TD><TD>15</TD><TD>1</TD><TD>11866</TD><TD>40</TD>
<TD>MMP16</TD></TR>
<TR><TD>4.948e-02</TD><TD>-3.01</TD><TD>response to hormone</TD><TD>biological process</TD><TD>GO:0009725</TD><TD>1003</TD><TD>6</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2,CAMK2D,FGF9,NR2F2,PPARG,NR2F1</TD></TR>
<TR><TD>4.951e-02</TD><TD>-3.01</TD><TD>PEPPER_CHRONIC_LYMPHOCYTIC_LEUKEMIA_DN</TD><TD>MSigDB lists</TD><TD>PEPPER_CHRONIC_LYMPHOCYTIC_LEUKEMIA_DN</TD><TD>20</TD><TD>1</TD><TD>17758</TD><TD>45</TD>
<TD>PDE10A</TD></TR>
<TR><TD>4.951e-02</TD><TD>-3.01</TD><TD>HEDENFALK_BREAST_CANCER_BRACX_UP</TD><TD>MSigDB lists</TD><TD>HEDENFALK_BREAST_CANCER_BRACX_UP</TD><TD>20</TD><TD>1</TD><TD>17758</TD><TD>45</TD>
<TD>TANK</TD></TR>
<TR><TD>4.951e-02</TD><TD>-3.01</TD><TD>ZHU_SKIL_TARGETS_UP</TD><TD>MSigDB lists</TD><TD>ZHU_SKIL_TARGETS_UP</TD><TD>20</TD><TD>1</TD><TD>17758</TD><TD>45</TD>
<TD>MMP16</TD></TR>
<TR><TD>4.951e-02</TD><TD>-3.01</TD><TD>ST_WNT_CA2_CYCLIC_GMP_PATHWAY</TD><TD>MSigDB lists</TD><TD>ST_WNT_CA2_CYCLIC_GMP_PATHWAY</TD><TD>20</TD><TD>1</TD><TD>17758</TD><TD>45</TD>
<TD>CAMK2D</TD></TR>
<TR><TD>4.951e-02</TD><TD>-3.01</TD><TD>WEST_ADRENOCORTICAL_TUMOR_MARKERS_DN</TD><TD>MSigDB lists</TD><TD>WEST_ADRENOCORTICAL_TUMOR_MARKERS_DN</TD><TD>20</TD><TD>1</TD><TD>17758</TD><TD>45</TD>
<TD>VSNL1</TD></TR>
<TR><TD>4.963e-02</TD><TD>-3.00</TD><TD>PUIFFE_INVASION_INHIBITED_BY_ASCITES_DN</TD><TD>MSigDB lists</TD><TD>PUIFFE_INVASION_INHIBITED_BY_ASCITES_DN</TD><TD>141</TD><TD>2</TD><TD>17758</TD><TD>45</TD>
<TD>MSX2,CD44</TD></TR>
<TR><TD>4.965e-02</TD><TD>-3.00</TD><TD>pleura</TD><TD>COSMIC cancer mutations</TD><TD>pleura</TD><TD>5040</TD><TD>18</TD><TD>17775</TD><TD>44</TD>
<TD>LAMA4,TNIK,PBX1,VIM,NR2F1,RHOU,CAMK2D,NEBL,PDE10A,TANK,CSMD3,WNT16,CD44,NR2F2,ITGB4,ETV1,PRPS1,MMP16</TD></TR>
<TR><TD>4.967e-02</TD><TD>-3.00</TD><TD>regulation of water loss via skin</TD><TD>biological process</TD><TD>GO:0033561</TD><TD>19</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>GRHL3</TD></TR>
<TR><TD>4.967e-02</TD><TD>-3.00</TD><TD>osteoblast development</TD><TD>biological process</TD><TD>GO:0002076</TD><TD>19</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>MSX2</TD></TR>
<TR><TD>4.967e-02</TD><TD>-3.00</TD><TD>regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ion</TD><TD>biological process</TD><TD>GO:0010881</TD><TD>19</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>CAMK2D</TD></TR>
<TR><TD>4.967e-02</TD><TD>-3.00</TD><TD>response to lipoprotein particle</TD><TD>biological process</TD><TD>GO:0055094</TD><TD>19</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>PPARG</TD></TR>
<TR><TD>4.967e-02</TD><TD>-3.00</TD><TD>Rac protein signal transduction</TD><TD>biological process</TD><TD>GO:0016601</TD><TD>19</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>RHOU</TD></TR>
<TR><TD>4.967e-02</TD><TD>-3.00</TD><TD>response to vitamin A</TD><TD>biological process</TD><TD>GO:0033189</TD><TD>19</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>PPARG</TD></TR>
<TR><TD>4.967e-02</TD><TD>-3.00</TD><TD>intermediate filament organization</TD><TD>biological process</TD><TD>GO:0045109</TD><TD>19</TD><TD>1</TD><TD>16441</TD><TD>44</TD>
<TD>VIM</TD></TR>
<TR><TD>4.982e-02</TD><TD>-3.00</TD><TD>presynapse</TD><TD>cellular component</TD><TD>GO:0098793</TD><TD>143</TD><TD>2</TD><TD>17570</TD><TD>44</TD>
<TD>SLC40A1,UNC13A</TD></TR>
<TR><TD>4.982e-02</TD><TD>-3.00</TD><TD>meninges-meningioma</TD><TD>COSMIC cancer mutations</TD><TD>meninges-meningioma</TD><TD>335</TD><TD>3</TD><TD>17775</TD><TD>44</TD>
<TD>CSMD3,CAMK2D,ITGB4</TD></TR>
<TR><TD>4.994e-02</TD><TD>-3.00</TD><TD>APBA1 (amyloid beta (A4) precursor protein-binding, family A, member 1)</TD><TD>protein interactions</TD><TD>320</TD><TD>20</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>CNTNAP3</TD></TR>
<TR><TD>4.994e-02</TD><TD>-3.00</TD><TD>RFX5 (regulatory factor X, 5 (influences HLA class II expression))</TD><TD>protein interactions</TD><TD>5993</TD><TD>20</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>PPARG</TD></TR>
<TR><TD>4.994e-02</TD><TD>-3.00</TD><TD>KCNA2 (potassium channel, voltage gated shaker related subfamily A, member 2)</TD><TD>protein interactions</TD><TD>3737</TD><TD>20</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>ETV1</TD></TR>
<TR><TD>4.994e-02</TD><TD>-3.00</TD><TD>SLC9A1 (solute carrier family 9, subfamily A (NHE1, cation proton antiporter 1), member 1)</TD><TD>protein interactions</TD><TD>6548</TD><TD>20</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>TNIK</TD></TR>
<TR><TD>4.994e-02</TD><TD>-3.00</TD><TD>CRCT1 (cysteine rich C-terminal 1)</TD><TD>protein interactions</TD><TD>54544</TD><TD>20</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>VIM</TD></TR>
<TR><TD>4.994e-02</TD><TD>-3.00</TD><TD>CD74 (CD74 molecule, major histocompatibility complex, class II invariant chain)</TD><TD>protein interactions</TD><TD>972</TD><TD>20</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>CD44</TD></TR>
<TR><TD>4.994e-02</TD><TD>-3.00</TD><TD>THOC3 (THO complex 3)</TD><TD>protein interactions</TD><TD>84321</TD><TD>20</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>VIM</TD></TR>
<TR><TD>4.994e-02</TD><TD>-3.00</TD><TD>ME1 (malic enzyme 1, NADP(+)-dependent, cytosolic)</TD><TD>protein interactions</TD><TD>4199</TD><TD>20</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>EFNB2</TD></TR>
<TR><TD>4.994e-02</TD><TD>-3.00</TD><TD>NMT2 (N-myristoyltransferase 2)</TD><TD>protein interactions</TD><TD>9397</TD><TD>20</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>PRPS1</TD></TR>
<TR><TD>4.994e-02</TD><TD>-3.00</TD><TD>MOAP1 (modulator of apoptosis 1)</TD><TD>protein interactions</TD><TD>64112</TD><TD>20</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>CAMK2D</TD></TR>
<TR><TD>4.994e-02</TD><TD>-3.00</TD><TD>PYCR2 (pyrroline-5-carboxylate reductase family, member 2)</TD><TD>protein interactions</TD><TD>29920</TD><TD>20</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>AHNAK2</TD></TR>
<TR><TD>4.994e-02</TD><TD>-3.00</TD><TD>ASB16 (ankyrin repeat and SOCS box containing 16)</TD><TD>protein interactions</TD><TD>92591</TD><TD>20</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>VIM</TD></TR>
<TR><TD>4.994e-02</TD><TD>-3.00</TD><TD>VPS33A (vacuolar protein sorting 33 homolog A (S. cerevisiae))</TD><TD>protein interactions</TD><TD>65082</TD><TD>20</TD><TD>1</TD><TD>16036</TD><TD>41</TD>
<TD>VIM</TD></TR>
</TABLE>
</BODY></HTML>
